UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
__________________________________________________________ 
FORM 10-Q
 
 __________________________________________________________ 
(Mark One)
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 26, 2016
or 
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number: 1-36214
__________________________________________________________ 
Hologic, Inc.
(Exact name of registrant as specified in its charter)
 __________________________________________________________
Delaware
 
04-2902449
(State of incorporation)
 
(I.R.S. Employer Identification No.)
250 Campus Drive,
Marlborough, Massachusetts
 
01752
(Address of principal executive offices)
 
(Zip Code)
(508) 263-2900
(Registrant’s telephone number, including area code)
 __________________________________________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):
Large accelerated filer
 
ý
  
Accelerated filer
 
¨
Non-accelerated filer
 
¨ (Do not check if a smaller reporting company)
  
Smaller reporting company
 
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)    Yes  ¨    No  ý
As of April 22, 2016, 278,829,786 shares of the registrant’s Common Stock, $0.01 par value, were outstanding.
 

Table of Contents

HOLOGIC, INC.
INDEX
 
 
Page
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
Item 3.
 
 
Item 4.
 
 
 
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 6.
 
 
 
 
EXHIBITS
 


2
Table of Contents

PART I – FINANCIAL INFORMATION
 
Item 1.
Financial Statements (unaudited)
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and per share data)
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Revenues:
 
 
 
 
 
 
 
Product
$
583.0

 
$
546.4

 
$
1,170.2

 
$
1,093.0

Service and other
110.3

 
109.1

 
218.2

 
215.3

 
693.3

 
655.5

 
1,388.4

 
1,308.3

Costs of revenues:
 
 
 
 
 
 
 
Product
182.0

 
186.7

 
370.1

 
373.4

Amortization of intangible assets
70.8

 
78.6

 
144.3

 
152.5

Service and other
55.5

 
54.2

 
109.9

 
107.8

Gross Profit
385.0

 
336.0

 
764.1

 
674.6

Operating expenses:
 
 
 
 
 
 
 
Research and development
59.1

 
53.3

 
110.8

 
105.2

Selling and marketing
100.8

 
83.0

 
200.3

 
169.0

General and administrative
62.4

 
60.3

 
139.5

 
121.7

Amortization of intangible assets
22.8

 
27.6

 
45.4

 
55.4

Restructuring and divestiture charges
3.8

 
2.0

 
6.0

 
10.0

Total Operating Expenses
248.9

 
226.2

 
502.0

 
461.3

Income from operations
136.1

 
109.8

 
262.1

 
213.3

Interest income
0.2

 
0.3

 
0.4

 
0.7

Interest expense
(39.1
)
 
(49.4
)
 
(78.3
)
 
(101.9
)
Debt extinguishment loss
(4.5
)
 
—

 
(4.5
)
 
(6.7
)
Other income (expense), net
(0.8
)
 
0.1

 
26.9

 
(0.5
)
Income before income taxes
91.9

 
60.8

 
206.6

 
104.9

Provision for income taxes
23.0

 
13.0

 
52.8

 
27.9

Net income
$
68.9

 
$
47.8

 
$
153.8

 
$
77.0

Net income per common share:
 
 
 
 
 
 
 
Basic
$
0.24

 
$
0.17

 
$
0.54

 
$
0.28

Diluted
$
0.24

 
$
0.17

 
$
0.53

 
$
0.27

Weighted average number of shares outstanding:
 
 
 
 
 
 
 
Basic
282,474

 
280,338

 
282,725

 
279,505

Diluted
287,857

 
287,580

 
289,914

 
285,378



See accompanying notes.

3
Table of Contents

HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In millions)
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Net income
$
68.9

 
$
47.8

 
$
153.8

 
$
77.0

Changes in foreign currency translation adjustment
(1.2
)
 
(9.5
)
 
(5.4
)
 
(18.5
)
Changes in unrealized holding gains and losses on available-for-sale securities:
 
 
 
 
 
 
 
Loss recognized in other comprehensive income
(0.6
)
 
(8.3
)
 
(1.2
)
 
(3.2
)
Gain reclassified from accumulated other comprehensive loss to the statement of income
—

 
—

 
(7.2
)
 
—

Changes in pension plans, net of taxes
—

 
—

 
—

 
0.1

Changes in value of hedged interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 26, 2016 and $0.9 for the three and six months ended March 28, 2015:
 
 
 
 
 
 
 
Loss recognized in other comprehensive loss, net
(2.2
)
 
(1.6
)
 
(1.9
)
 
(1.6
)
Loss reclassified from accumulated other comprehensive loss to the statement of income
0.7

 
—

 
1.0

 
—

Other comprehensive loss
(3.3
)
 
(19.4
)
 
(14.7
)
 
(23.2
)
Comprehensive income
$
65.6

 
$
28.4

 
$
139.1

 
$
53.8

See accompanying notes.


4
Table of Contents

HOLOGIC, INC.

CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and par value)
 
 
March 26,
2016
 
September 26,
2015
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
316.3

 
$
491.3

Restricted cash
—

 
1.4

Accounts receivable, less reserves of $10.4 and $11.1, respectively
422.6

 
416.1

Inventories
285.1

 
283.1

Deferred income tax assets
—

 
19.0

Prepaid income taxes
18.2

 
21.7

Prepaid expenses and other current assets
50.4

 
33.8

Total current assets
1,092.6

 
1,266.4

Property, plant and equipment, net
454.1

 
457.1

Intangible assets, net
2,837.5

 
3,023.2

Goodwill
2,806.4

 
2,808.2

Other assets
95.7

 
115.2

Total assets
$
7,286.3

 
$
7,670.1

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Current portion of long-term debt
$
307.7

 
$
391.8

Accounts payable
118.5

 
117.0

Accrued expenses
263.9

 
272.1

Deferred revenue
150.9

 
163.1

Total current liabilities
841.0

 
944.0

Long-term debt, net of current portion
3,098.0

 
3,248.0

Deferred income tax liabilities
1,071.0

 
1,178.4

Deferred revenue
19.3

 
19.6

Other long-term liabilities
212.6

 
200.9

Commitments and contingencies (Note 6)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued
—

 
—

Common stock, $0.01 par value – 750,000 shares authorized; 284,091 and 282,495 shares issued, respectively
2.8

 
2.8

Additional paid-in-capital
5,534.8

 
5,559.9

Accumulated deficit
(3,315.2
)
 
(3,469.0
)
Treasury stock, at cost – 4,331 shares at March 26, 2016
(148.8
)
 
—

Accumulated other comprehensive loss
(29.2
)
 
(14.5
)
Total stockholders’ equity
2,044.4

 
2,079.2

Total liabilities and stockholders’ equity
$
7,286.3

 
$
7,670.1

See accompanying notes.


5
Table of Contents


HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In millions)
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
OPERATING ACTIVITIES
 
 
 
Net income
$
153.8

 
$
77.0

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation
40.2

 
40.7

Amortization
189.7

 
207.9

Non-cash interest expense
26.1

 
33.2

Stock-based compensation expense
30.6

 
25.8

Excess tax benefit related to equity awards
(7.9
)
 
(6.0
)
Deferred income taxes
(64.7
)
 
(79.1
)
Gain on sale of available-for-sale marketable security
(25.1
)
 
—

Debt extinguishment loss
4.5

 
6.7

Other adjustments and non-cash items
1.0

 
3.9

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(7.0
)
 
3.3

Inventories
(2.3
)
 
29.0

Prepaid income taxes
3.4

 
1.3

Prepaid expenses and other assets
(15.0
)
 
(2.6
)
Accounts payable
1.6

 
(17.8
)
Accrued expenses and other liabilities
(2.1
)
 
(19.3
)
Deferred revenue
(12.4
)
 
7.3

Net cash provided by operating activities
314.4

 
311.3

INVESTING ACTIVITIES
 
 
 
Purchase of property and equipment
(19.4
)
 
(20.0
)
Increase in equipment under customer usage agreements
(22.3
)
 
(19.7
)
Proceeds from sale of available-for-sale marketable security
31.1

 
—

Purchases of insurance contracts
(5.2
)
 
(6.4
)
Sales of mutual funds
5.2

 
7.7

Purchase of intellectual property
(4.0
)
 
—

Increase in other assets
0.1

 
(0.6
)
Net cash used in investing activities
(14.5
)
 
(39.0
)
FINANCING ACTIVITIES
 
 
 
Repayment of long-term debt
(37.5
)
 
(357.5
)
Repurchase of common stock
(135.9
)
 
—

Payments to extinguish convertible notes
(311.5
)
 
—

Proceeds from amounts borrowed under revolving credit line
50.0

 
—

Repayment of amounts borrowed under revolving credit line
(50.0
)
 
—

Purchase of interest rate caps
—

 
(6.1
)
Net proceeds from issuance of common stock pursuant to employee stock plans
19.0

 
37.4

Excess tax benefit related to equity awards
7.9

 
6.0

Payment of minimum tax withholdings on net share settlements of equity awards
(15.6
)
 
(12.1
)
Net cash used in financing activities
(473.6
)
 
(332.3
)
Effect of exchange rate changes on cash and cash equivalents
(1.3
)
 
(5.6
)
Net decrease in cash and cash equivalents
(175.0
)
 
(65.6
)
Cash and cash equivalents, beginning of period
491.3

 
736.1

Cash and cash equivalents, end of period
$
316.3

 
$
670.5


See accompanying notes.

6
Table of Contents

HOLOGIC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(all tabular amounts in millions, except number of shares, which are reflected in thousands, and per share data)
(1) Basis of Presentation
The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”). These financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended September 26, 2015 included in the Company’s Form 10-K filed with the SEC on November 19, 2015. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and six months ended March 26, 2016 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 24, 2016.
Subsequent Events Consideration
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There was one unrecognized subsequent event related to the unaudited consolidated financial statements for the three and six months ended March 26, 2016 related to the Company's execution of a $200.0 million accounts receivable securitization program with several of its wholly owned subsidiaries and certain financial institutions on April 25, 2016 (see Note 4). There were no material recognized subsequent events recorded in the unaudited consolidated financial statements as of and for the three and six months ended March 26, 2016.

7
Table of Contents

(2) Fair Value Measurements
Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
The Company has investments in publicly-traded companies, which are valued using quoted market prices, representing Level 1 assets, and investments in derivative instruments comprised of interest rate caps and forward foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of the Company's interest rate caps and forward foreign currency contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 5 for further discussion and information on the interest rate caps and forward foreign currency contracts.
The Company has a payment obligation to the participants under its Nonqualified Deferred Compensation Plan (“DCP”). This liability is recorded at fair value based on the underlying value of certain hypothetical investments under the DCP as designated by each participant for their benefit. Since the value of the DCP obligation is based on market prices, the liability is classified within Level 1.
Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 26, 2016: 
 
 
 
Fair Value at Reporting Date Using
 
Balance as of March 26, 2016
 
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Equity securities
$
0.8

 
$
0.8

 
$
—

 
$
—

Interest rate cap - derivative
3.7

 
—

 
3.7

 
—

Forward foreign currency contracts
1.2

 
—

 
1.2

 
—

Total
$
5.7

 
$
0.8

 
$
4.9

 
$
—

Liabilities:
 
 
 
 
 
 
 
Deferred compensation liabilities
$
37.6

 
$
37.6

 
$
—

 
$
—

Forward foreign currency contracts
0.9

 
—

 
0.9

 
—

Total
$
38.5

 
$
37.6

 
$
0.9

 
$
—

Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of cost-method equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill.
The Company holds certain cost-method equity investments in non-publicly traded securities aggregating $3.5 million and $4.2 million at March 26, 2016 and September 26, 2015, respectively, which are included in other long-term assets on the Company’s Consolidated Balance Sheets. These investments are generally carried at cost, less any write-downs for other-than-temporary impairment charges. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost method investment’s fair value is not estimated as there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment and to make such an estimate would be impractical.
Disclosure of Fair Value of Financial Instruments
The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, marketable securities, cost-method equity investments, interest rate caps, forward foreign currency contracts, insurance contracts, DCP liability, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s marketable securities, interest rate caps, and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value, and the related DCP liability is recorded at fair value. The Company believes the carrying amounts of its cost-method equity investments approximate fair value.

8
Table of Contents

Amounts outstanding under the Company’s Credit Agreement of $1.62 billion aggregate principal as of March 26, 2016 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 2022 Senior Notes had a fair value of approximately $1.04 billion as of March 26, 2016 based on their trading price, representing a Level 1 measurement. The fair value of the Company’s Convertible Notes is based on the trading prices of the respective notes and represents a Level 1 measurement. Refer to Note 4 for the carrying amounts of the various components of the Company’s debt.
The estimated fair values of the Company’s Convertible Notes at March 26, 2016 were as follows:
 
2010 Notes
$
90.0

2012 Notes
459.9

2013 Notes
459.7

 
$
1,009.6


(3) Restructuring and Divestiture Charges
The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. In addition, the Company continually assesses its management structure. As a result of these assessments, the Company has undertaken various restructuring actions, which are described below. The following table displays charges taken in the fiscal 2016 year to date period and fiscal 2015 related to these actions and a rollforward of the accrued balances from September 26, 2015 to March 26, 2016:
 
 
Fiscal 2016 Actions
 
Fiscal 2015 Actions
 
Fiscal 2014 Actions
 
Other Operating Cost Reductions
 
Total    
Restructuring and Divestiture Charges
 
 
 
 
 
 
 
 
 
 
Fiscal 2015 charges:
 
 
 
 
 
 
 
 
 
 
Workforce reductions
 
$
—

 
$
10.0

 
$
6.0

 
$
0.3

 
$
16.3

Facility closure costs
 
—

 
—

 
2.0

 
0.6

 
2.6

Fiscal 2015 restructuring charges
 
$
—

 
$
10.0

 
$
8.0

 
$
0.9

 
$
18.9

Divestiture net charges
 
 
 
 
 
 
 
 
 
9.6

Fiscal 2015 restructuring and divestiture charges
 
 
 
 
 
 
 
 
 
$
28.5

Fiscal 2016 charges:
 
 
 
 
 
 
 
 
 

Workforce reductions
 
$
6.0

 
$
—

 
$
—

 
$
—

 
$
6.0

Fiscal 2016 restructuring charges
 
$
6.0

 
$
—

 
$
—

 
$
—

 
$
6.0

 
 
Fiscal 2016 Actions
 
Fiscal 2015 Actions
 
Fiscal 2014 Actions
 
Other Operating Cost Reductions  
 
Total    
Rollforward of Accrued Restructuring
 
 
 
 
 
 
 
 
 
 
Balance as of September 26, 2015
 
$
—

 
$
3.1

 
$
2.5

 
$
0.1

 
$
5.7

Fiscal 2016 restructuring charges
 
6.0

 
—

 
—

 
—

 
6.0

Severance payments
 
(2.3
)
 
(2.4
)
 
(1.4
)
 
(0.1
)
 
(6.2
)
Other payments
 
—

 
—

 
(0.2
)
 
—

 
(0.2
)
Balance as of March 26, 2016
 
$
3.7

 
$
0.7

 
$
0.9

 
$
—

 
$
5.3


9
Table of Contents

Fiscal 2016 Actions

During the third quarter of fiscal 2015, the Company decided to close its Bedford, Massachusetts facility where it manufactures its Skeletal Health products and provides certain support manufacturing services for its Breast Health segment. The manufacturing of the Skeletal Health products will be outsourced to a third-party, and the Breast Health manufacturing services will be moved to the Company's Danbury, Connecticut and Marlborough, Massachusetts facilities. In addition, research and development, sales and services support and administrative functions will be moved to both Marlborough and Danbury. The transition is expected to be completed by the end of calendar 2016. In connection with this plan, certain employees, primarily in manufacturing, will be terminated. The employees were notified of termination and related benefits in the first quarter of fiscal 2016, and the Company is recording these charges pursuant to ASC 420 Exit or Disposal Cost Obligations (ASC 420). Employees are required to remain employed during this transition period and charges are being recorded ratably over the required service period. The Company recorded $0.5 million and $0.9 million in severance and benefits charges in the three and six months ended March 26, 2016, respectively, related to this plan. The Company estimates the total severance and benefits charges will be approximately $1.7 million.
During the first quarter of fiscal 2016, the Company began implementing a second plan to consolidate and improve operational efficiency of its international sales and marketing and field services operations and certain support functions. As a result, the Company identified and terminated certain employees in the first and second quarters of fiscal 2016. Severance and benefits under this action were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712), and ASC 420 depending on the circumstances. The Company recorded severance and benefit charges of $3.3 million and $5.1 million in the three and six months ended March 26, 2016, respectively, related to this plan. The Company is continuing to assess its organizational structure and finalize its plans and additional severance charges are expected in fiscal 2016.
Fiscal 2015 Actions
During each quarter of fiscal 2015, the Company continued to make executive management changes resulting in the termination of certain executives and employees on a worldwide basis. In addition, the Company continued to consolidate and close certain international offices to improve operational efficiency and reduce costs. Severance and benefit charges under these actions were recorded pursuant to ASC 420 and ASC 712 depending on the circumstances, and the Company recorded severance and benefit charges of $10.0 million in fiscal 2015, including $4.1 million of stock-based compensation. During the three and six months ended March 28, 2015, the Company recorded $0.5 million and $3.0 million, respectively, for severance and benefits charges. No additional charges are expected under these actions.
In connection with its review of operations, the Company decided to shut-down its manufacturing operation in China, which manufactured mammography systems for the Chinese market. As a result, the Company terminated manufacturing and research and development personnel located in China, and the severance charge was insignificant.
Fiscal 2014 Actions
In each quarter of fiscal 2014, the Company made executive management changes, including appointing Stephen P. MacMillan as President, Chief Executive Officer and a director of the Company, and implemented a number of cost reduction initiatives resulting in the termination of certain executives and employees on a worldwide basis. In addition, in the fourth quarter of fiscal 2014, the Company decided to consolidate and close certain international offices. Severance and benefit charges under these actions were recorded pursuant to ASC 420 and ASC 712 depending on the circumstances. For those employees who continued to be employed beyond the minimum retention period, charges were recorded ratably over the estimated period of the affected employees.
During fiscal 2015, in connection with these actions, the Company recorded $6.0 million for severance and benefits costs and $2.0 million for facility closure costs related to this action. The facility closure costs primarily related to lease obligation charges for three office locations where the Company had met the cease-use date criteria. During the three and six months ended March 28, 2015, the Company recorded severance and benefit charges of $1.4 million and $5.9 million, respectively. This action was completed in fiscal 2015.    

10
Table of Contents

Divestitures
In the fourth quarter of fiscal 2014, the Company completed the sale of its MRI breast coils product line and recorded a loss on disposal of $5.3 million. The Company also provided certain transition services through April 2015, including the manufacturing and sale of inventory to the buyer. Since all operations had ceased during the third quarter of fiscal 2015, the Company concluded that this subsidiary had been substantially liquidated and recorded a $9.6 million charge in the third quarter of fiscal 2015 to write off the cumulative translation adjustment related to the subsidiary.

(4) Borrowings and Credit Arrangements
The Company’s borrowings consisted of the following: 
 
March 26,
2016
 
September 26,
2015
Current debt obligations, net of debt discount:
 
 
 
Term Loan
$
74.7

 
$
74.6

Revolver
175.0

 
175.0

Convertible Notes
58.0

 
142.2

Total current debt obligations
$
307.7

 
$
391.8

Long-term debt obligations, net of debt discount:
 
 
 
Term Loan
1,363.1

 
1,399.8

2022 Senior Notes
987.7

 
986.7

Convertible Notes
747.2

 
861.5

Total long-term debt obligations
$
3,098.0

 
$
3,248.0

Total debt obligations
$
3,405.7

 
$
3,639.8

Credit Agreement
Borrowings outstanding under the Credit Agreement for the three and six months ended March 26, 2016 had weighted-average interest rates of 2.18% and 2.06%, respectively. The interest rate on the outstanding Term Loan borrowing at March 26, 2016 was 2.18%. Borrowings outstanding under the Prior Credit Agreement for the three and six months ended March 28, 2015 had weighted-average interest rates of 2.62% and 2.70%, respectively. Interest expense under the Credit Agreement aggregated $10.8 million and $20.7 million for the three and six months ended March 26, 2016, respectively, which includes non-cash interest expense of $1.1 million and $2.1 million, respectively, related to the amortization of the deferred issuance costs and accretion of the debt discount. Interest expense under the Prior Credit Agreement aggregated $14.4 million and $31.9 million for the three and six months ended March 28, 2015, respectively, which included $2.7 million and $5.8 million, respectively, of non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount.  
The Credit Agreement contains two financial covenants, a total net leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and the calculation thereof, are defined in further detail in the Credit Agreement. As of March 26, 2016, the Company was in compliance with these covenants.
On December 24, 2014, the Company voluntarily pre-paid $300.0 million of its Term Loan B facility under its Prior Credit Agreement. Pursuant to ASC 470, Debt (ASC 470), the Company recorded a debt extinguishment loss of $6.7 million in the first quarter of fiscal 2015 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to this voluntary prepayment.
2022 Senior Notes
The Company's 5.250% Senior Notes due 2022 (the “2022 Senior Notes”) mature on July 15, 2022 and bear interest at the rate of 5.250% per year, payable semi-annually on January 15 and July 15 of each year, commencing on January 15, 2016. The Company recorded interest expense of $13.9 million and $27.9 million in the three and six month periods ended March 26, 2016, respectively, which includes non-cash interest expense of $1.0 million and $1.9 million, respectively, related to the amortization of the deferred issuance costs and accretion of the debt discount. The Company used the net proceeds from the 2022 Senior Notes, plus available cash to discharge and redeem all of its outstanding 6.25% Senior Notes due 2020 ("Senior Notes"). The Company recorded interest expense related to its Senior Notes of $16.0 million and $32.0 million in the three and

11
Table of Contents

six month periods ended March 28, 2015, respectively, which included non-cash interest expense of $0.4 million and $0.8 million, respectively, related to the amortization of deferred issuance costs.
Convertible Notes
During the second quarter of fiscal 2016, the closing price of the Company's common stock exceeded 130% of the applicable conversion price of its 2010 Notes on at least 20 of the last 30 consecutive trading days of the quarter. As a result, holders of 2010 Notes are able to convert their notes during the third quarter of fiscal 2016. Therefore, the Company classified the $58.0 million carrying value of its 2010 Notes (which have a principal value of $59.9 million) as a current debt obligation. In the event the closing price conditions are met in the third quarter of fiscal 2016 or a future fiscal quarter, the 2010 Notes will be convertible at a holder's option during the immediately following fiscal quarter. As of March 26, 2016, the if-converted value of the 2010 Notes exceeded the aggregate principal amount by approximately $30.1 million. It is the Company's current intent and policy to settle any conversion of the Convertible Notes as if the Company had elected to make either a net share settlement or all cash election, such that upon conversion, the Company intends to pay the holders in cash for the principal amount of the 2010 Notes and, if applicable, shares of its common stock or cash to satisfy the premium based on a calculated daily conversion value.
On various dates during the second quarter of fiscal 2016, the Company entered into privately negotiated repurchase transactions and extinguished $90.0 million and $136.6 million principal amount of the 2010 Notes and 2012 Notes, respectively, for total payments of $140.1 million and $171.3 million, respectively. These amounts include the conversion premium resulting from the Company's stock price on the date of the transactions being in excess of the conversion price of $23.03 and $31.175 for the 2010 Notes and 2012 Notes, respectively.
The Company accounted for the 2010 Notes and 2012 Notes extinguishment under the derecognition provisions of subtopic ASC 470-20-40, which requires the allocation of the fair value of the consideration transferred and transaction costs incurred to the extinguishment of the liability component and the reacquisition of the equity component. In connection with these transactions, the Company recorded a debt extinguishment loss on the 2010 Notes of $3.8 million and a debt extinguishment loss on the 2012 Notes of $0.7 million, for a total debt extinguishment loss of $4.5 million in the second quarter of fiscal 2016. The 2010 Notes debt extinguishment loss was comprised of the loss on the debt itself of $3.3 million, the write-off of the pro-rata amount of debt issuance costs of $0.3 million allocated to the notes retired, and allocated third party costs of $0.2 million. The 2012 Notes debt extinguishment loss was comprised of the write-off of the pro-rata amount of debt issuance costs of $0.5 million allocated to the notes retired, and allocated third party costs of $0.2 million. The loss on the debt itself was calculated as the difference between the fair value of the liability component of the 2010 Notes amount retired immediately before the respective exchanges and its related carrying value immediately before the repurchases. The fair value of the liability component was calculated using a discounted cash flow technique, and the Company used effective interest rates of 2.71% for the 2010 Notes and 3.87% and 3.41% for the 2012 Notes, which had two valuation dates, representing the estimated rate for non-convertible debt (with similar features as the 2010 and 2012 Notes excluding the conversion feature) issued by a company with a credit rating similar to the Company. In addition, under this accounting standard, a portion of the fair value of the consideration transferred is allocated to the reacquisition of the equity component, which is the difference between the fair value of the consideration transferred and the fair value of the liability component immediately before the extinguishment. As a result, on a gross basis, $49.9 million related to the 2010 Notes and $38.9 million related to the 2012 Notes were allocated to the reacquisition of the equity component of the original instrument, which was recorded net of deferred taxes of $10.0 million and $12.5 million, respectively, within additional paid-in-capital.
Interest expense under the Convertible Notes was as follows: 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Amortization of debt discount
$
5.8

 
$
9.0

 
$
12.2

 
$
17.8

Amortization of deferred financing costs
0.3

 
0.4

 
0.6

 
0.9

Principal accretion
4.1

 
4.0

 
8.2

 
7.9

Non-cash interest expense
10.2

 
13.4

 
21.0

 
26.6

2.00% accrued interest (cash)
2.7

 
4.8

 
5.9

 
9.5

 
$
12.9

 
$
18.2

 
$
26.9

 
$
36.1


12
Table of Contents

Accounts Receivable Securitization Program
On April 25, 2016, the Company entered into a $200.0 million accounts receivable securitization program (the "Securitization Program") with several of its wholly owned subsidiaries and certain financial institutions. Under the terms of the Securitization Program, the Company and certain of its wholly-owned subsidiaries will sell their respective customer receivables to a bankruptcy remote special purpose entity, which is wholly-owned by the Company. The Company will also contribute a portion of its customer receivables to the special purpose entity. The Company retains servicing responsibility. The special purpose entity, as borrower, and the Company, as servicer, have entered into a Credit and Security Agreement with several lenders pursuant to which the special purpose entity may borrow up to $200.0 million from the lenders, with the loans secured by the receivables. In addition, the Company may request from the lenders an increase in the borrowing limit of up to $50.0 million during the term of the agreement, although such additional borrowing limit is uncommitted. Borrowings outstanding under the Securitization Program will bear interest at LIBOR plus the applicable margin of 0.7% and will be included as a component of current liabilities in the Company's consolidated balance sheet, while the accounts receivable securing these obligations will be included as a component of net receivables in the Company's consolidated balance sheet. The Company and the special purpose entity have been formed and are operated and maintained as separate legal entities. The assets and liabilities of the special purpose entity, which are separate from those of the Company, are not available to pay the debts of the Company and do not constitute obligations of the Company.

(5) Derivatives
Interest Rate Cap - Cash Flow Hedge
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk by the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in Other income (expense) in the Consolidated Statements of Income.
During fiscal 2015, the Company entered into separate interest rate cap agreements with multiple counter-parties to help mitigate the interest rate volatility associated with the variable rate interest on its credit facilities under the Prior Credit Agreement, which was replaced by the new Credit Agreement. Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid by the Company for the interest rate cap agreements was $13.2 million, which was the initial fair value of the instruments recorded in the Company's financial statements.
The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under the Prior Credit Agreement. The terms in the new Credit Agreement are consistent with the Prior Credit Agreement, and therefore the interest rate caps continue to be highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal for a three-year period, which ends on December 29, 2017.
As of March 26, 2016, the Company determined that the existence of hedge ineffectiveness, if any, was immaterial and all changes in the fair value of the interest rate caps were recorded in the Consolidated Statements of Comprehensive Income as a component of AOCI.
During the three and six months ended March 26, 2016, $0.7 million and $1.0 million, respectively, was reclassified from AOCI to the Company’s Consolidated Statements of Income related to the interest rate cap agreements. The Company expects to similarly reclassify approximately $6.1 million from AOCI to the Consolidated Statements of Income in the next twelve months.
The aggregate fair value of these interest rate caps was $3.7 million and $6.9 million at March 26, 2016 and September 26, 2015, respectively and is included in both Prepaid expenses and other current assets and Other assets on the Company’s Consolidated Balance Sheet. Refer to Note 2 “Fair Value Measurements” above for related fair value disclosures.
Forward Foreign Currency Contracts
The Company enters into forward foreign currency exchange contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, and the Australian dollar. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are for periods of one year or less. During the first quarter of fiscal 2016, the

13
Table of Contents

Company began to execute forward foreign currency contracts in order to mitigate its exposure to fluctuations in various currencies against its reporting currency, the U.S. dollar. The Company did not elect hedge accounting for these forward foreign currency contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. During the three and six months ended March 26, 2016, the Company recorded a net unrealized loss of $0.7 million and an unrealized gain of $0.3 million, respectively, on the mark-to-market for its outstanding forward foreign currency contracts within other income (expense), net in the Consolidated Statements of Income and a realized gain of $0.6 million and $1.0 million, respectively from settling forward foreign currency contracts.
As of March 26, 2016, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro, UK Pound and the Australian dollar with a notional amount of $65.5 million.
Financial Instrument Presentation
The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 26, 2016:
 
Balance Sheet Location
 
March 26, 2016
 
September 26, 2015
Assets:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate cap agreements
Prepaid expenses and other current assets
 
$
0.9

 
$
0.7

Interest rate cap agreements
Other assets
 
2.8

 
6.2

 
 
 
$
3.7

 
$
6.9

 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Prepaid expenses and other current assets
 
$
1.2

 
$
—

 
 
 
 
 
 
Liabilities:
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Accrued expenses
 
$
0.9

 
$
—



The following table presents the unrealized loss recognized in AOCI related to the interest rate caps for the following reporting periods:
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
March 26, 2016
 
March 28, 2015
Amount of loss recognized in other comprehensive income, net of taxes:
 
 
 
 
 
 
 
Interest rate cap agreements
$
(2.2
)
 
$
(1.6
)
 
$
(1.9
)
 
$
(1.6
)
The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:
Derivatives not classified as hedging instruments
 
Amount of Gain (Loss) Recognized in Income
 
Location of Gain (Loss) Recognized in Income
 
 
Three Months Ended March 26, 2016
 
Six Months Ended March 26, 2016
 
 
Forward foreign currency contracts
 
$
(0.1
)
 
$
1.3

 
Other income (expense), net


14
Table of Contents

(6) Commitments and Contingencies
Litigation and Related Matters

On June 9, 2010, Smith & Nephew, Inc. ("Smith & Nephew") filed suit against Interlace Medical, Inc. ("Interlace"), which the Company acquired on January 6, 2011, in the United States District Court for the District of Massachusetts. The complaint alleged that the Interlace MyoSure hysteroscopic tissue removal device infringed U.S. patent 7,226,459. On November 22, 2011, Smith & Nephew filed suit against the Company in the United States District Court for the District of Massachusetts. The complaint alleged that use of the MyoSure hysteroscopic tissue removal system infringed U.S. patent 8,061,359. Both complaints sought permanent injunctive relief and unspecified damages. On September 4, 2012, following a two week trial, the jury returned a verdict of infringement of both the ‘459 and ‘359 patents and assessed damages of $4.0 million. A bench trial regarding the Company’s assertion of inequitable conduct on the part of Smith & Nephew with regard to the ‘359 patent was held on December 9, 2012 and oral arguments on the issue of inequitable conduct were presented on February 27, 2013. On June 27, 2013, the Court denied the Company’s motions related to inequitable conduct and allowed Smith & Nephew’s request for injunction, but ordered that enforcement of the injunction be stayed until final resolution, including appeal, of the current re-examinations of both patents at the United States Patent and Trademark Office (“USPTO”). The Court also rejected the jury’s damage award and ordered the parties to identify a mechanism for resolving the damages issue. The Company intends to file post-trial motions seeking to reverse the jury’s verdict. The USPTO has issued final decisions that the claims of the ‘459 and the '359 patents asserted as part of the litigation are not patentable. Smith & Nephew has appealed these decisions to the U.S. Patent Trial and Appeal Board. On January 20, 2016 the U.S. Patent Trial and Appeal Board affirmed the USPTO decision holding the claims at issue in the ‘459 patent as invalid. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
In January 2012, Enzo Life Sciences, Inc. ("Enzo") filed suit against the Company's subsidiary, Gen-Probe Incorporated ("Gen-Probe"), in the United States District Court for the District of Delaware. The Gen-Probe complaint alleged that certain of Gen-Probe’s diagnostics products, including products that incorporate Gen-Probe’s patented hybridization protection assay technology, such as the Aptima Combo 2 and Aptima HPV assays, infringe Enzo’s U.S. patent 6,992,180. On March 6, 2012, Enzo filed suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain of the Company’s molecular diagnostics products, including without limitation products based on its proprietary Invader chemistry, such as Cervista HPV HR and Cervista HPV 16/18, infringe Enzo’s U.S. patent 6,992,180. The complaint seeks permanent injunctive relief and unspecified damages. On September 30, 2013, Enzo amended its list of accused products to include Prodesse, MilliPROBE, PACE and Procleix assays. The complaint seeks permanent injunctive relief and unspecified damages. Enzo has asserted the ‘180 patent claims against six other companies. The court issued a Markman order on July 7, 2015 construing the claims, and it is expected that summary judgment motions will be heard in the fall of 2016. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
On March 27, 2015, Enzo filed an additional suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain additional Company molecular diagnostic products, including, inter alia, the Procleix Parvo/HAV assays and coagulation products, including the Invader Factor II test and the Invader Factor V test, also infringe U.S. Patent 6,992,180. The complaint further alleged that certain of the Company’s molecular diagnostic products, including the Company’s Progensa PCA3 products, all Aptima products and all Procleix products infringe Enzo’s U. S. Patent 7,064,197. On June 11, 2015, this matter was stayed pending the resolution of summary judgment motions in the 2012 case referenced above. On March 30, 2016 Hologic filed a request for inter-parties review of the ‘179 patent at the USPTO. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

15
Table of Contents


(7) Marketable Securities
The following reconciles the cost basis to the fair market value of the Company’s equity securities that are classified as available-for-sale: 
Period Ended:
Cost
 
Gross Unrealized
Gains
 
Gross Unrealized
Losses
 
Other Than Temporary Impairment
 
Fair Value
Six Months Ended March 26, 2016
$
2.4

 
$
—

 
$
(1.5
)
 
$
—

 
$
0.9

Year Ended September 26, 2015
$
16.1

 
$
7.2

 
$
(0.3
)
 
$
(7.8
)
 
$
15.2

In the first quarter of fiscal 2016, the Company sold all of its shares in one of its marketable securities and recorded a realized gain of $25.1 million in Other income (expense), net.
In the fourth quarter of fiscal 2015, the Company concluded that the decline in fair value of one of its marketable securities was other-than-temporary based on the length of time the security's market value was significantly below its carrying value and recorded an impairment charge of $7.8 million.

(8) Net Income Per Share
A reconciliation of basic and diluted share amounts is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Basic weighted average common shares outstanding
282,474

 
280,338

 
282,725

 
279,505

Weighted average common stock equivalents from assumed exercise of stock options and stock units
2,301

 
2,492

 
2,705

 
2,478

Incremental shares from Convertible Notes premium
3,082

 
4,750

 
4,484

 
3,395

Diluted weighted average common shares outstanding
287,857

 
287,580

 
289,914

 
285,378

Weighted-average anti-dilutive shares related to:
 
 
 
 
 
 
 
Outstanding stock options
1,106

 
1,865

 
919

 
2,824

Stock units
150

 
46

 
109

 
93

The Company has outstanding Convertible Notes, and the principal balance and any conversion premium may be satisfied, at the Company’s option, by issuing shares of common stock, cash or a combination of shares and cash. The Company's current policy is that it will settle the principal balance of the Convertible Notes in cash. As such, the Company applies the treasury stock method to these securities and the dilution related to the conversion premium of the 2010, 2012 and 2013 Notes is included in the calculation of diluted weighted-average shares outstanding to the extent each issuance is dilutive based on the average stock price during each reporting period being greater than the conversion price of the respective Notes.

16
Table of Contents


(9) Stock-Based Compensation
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Cost of revenues
$
2.5

 
$
2.3

 
$
4.7

 
$
4.3

Research and development
2.6

 
2.2

 
5.0

 
4.1

Selling and marketing
2.7

 
2.3

 
5.2

 
4.3

General and administrative
6.9

 
6.9

 
15.7

 
13.0

Restructuring and divestiture
—

 
—

 
—

 
0.1

 
$
14.7

 
$
13.7

 
$
30.6

 
$
25.8

The Company granted 1.0 million and 1.2 million stock options during the six months ended March 26, 2016 and March 28, 2015, respectively, with weighted-average exercise prices of $39.47 and $26.42, respectively. There were 6.7 million options outstanding at March 26, 2016 with a weighted-average exercise price of $24.80.
The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Risk-free interest rate
1.6
%
 
1.7
%
 
1.6
%
 
1.7
%
Expected volatility
37.8
%
 
38.6
%
 
37.8
%
 
38.6
%
Expected life (in years)
4.7

 
5.3

 
4.7

 
5.3

Dividend yield
—

 
—

 
—

 
—

Weighted average fair value of options granted
$
11.80

 
$
10.36

 
$
12.98

 
$
9.55

The Company granted 1.0 million and 1.4 million restricted stock units (RSUs) during the six months ended March 26, 2016 and March 28, 2015, respectively, with weighted-average grant date fair values of $39.63 and $26.35 per unit, respectively. As of March 26, 2016, there were 3.3 million unvested RSUs outstanding with a weighted-average grant date fair value of $29.58 per unit. In addition, the Company granted 0.2 million and 0.3 million performance stock units (PSUs) during the six months ended March 26, 2016 and March 28, 2015, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $39.72 and $26.58 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company is recognizing compensation expense ratably over the required service period based on its estimate of the number of shares that will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made.
At March 26, 2016, there was $27.3 million and $97.7 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs and PSUs), respectively, to be recognized over a weighted-average period of 3.3 years and 2.4 years, respectively.

(10) Share Repurchase
On November 11, 2013, the Company announced that its Board of Directors authorized the repurchase of up to $250.0 million of its outstanding common stock over the next three years. During the second quarter of fiscal 2016, the Company repurchased 4.3 million shares of its common stock for total consideration of $148.8 million with a weighted average per share price of $34.36. Total cash paid for these transactions during the second quarter aggregated $135.9 million with $12.9 million remaining unpaid as of March 26, 2016.


17
Table of Contents


(11) Other Balance Sheet Information

 
March 26,
2016
 
September 26,
2015
Inventories
 
 
 
Raw materials
$
98.6

 
$
98.3

Work-in-process
55.3

 
58.7

Finished goods
131.2

 
126.1

 
$
285.1

 
$
283.1

Property, plant and equipment
 
 
 
Equipment and software
$
377.8

 
$
365.9

Equipment under customer usage agreements
319.3

 
305.7

Building and improvements
182.8

 
182.1

Leasehold improvements
59.1

 
59.2

Land
51.4

 
51.4

Furniture and fixtures
18.1

 
17.3

 
1,008.5

 
981.6

Less – accumulated depreciation and amortization
(554.4
)
 
(524.5
)
 
$
454.1

 
$
457.1


18
Table of Contents


(12) Business Segments and Geographic Information
The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.
Identifiable assets for the four principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues during the three and six months ended March 26, 2016 and March 28, 2015. Segment information is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Total revenues:
 
 
 
 
 
 
 
Diagnostics
$
304.4

 
$
296.7

 
$
615.1

 
$
600.8

Breast Health
275.8

 
255.5

 
537.9

 
497.5

GYN Surgical
90.9

 
79.1

 
189.7

 
163.5

Skeletal Health
22.2

 
24.2

 
45.7

 
46.5

 
$
693.3


$
655.5


$
1,388.4


$
1,308.3

Income from operations:
 
 
 
 
 
 
 
Diagnostics
$
34.3

 
$
27.1

 
$
65.8

 
$
55.3

Breast Health
88.4

 
75.4

 
160.0

 
135.9

GYN Surgical
11.5

 
4.5

 
32.3

 
17.7

Skeletal Health
1.9

 
2.8

 
4.0

 
4.4

 
$
136.1


$
109.8

 
$
262.1

 
$
213.3

Depreciation and amortization:
 
 
 
 
 
 
 
Diagnostics
$
83.8

 
$
91.9

 
$
167.4

 
$
180.5

Breast Health
5.1

 
8.3

 
12.4

 
15.9

GYN Surgical
24.8

 
26.0

 
49.5

 
51.5

Skeletal Health
0.3

 
0.4

 
0.6

 
0.7

 
$
114.0


$
126.6


$
229.9


$
248.6

Capital expenditures:
 
 
 
 
 
 
 
Diagnostics
$
13.0

 
$
11.4

 
$
24.9

 
$
26.2

Breast Health
3.4

 
3.0

 
5.4

 
5.5

GYN Surgical
3.4

 
2.4

 
6.8

 
4.4

Skeletal Health
0.1

 
0.1

 
0.2

 
0.2

Corporate
2.1

 
1.8

 
4.4

 
3.4

 
$
22.0


$
18.7


$
41.7


$
39.7

 

19
Table of Contents

 
March 26,
2016
 
September 26,
2015
Identifiable assets:
 
 
 
Diagnostics
$
3,912.0

 
$
4,055.8

Breast Health
811.8

 
815.4

GYN Surgical
1,612.2

 
1,658.1

Skeletal Health
29.9

 
25.3

Corporate
920.4

 
1,115.5

 
$
7,286.3

 
$
7,670.1

The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 26, 2016 and March 28, 2015.
The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
United States
79.0
%
 
75.5
%
 
78.7
%
 
74.8
%
Europe
10.4
%
 
11.8
%
 
10.2
%
 
12.7
%
Asia-Pacific
7.4
%
 
8.9
%
 
7.6
%
 
8.8
%
All others
3.2
%
 
3.8
%
 
3.5
%
 
3.7
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%

(13) Income Taxes
In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.
The Company’s effective tax rate for the three and six months ended March 26, 2016 was 25.0% and 25.5%, respectively, compared to 21.4% and 26.6%, respectively, for the corresponding periods in the prior year. For the current three and six month periods, the effective tax rate was lower than the statutory tax rate primarily due to increased foreign profits at lower tax rates, the domestic production activities deduction benefit, and a change in the valuation allowance related to the sale of a marketable security that had a gain for book purposes. For the three and six months ended March 28, 2015, the effective tax rate differed from the statutory rate primarily due to the domestic production activities deduction benefit and reserve reversals attributable to a favorable income tax audit settlement.
In November 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred income taxes by eliminating the requirement for entities to separate deferred income tax liabilities and assets into current and noncurrent amounts in the balance sheet. Rather, it requires that deferred tax assets and liabilities are classified as noncurrent in the balance sheet. The Company adopted this standard prospectively in the first quarter of fiscal 2016, and prior periods were not retrospectively adjusted.


20
Table of Contents

(14) Intangible Assets
Intangible assets consisted of the following:
 
Description
As of March 26, 2016
 
As of September 26, 2015
Gross
Carrying
Value
 
Accumulated
Amortization
 
Gross
Carrying
Value
 
Accumulated
Amortization
Developed technology
$
3,983.8

 
$
1,843.1

 
$
3,979.1

 
$
1,698.5

In-process research and development
3.7

 
—

 
3.7

 
—

Customer relationships and contracts
1,100.0

 
507.0

 
1,101.1

 
467.5

Trade names
236.3

 
136.6

 
236.4

 
131.5

Business licenses
2.5

 
2.1

 
2.5

 
2.1

 
$
5,326.3


$
2,488.8


$
5,322.8


$
2,299.6

In the second quarter of fiscal 2016, the Company acquired certain intellectual property for $4.8 million, which was recorded in developed technology.
The estimated remaining amortization expense as of March 26, 2016 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2016
$
187.6

Fiscal 2017
$
366.1

Fiscal 2018
$
355.6

Fiscal 2019
$
343.9

Fiscal 2020
$
332.9


(15) Product Warranties
Product warranty activity was as follows:
 
 
Balance at
Beginning of
Period
 
Provisions
 
Settlements/
Adjustments
 
Balance at
End of Period
Six Months Ended:
 
 
 
 
 
 
 
March 26, 2016
$
5.4

 
$
7.3

 
$
(3.3
)
 
$
9.4

March 28, 2015
$
6.3

 
$
2.9

 
$
(3.5
)
 
$
5.7

During the first quarter of fiscal 2016, the Company recorded a warranty provision of $4.0 million related to certain products sold exclusively in the Chinese market.

21
Table of Contents

(16) Accumulated Other Comprehensive Loss

The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:

 
Three Months Ended March 26, 2016
 
Six Months Ended March 26, 2016
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(19.9
)
 
$
(0.9
)
 
$
(1.8
)
 
$
(3.3
)
 
$
(25.9
)
 
$
(15.7
)
 
$
6.9

 
$
(1.8
)
 
$
(3.9
)
 
$
(14.5
)
Other comprehensive income (loss) before reclassifications
(1.2
)
 
(0.6
)
 
—

 
(2.2
)
 
(4.0
)
 
(5.4
)
 
(1.2
)
 
—

 
(1.9
)
 
(8.5
)
Amounts reclassified to statement of income
—

 
—

 
—

 
0.7

 
0.7

 
—

 
(7.2
)
 
—

 
1.0

 
(6.2
)
Ending Balance
$
(21.1
)
 
$
(1.5
)
 
$
(1.8
)
 
$
(4.8
)
 
$
(29.2
)
 
$
(21.1
)
 
$
(1.5
)
 
$
(1.8
)
 
$
(4.8
)
 
$
(29.2
)

 
Three Months Ended March 28, 2015
 
Six Months Ended March 28, 2015
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(13.7
)
 
$
14.0

 
$
(1.5
)
 
$
—

 
$
(1.2
)
 
$
(4.7
)
 
$
8.9

 
$
(1.6
)
 
$
—

 
$
2.6

Other comprehensive income (loss) before reclassifications
(9.5
)
 
(8.3
)
 
—

 
(1.6
)
 
(19.4
)
 
(18.5
)
 
(3.2
)
 
0.1

 
(1.6
)
 
(23.2
)
Amounts reclassified to statement of income
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

Ending Balance
$
(23.2
)
 
$
5.7

 
$
(1.5
)
 
$
(1.6
)
 
$
(20.6
)
 
$
(23.2
)
 
$
5.7

 
$
(1.5
)
 
$
(1.6
)
 
$
(20.6
)


(17) New Accounting Pronouncements

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). The guidance changes how companies account for certain aspects of share-based payments to employees. Entities will be required to recognize income tax effects of awards in the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee's shares than it can today for tax withholding purposes by providing for withholding at the employee's maximum rate as opposed to the minimum rate without triggering liability accounting and by allowing an entity-wide policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December 15, 2016, and is applicable to the Company in fiscal 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The guidance requires an entity to recognize a right-of-use asset and a lease liability for virtually all of its leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The guidance is effective for annual periods beginning after December 15, 2018, and is applicable to the Company in fiscal 2020. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its consolidated financial position and results of operations.
 
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This guidance changes how entities measure equity investments that do not result in consolidation and are not accounted for under the equity method. Entities will be required to measure these investments at fair value at the end of each reporting period and recognize changes in fair value in net income. A practicability exception will be available for equity investments that do not have readily determinable fair values, however; the exception requires the Company to consider relevant transactions that can be reasonably known to identify any observable price changes that would impact the fair value. This guidance also changes certain disclosure requirements and other aspects of

22
Table of Contents

current US GAAP. This guidance is effective for annual periods beginning after December 15, 2017, and is applicable to the Company in fiscal 2019. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-01 on its consolidated financial position and results of operations.

In July 2015, the FASB issued guidance under ASC 330, Simplifying the Measurement of Inventory. The new guidance requires inventory to be measured at the lower of cost and net realizable value, which is defined as the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. This new guidance is effective for the Company's first quarter of fiscal 2018 and early adoption is permitted. The guidance must be applied prospectively. The Company is currently evaluating the impact of the adoption of this requirement on its consolidated financial statements but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Presentation of Debt Issuance Costs. This guidance intends to simplify the presentation of debt issuance costs and more closely align the presentation of debt issuance costs under U.S. GAAP to IFRS standards. This guidance is effective for annual periods beginning after December 15, 2015, and is applicable to the Company in fiscal 2017. Early adoption is permitted. The Company is currently evaluating this guidance, but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements.
    
In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. This guidance focuses on a reporting company’s consolidation evaluation to determine whether certain legal entities should be consolidated. This guidance is effective for annual periods beginning after December 15, 2015, and is applicable to the Company in fiscal 2017. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating this guidance, but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and is applicable to the Company in fiscal 2018. Early adoption is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on the Company's consolidated financial statements or disclosures.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 660), which provides guidance for revenue recognition. This ASU is applicable to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to receive in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current U.S. GAAP. These judgments may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. On July 9, 2015, the FASB voted in favor of delaying the effective date of the new standard by one year, with early adoption permitted as of the original effective date. ASU 2014-09 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2017, which is fiscal 2019 for the Company. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.

23
Table of Contents

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY STATEMENT
Some of the statements contained in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding:
 
•
the effect of the continuing worldwide macroeconomic uncertainty on our business and results of operations;
•
the coverage and reimbursement decisions of third-party payors and the guidelines, recommendations, and studies published by various organizations relating to the use of our products and treatments;
•
the uncertainty of the impact of cost containment efforts and federal healthcare reform legislation on our business and results of operations;
•
the ability to successfully manage ongoing organizational and strategic changes, including our ability to attract, motivate and retain key employees;
•
the impact and anticipated benefits of completed acquisitions and acquisitions we may complete in the future;
•
the ability to consolidate certain of our manufacturing and other operations on a timely basis and within budget, without disrupting our business and to achieve anticipated cost synergies related to such actions;
•
our goal of expanding our market positions;
•
the development of new competitive technologies and products;
•
regulatory approvals and clearances for our products;
•
production schedules for our products;
•
the anticipated development of markets we sell our products into and the success of our products in these markets;
•
the anticipated performance and benefits of our products;
•
business strategies;
•
estimated asset and liability values;
•
the impact and costs and expenses of any litigation we may be subject to now or in the future;
•
our compliance with covenants contained in our debt agreements;
•
anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations; and
•
our capital resources and the adequacy thereof.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial results include the cautionary statements set forth herein and in our other filings with the Securities and Exchange Commission, including those set forth under Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 26, 2015. We qualify all of our forward-looking statements by these cautionary statements.
OVERVIEW
We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. We sell and service our products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives.

24

We offer a wide range of diagnostic products which are used primarily to aid in the diagnosis of human diseases and screen donated human blood and plasma. Our primary diagnostics products include our Aptima family of assays, which run on our advanced instrumentation systems (Panther and Tigris), our ThinPrep system, the Rapid Fetal Fibronectin Test and our Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, or STDs, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus, or HPV, and Trichomonas vaginalis, the parasite that causes trichomoniasis. The ThinPrep System is primarily used in cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test assists physicians in assessing the risk of pre-term birth. In blood screening, we develop and manufacture the Procleix family of assays, which are used to detect various infectious diseases. These blood screening products are marketed worldwide by our blood screening collaborator, Grifols S.A., or Grifols, under Grifols' trademarks.
Our Breast Health products include a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, or CAD, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. Our most advanced breast imaging platform, Dimensions, utilizes a technology called tomosynthesis to produce 3D images that show multiple contiguous slice images of the breast, which we refer to as the Genius 3D Mammography exam, as well as conventional 2D full field digital mammography images. Our clinical results for FDA approval demonstrated that conventional 2D digital mammography with the addition of 3D tomosynthesis is superior to 2D digital mammography alone for both screening and diagnostics.
Our GYN Surgical products include our NovaSure Endometrial Ablation System or NovaSure, and our MyoSure Hysteroscopic Tissue Removal System or MyoSure. The NovaSure system involves a trans-cervical procedure for the treatment of abnormal uterine bleeding. The MyoSure system is a tissue removal device that is designed to provide incision-less removal of fibroids, polyps, and other pathology within the uterus.
Our Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems that assist in performing minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle.
Unless the context otherwise requires, references to we, us, Hologic or our company refer to Hologic, Inc. and its consolidated subsidiaries.
Trademark Notice
Hologic is a trademark of Hologic, Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3D, 3D Mammography, Affirm, Aptima, Aptima Combo 2, ATEC, Celero, Cervista, Contura, C-View, Cytyc, Dimensions, DirectRay, Discovery, Eviva, Fluoroscan, Genius, Gen-Probe, Healthcome, Horizon, Interlace, Invader, MultiCare, MyoSure, NovaSure, Panther, PreservCyt, Progensa, SecurView, Selenia, StereoLoc, TCT, ThinPrep, Tigris, TLI IQ, and TMA.


25
Table of Contents

RESULTS OF OPERATIONS
All dollar amounts in tables are presented in millions.
Product Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
Change
 
March 26, 2016
 
March 28, 2015
 
Change
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
Product Revenues
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostics
$
298.2

 
43.0
%
 
$
290.4

 
44.3
%
 
$
7.8

 
2.7
 %
 
$
601.6

 
43.3
%
 
$
586.6

 
44.8
%
 
$
15.0

 
2.6
 %
Breast Health
179.0

 
25.8
%
 
159.9

 
24.4
%
 
19.1

 
11.9
 %
 
347.4

 
25.0
%
 
310.7

 
23.8
%
 
36.7

 
11.8
 %
GYN Surgical
90.6

 
13.1
%
 
78.8

 
12.0
%
 
11.8

 
15.0
 %
 
189.1

 
13.6
%
 
162.9

 
12.4
%
 
26.2

 
16.1
 %
Skeletal Health
15.2

 
2.2
%
 
17.3

 
2.6
%
 
(2.1
)
 
(12.2
)%
 
32.1

 
2.3
%
 
32.8

 
2.5
%
 
(0.7
)
 
(2.1
)%
 
$
583.0

 
84.1
%
 
$
546.4

 
83.3
%
 
$
36.6

 
6.7
 %
 
$
1,170.2

 
84.2
%
 
$
1,093.0

 
83.5
%
 
$
77.2

 
7.1
 %
We generated an increase in product revenues in both the three and six month periods compared to the corresponding periods in the prior year across each of our business segments, with the exception of Skeletal Health. Product revenues increased 6.7% and 7.1%, respectively, in the current year periods, as reported growth was partially offset by the negative foreign currency exchange impact of the strengthening U.S. dollar against a number of currencies, most notably the Euro, Australian dollar and UK Pound.
Diagnostics product revenues increased 2.7% and 2.6% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year due to increases in Molecular Diagnostics of $5.6 million and $15.7 million, respectively, and Cytology & PeriNatal of $2.9 million and $3.5 million, respectively, partially offset by a decrease in Blood Screening of $0.7 million and $4.2 million, respectively.
Molecular Diagnostics product revenue, and in particular revenue related to our Aptima family of assays, increased in the current three and six month periods primarily due to our increased installed base of Panther instruments, which is driving higher volumes of assay testing. These increases were partially offset by a slight decline in average selling prices, a reduction in Cervista HPV revenues as our larger customers transition to our Panther system and the negative foreign currency exchange impact of the strengthening U.S. dollar on our sales denominated in foreign currencies, which had more of an impact on the six month results than the current three month results. The increase in our Cytology & PeriNatal products in the current three and six month periods compared to the corresponding periods in the prior year was primarily related to the increased sales of our ThinPrep Pap Test in the U.S. while international sales volumes were relatively flat. The international revenues in this business line were also impacted by the negative foreign currency exchange impact of the strengthening U.S. dollar on our sales denominated in foreign currencies, which had more of an impact on the six month results than the current three month results. Blood screening revenues decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to a reduction in volumes related to the agreement between Grifols and the Japanese Red Cross. This revenue decrease was partially offset by fluctuations in Grifols' domestic inventory levels, including increased fulfillment of the West Nile Virus assay.
Breast Health product revenues increased 11.9% and 11.8% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year primarily due to an increase in our digital mammography systems and related components revenue of $22.9 million and $40.8 million, respectively. This increase is primarily due to higher sales volume of our 3D Dimensions systems on a worldwide basis, principally driven by domestic sales, which represent a higher percentage of total 3D system sales and have higher average selling prices. In addition, we also had higher software sales primarily driven by our C-View product. These increases were partially offset by the negative foreign currency exchange impact of the strengthening U.S. dollar on our sales denominated in foreign currencies, which had more of an impact on the six month results than the current three month results, and decreases in the sales volume of our 2D Selenia product. In addition, the Company had no sales from its MRI coils business in fiscal 2016, which was fully disposed of during fiscal 2015 and contributed $5.1 million and $5.3 million for the three and six month periods ended March 28, 2015, respectively.

26
Table of Contents

GYN Surgical product revenues increased 15.0% and 16.1% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year primarily due to an increase in MyoSure system sales of $7.9 million and $19.2 million, respectively. NovaSure revenues increased by $3.6 million and $6.8 million, respectively, in the current three and six month periods compared to the corresponding periods in the prior year as volumes increased domestically, which we believe is partially attributable to a recent competitive withdrawal from the market, and to a lesser extent internationally. These increases were partially offset by the negative foreign currency exchange impact of the strengthening U.S. dollar on our sales denominated in foreign currencies, which had more of an impact on the six month results than the current three month results.
Skeletal Health product revenues decreased 12.2% and 2.1% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year primarily due to lower sales volumes of our older Discovery products, which were partially offset by increases in our Horizon osteoporosis assessment product sales volume. These decreases were driven by lower sales volumes internationally, which were partially offset by increased sales volumes domestically in both of the current three and six month periods. In addition, mini C-arm sales were lower in both of the current three and six month periods.
Product revenues by geography as a percentage of total product revenues were as follows:
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
March 26, 2016
 
March 28, 2015
United States
77.8
%
 
74.1
%
 
77.5
%
 
73.3
%
Europe
10.9
%
 
12.1
%
 
10.7
%
 
13.2
%
Asia-Pacific
8.1
%
 
9.9
%
 
8.4
%
 
9.7
%
All others
3.2
%
 
3.9
%
 
3.4
%
 
3.8
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
The increase in product revenues in the United States as a percentage of consolidated product revenues in the current three and six month periods compared to the corresponding periods in the prior year was primarily the result of higher total product revenue in the U.S. in our Breast Health and Molecular Diagnostic product lines. The impact of the U.S. increases, lower overall international revenues, and the negative impact of the strengthening U.S. dollar, primarily against the Euro and UK Pound, resulted in a reduction in European and Asia-Pacific revenues as a percentage of consolidated revenues in both the current year periods.
Service and Other Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
Change
 
March 26, 2016
 
March 28, 2015
 
Change
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
Service and Other Revenues
$
110.3

 
15.9
%
 
$
109.1

 
16.7
%
 
$
1.2

 
1.1
%
 
$
218.2

 
15.7
%
 
$
215.3

 
16.5
%
 
$
2.9

 
1.4
%
Service and other revenues are primarily comprised of revenue generated from our field service organization to provide ongoing service, installation and repair of our products. The majority of these revenues are generated within our Breast Health segment. Service and other revenues increased 1.1% and 1.4% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year primarily due to slightly higher service contract renewal rates and higher installation and training revenues related to our increased sales of 3D Dimensions systems, and an increase in spare parts sales.

27
Table of Contents

Cost of Product Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
Change
 
March 26, 2016
 
March 28, 2015
 
Change
 
Amount
 
% of
Product
Revenue
 
Amount
 
% of
Product
Revenue
 
Amount
 
%
 
Amount
 
% of
Product
Revenue
 
Amount
 
% of
Product
Revenue
 
Amount
 
%
Cost of Product Revenues
$
182.0

 
31.2
%
 
$
186.7

 
34.2
%
 
$
(4.7
)
 
(2.5
)%
 
$
370.1

 
31.6
%
 
$
373.4

 
34.2
%
 
$
(3.3
)
 
(0.9
)%
Amortization of Intangible Assets
70.8

 
12.2
%
 
78.6

 
14.4
%
 
(7.8
)
 
(9.9
)%
 
144.3

 
12.3
%
 
152.5

 
14.0
%
 
(8.2
)
 
(5.4
)%
 
$
252.8

 
43.4
%
 
$
265.3

 
48.6
%
 
$
(12.5
)
 
(4.7
)%
 
$
514.4

 
44.0
%
 
$
525.9

 
48.1
%
 
$
(11.5
)
 
(2.2
)%
Cost of Product Revenues. The cost of product revenues as a percentage of product revenues was 31.2% and 31.6% in the current three and six month periods, respectively, compared to 34.2% in each of the corresponding periods in the prior year. Cost of product revenues as a percentage of product revenues in both the current year periods decreased in each of our business segments compared to the corresponding periods in the prior year, resulting in the overall improvement in gross margins.
Diagnostics' product costs as a percentage of revenue decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to an increase in product revenue related to the increase in Aptima assay sales and related volumes resulting in favorable manufacturing variances, and lower production costs at our manufacturing facilities as we improve our operational effectiveness and renegotiate pricing with certain of our vendors. In addition, we generated an increase in domestic sales, which have higher average selling prices, while international sales declined in both the current three and six month periods compared to the corresponding periods in the prior year resulting in an improved gross margin. Partially offsetting these improvements was the negative impact of the strengthening U.S. dollar on our sales denominated in foreign currencies, primarily impacting the current six month period.

Breast Health’s product costs as a percentage of revenue decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the favorable product mix shift to our higher margin 3D Dimensions systems which also have higher average sales prices than our 2D systems. In addition, we had higher software sales primarily due to our C-View product, which have higher gross margins than capital equipment sales, and we experienced favorable manufacturing variances. Further, we generated an increase in domestic sales, which have higher average selling prices, while international sales declined in both the current three and six month periods compared to the corresponding periods in the prior year resulting in an improved gross margin. Partially offsetting these improvements was the negative impact of the strengthening U.S. dollar on our sales denominated in foreign currencies, which had more of an impact on the six month results than the current three month results, and a $6.0 million aggregate charge related to inventory and warranty costs associated with product produced exclusively for the Chinese market recorded in the first quarter of fiscal 2016.

GYN Surgical’s product costs as a percentage of revenue decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the increase in sales volume for both our MyoSure and NovaSure products resulting in favorable manufacturing variances, partially offset by product mix shift to our lower margin MyoSure product. In addition, the prior year periods included a $4.0 million charge to write-off inventory that would not be utilized.
 
Skeletal Health’s product costs as a percentage of revenue decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to favorable manufacturing variances as we build additional inventory in anticipation of outsourcing the manufacturing of a majority of the division's products to a third party.
Amortization of Intangible Assets. Amortization of intangible assets relates to acquired developed technology, which is generally amortized over its estimated useful life of between 8.5 and 15 years using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are expected to be consumed. Amortization expense decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to lower amortization expense from intangible assets from the Cytyc acquisition, which are being amortized based on the pattern of economic use, and the full amortization of assets acquired in our Suros acquisition.

28
Table of Contents

Cost of Service and Other Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
Change
 
March 26, 2016
 
March 28, 2015
 
Change
 
Amount
 
% of
Service
Revenue
 
Amount
 
% of
Service
Revenue
 
Amount
 
%
 
Amount
 
% of
Service
Revenue
 
Amount
 
% of
Service
Revenue
 
Amount
 
%
Cost of Service and Other Revenue
$
55.5

 
50.3
%
 
$
54.2

 
49.7
%
 
$
1.3

 
2.3
%
 
$
109.9

 
50.4
%
 
$
107.8

 
50.1
%
 
$
2.1

 
2.0
%
Service and other revenues gross margin decreased slightly to 49.7% and 49.6% in the current three and six month periods, respectively, compared to 50.3% and 49.9% in the corresponding periods in the prior year, respectively.
Operating Expenses
 
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
Change
 
March 26, 2016
 
March 28, 2015
 
Change
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
Operating Expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
$
59.1

 
8.5
%
 
$
53.3

 
8.1
%
 
$
5.8

 
11.0
 %
 
$
110.8

 
8.0
%
 
$
105.2

 
8.0
%
 
$
5.6

 
5.3
 %
Selling and marketing
100.8

 
14.5
%
 
83.0

 
12.7
%
 
17.8

 
21.4
 %
 
200.3

 
14.4
%
 
169.0

 
12.9
%
 
31.3

 
18.5
 %
General and administrative
62.4

 
9.0
%
 
60.3

 
9.2
%
 
2.1

 
3.5
 %
 
139.5

 
10.0
%
 
121.7

 
9.3
%
 
17.8

 
14.6
 %
Amortization of intangible assets
22.8

 
3.3
%
 
27.6

 
4.2
%
 
(4.8
)
 
(17.4
)%
 
45.4

 
3.3
%
 
55.4

 
4.2
%
 
(10.0
)
 
(18.0
)%
Restructuring and divestiture charges
3.8

 
0.5
%
 
2.0

 
0.3
%
 
1.8

 
90.0
 %
 
6.0

 
0.4
%
 
10.0

 
0.8
%
 
(4.0
)
 
(40.0
)%
 
$
248.9

 
35.9
%
 
$
226.2

 
34.5
%
 
$
22.7

 
10.0
 %
 
$
502.0

 
36.2
%
 
$
461.3

 
35.3
%
 
$
40.7

 
8.8
 %
Research and Development Expenses. Research and development expenses increased 11.0% and 5.3% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year primarily due to higher compensation, primarily in our Breast Health and GYN Surgical segments, partially from additional headcount in fiscal 2016. There was also an increase in new product development spend in Breast Health and GYN Surgical for prototype materials and consulting. These increases were partially offset by decreased program spend primarily within our Diagnostics business, including decreased clinical spending and lower spend for prototype materials. At any point in time, we have a number of different research projects and clinical trials being conducted and the timing of these projects and related costs can vary from period to period.
Selling and Marketing Expenses. Selling and marketing expenses increased 21.4% and 18.5% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year primarily due to higher compensation from an increase in headcount in Diagnostics, GYN Surgical and Breast Health, increased commissions as a result of higher sales, an increase in spending on a number of marketing initiatives primarily in our Breast Health and Diagnostics businesses, higher medical education spend in GYN Surgical and higher travel, trade show and meeting expenses.
General and Administrative Expenses. General and administrative expenses increased 3.5% and 14.6% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year. The increase in the current three and six month periods compared to the corresponding periods in the prior year is primarily due to higher salary and compensation from increased headcount and improved operating results, increased consulting, tax, and legal expenses for a number of corporate initiatives including organizational structure changes and finance operational improvements, and an increase in information systems infrastructure and project costs. These increases were partially offset by lower medical device excise taxes of $6.1 million and $5.1 million for the three and six months ended March 26, 2016, respectively, related to the Protecting Americans from Tax Hikes Act of 2015 ("PATH"), which went into effect December 15, 2015, and provides for a two-year moratorium on the 2.3% excise tax imposed on the sale of medical devices, covering sales made on or after January 1, 2016 through December 31, 2017. In addition, the increase

29
Table of Contents

in expenses in the current six month period was also driven by a $6.0 million charge for settling a fee dispute in the first quarter of fiscal 2016.
Amortization of Intangible Assets. Amortization of intangible assets results from customer relationships, trade names and business licenses related to our acquisitions. These intangible assets are generally amortized over their estimated useful lives of between 2 and 30 years using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are expected to be consumed utilizing expected undiscounted future cash flows. Amortization expense decreased 17.4% and 18.0% in the current three and six month periods, respectively, compared to the corresponding periods in the prior year primarily due to lower amortization expense from intangible assets from the Gen-Probe Incorporated acquisition (we phased out certain corporate trade names in fiscal 2015) and the Cytyc acquisition, which are being amortized based on the pattern of economic use.
Restructuring and Divestiture Charges. In fiscal 2014, we implemented cost containment measures that primarily resulted in headcount reductions and also started the process of reorganizing our senior management team and international structure, which led to additional headcount actions in fiscal 2015. In addition, in fiscal 2015, we decided to shut down our Bedford, Massachusetts facility and transfer production of our Skeletal Health products to a third-party contract manufacturer and other activities to our Marlborough, Massachusetts and Danbury, Connecticut facilities. As such, we will terminate certain manufacturing employees. We also implemented additional organizational changes to our international operations in the first two quarters of fiscal 2016, which we expect will continue throughout fiscal 2016 and result in additional charges. Pursuant to U.S. generally accepted accounting principles, the related severance and benefit charges are being recognized either ratably over the respective required employee service periods or up-front for contractual benefits, and other charges are being recognized as incurred. In the current three and six month periods, we recorded aggregate charges of $3.8 million and $6.0 million, respectively, related to these actions for severance and benefits. In the prior year period, we recorded aggregate charges of $2.0 million and $10.0 million, respectively, related to these actions, primarily for severance and benefits and, to a lesser extent facility closure costs. For additional information pertaining to restructuring actions and charges, please refer to Note 3 to the consolidated financial statements contained in Part I, Item 1 of this Quarterly Report.
Interest Expense
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Interest Expense
$
(39.1
)
 
$
(49.4
)
 
$
10.3

 
(20.9
)%
 
$
(78.3
)
 
$
(101.9
)
 
$
23.6

 
(23.1
)%

Interest expense consists primarily of the cash interest costs and the related amortization of the debt discount and deferred issuance costs on our Convertible Notes, 2022 Senior Notes and amounts borrowed under our Credit Agreement and Prior Credit Agreement. The decrease in interest expense in the current three and six month periods compared to the corresponding periods in the prior year was primarily due to lower outstanding debt balances as a result of scheduled principal payments, a term loan prepayment and extinguishments in fiscal 2015 and, to a lesser extent, Convertible Note repurchases in fiscal 2016 of $226.6 million principal amount, and lower interest rates in fiscal 2016 as a result of debt refinancings in fiscal 2015.

Debt Extinguishment Loss
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Debt Extinguishment Loss
$
(4.5
)
 
$
—

 
$
(4.5
)
 
(100.0
)%
 
$
(4.5
)
 
$
(6.7
)
 
$
2.2

 
(32.8
)%
On various dates during the second quarter of fiscal 2016, we entered into privately negotiated repurchase transactions and extinguished $90.0 million and $136.6 million principal amount of our 2010 Notes and 2012 Notes, respectively, for total payments of $140.1 million and $171.3 million, respectively. In connection with these transactions, we recorded a debt extinguishment loss of

30
Table of Contents

$3.8 million and $0.7 million on the 2010 Notes and 2012 Notes, respectively, related to the difference between the fair value of their respective liability components and carrying values at the repurchase dates plus a pro-rata amount of deferred issuance costs. The remaining cash payments of $88.8 million were allocated to the reacquisition of the equity component and recorded within additional paid-in capital within stockholders' equity.

In the first quarter of fiscal 2015, we made a voluntary pre-payment of $300.0 million on our Term Loan B facility under the Prior Credit Agreement. In connection with this transaction, we recorded a debt extinguishment loss of $6.7 million to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to this voluntary pre-payment. The prepayment was considered a partial debt extinguishment.
Other Income (Expense), net
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Other Income (Expense), net
$
(0.8
)
 
$
0.1

 
$
(0.9
)
 
(900.0
)%
 
$
26.9

 
$
(0.5
)
 
$
27.4

 
**
** Percentage not meaningful

For the current three month period, this account was primarily comprised of losses of $0.8 million on the cash surrender value of life insurance contracts and mutual funds related to our deferred compensation plan and net foreign currency exchange losses of $0.1 million. For the prior year corresponding three month period, this account was primarily comprised of gains of $0.5 million on the cash surrender value of life insurance contracts and mutual funds related to our deferred compensation plan, partially offset by net foreign currency exchange losses of $0.4 million.

For the current six month period, this account was primarily comprised of a $25.2 million realized gain on the sale of a marketable security, a gain of $0.4 million on the cash surrender value of life insurance contracts and mutual funds related to our deferred compensation plan and net foreign currency exchange gains of $1.0 million. For the prior year corresponding six month period, this account was primarily comprised of net foreign currency exchange losses of $1.9 million, partially offset by gains of $1.5 million on the cash surrender value of life insurance contracts and mutual funds related to our deferred compensation plan.
Provision for Income Taxes
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Provision for Income Taxes
$
23.0

 
$
13.0

 
$
10.0

 
76.9
%
 
$
52.8

 
$
27.9

 
$
24.9

 
89.2
%
Our effective tax rate for the current three and six month periods was 25.0% and 25.5%, respectively, compared to 21.4% and 26.6%, respectively, for the corresponding periods in the prior year. For the current three and six month periods, the effective tax rate was lower than the statutory tax rate primarily due to increased foreign profits at lower tax rates, the domestic production activities deduction benefit, and a change in the valuation allowance related to the sale of a marketable security that had a gain for book purposes. For the three and six months ended March 28, 2015, the effective tax rate differed from the statutory rate primarily due to the domestic production activities deduction benefit and reserve reversals attributable to a favorable income tax audit settlement.
Segment Results of Operations
We report our business as four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The accounting policies of the segments are the same as those described in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended September 26, 2015. We measure segment performance based on total revenues and operating income or loss. Revenues from product sales of each of these segments are described in further detail above. The discussion that follows is a summary analysis of total revenues and the primary changes in operating income or loss by segment.

31
Table of Contents

Diagnostics
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
304.4

 
$
296.7

 
$
7.7

 
2.6
%
 
$
615.1

 
$
600.8

 
$
14.3

 
2.4
%
Operating Income
$
34.3

 
$
27.1

 
$
7.2

 
26.6
%
 
$
65.8

 
$
55.3

 
$
10.5

 
19.0
%
Operating Income as a % of Segment Revenue
11.2
%
 
9.1
%
 
 
 
 
 
10.7
%
 
9.2
%
 
 
 
 
Diagnostics revenues increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the increase in product revenues discussed above.
Operating income for this business segment increased in the current three and six month periods compared to the corresponding periods in the prior year due to increased gross profit in absolute dollars, partially offset by higher operating expenses. Gross profit in absolute dollars increased in the current year periods primarily due to increased Aptima sales and related favorable manufacturing variances, and lower production costs at our manufacturing facilities as we improve our operational effectiveness and renegotiate pricing with certain of our vendors. In addition, amortization expense was lower in the current year periods due to lower amortization expense from intangible assets as discussed above. Partially offsetting these improvements was the negative impact of the strengthening U.S. dollar on our sales denominated in foreign currencies, primarily impacting the current six month period. As a result, gross margin improved to 50.3% in both the current three and six month periods, from 47.9% and 48.3% in the corresponding prior year periods, respectively.
Operating expenses increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to higher sales and marketing spend related to various initiatives and trade shows, and an increase in compensation from higher headcount and commissions, higher legal fees and information systems infrastructure costs. These increases were partially offset by a decrease in spending on research and development project spending for clinical trials and prototype materials, lower amortization expense from intangible assets as discussed above, and lower medical device excise taxes of $2.5 million in both periods. The increase in the six month period also included an increase in legal fees related to the settlement of a fee dispute for $6.0 million.
Breast Health
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
275.8

 
$
255.5

 
$
20.3

 
8.0
%
 
$
537.9

 
$
497.5

 
$
40.4

 
8.1
%
Operating Income
$
88.4

 
$
75.4

 
$
13.0

 
17.3
%
 
$
160.0

 
$
135.9

 
$
24.1

 
17.7
%
Operating Income as a % of Segment Revenue
32.1
%
 
29.5
%
 
 
 
 
 
29.7
%
 
27.3
%
 
 
 
 
Breast Health revenues increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the $19.1 million and $36.7 million increase in product revenue discussed above and the $1.2 million and $3.8 million increase in service revenue that was substantially related to slightly higher service contract renewal rates and higher installation and training revenues related to increased sales of our 3D Dimensions systems, and an increase in spare parts sales.
Operating income for this business segment increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to an increase in gross profit in absolute dollars from higher revenue, partially offset by an increase in operating expenses. The overall gross margin increased to 60.2% and 58.5% in the current three and six month periods, respectively, compared to 56.3% and 55.1% in the corresponding periods in the prior year. These increases were

32
Table of Contents

primarily due to the increase in 3D Dimensions sales, on both a unit basis and as a percentage of total digital mammography systems, and an increase in software related sales, each of which have higher gross margins. In addition, this business experienced favorable manufacturing variances. These increases were partially offset by the negative foreign currency impact of the strengthening U.S. dollar on our sales denominated in foreign currencies and a $6.0 million aggregate charge in the current six month period related to inventory and warranty costs associated with product produced exclusively for the Chinese market.
Operating expenses increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to an increase in compensation and commissions from an increased head count and improved operating results, higher marketing expenditures for a number of marketing programs, and increased trade show and meeting expenses, higher clinical trial and prototype materials expenses, and increased information systems infrastructure costs. These expense increases were partially offset by lower medical device excise taxes of $2.3 million and $1.5 million for the three and six months ended March 26, 2016, respectively, lower restructuring charges and lower intangible asset amortization expense.
GYN Surgical
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
90.9

 
$
79.1

 
$
11.8

 
14.9
%
 
$
189.7

 
$
163.5

 
$
26.2

 
16.0
%
Operating Income
$
11.5

 
$
4.5

 
$
7.0

 
153.9
%
 
$
32.3

 
$
17.7

 
$
14.6

 
82.5
%
Operating Income as a % of Segment Revenue
12.7
%
 
5.7
%
 
 
 
 
 
17.0
%
 
10.8
%
 
 
 
 
GYN Surgical revenues increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the change in product revenues discussed above.
Operating income for this business segment increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to an increase in gross profit in absolute dollars, partially offset by an increase in operating expenses. Gross margin increased to 59.8% and 61.7% in the current three and six month periods, respectively, from 50.2% and 55.2% in the corresponding periods in the prior year. These increases were primarily due to increased sales volumes for both our MyoSure and NovaSure products resulting in favorable manufacturing variances, partially offset by product mix shift to our lower margin MyoSure products. In addition, intangible asset amortization expense is lower in the current year periods. Gross margin is also higher in the current year periods as the prior year periods included a $4.0 million charge to write-off inventory that would not be utilized.
Operating expenses increased in the current three and six month periods primarily due to an increase in compensation from additional headcount, higher commissions due to increased sales, increased spend on marketing initiatives and medical education, increased research and development expenses as we develop next generation devices and higher legal expenses.

33
Table of Contents

Skeletal Health
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
Change
 
March 26,
2016
 
March 28,
2015
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
22.2

 
$
24.2

 
$
(2.0
)
 
(8.5
)%
 
$
45.7

 
$
46.5

 
$
(0.8
)
 
(1.8
)%
Operating Income
$
1.9

 
$
2.8

 
$
(0.9
)
 
(31.9
)%
 
$
4.0

 
$
4.4

 
$
(0.4
)
 
(8.9
)%
Operating Income as a % of Segment Revenue
8.7
%
 
11.7
%
 
 
 
 
 
8.8
%
 
9.5
%
 
 
 
 
Skeletal Health revenues decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the decrease in product revenues discussed above.
Operating income decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to higher operating expenses for compensation and additional investment in research and development projects, partially offset by the increase in gross profit in absolute dollars as a result of higher sales of our higher margin Horizon product and favorable manufacturing variances as we build up inventory in advance of transitioning production of these products to a third-party manufacturer. The gross margin rate increased to 51.0% and 49.6% in the current three and six month periods, respectively, from 43.4% and 42.8% in the corresponding periods in the prior year.

LIQUIDITY AND CAPITAL RESOURCES
At March 26, 2016, we had $251.6 million of working capital and our cash and cash equivalents totaled $316.3 million. Our cash and cash equivalents balance decreased by $175.0 million during the first six months of fiscal 2016 primarily due to payments to extinguish certain of our Convertible Notes and payments to repurchase common stock, partially offset by cash generated through operating activities.
In the first six months of fiscal 2016, our operating activities provided us with $314.4 million of cash, primarily due to net income of $153.8 million, non-cash charges for depreciation and amortization aggregating $229.9 million, non-cash interest expense of $26.1 million related to our outstanding debt and stock-based compensation expense of $30.6 million. These adjustments to net income were partially offset by a decrease in net deferred tax liabilities of $64.7 million, primarily from the amortization of intangible assets, and a gain on the sale of a marketable security of $25.1 million. Cash provided by operations also included a net cash outflow of $33.8 million from changes in our operating assets and liabilities. Changes in our operating assets and liabilities were driven primarily by an increase in prepaid expenses and other assets of $15.0 million due to the timing of the annual renewal of insurance coverage and software maintenance agreements, a decrease in deferred revenue of $12.4 million primarily due to meeting revenue recognition criteria on certain transactions in the second quarter, and an increase in accounts receivable of $7.0 million due to the increase in revenue and timing of cash receipts. These cash flow uses were partially offset by a decrease in prepaid income taxes of $3.4 million based on the timing of payments versus income tax expense.
In the first six months of fiscal 2016, we used $14.5 million of cash from investing activities, primarily related to $41.7 million for capital expenditures, which consisted of the placement of equipment under customer usage agreements and purchases of manufacturing equipment and computer hardware, partially offset by cash received from the sale of a marketable security for $31.1 million.
In the first six months of fiscal 2016, our financing activities used cash of $473.6 million primarily for payments to extinguish certain of our Convertible Notes of $311.5 million, repurchases of common stock of $135.9 million, payments related to our long term debt of $37.5 million and payments of $15.6 million for employee-related taxes withheld for the net share settlement of vested restricted stock units. Partially offsetting these uses of cash were proceeds of $19.0 million from our equity plans, primarily from the exercise of stock options.
Debt
We had total recorded debt outstanding of $3.4 billion at March 26, 2016, which is comprised of amounts outstanding under our Credit Agreement of $1.61 billion (principal $1.62 billion), 2022 Senior Notes of $987.7 million (principal $1.0

34

billion) and Convertible Notes of $805.2 million (principal $793.3 million), which includes accretion of interest at 4.0% per annum on the 2013 Notes.
Credit Agreement
The credit facilities under the Credit Agreement consist of:
•
A $1.5 billion secured term loan to Hologic with a final maturity date of May 29, 2020 (the "Term Loan"); and
•
A secured revolving credit facility under which we may borrow up to $1 billion, subject to certain sublimits, with a final maturity date of May 29, 2020 (the "Revolver").

Borrowings are secured by first-priority liens on, and a first-priority security interest in, substantially all of our assets, with certain exceptions.
We are required to make scheduled principal payments under the Term Loan in increasing amounts ranging from $18.75 million per three-month period commencing with the three-month period ending on September 25, 2015 to $37.5 million per three-month period commencing with the three-month period ending on September 28, 2018. The remaining balance of the Term Loan is due at maturity. Any amounts outstanding under the Revolver are due at maturity. In addition, subject to the terms and conditions set forth in the Credit Agreement, we are required to make certain mandatory prepayments from specified excess cash flows from operations (to the extent our net senior secured leverage ratio exceeds a certain ratio) and from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances and insurance recoveries (subject to certain reinvestment rights) (“Mandatory Prepayments”). Mandatory Prepayments are required to be applied by us, first, to the Term Loan, second, to any outstanding amount under the swing line sublimit, third, to the Revolver, and fourth to any outstanding amount under a letter of credit sublimit. Subject to certain limitations, we may voluntarily prepay any of the credit facilities under the Credit Agreement without premium or penalty.
The Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants restricting our ability and that of the subsidiary guarantors, subject to negotiated exceptions, to incur additional indebtedness and additional liens on our assets, engage in mergers or acquisitions or dispose of assets, enter into sale-leaseback transactions, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of our businesses.
The Credit Agreement contains two financial ratio covenants measured as of the last day of each fiscal quarter: a total net leverage ratio and an interest coverage ratio. We were in compliance with these covenants as of March 26, 2016.
Senior Notes
On July 2, 2015, we completed a private placement of $1.0 billion aggregate principal amount of our 2022 Senior Notes. The 2022 Senior Notes are our general senior unsecured obligations and are guaranteed on a senior unsecured basis by certain of our domestic subsidiaries (the "Guarantors"). The 2022 Senior Notes mature on July 15, 2022 and bear interest at the rate of 5.250% per year, payable semi-annually on January 15 and July 15 of each year, commencing on January 15, 2016.
We may redeem the 2022 Senior Notes at any time prior to July 15, 2018 at a price equal to 100% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date and a make-whole premium set forth in the 2022 Senior Notes indenture ("the Indenture"). We may also redeem up to 35% of the aggregate principal amount of our 2022 Senior Notes with the net cash proceeds of certain equity offerings at any time and from time to time before July 15, 2018, at a redemption price equal to 105.250% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date. We also have the option to redeem the 2022 Senior Notes on or after: July 15, 2018 through July 14, 2019 at 102.625% of par; July 15, 2019 through July 14, 2020 at 101.313% of par; and July 15, 2020 and thereafter at 100% of par. In addition, if we undergo a change of control, as provided in the Indenture, we will be required to make an offer to purchase each holder’s 2022 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date.
Convertible Notes
At March 26, 2016, our Convertible Notes, in the aggregate principal amount of $793.3 million, are recorded at $805.2 million, which includes accretion of interest at 4.0% per annum on the 2013 Notes and is net of the unamortized debt discount attributed to the embedded conversion feature of the convertible notes. These notes consist of:
 
•
$59.9 million of our 2.00% Convertible Exchange Senior Notes due 2037 issued in November 2010 ("2010 Notes");

35

•
$363.4 million of our 2.00% Convertible Senior Notes due 2042 issued in March 2012 ("2012 Notes"); and
•
$370.0 million of our 2.00% Convertible Senior Notes due 2043 issued in February 2013 ("2013 Notes").

The 2010 Notes, 2012 Notes and 2013 Notes have conversion prices of approximately $23.03, $31.175 and $38.59, respectively, and are subject in each case to adjustment. Holders of the 2010 Notes, 2012 Notes and 2013 Notes may convert their Convertible Notes at the applicable conversion price under certain circumstances, including without limitation (x) if the last reported sale price of our common stock exceeds 130% of the applicable conversion price for at least 20 trading days in the 30 consecutive trading days ending on the last trading day of the preceding calendar quarter and (y) if the applicable series of Convertible Notes has been called for redemption. It is our current intent and policy to settle any conversion of the Convertible Notes as if we had elected to make either a net share settlement or all cash election, such that upon conversion, we intend to pay the holders in cash for the principal amount of the Convertible Notes and, if applicable shares of our common stock or cash to satisfy the premium based on a calculated daily conversion value.
During the second quarter of fiscal 2016, the closing price of our common stock exceeded 130% of the applicable conversion price of our 2010 Notes on at least 20 of the last 30 consecutive trading days of the quarter. Therefore holders of the 2010 Notes are able to convert their notes during the third quarter of fiscal 2016. As such, we classified the $58.0 million carrying value of our 2010 Notes (which have a principal value of $59.9 million) as a current debt obligation. In the event the closing price conditions are met in the third quarter of fiscal 2016 or a future fiscal quarter, the 2010 Notes will be convertible at a holder's option during the immediately following fiscal quarter. As of March 26, 2016, the if-converted value of the 2010 Notes exceeded the aggregate principal amount by approximately $30.1 million.
Holders may require us to repurchase the 2010 Notes on each of December 15, 2016, 2020, 2025, on December 13, 2030 and on December 14, 2035, or upon a fundamental change, as provided in the indenture for the 2010 Notes, at a repurchase price equal to 100% of their accreted principal amount, plus accrued and unpaid interest.
Holders may require us to repurchase the 2012 Notes on each of March 1, 2018, 2022, 2027 and 2032, and on March 2, 2037, or upon a fundamental change, as provided in the indenture for the 2012 Notes, at a repurchase price equal to 100% of their accreted principal amount, plus accrued and unpaid interest.
Holders may require us to repurchase the 2013 Notes on each of December 15, 2017, 2022, 2027, 2032 and 2037, or upon a fundamental change, as provided in the indenture for the 2013 Notes, at a repurchase price equal to 100% of their accreted principal amount, plus accrued and unpaid interest.
We may redeem any of the 2010 Notes, 2012 Notes and 2013 Notes beginning December 19, 2016, March 6, 2018 and December 15, 2017, respectively. We may redeem all or a portion of the 2010 Notes, 2012 Notes, and 2013 Notes (i.e., in cash or a combination of cash and shares of our common stock) at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the applicable redemption date.
We have recorded deferred tax liabilities related to our Convertible Notes original issuance discount, representing the spread between the stated cash coupon rate and the higher interest rate that is deductible for tax purposes based on the type of security. When our Convertible Notes are extinguished, we are required to recapture the original issuance discount previously deducted for tax purposes. The tax recapture, however, decreases as the fair market value of the Convertible Notes and the amount paid on settlement increases.

Accounts Receivable Securitization Program
On April 25, 2016, we entered into a $200.0 million accounts receivable securitization program (the "Securitization Program") with several of our wholly owned subsidiaries and certain financial institutions. Under the terms of the Securitization Program, we and certain of our wholly-owned subsidiaries will sell our customer receivables to a bankruptcy remote special purpose entity, which is wholly-owned by us. We will also contribute a portion of our customer receivables to the special purpose entity. We retain servicing responsibility. The special purpose entity, as borrower, and we, as servicer, have entered into a Credit and Security Agreement with several lenders pursuant to which the special purpose entity may borrow from the lenders up to $200.0 million, with the loans secured by the receivables. In addition, we may request from the lenders an increase in the borrowing limit of up to $50.0 million during the term of the agreement, although such additional borrowing limit is uncommitted. Borrowings outstanding under the Securitization Program will bear interest at LIBOR plus the applicable margin of 0.7% and will be included as a component of current liabilities in our consolidated balance sheet, while the accounts receivable securing these obligations will be included as a component of net receivables in our consolidated balance sheet. We and the special purpose entity have been formed and are operated and maintained as separate legal entities. The assets and liabilities of the special purpose entity, which are separate from ours, are not available to pay our debts and do not constitute our obligations.

36

Stock Repurchase Program
On November 11, 2013, we announced that our Board of Directors authorized the repurchase of up to $250.0 million of our outstanding common stock over the next three years. Under the stock repurchase program, we are authorized to repurchase, from time-to-time, shares of our outstanding common stock on the open market or in privately negotiated transactions in the United States. The timing and amount of stock repurchases will be determined based upon our evaluation of market conditions and other factors. The stock repurchase program may be suspended, modified or discontinued at any time, and we have no obligation to repurchase any amount of our common stock under the program. During the second quarter of fiscal 2016, we repurchased 4.3 million shares of common stock for total consideration of $148.8 million with a weighted average per share price of $34.36. Total cash paid for these transactions during the second quarter aggregated $135.9 million with $12.9 million remaining unpaid as of March 26, 2016.
Legal Contingencies
We are currently involved in several legal proceedings and claims. In connection with these legal proceedings and claims, management periodically reviews estimates of potential costs to be incurred by us in connection with the adjudication or settlement, if any, of these proceedings. These estimates are developed, as applicable in consultation with outside counsel, and are based on an analysis of potential litigation outcomes and settlement strategies. In accordance with ASC 450, Contingencies, loss contingencies are accrued if, in the opinion of management, an adverse outcome is probable and such financial outcome can be reasonably estimated. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these proceedings.
Future Liquidity Considerations
We believe that our cash and cash equivalents, cash flows from operations and the cash available under our Revolver will provide us with sufficient funds in order to fund our expected normal operations and debt payments, including interest and potential payouts for any Convertible Notes for which conversion is triggered, over the next twelve months. Our longer-term liquidity is contingent upon future operating performance. We may also require additional capital in the future to fund capital expenditures, repayment of debt and related deferred tax liabilities, as applicable, acquisitions, strategic transactions or other investments. As described above, we have significant indebtedness outstanding under our Credit Agreement, 2022 Senior Notes and Convertible Notes. These capital requirements could be substantial. For a description of risks to our operating performance and our indebtedness, see “Risk Factors” in Part I, Item 1A in our Annual Report on Form 10-K for the fiscal year ended September 26, 2015.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The discussion and analysis of our financial condition and results of operations are based upon our interim consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition for multiple element arrangements, allowance for doubtful accounts, reserves for excess and obsolete inventories, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, stock-based compensation, contingent liabilities, tax reserves and recoverability of our net deferred tax assets and related valuation allowances. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates if past experience or other assumptions do not turn out to be substantially accurate. Any differences may have a material impact on our financial condition and results of operations. For a discussion of how these and other factors may affect our business, see the “Cautionary Statement” above and “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 26, 2015.

37
Table of Contents

The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our consolidated financial statements presented in this report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended September 26, 2015. There have been no material changes to our critical accounting policies or estimates from those set forth in our Annual Report on Form 10-K for the fiscal year ended September 26, 2015.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.
Financial Instruments, Other Financial Instruments, and Derivative Commodity Instruments. Financial instruments consist of cash equivalents, accounts receivable, publicly-traded equity securities, cost-method equity investments, insurance contracts and related deferred compensation plan liabilities, interest rate caps, forward foreign currency contracts, accounts payable and debt obligations. Except for our outstanding Convertible Notes and 2022 Senior Notes, the fair value of these financial instruments approximates their carrying amount. As of March 26, 2016, we have $793.3 million in principal amount of Convertible Notes outstanding, including $59.9 million principal amount of our 2010 Notes, $363.4 million principal amount of our 2012 Notes and $370.0 million principal amount of our 2013 Notes. The Convertible Notes are recorded net of the unamortized debt discount on our consolidated balance sheets. The fair value of our 2010 Notes, 2012 Notes and 2013 Notes as of March 26, 2016 was approximately $90.0 million, $459.9 million and $459.7 million, respectively. The fair value of our 2022 Senior Notes was approximately $1.04 billion. Amounts outstanding under our Credit Agreement aggregating $1.62 billion aggregate principal as of March 26, 2016 are subject to variable rates of interest based on current market rates, and as such, we believe the carrying amount of these obligations approximates fair value.
Primary Market Risk Exposures. Our primary market risk exposure is in the areas of interest rate risk and foreign currency exchange rate risk. We incur interest expense on borrowings outstanding under our Convertible Notes, 2022 Senior Notes and Credit Agreement, as well as under our accounts receivable securitization program. The Convertible Notes and 2022 Senior Notes have fixed interest rates. Borrowings under our Credit Agreement currently bear interest at the Eurocurrency Rate (i.e., Libor) plus the applicable margin of 1.75% per annum. Borrowings under our accounts receivable securitization program currently bear interest at Libor plus the applicable margin of 0.7%.
As of March 26, 2016, there was $1.62 billion of aggregate principal outstanding under the Credit Agreement comprised of $1.44 billion under the Term Loan facility and $175.0 million under the Revolver. Since these debt obligations are variable rate instruments, our interest expense associated with these instruments is subject to change. A 10% adverse movement (increase in LIBOR rate) would increase annual interest expense by less than $1.0 million due to the low current interest rate environment. During fiscal 2015, we entered into multiple interest rate cap agreements to help mitigate the interest rate volatility associated with the variable rate interest on the amounts outstanding. The critical terms of the interest rate caps were designed to mirror the terms of our LIBOR-based borrowings under the Credit Agreement, and therefore the interest rate caps are highly effective at offsetting the cash flows being hedged. We designated these derivatives as cash flow hedges of the variability of the Libor-based interest payments on $1.0 billion of principal over a 3-year period, which ends on December 31, 2017.
The return from cash and cash equivalents will vary as short-term interest rates change. A hypothetical 10% increase or decrease in interest rates, however, would not have a material adverse effect on our business, financial condition or results of operations.
Foreign Currency Exchange Risk. Our international business is subject to risks, including, but not limited to: unique economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. Accordingly, our future results could be materially adversely impacted by changes in these or other factors.

We conduct business worldwide and maintain sales and service offices outside the United States as well as manufacturing facilities in Costa Rica and the United Kingdom. Our international sales are denominated in a number of currencies, primarily the Euro, U.S. dollar, UK Pound and Renminbi. The expenses of our international offices are denominated in local currencies, except at our Costa Rica subsidiary, where the majority of the business is conducted in U.S. dollars. Fluctuations in foreign currency rates could affect our sales, cost of goods and operating margins and could result in exchange losses. In addition, currency devaluations can result in a loss if we hold deposits of that currency. We have executed forward foreign currency contracts to hedge a portion of results denominated in the Euro, UK Pound and Australian dollar. These contracts do not qualify for hedge accounting. As a result, we may experience volatility in our Consolidated Statements of Income due to (i) the impact of unrealized gains and losses reported in other income, net on the mark-to-market of outstanding contracts and (ii)

38
Table of Contents

realized gains and losses recognized in other income, net, whereas the offsetting economic gains and losses are reported in the line item of the underlying cash flow, for example, revenue.
We believe that the operating expenses of our international subsidiaries that are incurred in local currencies will not have a material adverse effect on our business, results of operations or financial condition. Our operating results and certain assets and liabilities that are denominated in the Euro are affected by changes in the relative strength of the U.S. dollar against the Euro. Our expenses, denominated in Euros, are positively affected when the U.S. dollar strengthens against the Euro and adversely affected when the U.S. dollar weakens. However, we believe that the foreign currency exchange risk is not significant. A hypothetical 10% increase or decrease in foreign currencies that we transact in would not have a material adverse impact on our business, financial condition or results of operations.

Item 4.    Controls and Procedures.
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As of March 26, 2016, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of March 26, 2016.
An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

39
Table of Contents

PART II – OTHER INFORMATION
Item 1.    Legal Proceedings.
Information with respect to this Item may be found in Note 6 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.
Additional information on our commitments and contingencies can be found in our Annual Report on Form 10-K for our fiscal year ended September 26, 2015.
Item 1A. Risk Factors.

There are no material changes from the risk factors as previously disclosed in our Annual Report on Form 10-K for our fiscal year ended September 26, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer's Purchases of Equity Securities

Period of Repurchase
Total Number of
Shares Purchased
(#) (1)
 
Average Price
Paid Per Share
($) (1)
 
Total Number of
Shares Purchased As Part of Publicly
Announced Plans or Programs 
(#) (2)
 
Average Price Paid Per Share As Part of Publicly Announced Plans or Programs($) (2)
 
Maximum
Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under Our
Programs
(in millions) 
December 27, 2015 – January 23, 2016
2,304

 
$
37.98

 
322,017

 
$
34.52

 
$
238.9

January 24, 2016 – February 20, 2016
9,624

 
34.34

 
1,280,036

 
33.83

 
195.6

February 21, 2016 – March 26, 2016
5,991

 
34.81

 
2,728,495

 
34.58

 
101.2

Total
17,919

 
$
—

 
4,330,548

 
$
—

 
$
101.2

 ___________________________________
(1)
For the majority of restricted stock units granted, the number of shares issued on the date that the restricted stock units vest is net of the minimum statutory tax withholding requirements that we pay in cash to the appropriate taxing authorities on behalf of our employees. These repurchases of our common stock were to cover employee income tax withholding obligations in connection with the vesting of restricted stock units under our equity incentive plans.
(2)
On November 11, 2013, we announced that our Board of Directors authorized the repurchase of up to $250.0 million of our outstanding common stock over the next three years. Through March 26, 2016, we repurchased 4.3 million shares of our common stock for total consideration of $148.8 million in cash with a weighted average per share price of $34.36. Total cash paid for these transactions during the quarter aggregated $135.9 million with $12.9 million remaining unpaid as of March 26, 2016.


40
Table of Contents


Item 6.    Exhibits.
(a) Exhibits
 
 
 
 
 
Incorporated by
Reference
Exhibit
Number
 
Exhibit Description
 
Form
 
Filing Date/
Period End
Date
 
 
 
 
 
 
 
3.1
 
Fifth Amended and Restated Bylaws of Hologic, Inc.
 
8-K
 
3/4/2016
 
 
 
 
 
 
 
10.1‡
 
Settlement Agreement dated January 8, 2016 between Hologic IP Ltd, Hologic, Inc. and Claus Egstrand
 
10-Q
 
12/26/2016
 
 
 
 
 
 
 
10.2‡
 
Hologic, Inc. 2012 Employee Stock Purchase Plan, as Amended
 
8-K
 
3/4/2016
 
 
 
 
 
 
 
31.1*
 
Certification of Hologic’s CEO pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
 
 
 
 
31.2*
 
Certification of Hologic’s CFO pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
 
 
 
 
32.1**
 
Certification of Hologic’s CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
 
 
 
 
32.2**
 
Certification of Hologic’s CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
 
 
 
 
101.INS*
 
XBRL Instance Document
 
 
 
 
 
 
 
 
 
 
 
101.SCH*
 
XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
 
 
 
 
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
 
 
 
 
 
 
 
 
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
 
 
 
 
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 
 
 
 
101.DEF*
 
XBRL Taxonomy Extension Definition
 
 
 
 
_______________

‡ Indicates management contract or compensatory plan, contract or arrangement.
*    Filed herewith.
**    Furnished herewith.





41
Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
Hologic, Inc.
 
 
 
(Registrant)
 
 
 
 
Date:
April 27, 2016
 
/s/    Stephen P. MacMillan        
 
 
 
 
 
 
 
Stephen P. MacMillan
Chairman, President and Chief Executive Officer
 
 
 
 
Date:
April 27, 2016
 
/s/    Robert W. McMahon        
 
 
 
 
 
 
 
Robert W. McMahon
 
 
 
Chief Financial Officer
(Principal Financial Officer)


42
Exhibit


Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen P. MacMillan, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Hologic, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 27, 2016
 
/s/    Stephen P. MacMillan        
 
Stephen P. MacMillan
 
Chairman, President and Chief Executive Officer
 


Exhibit


Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Robert W. McMahon, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Hologic, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 27, 2016
 
/s/    Robert W. McMahon
 
Robert W. McMahon
 
Chief Financial Officer
 


Exhibit


Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
I, Stephen P. MacMillan, Chief Executive Officer of Hologic, Inc., a Delaware corporation (the “Company”), do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), that:
(1)
The Quarterly Report on Form 10-Q for the quarter ended March 26, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: April 27, 2016
/s/    Stephen P. MacMillan        
 
Stephen P. MacMillan
 
Chairman, President and Chief Executive Officer
A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.


Exhibit


Exhibit 32.2
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
I, Robert W. McMahon, Chief Financial Officer of Hologic, Inc., a Delaware corporation (the “Company”), do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), that:
(1)
The Quarterly Report on Form 10-Q for the quarter ended March 26, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: April 27, 2016
/s/    Robert W. McMahon
 
Robert W. McMahon
 
Chief Financial Officer
A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.


holx-20160326.xml
Attachment: XBRL INSTANCE DOCUMENT

holx-20160326.xsd
Attachment: XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

holx-20160326_cal.xml
Attachment: XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

holx-20160326_def.xml
Attachment: XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

holx-20160326_lab.xml
Attachment: XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

holx-20160326_pre.xml
Attachment: XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

v3.4.0.3
Document and Entity Information - shares
 6 Months Ended
Mar. 26, 2016
Apr. 22, 2016
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 26, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Entity Registrant Name HOLOGIC INC  
Entity Central Index Key 0000859737  
Current Fiscal Year End Date --09-24  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   278,829,786
v3.4.0.3
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Revenues:        
Product $ 583.0 $ 546.4 $ 1,170.2 $ 1,093.0
Service and other 110.3 109.1 218.2 215.3
Revenues 693.3 655.5 1,388.4 1,308.3
Costs of revenues:        
Product 182.0 186.7 370.1 373.4
Amortization of intangible assets 70.8 78.6 144.3 152.5
Service and other 55.5 54.2 109.9 107.8
Gross Profit 385.0 336.0 764.1 674.6
Operating expenses:        
Research and development 59.1 53.3 110.8 105.2
Selling and marketing 100.8 83.0 200.3 169.0
General and administrative 62.4 60.3 139.5 121.7
Amortization of intangible assets 22.8 27.6 45.4 55.4
Restructuring and divestiture charges 3.8 2.0 6.0 10.0
Operating expenses 248.9 226.2 502.0 461.3
Income from operations 136.1 109.8 262.1 213.3
Interest income 0.2 0.3 0.4 0.7
Interest expense (39.1) (49.4) (78.3) (101.9)
Debt extinguishment loss (4.5) 0.0 (4.5) (6.7)
Other income (expense), net (0.8) 0.1 26.9 (0.5)
Income before income taxes 91.9 60.8 206.6 104.9
Provision for income taxes 23.0 13.0 52.8 27.9
Net income $ 68.9 $ 47.8 $ 153.8 $ 77.0
Net income per common share:        
Basic $ 0.24 $ 0.17 $ 0.54 $ 0.28
Diluted $ 0.24 $ 0.17 $ 0.53 $ 0.27
Weighted average number of shares outstanding:        
Basic 282,474 280,338 282,725 279,505
Diluted 287,857 287,580 289,914 285,378
v3.4.0.3
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Statement of Comprehensive Income [Abstract]        
Net income $ 68.9 $ 47.8 $ 153.8 $ 77.0
Changes in foreign currency translation adjustment (1.2) (9.5) (5.4) (18.5)
Changes in unrealized holding gains and losses on available-for-sale securities: (0.6) (8.3) (1.2) (3.2)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 0.0 0.0 (7.2) 0.0
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent 0.0 0.0 0.0 0.1
Changes in value of hedged interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 26, 2016 and $0.9 for the three and six months ended March 28, 2015: (2.2) (1.6) (1.9) (1.6)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax 0.7 0.0 1.0 0.0
Other comprehensive loss (3.3) (19.4) (14.7) (23.2)
Comprehensive income $ 65.6 $ 28.4 $ 139.1 $ 53.8
v3.4.0.3
Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Statement of Comprehensive Income [Abstract]        
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax $ 1.4 $ 0.9 $ 1.2 $ 0.9
v3.4.0.3
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Current assets:    
Cash and cash equivalents $ 316.3 $ 491.3
Restricted cash 0.0 1.4
Accounts receivable, less reserves of $10.4 and $11.1, respectively 422.6 416.1
Inventories 285.1 283.1
Deferred income tax assets 0.0 19.0
Prepaid income taxes 18.2 21.7
Prepaid expenses and other current assets 50.4 33.8
Total current assets 1,092.6 1,266.4
Property, plant and equipment, net 454.1 457.1
Intangible assets, net 2,837.5 3,023.2
Goodwill 2,806.4 2,808.2
Other assets 95.7 115.2
Total assets 7,286.3 7,670.1
Current liabilities:    
Current portion of long-term debt 307.7 391.8
Accounts payable 118.5 117.0
Accrued expenses 263.9 272.1
Deferred revenue 150.9 163.1
Total current liabilities 841.0 944.0
Long-term debt, net of current portion 3,098.0 3,248.0
Deferred income tax liabilities 1,071.0 1,178.4
Deferred revenue 19.3 19.6
Other long-term liabilities $ 212.6 $ 200.9
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued $ 0.0 $ 0.0
Common stock, $0.01 par value – 750,000 shares authorized; 284,091 and 282,495 shares issued, respectively 2.8 2.8
Additional paid-in-capital 5,534.8 5,559.9
Accumulated deficit (3,315.2) (3,469.0)
Treasury stock, at cost – 4,331 shares at March 26, 2016 (148.8) 0.0
Accumulated other comprehensive loss (29.2) (14.5)
Total stockholders’ equity 2,044.4 2,079.2
Total liabilities and stockholders’ equity $ 7,286.3 $ 7,670.1
v3.4.0.3
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Statement of Financial Position [Abstract]    
Accounts receivable, reserves $ 10.4 $ 11.1
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 1,623,000 1,623,000
Preferred stock, issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 750,000,000 750,000,000
Common stock, issued (in shares) 284,091,000 282,495,000
Treasury Stock, Shares 4,331,000 0
v3.4.0.3
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
OPERATING ACTIVITIES    
Net income $ 153.8 $ 77.0
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 40.2 40.7
Amortization 189.7 207.9
Non-cash interest expense 26.1 33.2
Stock-based compensation expense 30.6 25.8
Excess tax benefit related to equity awards (7.9) (6.0)
Deferred income taxes (64.7) (79.1)
Gain (Loss) on Disposition of Intangible Assets (25.1) 0.0
Debt extinguishment loss 4.5 6.7
Other adjustments and non-cash items 1.0 3.9
Changes in operating assets and liabilities:    
Accounts receivable (7.0) 3.3
Inventories (2.3) 29.0
Prepaid income taxes 3.4 1.3
Prepaid expenses and other assets (15.0) (2.6)
Accounts payable 1.6 (17.8)
Accrued expenses and other liabilities (2.1) (19.3)
Deferred revenue (12.4) 7.3
Net cash provided by operating activities 314.4 311.3
INVESTING ACTIVITIES    
Purchase of property and equipment (19.4) (20.0)
Increase in equipment under customer usage agreements (22.3) (19.7)
Proceeds from Sale of Available-for-sale Securities 31.1 0.0
Purchases of insurance contracts (5.2) (6.4)
Sales of mutual funds 5.2 7.7
Payments to Acquire Intangible Assets (4.0) 0.0
Increase in other assets 0.1 (0.6)
Net cash used in investing activities (14.5) (39.0)
FINANCING ACTIVITIES    
Repayment of long-term debt (37.5) (357.5)
Payments for Repurchase of Common Stock (135.9) 0.0
Repayments of Convertible Debt (311.5) 0.0
Proceeds from Lines of Credit 50.0 0.0
Repayments of Lines of Credit (50.0) 0.0
Interest Rate Cap Agreements Aggregate Premium Payable 0.0 (6.1)
Net proceeds from issuance of common stock pursuant to employee stock plans 19.0 37.4
Excess tax benefit related to equity awards 7.9 6.0
Payment of minimum tax withholdings on net share settlements of equity awards (15.6) (12.1)
Net cash used in financing activities (473.6) (332.3)
Effect of exchange rate changes on cash and cash equivalents (1.3) (5.6)
Net decrease in cash and cash equivalents (175.0) (65.6)
Cash and cash equivalents, beginning of period 491.3 736.1
Cash and cash equivalents, end of period $ 316.3 $ 670.5
v3.4.0.3
Basis of Presentation
 6 Months Ended
Mar. 26, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”). These financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended September 26, 2015 included in the Company’s Form 10-K filed with the SEC on November 19, 2015. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and six months ended March 26, 2016 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 24, 2016.
Subsequent Events Consideration
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There was one unrecognized subsequent event related to the unaudited consolidated financial statements for the three and six months ended March 26, 2016 related to the Company's execution of a $200.0 million accounts receivable securitization program with several of its wholly owned subsidiaries and certain financial institutions on April 25, 2016 (see Note 4). There were no material recognized subsequent events recorded in the unaudited consolidated financial statements as of and for the three and six months ended March 26, 2016.
v3.4.0.3
Fair Value Measurements
 6 Months Ended
Mar. 26, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
The Company has investments in publicly-traded companies, which are valued using quoted market prices, representing Level 1 assets, and investments in derivative instruments comprised of interest rate caps and forward foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of the Company's interest rate caps and forward foreign currency contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 5 for further discussion and information on the interest rate caps and forward foreign currency contracts.
The Company has a payment obligation to the participants under its Nonqualified Deferred Compensation Plan (“DCP”). This liability is recorded at fair value based on the underlying value of certain hypothetical investments under the DCP as designated by each participant for their benefit. Since the value of the DCP obligation is based on market prices, the liability is classified within Level 1.
Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 26, 2016: 
 
 
 
Fair Value at Reporting Date Using
 
Balance as of March 26, 2016
 
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Equity securities
$
0.8

 
$
0.8

 
$
—

 
$
—

Interest rate cap - derivative
3.7

 
—

 
3.7

 
—

Forward foreign currency contracts
1.2

 
—

 
1.2

 
—

Total
$
5.7

 
$
0.8

 
$
4.9

 
$
—

Liabilities:
 
 
 
 
 
 
 
Deferred compensation liabilities
$
37.6

 
$
37.6

 
$
—

 
$
—

Forward foreign currency contracts
0.9

 
—

 
0.9

 
—

Total
$
38.5

 
$
37.6

 
$
0.9

 
$
—


Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of cost-method equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill.
The Company holds certain cost-method equity investments in non-publicly traded securities aggregating $3.5 million and $4.2 million at March 26, 2016 and September 26, 2015, respectively, which are included in other long-term assets on the Company’s Consolidated Balance Sheets. These investments are generally carried at cost, less any write-downs for other-than-temporary impairment charges. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost method investment’s fair value is not estimated as there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment and to make such an estimate would be impractical.
Disclosure of Fair Value of Financial Instruments
The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, marketable securities, cost-method equity investments, interest rate caps, forward foreign currency contracts, insurance contracts, DCP liability, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s marketable securities, interest rate caps, and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value, and the related DCP liability is recorded at fair value. The Company believes the carrying amounts of its cost-method equity investments approximate fair value.
Amounts outstanding under the Company’s Credit Agreement of $1.62 billion aggregate principal as of March 26, 2016 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 2022 Senior Notes had a fair value of approximately $1.04 billion as of March 26, 2016 based on their trading price, representing a Level 1 measurement. The fair value of the Company’s Convertible Notes is based on the trading prices of the respective notes and represents a Level 1 measurement. Refer to Note 4 for the carrying amounts of the various components of the Company’s debt.
The estimated fair values of the Company’s Convertible Notes at March 26, 2016 were as follows:
 
2010 Notes
$
90.0

2012 Notes
459.9

2013 Notes
459.7

 
$
1,009.6
v3.4.0.3
Restructuring and Divestiture Charges
 6 Months Ended
Mar. 26, 2016
Restructuring and Related Activities [Abstract]  
Restructuring and Divestiture Charges
Restructuring and Divestiture Charges
The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. In addition, the Company continually assesses its management structure. As a result of these assessments, the Company has undertaken various restructuring actions, which are described below. The following table displays charges taken in the fiscal 2016 year to date period and fiscal 2015 related to these actions and a rollforward of the accrued balances from September 26, 2015 to March 26, 2016:
 
 
Fiscal 2016 Actions
 
Fiscal 2015 Actions
 
Fiscal 2014 Actions
 
Other Operating Cost Reductions
 
Total    
Restructuring and Divestiture Charges
 
 
 
 
 
 
 
 
 
 
Fiscal 2015 charges:
 
 
 
 
 
 
 
 
 
 
Workforce reductions
 
$
—

 
$
10.0

 
$
6.0

 
$
0.3

 
$
16.3

Facility closure costs
 
—

 
—

 
2.0

 
0.6

 
2.6

Fiscal 2015 restructuring charges
 
$
—

 
$
10.0

 
$
8.0

 
$
0.9

 
$
18.9

Divestiture net charges
 
 
 
 
 
 
 
 
 
9.6

Fiscal 2015 restructuring and divestiture charges
 
 
 
 
 
 
 
 
 
$
28.5

Fiscal 2016 charges:
 
 
 
 
 
 
 
 
 

Workforce reductions
 
$
6.0

 
$
—

 
$
—

 
$
—

 
$
6.0

Fiscal 2016 restructuring charges
 
$
6.0

 
$
—

 
$
—

 
$
—

 
$
6.0


 
 
Fiscal 2016 Actions
 
Fiscal 2015 Actions
 
Fiscal 2014 Actions
 
Other Operating Cost Reductions  
 
Total    
Rollforward of Accrued Restructuring
 
 
 
 
 
 
 
 
 
 
Balance as of September 26, 2015
 
$
—

 
$
3.1

 
$
2.5

 
$
0.1

 
$
5.7

Fiscal 2016 restructuring charges
 
6.0

 
—

 
—

 
—

 
6.0

Severance payments
 
(2.3
)
 
(2.4
)
 
(1.4
)
 
(0.1
)
 
(6.2
)
Other payments
 
—

 
—

 
(0.2
)
 
—

 
(0.2
)
Balance as of March 26, 2016
 
$
3.7

 
$
0.7

 
$
0.9

 
$
—

 
$
5.3


Fiscal 2016 Actions

During the third quarter of fiscal 2015, the Company decided to close its Bedford, Massachusetts facility where it manufactures its Skeletal Health products and provides certain support manufacturing services for its Breast Health segment. The manufacturing of the Skeletal Health products will be outsourced to a third-party, and the Breast Health manufacturing services will be moved to the Company's Danbury, Connecticut and Marlborough, Massachusetts facilities. In addition, research and development, sales and services support and administrative functions will be moved to both Marlborough and Danbury. The transition is expected to be completed by the end of calendar 2016. In connection with this plan, certain employees, primarily in manufacturing, will be terminated. The employees were notified of termination and related benefits in the first quarter of fiscal 2016, and the Company is recording these charges pursuant to ASC 420 Exit or Disposal Cost Obligations (ASC 420). Employees are required to remain employed during this transition period and charges are being recorded ratably over the required service period. The Company recorded $0.5 million and $0.9 million in severance and benefits charges in the three and six months ended March 26, 2016, respectively, related to this plan. The Company estimates the total severance and benefits charges will be approximately $1.7 million.
During the first quarter of fiscal 2016, the Company began implementing a second plan to consolidate and improve operational efficiency of its international sales and marketing and field services operations and certain support functions. As a result, the Company identified and terminated certain employees in the first and second quarters of fiscal 2016. Severance and benefits under this action were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712), and ASC 420 depending on the circumstances. The Company recorded severance and benefit charges of $3.3 million and $5.1 million in the three and six months ended March 26, 2016, respectively, related to this plan. The Company is continuing to assess its organizational structure and finalize its plans and additional severance charges are expected in fiscal 2016.
Fiscal 2015 Actions
During each quarter of fiscal 2015, the Company continued to make executive management changes resulting in the termination of certain executives and employees on a worldwide basis. In addition, the Company continued to consolidate and close certain international offices to improve operational efficiency and reduce costs. Severance and benefit charges under these actions were recorded pursuant to ASC 420 and ASC 712 depending on the circumstances, and the Company recorded severance and benefit charges of $10.0 million in fiscal 2015, including $4.1 million of stock-based compensation. During the three and six months ended March 28, 2015, the Company recorded $0.5 million and $3.0 million, respectively, for severance and benefits charges. No additional charges are expected under these actions.
In connection with its review of operations, the Company decided to shut-down its manufacturing operation in China, which manufactured mammography systems for the Chinese market. As a result, the Company terminated manufacturing and research and development personnel located in China, and the severance charge was insignificant.
Fiscal 2014 Actions
In each quarter of fiscal 2014, the Company made executive management changes, including appointing Stephen P. MacMillan as President, Chief Executive Officer and a director of the Company, and implemented a number of cost reduction initiatives resulting in the termination of certain executives and employees on a worldwide basis. In addition, in the fourth quarter of fiscal 2014, the Company decided to consolidate and close certain international offices. Severance and benefit charges under these actions were recorded pursuant to ASC 420 and ASC 712 depending on the circumstances. For those employees who continued to be employed beyond the minimum retention period, charges were recorded ratably over the estimated period of the affected employees.
During fiscal 2015, in connection with these actions, the Company recorded $6.0 million for severance and benefits costs and $2.0 million for facility closure costs related to this action. The facility closure costs primarily related to lease obligation charges for three office locations where the Company had met the cease-use date criteria. During the three and six months ended March 28, 2015, the Company recorded severance and benefit charges of $1.4 million and $5.9 million, respectively. This action was completed in fiscal 2015.    
Divestitures
In the fourth quarter of fiscal 2014, the Company completed the sale of its MRI breast coils product line and recorded a loss on disposal of $5.3 million. The Company also provided certain transition services through April 2015, including the manufacturing and sale of inventory to the buyer. Since all operations had ceased during the third quarter of fiscal 2015, the Company concluded that this subsidiary had been substantially liquidated and recorded a $9.6 million charge in the third quarter of fiscal 2015 to write off the cumulative translation adjustment related to the subsidiary.
v3.4.0.3
Borrowings and Credit Arrangements
 6 Months Ended
Mar. 26, 2016
Debt Disclosure [Abstract]  
Borrowings and Credit Arrangements
Borrowings and Credit Arrangements
The Company’s borrowings consisted of the following: 
 
March 26,
2016
 
September 26,
2015
Current debt obligations, net of debt discount:
 
 
 
Term Loan
$
74.7

 
$
74.6

Revolver
175.0

 
175.0

Convertible Notes
58.0

 
142.2

Total current debt obligations
$
307.7

 
$
391.8

Long-term debt obligations, net of debt discount:
 
 
 
Term Loan
1,363.1

 
1,399.8

2022 Senior Notes
987.7

 
986.7

Convertible Notes
747.2

 
861.5

Total long-term debt obligations
$
3,098.0

 
$
3,248.0

Total debt obligations
$
3,405.7

 
$
3,639.8


Credit Agreement
Borrowings outstanding under the Credit Agreement for the three and six months ended March 26, 2016 had weighted-average interest rates of 2.18% and 2.06%, respectively. The interest rate on the outstanding Term Loan borrowing at March 26, 2016 was 2.18%. Borrowings outstanding under the Prior Credit Agreement for the three and six months ended March 28, 2015 had weighted-average interest rates of 2.62% and 2.70%, respectively. Interest expense under the Credit Agreement aggregated $10.8 million and $20.7 million for the three and six months ended March 26, 2016, respectively, which includes non-cash interest expense of $1.1 million and $2.1 million, respectively, related to the amortization of the deferred issuance costs and accretion of the debt discount. Interest expense under the Prior Credit Agreement aggregated $14.4 million and $31.9 million for the three and six months ended March 28, 2015, respectively, which included $2.7 million and $5.8 million, respectively, of non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount.  
The Credit Agreement contains two financial covenants, a total net leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and the calculation thereof, are defined in further detail in the Credit Agreement. As of March 26, 2016, the Company was in compliance with these covenants.
On December 24, 2014, the Company voluntarily pre-paid $300.0 million of its Term Loan B facility under its Prior Credit Agreement. Pursuant to ASC 470, Debt (ASC 470), the Company recorded a debt extinguishment loss of $6.7 million in the first quarter of fiscal 2015 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to this voluntary prepayment.
2022 Senior Notes
The Company's 5.250% Senior Notes due 2022 (the “2022 Senior Notes”) mature on July 15, 2022 and bear interest at the rate of 5.250% per year, payable semi-annually on January 15 and July 15 of each year, commencing on January 15, 2016. The Company recorded interest expense of $13.9 million and $27.9 million in the three and six month periods ended March 26, 2016, respectively, which includes non-cash interest expense of $1.0 million and $1.9 million, respectively, related to the amortization of the deferred issuance costs and accretion of the debt discount. The Company used the net proceeds from the 2022 Senior Notes, plus available cash to discharge and redeem all of its outstanding 6.25% Senior Notes due 2020 ("Senior Notes"). The Company recorded interest expense related to its Senior Notes of $16.0 million and $32.0 million in the three and six month periods ended March 28, 2015, respectively, which included non-cash interest expense of $0.4 million and $0.8 million, respectively, related to the amortization of deferred issuance costs.
Convertible Notes
During the second quarter of fiscal 2016, the closing price of the Company's common stock exceeded 130% of the applicable conversion price of its 2010 Notes on at least 20 of the last 30 consecutive trading days of the quarter. As a result, holders of 2010 Notes are able to convert their notes during the third quarter of fiscal 2016. Therefore, the Company classified the $58.0 million carrying value of its 2010 Notes (which have a principal value of $59.9 million) as a current debt obligation. In the event the closing price conditions are met in the third quarter of fiscal 2016 or a future fiscal quarter, the 2010 Notes will be convertible at a holder's option during the immediately following fiscal quarter. As of March 26, 2016, the if-converted value of the 2010 Notes exceeded the aggregate principal amount by approximately $30.1 million. It is the Company's current intent and policy to settle any conversion of the Convertible Notes as if the Company had elected to make either a net share settlement or all cash election, such that upon conversion, the Company intends to pay the holders in cash for the principal amount of the 2010 Notes and, if applicable, shares of its common stock or cash to satisfy the premium based on a calculated daily conversion value.
On various dates during the second quarter of fiscal 2016, the Company entered into privately negotiated repurchase transactions and extinguished $90.0 million and $136.6 million principal amount of the 2010 Notes and 2012 Notes, respectively, for total payments of $140.1 million and $171.3 million, respectively. These amounts include the conversion premium resulting from the Company's stock price on the date of the transactions being in excess of the conversion price of $23.03 and $31.175 for the 2010 Notes and 2012 Notes, respectively.
The Company accounted for the 2010 Notes and 2012 Notes extinguishment under the derecognition provisions of subtopic ASC 470-20-40, which requires the allocation of the fair value of the consideration transferred and transaction costs incurred to the extinguishment of the liability component and the reacquisition of the equity component. In connection with these transactions, the Company recorded a debt extinguishment loss on the 2010 Notes of $3.8 million and a debt extinguishment loss on the 2012 Notes of $0.7 million, for a total debt extinguishment loss of $4.5 million in the second quarter of fiscal 2016. The 2010 Notes debt extinguishment loss was comprised of the loss on the debt itself of $3.3 million, the write-off of the pro-rata amount of debt issuance costs of $0.3 million allocated to the notes retired, and allocated third party costs of $0.2 million. The 2012 Notes debt extinguishment loss was comprised of the write-off of the pro-rata amount of debt issuance costs of $0.5 million allocated to the notes retired, and allocated third party costs of $0.2 million. The loss on the debt itself was calculated as the difference between the fair value of the liability component of the 2010 Notes amount retired immediately before the respective exchanges and its related carrying value immediately before the repurchases. The fair value of the liability component was calculated using a discounted cash flow technique, and the Company used effective interest rates of 2.71% for the 2010 Notes and 3.87% and 3.41% for the 2012 Notes, which had two valuation dates, representing the estimated rate for non-convertible debt (with similar features as the 2010 and 2012 Notes excluding the conversion feature) issued by a company with a credit rating similar to the Company. In addition, under this accounting standard, a portion of the fair value of the consideration transferred is allocated to the reacquisition of the equity component, which is the difference between the fair value of the consideration transferred and the fair value of the liability component immediately before the extinguishment. As a result, on a gross basis, $49.9 million related to the 2010 Notes and $38.9 million related to the 2012 Notes were allocated to the reacquisition of the equity component of the original instrument, which was recorded net of deferred taxes of $10.0 million and $12.5 million, respectively, within additional paid-in-capital.
Interest expense under the Convertible Notes was as follows: 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Amortization of debt discount
$
5.8

 
$
9.0

 
$
12.2

 
$
17.8

Amortization of deferred financing costs
0.3

 
0.4

 
0.6

 
0.9

Principal accretion
4.1

 
4.0

 
8.2

 
7.9

Non-cash interest expense
10.2

 
13.4

 
21.0

 
26.6

2.00% accrued interest (cash)
2.7

 
4.8

 
5.9

 
9.5

 
$
12.9

 
$
18.2

 
$
26.9

 
$
36.1


Accounts Receivable Securitization Program
On April 25, 2016, the Company entered into a $200.0 million accounts receivable securitization program (the "Securitization Program") with several of its wholly owned subsidiaries and certain financial institutions. Under the terms of the Securitization Program, the Company and certain of its wholly-owned subsidiaries will sell their respective customer receivables to a bankruptcy remote special purpose entity, which is wholly-owned by the Company. The Company will also contribute a portion of its customer receivables to the special purpose entity. The Company retains servicing responsibility. The special purpose entity, as borrower, and the Company, as servicer, have entered into a Credit and Security Agreement with several lenders pursuant to which the special purpose entity may borrow up to $200.0 million from the lenders, with the loans secured by the receivables. In addition, the Company may request from the lenders an increase in the borrowing limit of up to $50.0 million during the term of the agreement, although such additional borrowing limit is uncommitted. Borrowings outstanding under the Securitization Program will bear interest at LIBOR plus the applicable margin of 0.7% and will be included as a component of current liabilities in the Company's consolidated balance sheet, while the accounts receivable securing these obligations will be included as a component of net receivables in the Company's consolidated balance sheet. The Company and the special purpose entity have been formed and are operated and maintained as separate legal entities. The assets and liabilities of the special purpose entity, which are separate from those of the Company, are not available to pay the debts of the Company and do not constitute obligations of the Company.
v3.4.0.3
Derivatives (Notes)
 6 Months Ended
Mar. 26, 2016
Derivatives [Abstract]  
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Derivatives
Interest Rate Cap - Cash Flow Hedge
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk by the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in Other income (expense) in the Consolidated Statements of Income.
During fiscal 2015, the Company entered into separate interest rate cap agreements with multiple counter-parties to help mitigate the interest rate volatility associated with the variable rate interest on its credit facilities under the Prior Credit Agreement, which was replaced by the new Credit Agreement. Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid by the Company for the interest rate cap agreements was $13.2 million, which was the initial fair value of the instruments recorded in the Company's financial statements.
The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under the Prior Credit Agreement. The terms in the new Credit Agreement are consistent with the Prior Credit Agreement, and therefore the interest rate caps continue to be highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal for a three-year period, which ends on December 29, 2017.
As of March 26, 2016, the Company determined that the existence of hedge ineffectiveness, if any, was immaterial and all changes in the fair value of the interest rate caps were recorded in the Consolidated Statements of Comprehensive Income as a component of AOCI.
During the three and six months ended March 26, 2016, $0.7 million and $1.0 million, respectively, was reclassified from AOCI to the Company’s Consolidated Statements of Income related to the interest rate cap agreements. The Company expects to similarly reclassify approximately $6.1 million from AOCI to the Consolidated Statements of Income in the next twelve months.
The aggregate fair value of these interest rate caps was $3.7 million and $6.9 million at March 26, 2016 and September 26, 2015, respectively and is included in both Prepaid expenses and other current assets and Other assets on the Company’s Consolidated Balance Sheet. Refer to Note 2 “Fair Value Measurements” above for related fair value disclosures.
Forward Foreign Currency Contracts
The Company enters into forward foreign currency exchange contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, and the Australian dollar. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are for periods of one year or less. During the first quarter of fiscal 2016, the Company began to execute forward foreign currency contracts in order to mitigate its exposure to fluctuations in various currencies against its reporting currency, the U.S. dollar. The Company did not elect hedge accounting for these forward foreign currency contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. During the three and six months ended March 26, 2016, the Company recorded a net unrealized loss of $0.7 million and an unrealized gain of $0.3 million, respectively, on the mark-to-market for its outstanding forward foreign currency contracts within other income (expense), net in the Consolidated Statements of Income and a realized gain of $0.6 million and $1.0 million, respectively from settling forward foreign currency contracts.
As of March 26, 2016, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro, UK Pound and the Australian dollar with a notional amount of $65.5 million.
Financial Instrument Presentation
The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 26, 2016:
 
Balance Sheet Location
 
March 26, 2016
 
September 26, 2015
Assets:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate cap agreements
Prepaid expenses and other current assets
 
$
0.9

 
$
0.7

Interest rate cap agreements
Other assets
 
2.8

 
6.2

 
 
 
$
3.7

 
$
6.9

 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Prepaid expenses and other current assets
 
$
1.2

 
$
—

 
 
 
 
 
 
Liabilities:
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Accrued expenses
 
$
0.9

 
$
—




The following table presents the unrealized loss recognized in AOCI related to the interest rate caps for the following reporting periods:
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
March 26, 2016
 
March 28, 2015
Amount of loss recognized in other comprehensive income, net of taxes:
 
 
 
 
 
 
 
Interest rate cap agreements
$
(2.2
)
 
$
(1.6
)
 
$
(1.9
)
 
$
(1.6
)

The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:
Derivatives not classified as hedging instruments
 
Amount of Gain (Loss) Recognized in Income
 
Location of Gain (Loss) Recognized in Income
 
 
Three Months Ended March 26, 2016
 
Six Months Ended March 26, 2016
 
 
Forward foreign currency contracts
 
$
(0.1
)
 
$
1.3

 
Other income (expense), net
v3.4.0.3
Commitments and Contingencies
 6 Months Ended
Mar. 26, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Litigation and Related Matters

On June 9, 2010, Smith & Nephew, Inc. ("Smith & Nephew") filed suit against Interlace Medical, Inc. ("Interlace"), which the Company acquired on January 6, 2011, in the United States District Court for the District of Massachusetts. The complaint alleged that the Interlace MyoSure hysteroscopic tissue removal device infringed U.S. patent 7,226,459. On November 22, 2011, Smith & Nephew filed suit against the Company in the United States District Court for the District of Massachusetts. The complaint alleged that use of the MyoSure hysteroscopic tissue removal system infringed U.S. patent 8,061,359. Both complaints sought permanent injunctive relief and unspecified damages. On September 4, 2012, following a two week trial, the jury returned a verdict of infringement of both the ‘459 and ‘359 patents and assessed damages of $4.0 million. A bench trial regarding the Company’s assertion of inequitable conduct on the part of Smith & Nephew with regard to the ‘359 patent was held on December 9, 2012 and oral arguments on the issue of inequitable conduct were presented on February 27, 2013. On June 27, 2013, the Court denied the Company’s motions related to inequitable conduct and allowed Smith & Nephew’s request for injunction, but ordered that enforcement of the injunction be stayed until final resolution, including appeal, of the current re-examinations of both patents at the United States Patent and Trademark Office (“USPTO”). The Court also rejected the jury’s damage award and ordered the parties to identify a mechanism for resolving the damages issue. The Company intends to file post-trial motions seeking to reverse the jury’s verdict. The USPTO has issued final decisions that the claims of the ‘459 and the '359 patents asserted as part of the litigation are not patentable. Smith & Nephew has appealed these decisions to the U.S. Patent Trial and Appeal Board. On January 20, 2016 the U.S. Patent Trial and Appeal Board affirmed the USPTO decision holding the claims at issue in the ‘459 patent as invalid. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
In January 2012, Enzo Life Sciences, Inc. ("Enzo") filed suit against the Company's subsidiary, Gen-Probe Incorporated ("Gen-Probe"), in the United States District Court for the District of Delaware. The Gen-Probe complaint alleged that certain of Gen-Probe’s diagnostics products, including products that incorporate Gen-Probe’s patented hybridization protection assay technology, such as the Aptima Combo 2 and Aptima HPV assays, infringe Enzo’s U.S. patent 6,992,180. On March 6, 2012, Enzo filed suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain of the Company’s molecular diagnostics products, including without limitation products based on its proprietary Invader chemistry, such as Cervista HPV HR and Cervista HPV 16/18, infringe Enzo’s U.S. patent 6,992,180. The complaint seeks permanent injunctive relief and unspecified damages. On September 30, 2013, Enzo amended its list of accused products to include Prodesse, MilliPROBE, PACE and Procleix assays. The complaint seeks permanent injunctive relief and unspecified damages. Enzo has asserted the ‘180 patent claims against six other companies. The court issued a Markman order on July 7, 2015 construing the claims, and it is expected that summary judgment motions will be heard in the fall of 2016. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
On March 27, 2015, Enzo filed an additional suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain additional Company molecular diagnostic products, including, inter alia, the Procleix Parvo/HAV assays and coagulation products, including the Invader Factor II test and the Invader Factor V test, also infringe U.S. Patent 6,992,180. The complaint further alleged that certain of the Company’s molecular diagnostic products, including the Company’s Progensa PCA3 products, all Aptima products and all Procleix products infringe Enzo’s U. S. Patent 7,064,197. On June 11, 2015, this matter was stayed pending the resolution of summary judgment motions in the 2012 case referenced above. On March 30, 2016 Hologic filed a request for inter-parties review of the ‘179 patent at the USPTO. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.
v3.4.0.3
Marketable Securities
 6 Months Ended
Mar. 26, 2016
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities
Marketable Securities
The following reconciles the cost basis to the fair market value of the Company’s equity securities that are classified as available-for-sale: 
Period Ended:
Cost
 
Gross Unrealized
Gains
 
Gross Unrealized
Losses
 
Other Than Temporary Impairment
 
Fair Value
Six Months Ended March 26, 2016
$
2.4

 
$
—

 
$
(1.5
)
 
$
—

 
$
0.9

Year Ended September 26, 2015
$
16.1

 
$
7.2

 
$
(0.3
)
 
$
(7.8
)
 
$
15.2


In the first quarter of fiscal 2016, the Company sold all of its shares in one of its marketable securities and recorded a realized gain of $25.1 million in Other income (expense), net.
In the fourth quarter of fiscal 2015, the Company concluded that the decline in fair value of one of its marketable securities was other-than-temporary based on the length of time the security's market value was significantly below its carrying value and recorded an impairment charge of $7.8 million.
v3.4.0.3
Net Income (Loss) Per Share
 6 Months Ended
Mar. 26, 2016
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share
Net Income Per Share
A reconciliation of basic and diluted share amounts is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Basic weighted average common shares outstanding
282,474

 
280,338

 
282,725

 
279,505

Weighted average common stock equivalents from assumed exercise of stock options and stock units
2,301

 
2,492

 
2,705

 
2,478

Incremental shares from Convertible Notes premium
3,082

 
4,750

 
4,484

 
3,395

Diluted weighted average common shares outstanding
287,857

 
287,580

 
289,914

 
285,378

Weighted-average anti-dilutive shares related to:
 
 
 
 
 
 
 
Outstanding stock options
1,106

 
1,865

 
919

 
2,824

Stock units
150

 
46

 
109

 
93


The Company has outstanding Convertible Notes, and the principal balance and any conversion premium may be satisfied, at the Company’s option, by issuing shares of common stock, cash or a combination of shares and cash. The Company's current policy is that it will settle the principal balance of the Convertible Notes in cash. As such, the Company applies the treasury stock method to these securities and the dilution related to the conversion premium of the 2010, 2012 and 2013 Notes is included in the calculation of diluted weighted-average shares outstanding to the extent each issuance is dilutive based on the average stock price during each reporting period being greater than the conversion price of the respective Notes.
v3.4.0.3
Stock-Based Compensation
 6 Months Ended
Mar. 26, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Cost of revenues
$
2.5

 
$
2.3

 
$
4.7

 
$
4.3

Research and development
2.6

 
2.2

 
5.0

 
4.1

Selling and marketing
2.7

 
2.3

 
5.2

 
4.3

General and administrative
6.9

 
6.9

 
15.7

 
13.0

Restructuring and divestiture
—

 
—

 
—

 
0.1

 
$
14.7

 
$
13.7

 
$
30.6

 
$
25.8


The Company granted 1.0 million and 1.2 million stock options during the six months ended March 26, 2016 and March 28, 2015, respectively, with weighted-average exercise prices of $39.47 and $26.42, respectively. There were 6.7 million options outstanding at March 26, 2016 with a weighted-average exercise price of $24.80.
The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Risk-free interest rate
1.6
%
 
1.7
%
 
1.6
%
 
1.7
%
Expected volatility
37.8
%
 
38.6
%
 
37.8
%
 
38.6
%
Expected life (in years)
4.7

 
5.3

 
4.7

 
5.3

Dividend yield
—

 
—

 
—

 
—

Weighted average fair value of options granted
$
11.80

 
$
10.36

 
$
12.98

 
$
9.55


The Company granted 1.0 million and 1.4 million restricted stock units (RSUs) during the six months ended March 26, 2016 and March 28, 2015, respectively, with weighted-average grant date fair values of $39.63 and $26.35 per unit, respectively. As of March 26, 2016, there were 3.3 million unvested RSUs outstanding with a weighted-average grant date fair value of $29.58 per unit. In addition, the Company granted 0.2 million and 0.3 million performance stock units (PSUs) during the six months ended March 26, 2016 and March 28, 2015, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $39.72 and $26.58 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company is recognizing compensation expense ratably over the required service period based on its estimate of the number of shares that will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made.
At March 26, 2016, there was $27.3 million and $97.7 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs and PSUs), respectively, to be recognized over a weighted-average period of 3.3 years and 2.4 years, respectively.
v3.4.0.3
Share Repurchase (Notes)
 6 Months Ended
Mar. 26, 2016
Share Repurchase [Abstract]  
Treasury Stock [Text Block]
(10) Share Repurchase
On November 11, 2013, the Company announced that its Board of Directors authorized the repurchase of up to $250.0 million of its outstanding common stock over the next three years. During the second quarter of fiscal 2016, the Company repurchased 4.3 million shares of its common stock for total consideration of $148.8 million with a weighted average per share price of $34.36. Total cash paid for these transactions during the second quarter aggregated $135.9 million with $12.9 million remaining unpaid as of March 26, 2016.
v3.4.0.3
Other Balance Sheet Information
 6 Months Ended
Mar. 26, 2016
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Information
Other Balance Sheet Information

 
March 26,
2016
 
September 26,
2015
Inventories
 
 
 
Raw materials
$
98.6

 
$
98.3

Work-in-process
55.3

 
58.7

Finished goods
131.2

 
126.1

 
$
285.1

 
$
283.1


Property, plant and equipment
 
 
 
Equipment and software
$
377.8

 
$
365.9

Equipment under customer usage agreements
319.3

 
305.7

Building and improvements
182.8

 
182.1

Leasehold improvements
59.1

 
59.2

Land
51.4

 
51.4

Furniture and fixtures
18.1

 
17.3

 
1,008.5

 
981.6

Less – accumulated depreciation and amortization
(554.4
)
 
(524.5
)
 
$
454.1

 
$
457.1
v3.4.0.3
Business Segments and Geographic Information
 6 Months Ended
Mar. 26, 2016
Segment Reporting [Abstract]  
Business Segments and Geographic Information
Business Segments and Geographic Information
The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.
Identifiable assets for the four principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues during the three and six months ended March 26, 2016 and March 28, 2015. Segment information is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Total revenues:
 
 
 
 
 
 
 
Diagnostics
$
304.4

 
$
296.7

 
$
615.1

 
$
600.8

Breast Health
275.8

 
255.5

 
537.9

 
497.5

GYN Surgical
90.9

 
79.1

 
189.7

 
163.5

Skeletal Health
22.2

 
24.2

 
45.7

 
46.5

 
$
693.3


$
655.5


$
1,388.4


$
1,308.3

Income from operations:
 
 
 
 
 
 
 
Diagnostics
$
34.3

 
$
27.1

 
$
65.8

 
$
55.3

Breast Health
88.4

 
75.4

 
160.0

 
135.9

GYN Surgical
11.5

 
4.5

 
32.3

 
17.7

Skeletal Health
1.9

 
2.8

 
4.0

 
4.4

 
$
136.1


$
109.8

 
$
262.1

 
$
213.3

Depreciation and amortization:
 
 
 
 
 
 
 
Diagnostics
$
83.8

 
$
91.9

 
$
167.4

 
$
180.5

Breast Health
5.1

 
8.3

 
12.4

 
15.9

GYN Surgical
24.8

 
26.0

 
49.5

 
51.5

Skeletal Health
0.3

 
0.4

 
0.6

 
0.7

 
$
114.0


$
126.6


$
229.9


$
248.6

Capital expenditures:
 
 
 
 
 
 
 
Diagnostics
$
13.0

 
$
11.4

 
$
24.9

 
$
26.2

Breast Health
3.4

 
3.0

 
5.4

 
5.5

GYN Surgical
3.4

 
2.4

 
6.8

 
4.4

Skeletal Health
0.1

 
0.1

 
0.2

 
0.2

Corporate
2.1

 
1.8

 
4.4

 
3.4

 
$
22.0


$
18.7


$
41.7


$
39.7

 
 
March 26,
2016
 
September 26,
2015
Identifiable assets:
 
 
 
Diagnostics
$
3,912.0

 
$
4,055.8

Breast Health
811.8

 
815.4

GYN Surgical
1,612.2

 
1,658.1

Skeletal Health
29.9

 
25.3

Corporate
920.4

 
1,115.5

 
$
7,286.3

 
$
7,670.1


The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 26, 2016 and March 28, 2015.
The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
United States
79.0
%
 
75.5
%
 
78.7
%
 
74.8
%
Europe
10.4
%
 
11.8
%
 
10.2
%
 
12.7
%
Asia-Pacific
7.4
%
 
8.9
%
 
7.6
%
 
8.8
%
All others
3.2
%
 
3.8
%
 
3.5
%
 
3.7
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
v3.4.0.3
Income Taxes
 6 Months Ended
Mar. 26, 2016
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.
The Company’s effective tax rate for the three and six months ended March 26, 2016 was 25.0% and 25.5%, respectively, compared to 21.4% and 26.6%, respectively, for the corresponding periods in the prior year. For the current three and six month periods, the effective tax rate was lower than the statutory tax rate primarily due to increased foreign profits at lower tax rates, the domestic production activities deduction benefit, and a change in the valuation allowance related to the sale of a marketable security that had a gain for book purposes. For the three and six months ended March 28, 2015, the effective tax rate differed from the statutory rate primarily due to the domestic production activities deduction benefit and reserve reversals attributable to a favorable income tax audit settlement.
In November 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred income taxes by eliminating the requirement for entities to separate deferred income tax liabilities and assets into current and noncurrent amounts in the balance sheet. Rather, it requires that deferred tax assets and liabilities are classified as noncurrent in the balance sheet. The Company adopted this standard prospectively in the first quarter of fiscal 2016, and prior periods were not retrospectively adjusted.
v3.4.0.3
Intangible Assets
 6 Months Ended
Mar. 26, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Intangible Assets
Intangible assets consisted of the following:
 
Description
As of March 26, 2016
 
As of September 26, 2015
Gross
Carrying
Value
 
Accumulated
Amortization
 
Gross
Carrying
Value
 
Accumulated
Amortization
Developed technology
$
3,983.8

 
$
1,843.1

 
$
3,979.1

 
$
1,698.5

In-process research and development
3.7

 
—

 
3.7

 
—

Customer relationships and contracts
1,100.0

 
507.0

 
1,101.1

 
467.5

Trade names
236.3

 
136.6

 
236.4

 
131.5

Business licenses
2.5

 
2.1

 
2.5

 
2.1

 
$
5,326.3


$
2,488.8


$
5,322.8


$
2,299.6


In the second quarter of fiscal 2016, the Company acquired certain intellectual property for $4.8 million, which was recorded in developed technology.
The estimated remaining amortization expense as of March 26, 2016 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2016
$
187.6

Fiscal 2017
$
366.1

Fiscal 2018
$
355.6

Fiscal 2019
$
343.9

Fiscal 2020
$
332.9
v3.4.0.3
Product Warranties
 6 Months Ended
Mar. 26, 2016
Guarantees [Abstract]  
Product Warranties
Product Warranties
Product warranty activity was as follows:
 
 
Balance at
Beginning of
Period
 
Provisions
 
Settlements/
Adjustments
 
Balance at
End of Period
Six Months Ended:
 
 
 
 
 
 
 
March 26, 2016
$
5.4

 
$
7.3

 
$
(3.3
)
 
$
9.4

March 28, 2015
$
6.3

 
$
2.9

 
$
(3.5
)
 
$
5.7


During the first quarter of fiscal 2016, the Company recorded a warranty provision of $4.0 million related to certain products sold exclusively in the Chinese market.
v3.4.0.3
Accumuated Other Comprehensive Income (Notes)
 6 Months Ended
Mar. 26, 2016
Accumulated Other Comprehensive Income [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
(16) Accumulated Other Comprehensive Loss

The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:

 
Three Months Ended March 26, 2016
 
Six Months Ended March 26, 2016
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(19.9
)
 
$
(0.9
)
 
$
(1.8
)
 
$
(3.3
)
 
$
(25.9
)
 
$
(15.7
)
 
$
6.9

 
$
(1.8
)
 
$
(3.9
)
 
$
(14.5
)
Other comprehensive income (loss) before reclassifications
(1.2
)
 
(0.6
)
 
—

 
(2.2
)
 
(4.0
)
 
(5.4
)
 
(1.2
)
 
—

 
(1.9
)
 
(8.5
)
Amounts reclassified to statement of income
—

 
—

 
—

 
0.7

 
0.7

 
—

 
(7.2
)
 
—

 
1.0

 
(6.2
)
Ending Balance
$
(21.1
)
 
$
(1.5
)
 
$
(1.8
)
 
$
(4.8
)
 
$
(29.2
)
 
$
(21.1
)
 
$
(1.5
)
 
$
(1.8
)
 
$
(4.8
)
 
$
(29.2
)

 
Three Months Ended March 28, 2015
 
Six Months Ended March 28, 2015
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(13.7
)
 
$
14.0

 
$
(1.5
)
 
$
—

 
$
(1.2
)
 
$
(4.7
)
 
$
8.9

 
$
(1.6
)
 
$
—

 
$
2.6

Other comprehensive income (loss) before reclassifications
(9.5
)
 
(8.3
)
 
—

 
(1.6
)
 
(19.4
)
 
(18.5
)
 
(3.2
)
 
0.1

 
(1.6
)
 
(23.2
)
Amounts reclassified to statement of income
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

Ending Balance
$
(23.2
)
 
$
5.7

 
$
(1.5
)
 
$
(1.6
)
 
$
(20.6
)
 
$
(23.2
)
 
$
5.7

 
$
(1.5
)
 
$
(1.6
)
 
$
(20.6
)
v3.4.0.3
New Accounting Pronouncements
 6 Months Ended
Mar. 26, 2016
Accounting Changes and Error Corrections [Abstract]  
New Accounting Pronouncements
New Accounting Pronouncements

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). The guidance changes how companies account for certain aspects of share-based payments to employees. Entities will be required to recognize income tax effects of awards in the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee's shares than it can today for tax withholding purposes by providing for withholding at the employee's maximum rate as opposed to the minimum rate without triggering liability accounting and by allowing an entity-wide policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December 15, 2016, and is applicable to the Company in fiscal 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial position and results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The guidance requires an entity to recognize a right-of-use asset and a lease liability for virtually all of its leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The guidance is effective for annual periods beginning after December 15, 2018, and is applicable to the Company in fiscal 2020. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its consolidated financial position and results of operations.
 
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This guidance changes how entities measure equity investments that do not result in consolidation and are not accounted for under the equity method. Entities will be required to measure these investments at fair value at the end of each reporting period and recognize changes in fair value in net income. A practicability exception will be available for equity investments that do not have readily determinable fair values, however; the exception requires the Company to consider relevant transactions that can be reasonably known to identify any observable price changes that would impact the fair value. This guidance also changes certain disclosure requirements and other aspects of current US GAAP. This guidance is effective for annual periods beginning after December 15, 2017, and is applicable to the Company in fiscal 2019. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-01 on its consolidated financial position and results of operations.

In July 2015, the FASB issued guidance under ASC 330, Simplifying the Measurement of Inventory. The new guidance requires inventory to be measured at the lower of cost and net realizable value, which is defined as the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. This new guidance is effective for the Company's first quarter of fiscal 2018 and early adoption is permitted. The guidance must be applied prospectively. The Company is currently evaluating the impact of the adoption of this requirement on its consolidated financial statements but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Presentation of Debt Issuance Costs. This guidance intends to simplify the presentation of debt issuance costs and more closely align the presentation of debt issuance costs under U.S. GAAP to IFRS standards. This guidance is effective for annual periods beginning after December 15, 2015, and is applicable to the Company in fiscal 2017. Early adoption is permitted. The Company is currently evaluating this guidance, but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements.
    
In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. This guidance focuses on a reporting company’s consolidation evaluation to determine whether certain legal entities should be consolidated. This guidance is effective for annual periods beginning after December 15, 2015, and is applicable to the Company in fiscal 2017. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating this guidance, but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and is applicable to the Company in fiscal 2018. Early adoption is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on the Company's consolidated financial statements or disclosures.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 660), which provides guidance for revenue recognition. This ASU is applicable to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to receive in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current U.S. GAAP. These judgments may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. On July 9, 2015, the FASB voted in favor of delaying the effective date of the new standard by one year, with early adoption permitted as of the original effective date. ASU 2014-09 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2017, which is fiscal 2019 for the Company. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
v3.4.0.3
Fair Value Measurements (Tables)
 6 Months Ended
Mar. 26, 2016
Fair Value Disclosures [Abstract]  
Fair Value Assets and Liabilities Measured on Recurring Basis
Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 26, 2016: 
 
 
 
Fair Value at Reporting Date Using
 
Balance as of March 26, 2016
 
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Equity securities
$
0.8

 
$
0.8

 
$
—

 
$
—

Interest rate cap - derivative
3.7

 
—

 
3.7

 
—

Forward foreign currency contracts
1.2

 
—

 
1.2

 
—

Total
$
5.7

 
$
0.8

 
$
4.9

 
$
—

Liabilities:
 
 
 
 
 
 
 
Deferred compensation liabilities
$
37.6

 
$
37.6

 
$
—

 
$
—

Forward foreign currency contracts
0.9

 
—

 
0.9

 
—

Total
$
38.5

 
$
37.6

 
$
0.9

 
$
—
Estimated Fair Values of Convertible Notes
The estimated fair values of the Company’s Convertible Notes at March 26, 2016 were as follows:
 
2010 Notes
$
90.0

2012 Notes
459.9

2013 Notes
459.7

 
$
1,009.6
v3.4.0.3
Restructuring and Divestiture Charges (Tables)
 6 Months Ended
Mar. 26, 2016
Restructuring and Related Activities [Abstract]  
Charges Taken Related to Restructuring Actions
The following table displays charges taken in the fiscal 2016 year to date period and fiscal 2015 related to these actions and a rollforward of the accrued balances from September 26, 2015 to March 26, 2016:
 
 
Fiscal 2016 Actions
 
Fiscal 2015 Actions
 
Fiscal 2014 Actions
 
Other Operating Cost Reductions
 
Total    
Restructuring and Divestiture Charges
 
 
 
 
 
 
 
 
 
 
Fiscal 2015 charges:
 
 
 
 
 
 
 
 
 
 
Workforce reductions
 
$
—

 
$
10.0

 
$
6.0

 
$
0.3

 
$
16.3

Facility closure costs
 
—

 
—

 
2.0

 
0.6

 
2.6

Fiscal 2015 restructuring charges
 
$
—

 
$
10.0

 
$
8.0

 
$
0.9

 
$
18.9

Divestiture net charges
 
 
 
 
 
 
 
 
 
9.6

Fiscal 2015 restructuring and divestiture charges
 
 
 
 
 
 
 
 
 
$
28.5

Fiscal 2016 charges:
 
 
 
 
 
 
 
 
 

Workforce reductions
 
$
6.0

 
$
—

 
$
—

 
$
—

 
$
6.0

Fiscal 2016 restructuring charges
 
$
6.0

 
$
—

 
$
—

 
$
—

 
$
6.0
Charges Taken Related to Accrued Restructuring Actions
 
 
Fiscal 2016 Actions
 
Fiscal 2015 Actions
 
Fiscal 2014 Actions
 
Other Operating Cost Reductions  
 
Total    
Rollforward of Accrued Restructuring
 
 
 
 
 
 
 
 
 
 
Balance as of September 26, 2015
 
$
—

 
$
3.1

 
$
2.5

 
$
0.1

 
$
5.7

Fiscal 2016 restructuring charges
 
6.0

 
—

 
—

 
—

 
6.0

Severance payments
 
(2.3
)
 
(2.4
)
 
(1.4
)
 
(0.1
)
 
(6.2
)
Other payments
 
—

 
—

 
(0.2
)
 
—

 
(0.2
)
Balance as of March 26, 2016
 
$
3.7

 
$
0.7

 
$
0.9

 
$
—

 
$
5.3
v3.4.0.3
Borrowings and Credit Arrangements (Tables)
 6 Months Ended
Mar. 26, 2016
Debt Disclosure [Abstract]  
Company's Borrowings
The Company’s borrowings consisted of the following: 
 
March 26,
2016
 
September 26,
2015
Current debt obligations, net of debt discount:
 
 
 
Term Loan
$
74.7

 
$
74.6

Revolver
175.0

 
175.0

Convertible Notes
58.0

 
142.2

Total current debt obligations
$
307.7

 
$
391.8

Long-term debt obligations, net of debt discount:
 
 
 
Term Loan
1,363.1

 
1,399.8

2022 Senior Notes
987.7

 
986.7

Convertible Notes
747.2

 
861.5

Total long-term debt obligations
$
3,098.0

 
$
3,248.0

Total debt obligations
$
3,405.7

 
$
3,639.8
Interest Expense under Convertible Notes
Interest expense under the Convertible Notes was as follows: 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Amortization of debt discount
$
5.8

 
$
9.0

 
$
12.2

 
$
17.8

Amortization of deferred financing costs
0.3

 
0.4

 
0.6

 
0.9

Principal accretion
4.1

 
4.0

 
8.2

 
7.9

Non-cash interest expense
10.2

 
13.4

 
21.0

 
26.6

2.00% accrued interest (cash)
2.7

 
4.8

 
5.9

 
9.5

 
$
12.9

 
$
18.2

 
$
26.9

 
$
36.1
v3.4.0.3
Derivatives Schedule of Derivative Assets at Fair Value (Tables)
 6 Months Ended
Mar. 26, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Assets at Fair Value [Table Text Block]
The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 26, 2016:
 
Balance Sheet Location
 
March 26, 2016
 
September 26, 2015
Assets:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate cap agreements
Prepaid expenses and other current assets
 
$
0.9

 
$
0.7

Interest rate cap agreements
Other assets
 
2.8

 
6.2

 
 
 
$
3.7

 
$
6.9

 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Prepaid expenses and other current assets
 
$
1.2

 
$
—

 
 
 
 
 
 
Liabilities:
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Accrued expenses
 
$
0.9

 
$
—
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]
The following table presents the unrealized loss recognized in AOCI related to the interest rate caps for the following reporting periods:
 
Three Months Ended
 
Six Months Ended
 
March 26, 2016
 
March 28, 2015
 
March 26, 2016
 
March 28, 2015
Amount of loss recognized in other comprehensive income, net of taxes:
 
 
 
 
 
 
 
Interest rate cap agreements
$
(2.2
)
 
$
(1.6
)
 
$
(1.9
)
 
$
(1.6
)
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]
The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:
Derivatives not classified as hedging instruments
 
Amount of Gain (Loss) Recognized in Income
 
Location of Gain (Loss) Recognized in Income
 
 
Three Months Ended March 26, 2016
 
Six Months Ended March 26, 2016
 
 
Forward foreign currency contracts
 
$
(0.1
)
 
$
1.3

 
Other income (expense), net
v3.4.0.3
Marketable Securities (Tables)
 6 Months Ended
Mar. 26, 2016
Investments, Debt and Equity Securities [Abstract]  
Reconciles Cost Basis to Fair Market Value of Company's Equity Security
The following reconciles the cost basis to the fair market value of the Company’s equity securities that are classified as available-for-sale: 
Period Ended:
Cost
 
Gross Unrealized
Gains
 
Gross Unrealized
Losses
 
Other Than Temporary Impairment
 
Fair Value
Six Months Ended March 26, 2016
$
2.4

 
$
—

 
$
(1.5
)
 
$
—

 
$
0.9

Year Ended September 26, 2015
$
16.1

 
$
7.2

 
$
(0.3
)
 
$
(7.8
)
 
$
15.2
v3.4.0.3
Net Income (Loss) Per Share (Tables)
 6 Months Ended
Mar. 26, 2016
Earnings Per Share [Abstract]  
Reconciliation of Basic and Diluted Share Amounts
A reconciliation of basic and diluted share amounts is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Basic weighted average common shares outstanding
282,474

 
280,338

 
282,725

 
279,505

Weighted average common stock equivalents from assumed exercise of stock options and stock units
2,301

 
2,492

 
2,705

 
2,478

Incremental shares from Convertible Notes premium
3,082

 
4,750

 
4,484

 
3,395

Diluted weighted average common shares outstanding
287,857

 
287,580

 
289,914

 
285,378

Weighted-average anti-dilutive shares related to:
 
 
 
 
 
 
 
Outstanding stock options
1,106

 
1,865

 
919

 
2,824

Stock units
150

 
46

 
109

 
93
v3.4.0.3
Stock-Based Compensation (Tables)
 6 Months Ended
Mar. 26, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation Expense in Consolidated Statements of Operations
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Cost of revenues
$
2.5

 
$
2.3

 
$
4.7

 
$
4.3

Research and development
2.6

 
2.2

 
5.0

 
4.1

Selling and marketing
2.7

 
2.3

 
5.2

 
4.3

General and administrative
6.9

 
6.9

 
15.7

 
13.0

Restructuring and divestiture
—

 
—

 
—

 
0.1

 
$
14.7

 
$
13.7

 
$
30.6

 
$
25.8
Weighted-Average Assumptions Utilized to Value Stock Options
The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Risk-free interest rate
1.6
%
 
1.7
%
 
1.6
%
 
1.7
%
Expected volatility
37.8
%
 
38.6
%
 
37.8
%
 
38.6
%
Expected life (in years)
4.7

 
5.3

 
4.7

 
5.3

Dividend yield
—

 
—

 
—

 
—

Weighted average fair value of options granted
$
11.80

 
$
10.36

 
$
12.98

 
$
9.55
v3.4.0.3
Other Balance Sheet Information (Tables)
 6 Months Ended
Mar. 26, 2016
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Information of Inventories
 
March 26,
2016
 
September 26,
2015
Inventories
 
 
 
Raw materials
$
98.6

 
$
98.3

Work-in-process
55.3

 
58.7

Finished goods
131.2

 
126.1

 
$
285.1

 
$
283.1
Other Balance Sheet Information of Property, Plant and Equipment
Property, plant and equipment
 
 
 
Equipment and software
$
377.8

 
$
365.9

Equipment under customer usage agreements
319.3

 
305.7

Building and improvements
182.8

 
182.1

Leasehold improvements
59.1

 
59.2

Land
51.4

 
51.4

Furniture and fixtures
18.1

 
17.3

 
1,008.5

 
981.6

Less – accumulated depreciation and amortization
(554.4
)
 
(524.5
)
 
$
454.1

 
$
457.1
v3.4.0.3
Business Segments and Geographic Information (Tables)
 6 Months Ended
Mar. 26, 2016
Segment Reporting [Abstract]  
Segment Information
Segment information is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
Total revenues:
 
 
 
 
 
 
 
Diagnostics
$
304.4

 
$
296.7

 
$
615.1

 
$
600.8

Breast Health
275.8

 
255.5

 
537.9

 
497.5

GYN Surgical
90.9

 
79.1

 
189.7

 
163.5

Skeletal Health
22.2

 
24.2

 
45.7

 
46.5

 
$
693.3


$
655.5


$
1,388.4


$
1,308.3

Income from operations:
 
 
 
 
 
 
 
Diagnostics
$
34.3

 
$
27.1

 
$
65.8

 
$
55.3

Breast Health
88.4

 
75.4

 
160.0

 
135.9

GYN Surgical
11.5

 
4.5

 
32.3

 
17.7

Skeletal Health
1.9

 
2.8

 
4.0

 
4.4

 
$
136.1


$
109.8

 
$
262.1

 
$
213.3

Depreciation and amortization:
 
 
 
 
 
 
 
Diagnostics
$
83.8

 
$
91.9

 
$
167.4

 
$
180.5

Breast Health
5.1

 
8.3

 
12.4

 
15.9

GYN Surgical
24.8

 
26.0

 
49.5

 
51.5

Skeletal Health
0.3

 
0.4

 
0.6

 
0.7

 
$
114.0


$
126.6


$
229.9


$
248.6

Capital expenditures:
 
 
 
 
 
 
 
Diagnostics
$
13.0

 
$
11.4

 
$
24.9

 
$
26.2

Breast Health
3.4

 
3.0

 
5.4

 
5.5

GYN Surgical
3.4

 
2.4

 
6.8

 
4.4

Skeletal Health
0.1

 
0.1

 
0.2

 
0.2

Corporate
2.1

 
1.8

 
4.4

 
3.4

 
$
22.0


$
18.7


$
41.7


$
39.7

 
 
March 26,
2016
 
September 26,
2015
Identifiable assets:
 
 
 
Diagnostics
$
3,912.0

 
$
4,055.8

Breast Health
811.8

 
815.4

GYN Surgical
1,612.2

 
1,658.1

Skeletal Health
29.9

 
25.3

Corporate
920.4

 
1,115.5

 
$
7,286.3

 
$
7,670.1
Revenues by Geography
Revenues by geography as a percentage of total revenues were as follows:
 
 
Three Months Ended
 
Six Months Ended
 
March 26,
2016
 
March 28,
2015
 
March 26,
2016
 
March 28,
2015
United States
79.0
%
 
75.5
%
 
78.7
%
 
74.8
%
Europe
10.4
%
 
11.8
%
 
10.2
%
 
12.7
%
Asia-Pacific
7.4
%
 
8.9
%
 
7.6
%
 
8.8
%
All others
3.2
%
 
3.8
%
 
3.5
%
 
3.7
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
v3.4.0.3
Intangible Assets (Tables)
 6 Months Ended
Mar. 26, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Intangible assets consisted of the following:
 
Description
As of March 26, 2016
 
As of September 26, 2015
Gross
Carrying
Value
 
Accumulated
Amortization
 
Gross
Carrying
Value
 
Accumulated
Amortization
Developed technology
$
3,983.8

 
$
1,843.1

 
$
3,979.1

 
$
1,698.5

In-process research and development
3.7

 
—

 
3.7

 
—

Customer relationships and contracts
1,100.0

 
507.0

 
1,101.1

 
467.5

Trade names
236.3

 
136.6

 
236.4

 
131.5

Business licenses
2.5

 
2.1

 
2.5

 
2.1

 
$
5,326.3


$
2,488.8


$
5,322.8


$
2,299.6
Schedule of Estimated Amortization Expense
The estimated remaining amortization expense as of March 26, 2016 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2016
$
187.6

Fiscal 2017
$
366.1

Fiscal 2018
$
355.6

Fiscal 2019
$
343.9

Fiscal 2020
$
332.9
v3.4.0.3
Product Warranties (Tables)
 6 Months Ended
Mar. 26, 2016
Guarantees [Abstract]  
Product Warranty
Product warranty activity was as follows:
 
 
Balance at
Beginning of
Period
 
Provisions
 
Settlements/
Adjustments
 
Balance at
End of Period
Six Months Ended:
 
 
 
 
 
 
 
March 26, 2016
$
5.4

 
$
7.3

 
$
(3.3
)
 
$
9.4

March 28, 2015
$
6.3

 
$
2.9

 
$
(3.5
)
 
$
5.7
v3.4.0.3
Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)
 6 Months Ended
Mar. 26, 2016
Accumulated Other Comprehensive Income [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:

 
Three Months Ended March 26, 2016
 
Six Months Ended March 26, 2016
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(19.9
)
 
$
(0.9
)
 
$
(1.8
)
 
$
(3.3
)
 
$
(25.9
)
 
$
(15.7
)
 
$
6.9

 
$
(1.8
)
 
$
(3.9
)
 
$
(14.5
)
Other comprehensive income (loss) before reclassifications
(1.2
)
 
(0.6
)
 
—

 
(2.2
)
 
(4.0
)
 
(5.4
)
 
(1.2
)
 
—

 
(1.9
)
 
(8.5
)
Amounts reclassified to statement of income
—

 
—

 
—

 
0.7

 
0.7

 
—

 
(7.2
)
 
—

 
1.0

 
(6.2
)
Ending Balance
$
(21.1
)
 
$
(1.5
)
 
$
(1.8
)
 
$
(4.8
)
 
$
(29.2
)
 
$
(21.1
)
 
$
(1.5
)
 
$
(1.8
)
 
$
(4.8
)
 
$
(29.2
)

 
Three Months Ended March 28, 2015
 
Six Months Ended March 28, 2015
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Marketable Securities
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(13.7
)
 
$
14.0

 
$
(1.5
)
 
$
—

 
$
(1.2
)
 
$
(4.7
)
 
$
8.9

 
$
(1.6
)
 
$
—

 
$
2.6

Other comprehensive income (loss) before reclassifications
(9.5
)
 
(8.3
)
 
—

 
(1.6
)
 
(19.4
)
 
(18.5
)
 
(3.2
)
 
0.1

 
(1.6
)
 
(23.2
)
Amounts reclassified to statement of income
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

Ending Balance
$
(23.2
)
 
$
5.7

 
$
(1.5
)
 
$
(1.6
)
 
$
(20.6
)
 
$
(23.2
)
 
$
5.7

 
$
(1.5
)
 
$
(1.6
)
 
$
(20.6
)
v3.4.0.3
Basis of Presentation Additional Information (Details)
$ in Millions
Mar. 26, 2016
USD ($)
Subsequent Events [Abstract]  
Accounts Receivable from Securitization $ 200.0
v3.4.0.3
Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Assets:    
Assets measured at fair value on a recurring basis $ 5.7  
Interest Rate Cash Flow Hedge Asset at Fair Value   $ 6.9
Liabilities:    
Liabilities measured at fair value on a recurring basis 38.5  
Equity securities    
Assets:    
Assets measured at fair value on a recurring basis 0.8  
Interest rate cap - derivative    
Assets:    
Interest Rate Cash Flow Hedge Asset at Fair Value 3.7  
Foreign Exchange Contract [Member]    
Assets:    
Foreign Currency Contract, Asset, Fair Value Disclosure 1.2  
Liabilities:    
Foreign Currency Contracts, Liability, Fair Value Disclosure 0.9  
Deferred compensation liabilities    
Liabilities:    
Liabilities measured at fair value on a recurring basis 37.6  
Quoted Prices in Active Market for Identical Assets (Level 1)    
Assets:    
Assets measured at fair value on a recurring basis 0.8  
Liabilities:    
Liabilities measured at fair value on a recurring basis 37.6  
Quoted Prices in Active Market for Identical Assets (Level 1) | Equity securities    
Assets:    
Assets measured at fair value on a recurring basis 0.8  
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest rate cap - derivative    
Assets:    
Assets measured at fair value on a recurring basis 0.0  
Quoted Prices in Active Market for Identical Assets (Level 1) | Foreign Exchange Contract [Member]    
Assets:    
Assets measured at fair value on a recurring basis 0.0  
Liabilities:    
Liabilities measured at fair value on a recurring basis 0.0  
Quoted Prices in Active Market for Identical Assets (Level 1) | Deferred compensation liabilities    
Liabilities:    
Liabilities measured at fair value on a recurring basis 37.6  
Significant Other Observable Inputs (Level 2)    
Assets:    
Assets measured at fair value on a recurring basis 4.9  
Liabilities:    
Liabilities measured at fair value on a recurring basis 0.9  
Significant Other Observable Inputs (Level 2) | Equity securities    
Assets:    
Assets measured at fair value on a recurring basis 0.0  
Significant Other Observable Inputs (Level 2) | Interest rate cap - derivative    
Assets:    
Assets measured at fair value on a recurring basis 3.7  
Significant Other Observable Inputs (Level 2) | Foreign Exchange Contract [Member]    
Assets:    
Assets measured at fair value on a recurring basis 1.2  
Liabilities:    
Liabilities measured at fair value on a recurring basis 0.9  
Significant Other Observable Inputs (Level 2) | Deferred compensation liabilities    
Liabilities:    
Liabilities measured at fair value on a recurring basis 0.0  
Significant Unobservable Inputs (Level 3)    
Assets:    
Assets measured at fair value on a recurring basis 0.0  
Liabilities:    
Liabilities measured at fair value on a recurring basis 0.0  
Significant Unobservable Inputs (Level 3) | Equity securities    
Assets:    
Assets measured at fair value on a recurring basis 0.0  
Significant Unobservable Inputs (Level 3) | Interest rate cap - derivative    
Assets:    
Assets measured at fair value on a recurring basis 0.0  
Significant Unobservable Inputs (Level 3) | Foreign Exchange Contract [Member]    
Assets:    
Assets measured at fair value on a recurring basis 0.0  
Liabilities:    
Liabilities measured at fair value on a recurring basis 0.0  
Significant Unobservable Inputs (Level 3) | Deferred compensation liabilities    
Liabilities:    
Liabilities measured at fair value on a recurring basis $ 0.0  
v3.4.0.3
Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Cost Method Investments $ 3.5 $ 4.2
Borrowed principal under credit agreement 1,000.0  
Credit Agreement    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Borrowed principal under credit agreement 1,620.0  
Senior Notes    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Fair value of debt instrument $ 1,040.0  
v3.4.0.3
Fair Value Measurements - Estimated Fair Values of Convertible Notes (Detail)
$ in Millions
Mar. 26, 2016
USD ($)
Estimated Fair Value Of Financial Instruments [Line Items]  
Estimated fair values of debt instruments $ 1,009.6
2010 Notes  
Estimated Fair Value Of Financial Instruments [Line Items]  
Estimated fair values of debt instruments 90.0
2012 Notes  
Estimated Fair Value Of Financial Instruments [Line Items]  
Estimated fair values of debt instruments 459.9
2013 Notes  
Estimated Fair Value Of Financial Instruments [Line Items]  
Estimated fair values of debt instruments $ 459.7
v3.4.0.3
Restructuring and Divestiture Charges - Charges Taken Related to Restructuring Actions (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Sep. 26, 2015
Restructuring Cost and Reserve [Line Items]          
Fiscal restructuring and divestiture charges $ 3.8 $ 2.0 $ 6.0 $ 10.0  
Restructuring | Two Thousand Fifteen [Member]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions         $ 16.3
Facility closure costs         2.6
Fiscal restructuring charges         18.9
Divestiture net charges         9.6
Fiscal restructuring and divestiture charges         28.5
Restructuring | Year Two Thousand Sixteen [Domain]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions     6.0    
Fiscal restructuring charges     6.0    
Restructuring | Fiscal 2016 Actions [Domain] | Two Thousand Fifteen [Member]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions         0.0
Facility closure costs         0.0
Fiscal restructuring charges         0.0
Restructuring | Fiscal 2016 Actions [Domain] | Year Two Thousand Sixteen [Domain]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions     6.0    
Fiscal restructuring charges     6.0    
Restructuring | Fiscal 2015 Actions | Two Thousand Fifteen [Member]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions         10.0
Facility closure costs         0.0
Fiscal restructuring charges         10.0
Restructuring | Fiscal 2015 Actions | Year Two Thousand Sixteen [Domain]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions     0.0    
Fiscal restructuring charges     0.0    
Restructuring | Fiscal 2014 Actions | Two Thousand Fifteen [Member]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions         6.0
Facility closure costs         2.0
Fiscal restructuring charges         8.0
Restructuring | Fiscal 2014 Actions | Year Two Thousand Sixteen [Domain]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions     0.0    
Fiscal restructuring charges     0.0    
Restructuring | Other Operating Cost Reductions | Two Thousand Fifteen [Member]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions         0.3
Facility closure costs         0.6
Fiscal restructuring charges         $ 0.9
Restructuring | Other Operating Cost Reductions | Year Two Thousand Sixteen [Domain]          
Restructuring Cost and Reserve [Line Items]          
Workforce reductions     0.0    
Fiscal restructuring charges     $ 0.0    
v3.4.0.3
Restructuring and Divestiture Charges - Charges Taken Related to Accrued Restructuring Actions (Detail) - Restructuring - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Mar. 26, 2016
Sep. 26, 2015
Two Thousand Fifteen    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan   $ 18.9
Restructuring Reserve [Roll Forward]    
Period beginning balance $ 5.7  
Period end balance   5.7
Two Thousand Fifteen | Restructuring Action Two Thousand Sixteen [Domain]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan   0.0
Restructuring Reserve [Roll Forward]    
Period beginning balance 0.0  
Period end balance   0.0
Two Thousand Fifteen | Fiscal 2015 Actions    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan   10.0
Restructuring Reserve [Roll Forward]    
Period beginning balance 3.1  
Period end balance   3.1
Two Thousand Fifteen | Fiscal 2014 Actions    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan   8.0
Restructuring Reserve [Roll Forward]    
Period beginning balance 2.5  
Period end balance   2.5
Two Thousand Fifteen | Other Operating Cost Reductions    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan   0.9
Restructuring Reserve [Roll Forward]    
Period beginning balance 0.1  
Period end balance   $ 0.1
Two Thousand Sixteen [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan 6.0  
Restructuring Reserve [Roll Forward]    
Severance payments 6.2  
Other payments 0.2  
Period end balance 5.3  
Two Thousand Sixteen [Member] | Restructuring Action Two Thousand Sixteen [Domain]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan 6.0  
Restructuring Reserve [Roll Forward]    
Severance payments 2.3  
Other payments 0.0  
Period end balance 3.7  
Two Thousand Sixteen [Member] | Fiscal 2015 Actions    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan 0.0  
Restructuring Reserve [Roll Forward]    
Severance payments 2.4  
Other payments 0.0  
Period end balance 0.7  
Two Thousand Sixteen [Member] | Fiscal 2014 Actions    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan 0.0  
Restructuring Reserve [Roll Forward]    
Severance payments 1.4  
Other payments 0.2  
Period end balance 0.9  
Two Thousand Sixteen [Member] | Other Operating Cost Reductions    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges Under Exit Or Disposal Plan 0.0  
Restructuring Reserve [Roll Forward]    
Severance payments 0.1  
Other payments 0.0  
Period end balance $ 0.0  
v3.4.0.3
Restructuring and Divestiture Charges - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 26, 2016
Jun. 27, 2015
Mar. 28, 2015
Sep. 27, 2014
Mar. 26, 2016
Mar. 28, 2015
Sep. 26, 2015
Restructuring Cost and Reserve [Line Items]              
Loss on disposal of business       $ 5.3      
Restructuring Reserve, Translation and Other Adjustment   $ 9.6          
Bedford [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring and Related Cost, Expected Cost $ 1.7       $ 1.7    
Restructuring | Bedford [Member]              
Restructuring Cost and Reserve [Line Items]              
Severance charges 0.5       0.9    
Restructuring | International [Member]              
Restructuring Cost and Reserve [Line Items]              
Severance charges $ 3.3       $ 5.1    
Restructuring | Fiscal 2015 charges:              
Restructuring Cost and Reserve [Line Items]              
Severance charges     $ 0.5     $ 3.0 $ 10.0
Share Based Compensation Expense Included Other Restructuring Costs             4.1
Restructuring | Fiscal 2014 Charges [Member]              
Restructuring Cost and Reserve [Line Items]              
Severance charges     $ 1.4     $ 5.9 6.0
Facility closure costs             $ 2.0
Number Office Locations related to Facility Closure Costs             0.0
v3.4.0.3
Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Debt Instrument [Line Items]    
Current debt obligations, net of debt discount $ 307.7 $ 391.8
Convertible Notes Payable, Current 58.0 142.2
Convertible Notes 747.2 861.5
Total long-term debt obligations 3,098.0 3,248.0
Total debt obligations 3,405.7 3,639.8
Term Loan [Member]    
Debt Instrument [Line Items]    
Current debt obligations, net of debt discount 74.7 74.6
Long-term debt obligations, net of debt discount 1,363.1 1,399.8
Revolver [Member]    
Debt Instrument [Line Items]    
Current debt obligations, net of debt discount 175.0 175.0
2022 Notes [Member]    
Debt Instrument [Line Items]    
Long-term debt obligations, net of debt discount $ 987.7 $ 986.7
v3.4.0.3
Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Sep. 26, 2015
Debt Conversion [Line Items]          
Non-cash interest expense     $ 26.1 $ 33.2  
Convertible Notes Payable          
Debt Conversion [Line Items]          
Amortization of debt discount $ 5.8 $ 9.0 12.2 17.8  
Amortization of deferred financing costs 0.3 0.4 0.6 0.9  
Principal accretion 4.1 4.0 8.2 7.9  
Non-cash interest expense 10.2 13.4 21.0 26.6  
2.00% accrued interest (cash) $ 2.7 4.8 $ 5.9 9.5  
Convertible Notes Interest Expense 2.00%   2.00%   2.00%
Interest expense, net $ 12.9 $ 18.2 $ 26.9 $ 36.1  
v3.4.0.3
Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($)
$ / shares in Millions
 3 Months Ended 6 Months Ended 9 Months Ended
Dec. 24, 2014
Mar. 26, 2016
Mar. 28, 2015
Dec. 27, 2014
Mar. 26, 2016
Mar. 28, 2015
Jul. 01, 2015
Sep. 26, 2015
Debt Instrument [Line Items]                
Non-cash interest expense amortization of debt discount and deferred financing costs         $ 26,100,000 $ 33,200,000    
Debt extinguishment loss   $ (4,500,000) $ 0   (4,500,000) (6,700,000)    
Convertible Notes Payable, Current   58,000,000     58,000,000     $ 142,200,000
Repayments of Convertible Debt         (311,500,000) $ 0    
Accounts Receivable from Securitization   200,000,000     200,000,000      
Additional borrowing under Accounts Receivable Securitization   $ 50,000,000     $ 50,000,000      
Debt Instrument, Description of Variable Rate Basis         0.007      
Credit Agreement                
Debt Instrument [Line Items]                
Weighted average interest rates, Borrowings outstanding under the credit agreement   2.18% 2.62%   2.06% 2.70%    
Interest expense   $ 10,800,000 $ 14,400,000   $ 20,700,000 $ 31,900,000    
Non-cash interest expense amortization of debt discount and deferred financing costs   $ 1,100,000 2,700,000   2,100,000 5,800,000    
Term Loan [Member]                
Debt Instrument [Line Items]                
Weighted average interest rates, Borrowings outstanding under the credit agreement   2.18%            
2022 Notes [Member]                
Debt Instrument [Line Items]                
Interest expense   $ 13,900,000     27,900,000      
Non-cash interest expense amortization of debt discount and deferred financing costs   1,000,000     $ 1,900,000      
Senior note interest rate per year         5.25%      
Senior Notes                
Debt Instrument [Line Items]                
Interest expense     16,000,000     32,000,000    
Non-cash interest expense amortization of debt discount and deferred financing costs     $ 400,000     $ 800,000    
Senior note interest rate per year             6.25%  
Maximum [Member]                
Debt Instrument [Line Items]                
Accounts Receivable from Securitization   200,000,000     $ 200,000,000      
Two Thousand Ten Original Notes [Member] | Convertible Notes Payable [Member]                
Debt Instrument [Line Items]                
Debt extinguishment loss   3,800,000            
Gains (Losses) on Recourse Debt   3,300,000            
Exceeds Percentage Of Conversion Price Of Common Stock         130.00%      
Convertible Notes Payable, Current   58,000,000.0     $ 58,000,000.0      
Debt Instrument, Face Amount   59,900,000.0     59,900,000.0      
Amount by which the if-converted value exceeds the principal amount   30,100,000.0     $ 30,100,000.0      
Repayments of Convertible Debt   $ 140,100,000            
Conversion Of Notes Into Shares Conversion Price   $ 0.0            
Write off of Deferred Debt Issuance Cost   $ 300,000            
Allocated Third Party Costs   $ 200,000            
Debt Instrument Nonconvertible Effective Interest Rate   2.71%            
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt   $ 49,900,000            
Deferred Taxes, Reacquisition of Equity Component   10,000,000            
Two Thousand Ten Original Notes [Member] | Minimum [Member] | Convertible Notes Payable [Member]                
Debt Instrument [Line Items]                
Number Of Trading Days         20 days      
Two Thousand Ten Original Notes [Member] | Maximum [Member] | Convertible Notes Payable [Member]                
Debt Instrument [Line Items]                
Number Of Trading Days         30 days      
Two Thousand And Twelve Notes [Member] | Convertible Notes Payable [Member]                
Debt Instrument [Line Items]                
Debt extinguishment loss   700,000            
Debt Instrument, Face Amount   136,600,000     $ 136,600,000      
Repayments of Convertible Debt   $ 171,300,000            
Conversion Of Notes Into Shares Conversion Price   $ 0.0            
Write off of Deferred Debt Issuance Cost   $ 500,000            
Allocated Third Party Costs   200,000            
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt   38,900,000            
Deferred Taxes, Reacquisition of Equity Component   $ 12,500,000            
Two Thousand And Twelve Notes [Member] | First Valuation Date [Member] | Convertible Notes Payable [Member]                
Debt Instrument [Line Items]                
Debt Instrument Nonconvertible Effective Interest Rate   3.87%            
Two Thousand And Twelve Notes [Member] | Second Valuation Date [Member] | Convertible Notes Payable [Member]                
Debt Instrument [Line Items]                
Debt Instrument Nonconvertible Effective Interest Rate   3.41%            
Term Loan B [Member] | Credit Agreement                
Debt Instrument [Line Items]                
Prepaid principal amount $ 300,000,000              
Debt extinguishment loss       $ 6,700,000        
November Eighteen Two Thousand Ten Original Notes [Member] | Convertible Notes Payable [Member]                
Debt Instrument [Line Items]                
Debt Instrument, Face Amount   $ 90,000,000     $ 90,000,000      
v3.4.0.3
Derivatives Fair Value of Derivative Financial Instruments (Details) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Interest rate cap - derivative    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value $ 3.7 $ 6.9
Interest rate cap - derivative | Prepaid Expenses and Other Current Assets [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value 0.9 0.7
Interest rate cap - derivative | Other Assets [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value 2.8 6.2
Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value 1.2 0.0
Foreign Exchange Forward [Member] | Accrued Liabilities [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value $ 0.9 $ 0.0
v3.4.0.3
Derivatives Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Derivative Instruments, Gain (Loss) [Line Items]        
Changes in value of hedged interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 26, 2016 and $0.9 for the three and six months ended March 28, 2015: $ (2.2) $ (1.6) $ (1.9) $ (1.6)
Interest rate cap - derivative        
Derivative Instruments, Gain (Loss) [Line Items]        
Changes in value of hedged interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 26, 2016 and $0.9 for the three and six months ended March 28, 2015: $ (2.2) $ (1.6) $ (1.9) $ (1.6)
v3.4.0.3
Derivatives Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 26, 2016
Foreign Exchange Forward [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (Loss) on Fair Value Hedges Recognized in Earnings $ (0.1) $ 1.3
v3.4.0.3
Derivatives Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Sep. 26, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]          
Interest Rate Cap Agreements Aggregate Premium Payable     $ 0.0 $ (6.1) $ 13.2
Principal Amount Of Borrowings $ 1,000.0   1,000.0    
Interest Payment Duration three-year        
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax $ 0.7 $ 0.0 1.0 $ 0.0  
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred     6.1    
Interest Rate Cash Flow Hedge Asset at Fair Value         $ 6.9
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax 0.7   0.3    
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 0.6   1.0    
Notional Amount $ 65.5   $ 65.5    
v3.4.0.3
Commitments and Contingencies - Additional Information (Detail)
$ in Millions
Sep. 04, 2012
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Assessed damages $ 4.0
v3.4.0.3
Marketable Securities - Reconciles Cost Basis to Fair Market Value of Company's Equity Security (Detail) - Equity securities - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Schedule Of Marketable Securities [Line Items]    
Available-for-sale Equity Securities, Amortized Cost Basis $ 2.4 $ 16.1
Gross Unrealized Gains 0.0 7.2
Gross Unrealized Losses (1.5) (0.3)
Other than temporary impairment 0.0 7.8
Fair Value $ 0.9 $ 15.2
v3.4.0.3
Marketable Securities Additional Information (Details) - Equity securities - USD ($)
$ in Millions
 3 Months Ended
Dec. 26, 2015
Mar. 26, 2016
Sep. 26, 2015
Schedule of Available-for-sale Securities [Line Items]      
Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments $ (25.1)    
Other than temporary impairment   $ 0.0 $ 7.8
v3.4.0.3
Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares
shares in Thousands
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Earnings Per Share [Line Items]        
Basic weighted average common shares outstanding 282,474 280,338 282,725 279,505
Weighted average common stock equivalents from assumed exercise of stock options and stock units 2,301 2,492 2,705 2,478
Incremental shares from Convertible Notes premium 3,082 4,750 4,484 3,395
Diluted weighted average common shares outstanding 287,857 287,580 289,914 285,378
Outstanding Stock Options        
Weighted-average anti-dilutive shares related to:        
Weighted-average anti-dilutive shares (in shares) 1,106 1,865 919 2,824
Restricted stock units        
Weighted-average anti-dilutive shares related to:        
Weighted-average anti-dilutive shares (in shares) 150 46 109 93
v3.4.0.3
Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 14.7 $ 13.7 $ 30.6 $ 25.8
Cost of revenues        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 2.5 2.3 4.7 4.3
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 2.6 2.2 5.0 4.1
Selling and marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 2.7 2.3 5.2 4.3
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 6.9 6.9 15.7 13.0
Restructuring and divestiture        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 0.0 $ 0.0 $ 0.0 $ 0.1
v3.4.0.3
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Stock option plans    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted 1.0 1.2
Weighted-average exercise prices $ 39.47 $ 26.42
Share-based compensation, stock option outstanding 6.7  
Weighted-average exercise price of options outstanding $ 24.80  
Unrecognized compensation expense $ 27.3  
Weighted-average period for recognition of unrecognized stock-based compensation, years 3 years 3 months  
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Restricted stock units 1.0 1.4
Restricted stock units (RSUs), weighted average grant date fair values $ 39.63 $ 26.35
Unvested RSUs outstanding 3.3  
Unvested RSUs weighted-average grant date fair value $ 29.58  
Unrecognized compensation expense $ 97.7  
Weighted-average period for recognition of unrecognized stock-based compensation, years 2 years 5 months  
Performance shares    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Restricted stock units 0.2 0.3
Restricted stock units (RSUs), weighted average grant date fair values $ 39.72 $ 26.58
Minimum eligible percentage to receive target number of shares of company's common stock 0.00%  
Maximum eligible percentage to receive target number of shares of company's common stock 200.00%  
Performance stock units vesting period 3 years  
v3.4.0.3
Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk-free interest rate 1.60% 1.70% 1.60% 1.70%
Expected volatility 37.80% 38.60% 37.80% 38.60%
Expected life (in years) 4 years 8 months 5 years 3 months 3 days 4 years 8 months 5 years 4 months
Dividend yield $ 0 $ 0 $ 0 $ 0
Weighted average fair value of options granted $ 11.80 $ 10.36 $ 12.98 $ 9.55
v3.4.0.3
Share Repurchase (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Nov. 11, 2013
Mar. 26, 2016
Mar. 26, 2016
Mar. 28, 2015
Share Repurchase [Abstract]        
Treasury Stock Acquired, Repurchase Authorization 250000000      
Treasury Stock, Shares, Acquired   4.3    
Stock Repurchased During Period, Value   $ 148.8    
Treasury Stock Acquired, Average Cost Per Share   $ 34.36    
Payments for Repurchase of Common Stock   $ 135.9 $ (135.9) $ 0.0
Cash for shares repurchased remaining unpaid   $ 12.9 $ 12.9  
v3.4.0.3
Other Balance Sheet Information - Other Balance Sheet Information of Inventories (Detail) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Balance Sheet Related Disclosures [Abstract]    
Raw materials $ 98.6 $ 98.3
Work-in-process 55.3 58.7
Finished goods 131.2 126.1
Inventories $ 285.1 $ 283.1
v3.4.0.3
Other Balance Sheet Information - Other Balance Sheet Information of Property, Plant and Equipment (Detail) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Balance Sheet Related Disclosures [Abstract]    
Equipment and software $ 377.8 $ 365.9
Equipment under customer usage agreements 319.3 305.7
Building and improvements 182.8 182.1
Leasehold improvements 59.1 59.2
Land 51.4 51.4
Furniture and fixtures 18.1 17.3
Property, plant and equipment, gross 1,008.5 981.6
Less – accumulated depreciation and amortization (554.4) (524.5)
Property, plant and equipment, net $ 454.1 $ 457.1
v3.4.0.3
Business Segments and Geographic Information - Additional Information (Detail)
 3 Months Ended 6 Months Ended
Mar. 26, 2016
USD ($)
Customer
Segment
Mar. 28, 2015
USD ($)
Mar. 26, 2016
USD ($)
Customer
Segment
Mar. 28, 2015
USD ($)
Segment Reporting Disclosure [Line Items]        
Number of reportable segments | Segment     4  
Revenues | $ $ 693,300,000 $ 655,500,000 $ 1,388,400,000 $ 1,308,300,000
Customer represented greater than 10% of consolidated revenues 0 0 0 0
Countries with greater than 10% of consolidated revenue | Customer 0   0  
Number of reportable segments | Segment 4   4  
Intersegment        
Segment Reporting Disclosure [Line Items]        
Revenues | $ $ 0 $ 0 $ 0 $ 0
v3.4.0.3
Business Segments and Geographic Information - Segment Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Sep. 26, 2015
Segment Reporting Information [Line Items]          
Total revenues $ 693.3 $ 655.5 $ 1,388.4 $ 1,308.3  
Operating income (loss) 136.1 109.8 262.1 213.3  
Depreciation and amortization 114.0 126.6 229.9 248.6  
Capital expenditures 22.0 18.7 41.7 39.7  
Identifiable assets 7,286.3   7,286.3   $ 7,670.1
Diagnostics          
Segment Reporting Information [Line Items]          
Total revenues 304.4 296.7 615.1 600.8  
Operating income (loss) 34.3 27.1 65.8 55.3  
Depreciation and amortization 83.8 91.9 167.4 180.5  
Capital expenditures 13.0 11.4 24.9 26.2  
Identifiable assets 3,912.0   3,912.0   4,055.8
Breast Health          
Segment Reporting Information [Line Items]          
Total revenues 275.8 255.5 537.9 497.5  
Operating income (loss) 88.4 75.4 160.0 135.9  
Depreciation and amortization 5.1 8.3 12.4 15.9  
Capital expenditures 3.4 3.0 5.4 5.5  
Identifiable assets 811.8   811.8   815.4
GYN Surgical          
Segment Reporting Information [Line Items]          
Total revenues 90.9 79.1 189.7 163.5  
Operating income (loss) 11.5 4.5 32.3 17.7  
Depreciation and amortization 24.8 26.0 49.5 51.5  
Capital expenditures 3.4 2.4 6.8 4.4  
Identifiable assets 1,612.2   1,612.2   1,658.1
Skeletal Health          
Segment Reporting Information [Line Items]          
Total revenues 22.2 24.2 45.7 46.5  
Operating income (loss) 1.9 2.8 4.0 4.4  
Depreciation and amortization 0.3 0.4 0.6 0.7  
Capital expenditures 0.1 0.1 0.2 0.2  
Identifiable assets 29.9   29.9   25.3
Corporate          
Segment Reporting Information [Line Items]          
Capital expenditures 2.1 $ 1.8 4.4 $ 3.4  
Identifiable assets $ 920.4   $ 920.4   $ 1,115.5
v3.4.0.3
Business Segments and Geographic Information - Revenues by Geography (Detail)
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Schedule Of Geographical Segments [Line Items]        
Revenues 100.00% 100.00% 100.00% 100.00%
United States        
Schedule Of Geographical Segments [Line Items]        
Revenues 79.00% 75.50% 78.70% 74.80%
Europe        
Schedule Of Geographical Segments [Line Items]        
Revenues 10.40% 11.80% 10.20% 12.70%
Asia-Pacific        
Schedule Of Geographical Segments [Line Items]        
Revenues 7.40% 8.90% 7.60% 8.80%
All others        
Schedule Of Geographical Segments [Line Items]        
Revenues 3.20% 3.80% 3.50% 3.70%
v3.4.0.3
Income Taxes - Additional Information (Detail)
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Income Tax Disclosure [Abstract]        
Company's effective tax rate 25.00% 21.40% 25.50% 26.60%
v3.4.0.3
Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)
$ in Millions
Mar. 26, 2016
Sep. 26, 2015
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 5,326.3 $ 5,322.8
Accumulated Amortization 2,488.8 2,299.6
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 3,983.8 3,979.1
Accumulated Amortization 1,843.1 1,698.5
In-process research and development    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 3.7 3.7
Accumulated Amortization 0.0 0.0
Customer relationships and contracts    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 1,100.0 1,101.1
Accumulated Amortization 507.0 467.5
Trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 236.3 236.4
Accumulated Amortization 136.6 131.5
Business licenses    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2.5 2.5
Accumulated Amortization $ 2.1 $ 2.1
v3.4.0.3
Intangible Assets - Schedule of Estimated Amortization Expense (Detail)
$ in Millions
Mar. 26, 2016
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Remainder of Fiscal 2016 $ 187.6
Fiscal 2017 366.1
Fiscal 2018 355.6
Fiscal 2019 343.9
Fiscal 2020 $ 332.9
v3.4.0.3
Intangible Assets Additional Information (Details)
$ in Millions
 3 Months Ended
Mar. 26, 2016
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Indefinite-lived Intangible Assets Acquired $ 4.8
v3.4.0.3
Product Warranties - Product Warranty (Detail) - USD ($)
$ in Millions
 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]    
Balance at Beginning of Period $ 5.4 $ 6.3
Provisions 7.3 2.9
Settlements/ Adjustments (3.3) (3.5)
Balance at End of Period $ 9.4 $ 5.7
v3.4.0.3
Product Warranties Additional Information (Details) - USD ($)
$ in Millions
 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Product Warranty Liability [Line Items]    
Provisions $ 7.3 $ 2.9
CHINA    
Product Warranty Liability [Line Items]    
Provisions $ 4.0  
v3.4.0.3
Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 26, 2016
Mar. 28, 2015
Mar. 26, 2016
Mar. 28, 2015
Dec. 26, 2015
Sep. 26, 2015
Dec. 27, 2014
Sep. 27, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Changes in foreign currency translation adjustment $ (1.2) $ (9.5) $ (5.4) $ (18.5)        
Changes in unrealized holding gains and losses on available-for-sale securities: (0.6) (8.3) (1.2) (3.2)        
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent 0.0 0.0 0.0 (0.1)        
Changes in value of hedged interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 26, 2016 and $0.9 for the three and six months ended March 28, 2015: (2.2) (1.6) (1.9) (1.6)        
Other Comprehensive Income (Loss) before Reclassifications, Tax (4.0) (19.4) (8.5) (23.2)        
Restructuring Reserve, Translation and Other Adjustment 0.7 0.0 (6.2) 0.0        
Accumulated other comprehensive loss (29.2) (20.6) (29.2) (20.6) $ (25.9) $ (14.5) $ (1.2) $ 2.6
Foreign Currency Translation                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Changes in foreign currency translation adjustment (1.2) (9.5) (5.4) (18.5)        
Restructuring Reserve, Translation and Other Adjustment 0.0 0.0 0.0 0.0        
Accumulated other comprehensive loss (21.1) (23.2) (21.1) (23.2) (19.9) (15.7) (13.7) (4.7)
Equity securities                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Changes in unrealized holding gains and losses on available-for-sale securities: (0.6) (8.3) (1.2) (3.2)        
Restructuring Reserve, Translation and Other Adjustment 0.0 0.0 (7.2) 0.0        
Accumulated other comprehensive loss (1.5) 5.7 (1.5) 5.7 (0.9) 6.9 14.0 8.9
Pension in Accumulated Other Comprehensive Income [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent 0.0   0.0 (0.1)        
Restructuring Reserve, Translation and Other Adjustment 0.0 0.0 0.0 0.0        
Accumulated other comprehensive loss (1.8) (1.5) (1.8) (1.5) (1.8) (1.8) (1.5) (1.6)
Interest rate cap - derivative                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Changes in value of hedged interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 26, 2016 and $0.9 for the three and six months ended March 28, 2015: (2.2) (1.6) (1.9) (1.6)        
Restructuring Reserve, Translation and Other Adjustment 0.7 0.0 1.0 0.0        
Accumulated other comprehensive loss $ (4.8) $ (1.6) $ (4.8) $ (1.6) $ (3.3) $ (3.9) $ 0.0 $ 0.0
IDEA: XBRL DOCUMENT 
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ""!FTB8,EJF)0(  ,\I   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:S4[;0! '\%>)?*WBS7Y2*L*E<*5(\ );>Q);L;VKW26$M^_:@:J-
M H*62/]+'&=V9\8>^W?*Q?V3ISC;]=T0ET63DO_&6*P:ZFTLG:K55M1[:J'/F\I4RY-7W*\F-W:D&YLGU.P7<>FP/Z3EV._*F)XZBL?J[R,OE:]H91^Z]*'"S_>N#-1-:V+3^N=2U[N<)>;?ED6.
MQG=5.-SX5F=M/P[-#^N_=HSG_W@M!S=QVW=7P3ZV!P6V)QO3>"Q[VP['1O7H
MPN:G6%([9&G)"^^S='([_%WX\\%I^MCG.OT_;6A3\'(IL,)D?A0'P*D#PG2AP+I0X/T84#Z
M. /IXRM('^<@?? %2B,HHG(44CF*J1P%58ZB*D=AE:.XRE%@Y2BR"A19!8JL
M D56@2*K0)%5H,@J4&05*+(*%%D%BJP215:)(JM$D56BR"I19)4HLDH4626*
MK!)%5HDBJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5HQW8OG*\M"_V/Z'D4X$G1H>)%]2-F
M Q+M*;V"^GH A3&^.R6:E((C-Z."N[_8_ )02P,$%     @ ((&;2+ $-*=+
M @  +RH  !H   !X;"]??
M!8K/?6[6G]*Y*Z>AS\?3F%??+^<^K^?KF^I8RKBNZ[P]IDN7'X8Q]?/=_3!=
MNC+_G [UV&W?NT.JI6F\GF[G5"_/?\Y>O>TVU?2V"]7J2S<=4ME4WX;I/1]3
M*KF^?H6'>8'Y]L>8_F?Y8;\_;=/KL/UZ27WY1T7]:X&J7@Z2Y2"A!.ERD%*"
MXG)0I 39 O06CMX"
M]!;2LS9ZV.;H+4!OX>@M0&_AZ"U ;^'H+4!OX>@M0&_AZ"U ;^'H+4!OX>BM
M0&_EZ*U ;^7HK4!O)>V5H,T2CMX*]%:.W@KT5H[>"O16CMX*]%:.W@KT5H[>
M"O16CMX1Z!TY>D>@=^3H'8'>D:-W!'I'TEXWVNSFZ!V!WI&C=P1Z1X[>$>@=
M.7I'H'?DZ!V!WI&CMP&]C:.W ;V-H[=-4&'33AZ.]#;.7H[T-LY>CO0VSEZMT#OEJ-W>Z-W/G93VGTNTZD_Y'O7
M_#8<%MW@G:54GW]O/N_V77JSY#ZK[.A+S\ 4$L#!!0 
M   ( ""!FT@DK!HKM@,  !<1   0    9&]C4')O<',O87!P+GAM;+U877/:
M.A#]*QJ>T@=J2E(R-T.9(9!^S#0-4[C)LRHO6!-;\FAEFMQ??UKK4
M)N.6/II5I)=+*6"J19&!LE&_UQM$\&)!Q1!W\UW0SFCH=AGG>2H%MU*KT;T4
M1J->6G;W(B =1G\Z> 1%GH,HC+2OHU[I4S5YG[G@*4QHK]&2IPBEUYO1^TQT
MEG/U&I6?ODOUC/_F"SWE%JJH_0=E](0;B&G3O>@[H_?Y^DIYI@X[2;A:05SU
M/7RXY>(1#+I,/_3?]^AG1\'67L8&'DNUFG%I<#1VZ58BU<
MT?%Q0>?##OO%$=SR4V?-C>3*=AC*_^ACOU-N6UK].LW1FM&3-L^8 %@<1CNC
M7U9]JVMY-;KN>0]:[7M&N\Q&&]KV\G:6A;0IX,-RQHW]2U3XG+9$7/RW
M(1A7,;M3EN3(OJER*RI>E9+=:J(5ZE3&)*Z8S2W]<1&0Z25[()&$8IRHS\!<
M'?BV-2B[GE*+W'S "2=S.[GTDJ[)&G!;![X%B8
M,GJM[T^@WX6P-$;4RI=P*M=DDV0!-JD_B39&_R9_]( )30!IV=@8U]49U&*F
M8.2:CDRQV<4/;0'?-3"39=*6;/C@FA1%896@Z5F+N.?F&2S_E1+KY3AL\OP!
MEI0I= ;LXKM&?,=F8)@?8;7^6([VS&V!4@$B9;EZX^<+Z)7A>2)K,9ML%_RE@9)OI".UDHZ\,6*3Q&DH
MQ*01]L1=C1OY'0N:!(77=)F@(\U 0KQ1W5E#37XSPNG"EYFTK16M18MB&]3-
M+A9. V>HO#\(5WG_^JC*YS1[XX*(I9;=V$_7[S:;>OFT"-D!@\2\V2E7IZFPO;T#^78[M^JR\N&ZM=-6S:.20.TJ*>X29E=YI\$8OQ>@9@[DG06
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M;6S-D\%.PS ,AE\%]=ZEW<9 4=<#($Y,0F((Q"TDWA;6)E'BJ>O;DWFE9GCTUH%'#>%B7USQ;N4^Z+ZJ:9I1,Z&Z.'#.7AOJOP$4$L#!!0    ( ""!FTB97)PC$ 8  )PG   3    >&PO=&AE;64O
M=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8
MC6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;
MUKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB 
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M[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$X
MM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A6$G:
MA/@01AKBG'/F<]%L^P>E1M'V5;SCFED)
MO816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_+GW/
MI>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMN
MZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!O
MP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?
MF&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\3(Q%
MZ'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT
M%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]
M<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D
M?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2
M!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 Y3_;
MU UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @ ((&;
M2+>)=PAL @  @@P   T   !X;"]S='EL97,N>&ULS5=M;YLP$/XKECM-K30%
M2%72KH T58HT::LF-1_VK3)@B"6_,&.RI+]^-B:\9*-)NS?RQAG"M5/'><W=VYCY>
MW![BY_7&!026XV,:0L^_@L[II+-QVMDAL3]"W!&-!"Y>IN@Y28?4U\]K%7X.+1 %Y1/8(*K]/>.>""HD
M4+JSM(X:X8AAZW&'*(DE,6"&&*$["\\-4#=CX\<(%[+.;3,*.O5[,\0BEP^-I( H*I!26?*DO0&.O=H4^'!<<6Y&UWQ'O7**=-[_J
M!=2+SAL+F6+99O;@'HH"BC.E R3)UV95HC#2A5*":2,E*!<<44.YCV@,39M@
M2A_,H_\U&W!O,V!]3(U="(R*O:EO1&-V;6";H,]FN?NTEZ_B!=NL3:"C45'0
MW0=*=+^IA$2#6 )P09+19(^\EVB8H6W
MJNE@9YN-*7SMD?^FIC]_USHUN@7_]>WYK\G[M:D?0WB@YX12W%S"R6Q3$%:&*\+T&
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MY^9")$HUEVWE[ZFQV_?.HFF/VD[N7#+)I$0K;>
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M?P^/O]]]_(O45OR05:O$M9*NM>MV . # #[L KY3/-NV\*VEN.G\NZ#PAHS'E\HJY]D"'0:EQOC
ME7N'CZ.\4];>NM9^/2)=4RC*J5VJ*;3"OIFBO%/&WFMI'Q5%>D66J(+ZR+\!
MH+13QMH;VKMJ"E,K^=-\3@B5U39Q9]JW$YF
M0&.GC++=2\5WM6IML202U[$HZY2Q]9M?4O-[@;,O4:&X4\;^F5,?2TH(S?=MECW:=A5*U:TL"2] )1Z&C,.'I#DR+A
M3-LY3GG$-+1?["2"&%V-&5?WY!)Q=!\"H(="7V/&U\&L0G,\H%#;F-%V,*O$
MQXA">V/&7LPJ=U0HE2V-/*7>S7E$H;TQ8R^;&+8]A2$5H[PQ(^] A@@\G&G1
MYX3Q>5^6V+0+46AWPM@]&.A)C"A4/6%4'PST)$%4KY9@5-\)6*['$_0\83S?
MC5P6@XXGC..#(9R@XPDZGG".,I(/II9TBBB4/&4D'T:AY"E*GC*2#Z-0
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M7>[6_DHU)ZW*L#+JNM<4LBK"L/QM2GIW6&=,Q+SMJK.Z=RW
MYJN1X;X->;M ^NDW4$L#!!0    ( ""!FTA/ 1,V1 (  (X'   8    >&PO
M=V]R:W-H965T&UL?57;CILP$/T5Q @Q9C:3MC^?7TAK+,R?L&W<^:,A_%,-5'VSEN,1?!!^H'OPE:(<1M%
MO&DQ0?R%CGB0)Q?*"!)RR:X1'QE&9TTB?03C.(\(ZH:PKO3>*ZLK>A-]-^!7
M%O ;(8C].^">3KL0A(^-M^[:"K41U56T\,X=P0/OZ! P?-F%>[ ]@D1!-.)W
MAR=NS0/E_(G2=[7X>=Z%L?(!][@1R@22PQT?<=\K2U+Y[VST4U,1[?G#^G=]
M7>G^"7%\I/V?[BQ:Z6TO-'I!Y[OD"F##>VY_@;-C0M*'I0P(.C#
MC-V@Q\F0C(3DH4 -"$RGNE[?4,"U16C4\#,SQB1^N=@
MF\C(-8&\# _5D0Z70M35O8ZKZ*[,/"$.!@$U BR(2-I>!."ZP %:=.@2.-J(
MQ"V0>&Z0:'JBZ:F;GGKHJ::GFIXY V C()E;0E6']0<5VQ9R9[!FC(E6F6V*I%A1\CY=8"NY4^L9LY)
25I2JUO]MO'ZVK2_ND-5
M]8O?]>GNR'SZVKZONTE;E?C*J3RL(
MPVA5E\?SKGUO-^OFK3\=S]7W=M&]U779_K>M3LWU<2F6MPL_CJ^'?KRP
MVJQ7=[O]L:[.W;$Y+]KJY7'Y)!X*"2,R$?\^OZIKZ9+!=U^=N\'L_3Z]5\
MDX36C#8 :P!W@_L\M(&T!O+#0'D-E#507YU!6P,]FV%E?)]V+B_[&^E&-6B0<]Q&:W&+:K6XY?30$9BTO?+8J\E>&?O(7>+9
M[(1!X@G1B:28S#")8504*(K*,25$' 9 806>4(2II+W2'J\T]BHFO3)(:M<2
M!K1?#A6F@2#]PA2(A''+I73 ^!5Y_(JP7PGI5X1FB5+)^.506@>:] M30B8)
M'=;"Q<*$\RSV>!;C/$YI^\1CGWR>QP:)S#(3,D99@EU)HH#,G1Q3:W(!BAL5H9UW?O$HF< #)--E:QN2E3!C7
M'$B2"9Y;R(8Y4DQ>.E@4JR!B///(XY, =& E,"/XE$M(O#=D?FTM8R/*E-_,
MI9B2ESO46/')HU*X6*@#SC>?J@HLJY*LFEO+W";BCJ[%3.1I]@0[K#<\92D> :(>'3?.&(
M/MWD"4=X9<051@<;I(X<+7#3>< ZK^C2 5AVOTE.S%Q,I89A1E/BES[PB^/@!P'Z#H/L RGWJ7?LV[&:8939E/
MRD1?^OH &>+H,Z=$^C17BL^C+_%M,R2@8GJ#9EPHZ;XKGX\7 ZU.+A>G.F3*
MN/3)KH3/,T""LZ(XT>1.9'-.)[3ZSK@T%72*SS@MXWF.K]"/_G75ODZ/6[K%
MKGD[]R;P]ZOW1SI/TQ.=V?6M>,@$<3T7#X5Y8/,Q_&9]*5^KO\OV]7CN%L]-
MWS?U]+#AI6GZ:ECXD-7+Q:$J]_&PO=V]R:W-H965T&ULC9=-U;XK0)OT2ONWX40(,S[:IANVYHFQ\\:VA]V)M'BPZ)ET
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M8B3-$]^;ES<;1W45@:XFYE8Z$"HF:&V-- 1\OZJ%*+J?U?1N=5]$IWNW7B.-@4"
MQDO>&HOFZS-\EI[QD?S"_;'N!N.5LK&%$TW8@5)&QK0=:]R73F/S/E\TY,#X
M:32>][*=E1>,GF_=^?PO0O8?4$L#!!0    ( ""!FTB>R=%^]0$  &@%   8
M    >&PO=V]R:W-H965T&ULC53);MLP$/T50A]@:DU30Q80
MRP[20X$@A_9,RZ,%(465I*ST[\M%EN5 =GH1R>%[;Q:.)AVX>)>;T( "H4R"D0O)\B!4B.D'?\9-2\N#7&^/ZL_
MVVQU] ?T=W-4M0[6]] 12M)3]<:'%QA32(Q@P:FT7U3T4G%VIGB(D0^W
M-JU=!W?SZ(^T94(X$L*),/E9)D0C(;H0XKN$>"3$_^LA&0G))P_8Y6XKMR.*
M9*G@ Q+NM3MBFBI8)_IM"J3+)3US91_$(++TE#WX*3X9G2O(UD%""PFC)C.%+D?T-D:LPHSNUBBP_LOSD1IKQ'7YL
M^;&K=7 =8NLJX2"/KI"K> F3SS'^ZOL29G>M$RYA]K=T7#YXUD<,1&7_8(D*
MWK?*%6&R3D/B*31]^,F^#=9YL&#?Z:'B9L!%/DL[4L%/(JJFE>C E>Y^V[\E
MYPITT/Y*=WVMQ]YTH% JL_VF]\)- G=0O#O/M6FX9O\ 4$L#!!0    ( ""!
MFTCP) OG100  -P4   8    >&PO=V]R:W-H965T&ULC9A-
MCZ,X$(;_"LJ] 9YAI-$<9LYTXG2B@9 !NC/[[X]-4W7_;&W=
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M$# !<[Q"
M]+)(BEF2DCX6A9D5(F9F) ^XR+$+1;K(41\90$QZ+3W5.&^"]E($O!38BR:]
M%*@7T#GJ!7OQ59+SH@)>%/9B2"_J/]\.5@A#F] !$QJ94&076XT30,= ^L B
M$+&BG9B $X.=D).^-:B3/$6YB)U@D92QIIU,5.5!E&(OY("W3N.F)3509D[D/,L6EK@A14@#V0[Z(K=/HTM_12W!Q[
MLO%[R_D)T51@G&H:I\+CZ0A49E5H3';! %6$B"HP4C6-5(%Q"86,R4DL?9D"
M[GU#"*N L:IIK(*'RQ'RM!]?5K#?7PA!%3!4-0U5IUE>@\YHI'HBDS& AV#9
MB8&J:: Z3>$RV9#U2^FK(&/R&$(P!0Q33E.-U]/R&. JYJ]0/>W!\G
M7Z,I3CLEQB(>2XSQLZ#+C=&SM:*O]_:*VAV$Z5>-YMVR^+1=#
M>[GM)=XW-#>_ 5!+ P04    "  @@9M(1,'6-#$"  "9!P  &    'AL+W=O
MT20&JJJ750:S:)=
M.XD3T "FMA.F;U]?",4C8TT6P3;G^WT,B5U.A+ZQ!F/NO??=P Y^P_FX#P)V
M;G"/V(Z,>!!WKH3VB(LNO05LI!A=5*CO @A &O2H'?RJ5&,OM"K)G7?M@%^H
MQ^Y]C^C?(^[(=/!#_SGPVMX:+@>"J@R6W*7M\[O?!&V +?N^ KNG?\E4S?\;R&1!8\DXZI;^]\9YSTSXCO]>A=
M7]M!72=])\WGF#T YP!< F'L#$1S(/H0"+296M=7Q%%54C)Y5+^,$3.GE@,\^4M];@D496/JLC+X"'K&,A1(U AT$;4:R*-%B00\R\2T"$!53[2
M$H4]'SGRDA6:R6=F%]N@VH#"76A7B1TJL:$26E4T$P(%@9V=
MJKT31DRN4,F-V02JTR^6F^6 /VQ"KE)0ZIP2!6&5&J5*E93P3P&
M1;@E99(P+I)-*;GO;F]5P-#*K%HSI&>+HVC3R@ _Z@2K371$-_P3T5L[,.]$
MN-B/U8YZ)81C40CLQ#^C$>?DTNGPE%%CL17NMV$ILK&6YDA)OW[XZ
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MG9U-<.BY73 $TRW&GZ;N&A6;]?O&1-EZ]3Y6
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MW4.:>"Y12030^[#-GK91@1[ZH(*-/3B=P4UZQD=UCQD1,9.5$F)^9B*\P(2T#I2P?^\LH'3LO :65P
M6@I%(T]<2Q/08<4I6XKUL=/RAWCE91K%HO9"P8EFQPHXK0^4JV')RQ
MDIO;KRFJ-E ^=%J6?5J9Y):FE4N;HN:(Z1!!RS^M]\TG0[&5$V++&&N49(VK
M8FVOLSX.6\9A*^\,EB6I)I6Y9QFMDSB,[W@#9'U8M@S+VGMB]N(T5SN+RE+4
M%[Z/S):1V3OW\\O[V]W;
MHN^"YZ?NFG@XN7IJFKP9_@Y]%
M<*C*_>W+J7KIQ\MTN&[G YKY2]]F_\!4$L#!!0    ( ""!FTC*
M'RNXH $  +$#   8    >&PO=V]R:W-H965T&UL?5/;3N,P
M$/T5RQ^ TS0L;)5&HJQ6\+ 2XH%]=I-)8F%[LK;3L'^/+VDHJ/3%]HS/.7/&
MEW)"\VI[ $?>E-1V2WOGA@UCMNY!<7N% VB_TZ)1W/G0=,P.!G@324JR/,M^
M,,6%IE49!$SV9$V"]SWB:P@>FRW-@@604+N@P/UT@'N0,@CYPO]F
MS8^2@7BZ/JK_CMUZ]WMNX1[E7]&XWIO-*&F@Y:-TSS@]P-S"=1"L4=HXDGJT
M#M610HGB;VD6.LY3VKG-9MIY0CX3\B\$E@I%F[^XXU5I<"(F'>W PPVN-KD_
MB)IX;Y:&K=A]0%3EH5H5-R4[!*%/F%W"Y FS()A77TKDWY?8Y2?T_#Q]?<'A
M.M+7L\/;\P+%!8$B"A076_R,^?FE"#LY4P6FBT_'DAI'[=+A+=GE==[E\4X^
MX%4Y\ [^<-,);G;_9>#@=02P,$%     @ ((&;2+/D)D"@ 0  L0,  !@   !X;"]W;W)K25-/!HB9NT%O;O$13.
M![JAE\23[ 3XC/,?C1
M'F@1+8""QD<%$:8S/(!242@4_K-HOI:,Q.OU1?U;ZC:X/PD'#ZA^R]8/P6Q!
M20N=F)1_POD[+"WLHF"#RJ61-)/SJ"\42K1XR;,T:9[SSK9<:.\3^$+@*^%+
MD8SG0LGF5^%%75FH,Y
M9@S/F!7!@OI:@G]'']0O;PB42:"\V>);S/\NV=69
M:K!]>CJ.-#@9GP]OS:ZO\YZG.WF%U]4H>O@I;"^-(R?TX6;3W72('H*)XFY'
MR1#^SQHHZ'QV.]LX-6\9LW8/B]@8'T'ZG1:.X\Z'IF!T,\":2E&1YEMTRQ86F
M51ESKZ8J<712:'@UQ(Y*+X^J3_%;KW[ [?P@/*W:%SOS6:4--#R4;HWG)YA;F$3!&N4-HZD'JU#=:)0
MHOAGFH6.\Y1VBKN9=IF0SX1\(=QET7@J%&T^KTN!$3#K:@8<;7&US?Q U
M\=XL#5NQ^X"HRF.UVJQ+=@Q"WS#[A,D39D$PK[Z4R/]?8I^?T?/+]/45A^M(
M7\\.B\L"Q16!(@H45UO\CMG\4X2=G:D"T\6G8TF-HW;I\);L\CKO\W@G7_"J
M''@'/[GIA+;D@,[?;+R;%M&!-Y'=;"CI_?]9 @FM"\L??FW2DTJ!P^'T099?
M6OT%4$L#!!0    ( ""!FTA(UMA;H0$  +$#   9    >&PO=V]R:W-H965T
MV;ZP$\>=?*N#WMO1]VC+FZ!RW<'0Y@
MPDZ+5@L?0MLQ-U@032)IQ7A1W#,MI*%5F7(OMBIQ]$H:>+'$C5H+^^< "J<]
M7=$Y\2J[WL<$JTJV\!JIP3B)AEAH]_1IM3ML(B(!?DJ8W,6:1.]'Q+<8?&_V
MM(@60$'MHX((TPF>0:DH% K_/FM^E(S$R_6L_C5U&]P?A8-G5+]DX_M@MJ"D
M@5:,RK_B] W.+6RC8(W*I9'4H_.H9PHE6KSG69HT3WEG/=.N$_B9P!?"8Y&,
MYT+)YA?A155:G(C-1SN(>(.K'0\'49/@S=&XE;J/B*H\5:OM?@3YI Q
M/&,6! OJ2PG^_Q('?D'GU^GK&P[7B;X^.WRX+K"Y(;!) IN;+7[&//Y3A%V<
MJ0;;I:?C2(VC\?GPENSR.I]XNI,/>%4.HH,?PG;2.')$'VXVW4V+Z"&8*.ZV
ME/3A_RR!@M;'Y4-8V_RD^>&+6.V[D%Q>X4#:+_3HE'<^=!TS X&>!-)2K(BRZZ9XD+3
MJHRY)U.5.#HI-#P98D>EN'G?@\1I1W-Z2CR+KG86]@$P1JEC2.I1^M0G2B4
M*/Z69J'C/*6=FVRF7284,Z%8"#\B@:5"T>8]=[PJ#4[$I*,=>+C!?%OX@ZB)
M]V9IV(K=!T15'JM\\[-DQR#T!;-/F")A%@3SZDN)XO\E]L49O;A,7WWC_D
M$UZ5 ^_@-S>=T)8&UL?5/;;N,@$/T5Q <4QW&ZJ\BQU+2JVH=*51]VGXD]
MME&!<0''W;]?+HZ;KK)Y 68XY\P9+N6$YMWV (Y\*JGMCO;.#5O&;-V#XO8&
M!]!^IT6CN/.AZ9@=#/ FDI1D>9;=,L6%IE498&YA$P1KE#:.I!ZM0W6B4*+X9YJ%CO.4=C;Y3+M,R&="OA!^
M9M%X*A1M/G#'J]+@1$PZVH&'&UQM+ U;L?N J,ICM;I=E^P8A+YA
M]@F3)\R"8%Y]*9'_O\0^/Z/GE^GK*P[7D;Z>'1:7!8HK D44**ZV^!VS^:<(
M.SM3!::+3\>2&D?MTN$MV>5UWL5+9%_PJAQX!R_<=$);38OHP)O(
M;C:4]/[_+(&$UH7E#[\VZ4FEP.%P^B#++ZW^ E!+ P04    "  @@9M(0H8*
MWJ(!  "Q P  &0   'AL+W=O^>&'6.V[D%Q>X<#:+_3HE'<^=!TS X&>!-)2K(BR[9,
M<:%I5<;'=4!$P"\!D[U8D^#]B/@6@A_-GF;! DBH75#@?CK!$T@9A'SA]UGS
MLV0@7J[/ZM]BM][]D5MX0OE;-*[W9C-*&FCY*-TK3M]A;F$3!&N4-HZD'JU#
M=:90HOA'FH6.\Y1V-OE,NTXH9D*Q$!ZR:#P5BC:?N>-5:7 B)AWMP,,-YKO"
M'T1-O#=+PU;L/B"J\E3EVVW)3D'H"^:0,$7"+ CFU9<2Q?]+'(H+>G&=OKKA
M^[5)3RH%#H?S
M!UE^:?474$L#!!0    ( ""!FT@=T'VLH@$  +$#   9    >&PO=V]R:W-H
M965TDS39R+#5=K78?5JKZL'TF
M]MA&!<8+.&[_OEP2-UUE\P+,<,Z9&Y03VE?7 WCRII5Q6]I[/VP8+HE33P9(D;M1;V?0<*
MIRU=T)/C67:]CPY6E6SF-5*#<1(-L=!NZ<-BLUM%1 +\D3"YLS.)N>\17Z/Q
MJ]G2(J8 "FH?%438#O (2D6A$/CO4?,S9"2>GT_J/U*U(?N]+FEI(^_)_94-#Z>%R'L\U/*AL>A],'F7]I]0%02P,$%     @ ((&;2"L(
MI<:B 0  L0,  !D   !X;"]W;W)K&UL?5/;;N,@
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MR1>\+ ;1PD]A6ME;38/HP)O(;FXIZ?S_60(%C0O+C5^;]*12X' X
M?9#EEY9_ 5!+ P04    "  @@9M(DSEI Z0!  "Q P  &0   'AL+W=O"[33P]_B2AK+J\F)[QN><.>-+/J)YM2V (^]:=79/6^?Z'6.V;$$+
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M2+@/72.B 0  L0,  !D   !X;"]W;W)K&UL?5/+
M;MLP$/P5@A\0RK+2N(8L($Y1)(<"00[IF996$A&2JY*4E?Y]^+ 4IW!]X7-F
M=G:7+"#;&C4MS\W8/$:4=7=#YX$5WOP@&K2K;P&J% 
M6X&:&&AW]'ZUW1FAW-@@604+N@P/UTA >0,@CY
MP'].FI\A _%\/:O_C-EZ]P=NX0'E;]&XWIO-*&F@Y:-T+S@]PBF%VR!8H[1Q
M)/5H':J90HGB[VD6.LY3NBEFVF5"?B+D"V&31>,I4+3Y@SM>E08G8E)I!QXZ
MN-KFOA U\=XL#5LF,0^H+9)TR>, N">?4E1/[_$/O\C)Y?
MIJ^O.%Q'^CI%WV27!8HK D44**ZF^ 6S^3=)=E93!::+3\>2&D?M4O&6T^5U
MWN>Q)Y_PJAQX![^XZ82VY(#.=S;VID5TX$UD-[>4]/[_+!L)K0O+.[\VZ4FE
MC<-A_B#++ZT^ %!+ P04    "  @@9M(?;0!!J$!  "Q P  &0   'AL+W=O
M25-/!LB9NT
M%O;/ 13.>[JA2^)%]H./"597;.6U4H-Q$@VQT.WIXV9W*",B 7Y*F-W%FD3O
M1\37&'QO][2(%D!!XZ.""-,)GD"I*!0*_SYKOI>,Q,OUHOXU=1O<'X6#)U2_
M9.N'8+:@I(5.3,J_X/P-SBW<1\$&E4LC:2;G42\42K1XR[,T:9[S3KG0KA/X
MF87X45=69R)S4<[BGB#FQT/!]&0X,W1N)6ZCXBZ.M6;!UZQ
M4Q3Z@#ED#,^8%<&"^EJ"_[_$@5_0^77Z]H;#;:)OSPZWUP7*&P)E$BAOMO@1
M4_Y3A%V%V-HH&UL?5/;
M;N,@$/T5Q <4QT[:*G(L-5U5W8>5JCZTS\0>VZC > ''W;]?+HZ;KK)Y 68X
MY\P9+N6$YL/V (Y\*JGMCO;.#5O&;-V#XO8&!]!^IT6CN/.AZ9@=#/ FDI1D
M>9;=,L6%IE49-;]*!N+Y^J3^%+OU[@_+ U;L?N J,ICM;K?E.P8A+YA]@F3)\R"8%Y]*9'_O\0^/Z/G
ME^G%%8=%I!>SP]O+ NLK NLHL+[:XG?,W3]%V-F9*C!=?#J6U#AJEPYOR2ZO
M\R&/=_(%K\J!=_"+FTYH2P[H_,W&NVD1'7@3VV.=L[U6\9L
MU8'B]@9[T'ZG0:.X\Z%IF>T-\#J2E&1YEOU@B@M-RR+F'DU9X."DT/!HB!V4
MXN;?'B2..[J@I\23:#L7$JPLV,RKA0)M!6IBH-G1N\5VOPJ("'@6,-JS-0G>
M#XBO(?A3[V@6+("$R@4%[JY0O
MHG:=-YM14D/#!^F>TLUY.M,N$
M?"+D,V&31>.I4+3YP!TO"X,C,>EH>QYN<+'-_4%4Q'NS-&S%[@.B+([E8K,I
MV#$(?<+L$R9/F!G!O/I<(O^^Q#X_H^>7Z1OIPM_"7FU9H2P[H_,W&
MNVD0'7@3V%)^8%M+0NDJY!UM7.'DE#3Q8XB:MA?UW (7SGI;TG'B4_>!C@M456WFM
MU&"<1$,L='MZ5^X.VXA(@-\29G>Q)M'[$?$I!C_;/2VB!5#0^*@@PG2">U J
M"H7"?Q?-EY*1>+D^JW]/W0;W1^'@'M4?V?HAF"TH::$3D_*/./^ I87;*-B@
M0\ZC.%$BV>\RQ-FN>\P_E">Y_ %P)?"5^*9#P72C:_"2_JRN),;#[:
M4<0;+'<\'$1#@C='XU;J/B+JZE277\N*G:+0*\PA8WC&K @6U-<2_.,2!WY!
MY^_3-U<<;A)]LSC\0&![16";!+976WR-V;PIPB[.5(/MT]-QI,')^'QX:W9]
MG7?I$MD+O*Y&T<,O87MI'#FB#S>;[J9#]!!,%#>WE SA_ZR!@L['Y>>PMOE)
MY<#C>/X@ZR^M_P-02P,$%     @ ((&;2+UX-R*D 0  L0,  !D   !X;"]W
M;W)K&UL?5/;;N,@$/T5Q <4ASCM;N18:EI5W8>5
MJC[L/A-[;*,"XP*.V[\O8,=-5]F^ #.<<^8,EV)$^^(Z $_>M#)N1SOO^RUC
MKNI "W>%/9BPTZ#5PH?0MLSU%D2=2%HQGF773 MI:%FDW),M"QR\D@:>+'&#
MUL*^[T'AN*,K>DH\R[;S,<'*@BV\6FHP3J(A%IH=O5UM]WE$), ?":,[6Y/H
M_8#X$H-?]8YFT0(HJ'Q4$&$ZPATH%85"X==9\[-D))ZO3^H/J=O@_B #-T;B5NH^(LCB6JY]Y
MP8Y1Z MF/V'XA%D0+*@O)?C_2^SY&9U?IJ^_<;A.]/7L<'-9(/]&($\"^2QP
M?;'%KYB;?XJPLS/58-OT=!RI<#!^.KPEN[S.6Y[NY!->%KUHX;>PK32.'-"'
MFTUWTR!Z"":RJPTE7?@_2Z"@\7%Y$]9V>E)3X+$_?9#EEY8?4$L#!!0    (
M ""!FT@T_!F$I $  +$#   9    >&PO=V]R:W-H965T5-2VSWMG.MWC-FJ \7M#?:@_4Z#1G'G0],RVQO@
M=20IR?(L^\84%YJ61<2^=G)X=UE@PB]N6J$M.:+S-QOOID%TX$UD-UM*.O]_YD!"X\+R
MNU^;]*12X+ _?Y#YEY;_ 5!+ P04    "  @@9M(%-D!T:\!   6!   &0  
M 'AL+W=OZ<
MZ[>$V*H#R>R=[D'YDT8;R9Q?FI;8W@"K(TD*0K/LGDC&%2Z+N/=JRD(/3G %
MKP;904IF_N]!Z'&'5_BT\<;;SH4-4A9DYM5<@K)<*V2@V>''U7:?!T0$_.$P
MVHLY"MD/6K^'Q:]ZA[,0 014+B@P/QSA"80(0M[XWZ1YM@S$R_E)_3E6Z],?
MF(4G+?[RVG4^;(91#0T;A'O3XPM,)<2$E18V_J)JL$[+$P4CR3[2R%4XVE+_(2KDLUD7M#I,GU](^$ZTM?)/?_&?W-#8!,%
M-E.)=+'$:\QZV22_89)?"6P63:XQ^1<3#+*CE,S\/8#0
MTQ[G>)YXY5WOP@2I2K+P&BY!6:X5,M#N\5.^.Q0!$0&_.$SVHH]"]J/6;V'P
MH]GC+$0  ;4+"LPW)W@&(8*0-_YSUORP#,3+_JS^+5;KTQ^9A6]73=SB7$!/66MCX1?5HG98S!2/)WE/+56RGM%+,M'4"/1/H0GC,
M8O!D%&-^98Y5I=$3,FEK!Q9.,-]1OQ$U\MDL#DNQ^H"HRE-%L_N2G(+0%>:0
M,#1B\@5!O/IB0?]O<: 7=+I.W]Q(N(GT37(OMNL"VQL"VRBP/9?XL%KB->9Q
MW:2X85)<"7Q9-;G"Y-DG$W)QE4LGM,PN3^")QH/_@%?EP#KX
MR4S'E45'[?SUB1>@U=J!#Y'=^12]?Z3+0$#K0O?!]TVZMVG@]#"_PN574/T#
M4$L#!!0    ( ""!FTA%CM6ZKP$  !8$   9    >&PO=V]R:W-H965T@"+O@679I?TU@Y;C$W=@Z#F3@T@W4JKM*#6
M#76'S:"!-H$D."9I>H\%93*IRC#WKJM2C98S">\:F5$(JO_L@:MIEV3):>*#
M=;WU$[@J\<)KF !IF))(0[M+'K/MOO"( /C%8#(7?>2S'Y3Z](.W9I>D/@)P
MJ*U7H*XYPA-P[H6<\=>L>;;TQ,O^2?TE5.O2'ZB!)\5_L\;V+FR:H 9:.G+[
MH:97F$L("6O%3?BB>C16B1,E08)^QY;)T$YQ)<]GVCJ!S 2R$'ZD(7@T"C&?
MJ:55J=6$=-S:@?H3S+;$;42-7#:3^*50O4=4Y;$B65;BHQ>ZPNPCA@3,&8&=
M^F)!_F^Q)Q=TLD[?W$BX"?1-="\>U@7R&P)Y$,CG$LEJB=>8S;I)<<.DN!+(
M5TVN,<4_)OCBX 3H+MQ/@VHU2AM/:)E=GL C"0=_AE?E0#OX277'I$$'9=WU
M"1>@5N12]>Z3+@$-K???!]76\MW%@U7!ZA&PO=V]R:W-H965TJ7?30-@T8?@TARBQMIVC[$I&A#4W*@6I#NIE!;4NJ6NL6DUT#*0
M!,
MR01(PY1$&JI#])#LCZE'!, K@][,YLAG/RGU[A=_RD,4^PC H;!>@;KA#(_ 
MN1=RQO]&S2]+3YS/+^J_0K4N_8D:>%3\C96V<6'C")50T8[;%]7_AK&$G1'MNL#VBL V"&Q'@;O5$I>8^W63W163W5R Q*LF2\P/-YE>
M,4D7 F359(G9?#/!L^X0H.OP" PJ5"?MT ;3[O3.'DCHKB]XGK6TAK]4UTP:
M=%+6]6CHLDHI"RY$?.-*;=R78%IPJ*R?WKJY'A['L+"JO3SUZ7N3?P)02P,$
M%     @ ((&;2-D?&0RE 0  L0,  !D   !X;"]W;W)K&UL?5/+;MLP$/P5@A\0RK1L%X8L($X1M(<"00[MF996#X3D*B1EI7]?
M/F3%"=Q<^)R9G=TEBPG-B^T ''E34ML#[9P;]HS9J@,E[!T.H/U-@T8)Y[>F
M978P(.I(4I+Q+-LR)7I-RR*>/9FRP-')7L.3(7942IB_1Y X'>B*7@Z>^[9S
MX8"5!5MX=:] VQXU,= 4?_K:==YL1DD-C1BE>\;I
M!\PI;()@A=+&D52C=:@N%$J4>$MSK^,\I9L=GVFW"7PF\(7P+8O&4Z!H\[MP
MHBP,3L2DT@XB='"UY[X0%?'>+ U7,?N *(MSR7E>L',0^H Y)@R/F-6"8%Y]
M"<'_'^+(K^C\-GW]A<-UI*]3].WNMD#^A4 >!?(YQ4$]H7UP-X
M\JJ5<0?:>S_L&7-U#UJX.QS A)L6K18^F+9C;K @FD32BO&B^,2TD(969?(]
MV:K$T2MIX,D2-VHM[)\C*)P.=$4OCF?9]3XZ6%6RA==(#<9)-,1">Z /J_UQ
M$Q$)\%/"Y*[.).9^0GR)QO?F0(N8 BBH?50083O#(R@5A4+@W[/F6\A(O#Y?
MU+^F:D/V)^'@$=4OV?@^)%M0TD K1N6?@\Z@N%$BU>
M\RY-VJ=\LRUFVFT"GPE\(=PG LN!4II?A!=5:7$B-K=V$'&"JST/C:A)R,W1
M>)6JCXBJ/%><[TIVCD+O,,>,X0FS6A LJ"\A^/]#'/D5G=^FKS_(<)WHZQQ]
M5]P6V'P@L$D"F[G$^YLEOL=\_B<(N^JI!MNEI^-(C:/QN7F+=WF=#SS-Y U>
ME8/HX(>PG32.G-"'R:;9M(@>0A+%W9:2/OR?Q5#0^GC&PO=V]R:W-H965T
M*49M7VP$X]"Z%LGO<.=?O"+%5!Y+9.]V#\BN-
M-I(Y/S0ML;T!5D>2%(0FR0\B&5>X+.+>*%MYT+$Z0LR,*KN01EN5;(0+/'#^GNL F("/C+8;07?12R'[5^#8/?]1XG
M(0((J%Q08+XYP2,($82\\=NL^6D9B)?]L_K/6*U/?V06'K7XQVO7^; )1C4T
M;!#N18^_8"XA)JRTL/&+JL$Z+<\4C"1[GUJN8CM.*]M\IJT3Z$R@"^$^B<$G
MHQCSB3E6%D:/R$Q;V[-P@NF.^HVHD,]F<5B*U0=$69Q*FB4%.06A*\QAPM"(
M21<$\>J+!?W>XD OZ'2=GMU(F$5Z-KEOLW6!_(9 '@7RN<1TM<1KS#/]M*C2@W+3"2VSRQ-XH/'@/^%ET;,6_C#3(%:+1VX$,D=SY%YQ_I,A#0N-#=^KZ9[NTT<+H_O\+E5U!^ %!+ P04
M    "  @@9M(GI[15+ !   6!   &0   'AL+W=OOEX"
M32HF%[Q]V^^%?-#FW;8 #GU(H>P>M\YU.T)LV8)D]DYWH/Q*K8UDS@]-0VQG
M@%61) 6A6;8ADG&%BSS.O9@BU[T37,&+0;:7DIE_!Q!ZV.,%'B=>>=.Z,$&*
MG$R\BDM0EFN%#-1[_+#8'=8!$0%O' 9[T4-;\L _&R/ZK_BM7Z]$=FX5&+/[QRK0^;851!S7KA7O7P!.<2
M8L)2"QN_J.RMTW*D8"391VJYBNV05C8C;9Y SP0Z$;99#)Z,8LR?S+$B-WI 
M)FUMQ\()+G;4;T2)?#:+PU*L/B"*_%30Y3HGIR!TA3DD#(V8Q80@7GVRH/^W
M.- +.IVG+V\D7$;Z,KEOLWF!U0V!5118G4O#\M*G6O7#JA:79Z @\T'OP7O,@[UL!O9AJN+#IJYZ]/O "U
MU@Y\B.S.IVC](YT& FH7NO>^;]*]30.GN_$53K^"XA-02P,$%     @ ((&;
M2$H9P:.O 0  %@0  !D   !X;"]W;W)K&UL?53)
M;J,P&'X5BP>HP9!.%1&DIE75'D:J>I@Y._ #5KU0VX3.VX\70I.*YH*W;_N]
M4$Y*OYL>P*)/P:79);VUPQ9C4_<@J+E1 TBWTBHMJ'5#W6$S:*!-( F.29K>
M8D&93*HRS+WJJE2CY4S"JT9F%(+J?WO@:MHE67*:>&-=;_T$KDJ\\!HF0!JF
M)-+0[I+[;+O?>$0 _&$PF;,^\MD/2KW[P4NS2U(? 3C4UBM0UQSA 3CW0L[X
M8];\LO3$\_Y)_2E4Z](?J($'Q?^RQO8N;)J@!EHZ82P@):\5-^*)Z
M-%:)$R5!@G[&ELG03G%E4\RT=0*9"60AW*4A>#0*,1^II56IU81TW-J!^A/,
MML1M1(U<-I/XI5"]1U3EL2)%6N*C%[K [".&!$RV(+!37RS(SQ9[O"Q17!(H@4,PE9JLE7F)^2+FY8K*Y$,A732XQQ3<3?'9P G07
M[J=!M1JEC2>TS"Y/X)Z$@_^"5^5 ._A-=<>D00=EW?4)%Z!5RH(+D=ZX%+U[
MI,N 0VM]]Y?KZWAOX\"JX?0*EU]!]1]02P,$%     @ ((&;2"R[RB6Q 0  
M%@0  !D   !X;"]W;W)K&UL?53;;ILP&'X5RP]0
M$R>T6420FD[5=C&IZL5V[< /6/6!VB9T;S\?"$TJEAM\^DZ_#Q2C-F^V W#H
M0PIE][ASKM\18JL.)+-WN@?E5QIM)'-^:%IB>P.LCB0I",VR>R(95[@LXMR+
M*0L].,$5O!AD!RF9^7L H<<]7N'SQ"MO.Q=8K4]_9!:>M/C#:]?YL!E&-31L$.Y5CS]@*B$FK+2P\8NJP3HMSQ2,)/M(
M+5>Q'=-*OIYHRP0Z$>A,V&8Q>#**,;\SQ\K"Z!&9M+4]"R>XVE&_$17RV2P.
M2['Z@"B+4TDW>4%.0>@*(%:+1VX$-D=SY%YQ_I/!#0N-!]
M\'V3[FT:.-V?7^'\*RC_ 5!+ P04    "  @@9M()9B1(*0!  "Q P  &0  
M 'AL+W=O@^$WMLHP+C HZ[?U_ CINNTKYP/>?,F1DH1K0OK@/PY$TKXW:T
M\[[?,N:J#K1P5]B#"3<-6BU\V-J6N=Z"J!-)*\:S[)II(0TMBW3V:,L"!Z^D
M@4=+W*"UL/_VH'##IYDV_EXP,J"+;Q::C!.HB$6FAV]S;?[=40DP+.$
MT9VM2?1^0'R)F]_UCF;1 BBH?%0083K"'2@5A4+@UUGS(V0DGJ]/ZO84]A$P0J52R.I!N=1GRB4:/$VS=*D>9QN
M^,U,NTS@,X$OA)LL&9\")9N_A!=E87$D=BIM+V('\RT/A:A(\.9HO$K91T19
M'$N^R0IVC$*?,/L)PQ,F7Q LJ"\A^-2 /G0V]:9!]!!,9%<;2KKP?Y:-@L;'Y8^PMM.3FC8>^],'67YI^0Y02P,$
M%     @ ((&;2 E[(GVB 0  L0,  !D   !X;"]W;W)K&UL?5/;;N,@$/T5Q <4ASC=W5JC[L/A-[;*,"XP*.NW^_
M@!TWK=*^ #.<<^8&Q8CVQ74 GKQI9=R.=M[W6\9LMB#J1M&(\RZZ9%M+0LDB^)UL6.'@E#3Q9X@:MA?VW!X7CCJ[HR?$LV\Y'
M!RL+MO!JJ<$XB898:';T9K7=YQ&1 '\DC.[L3&+N!\27:#S6.YK%%$!!Y:."
M"-L1;D&I*!0"O\Z:[R$C\?Q\4K]/U8;L#\+!+:J_LO9=2#:CI(9&#,H_X_@ 
M \ZA.%$BW>IEV:M(_3S<]LIETF\)G /Q'8%"BE>2>\* N+
M([%3:WL1)[C:\M"(BH3<'(U7J?J(*(MCR3?K@AVCT ?,?L+PA%DM"!;4EQ#\
MZQ![?D;GE^GK;S)<)_IZBOYK)?7>&PH3-Z6GB5^\['!5:5;.(U4H-Q$@VQT&[H[6R]G4=$
M OR5,+BSG$3O.\2W6#PU&UI$"Z"@]E%!A'"$.U J"H7&[Z/F_Y:1>)Z?U!_2
M:8/[G7!PA^J?;'P7S!:4--"*@_*O.#S">(1%%*Q1N?0E]<%YU"<*)5I\Y"A-
MBD/>6=Z,M)\)?"3PB<"S\=PHV;P77E2EQ8'8/-I>Q!N*+9@"L\T8/F)6$X8%_:D)_Z4)3P+S4>#/SP+S7P3F2>!Z%+BY
M=&FRRXQ994Q1?&O"SL;2BST\"[N7QI$=^C#A-*,6T4-0*JX6E'3A'4^%@M;'
M=!5RFZ\V%Q[[TT.=_I;J"U!+ P04    "  @@9M((T]'TS,$  #3&@  &0  
M 'AL+W=O51<+35"=E
MEE?Q?C=^][79[^KWKL@K][6)VO>RS)I_7UQ1WYYC%G]^\2U_NW3#%\E^E]S7
MG?+256U>5U'CSL_Q;^SI8,Q@,EK\G;M;N_@<##/TW.<#CFXPAV[
MP476OWVX@RN*P5,?^=-_JVQ]NKD$-#H]UT8ZOT?&][>KRLZ>1+]SQZ@OIHV'G\;M
M&BSVNX\]U^DN^1@<>38ODPV?;-8L#DL++>XF29_ /0L.LN#C>C%GP=8=".! 
MC [D[."7)*NIC,G&CC9J8]:#2!!$>D'$6I"#7 31F^UZ$ 6"*&\KY+H##1QH
M+TNUNA63S7:T$7:CUJ,8$,5X4?2Z PL<6$K+M\#!EM#R[:+.=&/7@PRPA_E(
MO3"!LX9!Q!BE5(;X8/SQJ?1R8=#U5XYV&@8L"0[0PZ\4)[2KBA6TIU7($ _=A
M6+^VS$;S:6@V@6L#1\APYI4;:"Z'(X4T4SBB@5.FRFSTX!K#$3))%D:26@G_0*5)+*0IR"O&BO %C0[N*>%&&5"V"05E*M?8Q<@KQHKP!
M8P.=U8@73=)9&J&@*3I+$W261K1H3FF*1K1H06C*;(031:QH;[;8@-37B!6M
M2$V!M[,TI2D$G:41*=J;+#;4%$2*)MW1T@@#3;FG-1O!6@TBQ7B3Q89N_B%2
M#$ED&82!H8BLV0C7BD@Q)(EE$ :&(K$,X1^)0:08;ZK8@'@VB!1#NIUEX%U=
M0ZEU,C*KM2:+QP_7[,W]E35O>=5&KW77U>7X+.)&PO=V]R:W-H965TV$[=_7%T)A15!>\(69.3,^LK.!BW?9$*+ 
M!Z.=/'F-4OT10EDVA&&YXSWI])^:"X:57HH+E+T@N+(D1F& 4 P9;CLOS^S>
MJ\@S?E6T[08G7M4RTLF6=T"0^N1]
M\8^%CPS$(GZU9)"S.3#FSYR_F\6/ZN0AXX%04BHC@?5P(P6AU"CIRG]&T?\U
M#7$^OZM_LW&U_3.6I.#T=UNI1KM%'JA(C:]4O?'A.QDS[(U@R:FT7U!>I>+L
M3O$ PQ]N;#L[#NY/BD;:.B$8"<%$\*--0C@2PD\$Z)S97%^QPGDF^ "$:T:/
M3<_]8ZA/K@0ZC/3,+WMC- "\^(P@<.L(8HY(@XG"-0&)A?!
MAHO \L/11;HN$&X(A%8@&@4.2Y.=B^$PJ<6$N_T:IIACHEVP;B3:,!+-C1S0
MJA&'B2W&1PBM5]EO5-DOJOCK O&&0/S,@2<; LD3.9-YSCAXD#/=J)(NJCQH
MQV%#X/!,3G/;'U\0M/ 0KB8=0&ULC53+
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M'P+AOFV/S5\8[9'^$%6@O!Q*M"1OYKG^$5L0=0=F4]_/M P\/N\<7\A.+2]O)X,25[A'V
ME=><*Z+)X$;?PT:WXFE!2:W,=*?GPC4GMU"\O_?:J>&7_P!02P,$%     @ 
M((&;2/O8C-WL P  Y14  !D   !X;"]W;W)K&UL
MC9C;DJ(P$(9?A>(!A!PX68Y5,SK6[L563A5#>WZJLVR?_J-1I'@3M]BBJO)W)DZB[?_:RJ7+5
M73:'H#TU(M\-0549T#",@RHO:G^Y&.Z]-(_9/_3.:;:) ,BI^%N+2C4
MO_N+[[LG/^S;($JQ57V*O#M\BI4HRSY3Y_S')+U[]H'C\VOVS=#=KOD?>2M6
MLOQ5[-2Q:VWH>SNQS\^E>I>7;\+T(>H3;F79#K_>]MPJ65U#?*_*_^IC40_'
MB_XG#4V8/8": 'H+N/G8 Y@)8/< #@9P$\"Q#I$)B+ .L0F([P'Q4'Q=K*'4
MZUSERT4C+UZCY\=$:
M.F@HLTG68PFQ*39C!0OOFJ!KY*VEU-W2%SINA
MQPH2VOL2 7V))GWA]@0QD"#&5#,!$B23%D2V7FZ2435)/',,>@JXI!,7:RTW
M6I/I\9C%=I,,,,DF)HG5)!N9D'26V5WZA[+[H1%.?*R3:V-$VBAS]8: #R?R
M>*)OC,A4+9U%#B/@V?),Z,3(51,(:H*BFD!8$_YX)JZ-*/Z"Y-0% HY$CR?)
MVHA@%XA*$H]=7 \& G%)$E1%(>A(BF#;B'1?70V%J",9@FTC ETH!!T-$7 ;
M$>P"(4*,3WHBK'!!,
M%+7&40@FBEGEC"@&%W,* 4(89O0A"*@H1/$2(-\((HBXB
M"!Z,*+&Z!*,MJ4HTAV'WL/6V\EPK78';W=L.Y3/MM[2^W'\A\Q6QW%^3^:O>
M?[RG7RY.^4'\R)M#4;?>AU1*5L-6V%Y*);HVA[-N7A]%OKM=E&*O^M.D.V_T
M+J2^4/)TW52][>PN_P-02P,$%     @ ((&;2-WPNQ@Y!   :QD  !D   !X
M;"]W;W)K&ULC9G=CILZ$,=?!?$  7ML ZMLI&6/
MJIZ+(U6]:*_9Q$E0 >< V;1O7SZ<+);P[-R$C_P],_;,#V.SO9GV5W?6N@]^
MUU73/8?GOK\\15&W/^NZZ#;FHIOAGZ-IZZ(?+MM3U%U:71RF1G45\3A645V4
M3;C;3O>^M;NMN?95V>AO;=!=Z[IH_^2Z,K?GD(7W&]_+T[D?;T2[;?1H=RAK
MW72E:8)6'Y_#%_;TJI)1,BE^E/K6+GL-XC$%7>M^/)HKA
M\*Y?=56-E@;/_UNC'S['ALOSN_4O4W>'\-^*3K^:ZF=YZ,]#M'$8'/2QN%;]
M=W/[JFT?Y&AP;ZIN^@WVUZXW];U)&-3%[_E8-M/Q-O^3QK;9>@-N&_!'@X>?
M]09@&\!' S7U=(YLZM<_15_LMJVY!>V.?TW#-2IV
MV_<=L'0;O8^&'$T^:_BD86N*UZ4"X@]--$3P"(/[P\CYP@!?=;%4*%CW $A'
M86HO;$>S=0,",2 F V#[R-<-2,2 7$; 8[>7S=S+69/.0YUN/&$JQ(M:ALD]
MJ4@0 XD3)E\+,T\68$[%O19WXP
MZ+@+G?*8P(CBG))_CA'%@9!_OB0J]7C!B.*"DGZ.X<(E(?U6-*>%;SQ,<8PI
MKBCI5R0_&'C; "#"L@O>\!AA40WOAR*YKY]SRH (,*2&]\
M@/$"+B_9>J#)(OUJXQL0#"IP7OO ,R"I4V8^/QAYD'U>9CDLR9,;SY)"8.0)
M9SH#S] +C#S!*&4F,*@$)Y29%:%E)C"D!%#*3* K*$$H,RNZ/_Y]:<&X$Y)0
M9F+)G>>U2V#<"<)DEHOE9 :^18S X!0.G."K$(P[09K,!(:4($QFN16A8RHQ
MH"1I*I,84)(1BDPRI\@\2T.)42U,8G,J!$SQ#HC#N%&E=IC"H%&%=EBO"3H?"D%*D=9G"
MD%*24&9*.FGQ^4'W#!6AS!2!.X5QIQ)*DGU$$.\&4;TK(O#
MXZ+2QWX\38;S=OX6,%_TYG+_M/'XOK+["U!+ P04    "  @@9M(A2,FQ1D#
M  !5#0  &0   'AL+W=O<^_)3%Y]'="=<%G9$S;O@_!]+6!>./[=&CYQ87>TFJ*P_Z
M?N351=FX62K'7MLL)1=6E0U^;1UZJ>NB_;?"%;DN7>#>!M[*XXF) 2]+O9ZW
M+VO/BU7[J^T( KO&,B1,$O
M7WB-JTI$XIG_JJ#WG((XO+]%W\KIW;B:GW7V>-#<:G8&[GF
M6,TA% %WI*+RU]E=*"/UC>(Z=?'=7;OED(NY*5B1I2VY.FVW
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M*+'MDA<%BKM()DBN0""$8:Z9&\MU3OP;IW^H\(&)
MVYC?M]VIOWM@Y'S[B.F_I++_4$L#!!0    ( ""!FTBGG12#B0(  , )   9
M    >&PO=V]R:W-H965TU%IM1?MM9,X 2U@BIVP??OZ0%(<&8MJIQAZA'!MSS+QN'09#X'6IZMRSD
MN[>Q+,B-M4V/WT:'WKH.C7\/N"73W@7NX\5[.&7A?^T.S<=[FE#>F?$
ME[W[!>PJD J)5/QJ\$07;4? 'PGY$)T?Y[T;" ;C:]?$[J2Q;,9F:#<#8(GP8@LAK V0"^&/B*3,;U%3%4
M%B.9G%$E8T BYV '^62^:+('Y
MVH+)+#B9AI.8'>06!_F6_2.*VGH="#;LH%GT6"LK,_*JBO/E;X7-6J. QF8<
M]3"+YNW",^$98ZA>=/EJPH"M8(%00UIS82M9 &Y*FJW0@&A+TI:E!J3&Q5ZM
MBG086ZT!>K%92[2M0H!DTY38=C9(MZR5=%'D\VSM*'B1)0N9 O(79^V KO@G
M&J]-3YTC8?S8E@?OA1"&N;/ X]-3\^O4L]/B"Q/-E+='=<%0'4:&QWWI>6DK
M_P%02P,$%     @ ((&;2/K,>FKX @  N L  !D   !X;"]W;W)K&ULC5;;;J,P$/T5Q < QEPC@E1(H]V'E:H^[#[3Q$E0 6?!
M:;I_OS9VJ!T--'D(8,XY,V=L[,FNM'\?3H0PZ[-MNF%MGQ@[KUQWV)U(6PT.
M/9..OSG0OJT8?^R/[G#N2;4?26WC^IX7N6U5=W:>C6,O?9[1"VOJCKSTUG!I
MVZK_5Y"&7MF&FG963PYK^PFMM@@+R(CX79/K
MH-U;(ODW2M_%P\_]VO9$#J0A.R8D*G[Y("5I&J'$(_]5HE\Q!5&_OZEO1[L\
M_;=J("5M_M1[=N+9>K:U)X?JTK!7>OU!E(=0".YH,XS_UNXR,-K>*+;55I_R
M6G?C]2K?))ZBP01?$?R),,6!"5@1\!]?1J]7)]G"NQ#-$JXI.YLWA]!UN\&F=0(/+L(\>1E[D?0LC %!+C
MCQ@?0Y"-#D$3PN4)3%GX\UD4OAX!"E :B #,X5N1Y^]%MCHDPK 3O%!///*Q
MJN=,*8(%@6 4"&0ET5VU.^E48A+I(W(0!'K601@[/IQ*N)!*J*6"HQF!:$$@
M>J08\8) ;&0 %J.(-9^ADT"84F+B$9.")96(5);==WRPI 8HUF(9AI(%0XEA
M*  -)5H4SP%-ER8&U-F8F AT9&)2V%"Z8"@U#(6@H50+$L"KM9282&) .[I*
MXJ#4^('F=$8\9TZ+H,I=0)9VPMG"-/R#=LW65\
M.\Y,4 *!-H^ MK,@,^.E\P)A0P*L3*% R6UW E&EB4K@=;@Q4'SUS,R%CL+Z
M$2.MN5J7T9+^.#:$@[6CEX[)'7\:G9K.)U]T*7?C!5J5"!C?H-6S;"F_Y//L
M7!W)KZH_UMU@O5'&>Z.QNSE0R@A/VW/XD77B;?3TT) #$[NS]^5IN%WZCT53SJO=/]MUN^FRS<:C=?E<
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MRU3@@_*F@4F.[HP&R6LO>29T,"?M3Y-@#,RH#MX,KQB'/2PLM>(Y$C[.$!>] VG$;9,7\
M_&%2L+.DDA7NDR] L086Z1KW=8U;'G&!!(/+I(6!R,C5U86QX'Z[Q73\%JP(
MTO7!L:P0O[F^OC 6W&^CXD*^(CBD6ASI!3?7E\7W"Y",Q$%ZP8E>Y"KB ND%
M3](+@?1"D(XFTF,*(@.PR12^MESI,@62#$$D(X\4#X$(+M+VCG#S2'J2\%;-
M8?2Y/P(#1AP7I"G(33B67YF%0+&0& A2F?-@<[B\ $4*FD#T%H3>D4!542(VE:2!$$400;66VYOP*R>!>W%/[F
MZ@N2IH541OC;J\BF>.Y YW8;1I-(D&1&)B&\9*2O,K$H2%TD41NR*D3K^04H(JP2GE\1J;)AJ9+^_D5"5DBD
M59+(D,W#P4CG JN.1((EB6#9B.9))"[2I%0=B81 ^D(@+^GMY/D"%-EQ2\1L
M:8F+2&>J$%U5EC):A;BH6,)H+T"1/EPA(BI.7$1Z-H4(ID32:!%W5,+AK_*K
M/#R'A0>QE#CA*J<(<836\7JBR!GK%RA-#)%,)9RRSI5?ZYEA2'\5XJ.BQ3YR
M(&VN%Q2%**MH[0X7%/7UN#,2"K%6D>/.2$%Q(+]ECYR&(W9K6HS#0J_]W4'7
M)Z)@2 0^A@L*]^,SQWX^YY!U#&$.BS2>!A$'9-$'8.H8RAU
MPM7-^#VH1><6&#FD-?&>"3@6+^5?1?VR/32CQZIMJ_WI 8'GJFK+SE]VTS%N
M4Q;KCS>[\KGM+TUW70^/BPQOVNIX?OKEXQ&&ULC5;;CILP
M%/P5Q =@#,20B"!U4U7M0Z75/K3/#G$"6H.I[83MW]<70F$%%B_Q;Y2
M-Z05-6L]3JY'_PL\G"#2$(/X59->3/J>%G]F[%T/?ER.?J@U$$I*J2FP:A[D
M1"C53&KG/P/I_SUUX+3_9/]FTE7RSUB0$Z._ZXNLE-K0]R[DBN]4OK'^.QER
MV&G"DE%A?KWR+B1KGB&^U^ /V]:M:7N[DH5#V') - 1$8P!,G 'Q$!!_"@!6
MF80;S!A -M,HR!;=F(%0$*V(<=8JG(E9
M<12Z"@U&FRQQE1J,MU@23[*%0;1LB04A^P]9D>(J6CBOVFR%PE5N<+?)$%?!
M0;3%$#2Y&-8J9@"EBX: R<7>X1OYB?FM;H5W9E*]$>:6OS(FB2(* Y55I=[N
M<4#)5>INJOK
MF;TWGF?L)$E5XS?NB1.EB'^M,&'MT@_]R\9[=2REW@!Y!GK>OJ*X%A6K/8X/
M2_\E7&Q3C3" /Q5NQ6#NZ=QWC'WHQ>M^Z0/ 4=S4V '0'VA#Z.FQ!UA.A*B"<)<4>('XV0=(3D
M)@*PM1OG-DBB/..L];B][0;I/U6X2-3=%)ZR2_CZR%R(1N39.8_#YPRT=D5&:T819D>%'
MUBP8N 7B"8'8",1&()F/2-9&UL
M?53+CILP%/T5BWUC'DD[B@C2A%'5+BJ-9M&N';B -7Y0VX3IW]M<=@$$?G E]B#IC^CW&NNJ $[V1/0B[TTC%B;%+U6+=*R"U
M)W&&TSC^BCFA(BIR'WM512X'PZB 5X7TP#E1_X[ Y'B(DN@2>*-M9UP %SF>
M>37E(#25 BEH#M%SLB]W#N$!ORF,>C%'SOM)RG>W^%D?HMA9  :5<0K$#FP\Q1-MG9!.A'0FS'G6"=E$R.X(.#CS=;T0
M0XI>[#/;N0K98G3DMGR['*+(S\4V37)\=D(WF&/ I!Z39FN0
M<@FYBF!K8':1?N[BF"XSK"981]PDR!Z4F7GZ=BKS$X'M X&M%\@F@7A=8/= 
M8'?CX*Z+(K0A8)X\YDN\2=9 Y1*4;+([)WAQ_!Q4ZY^%1I4<
M^NMSA1=Y3UKX151+A48G:>PE]->HD=* -1%OK(O._AOF!8/&N.DW.U?AN82%
MD?WE\<]_H.(_4$L#!!0    ( ""!FTA3MI%+N (  .L)   9    >&PO=V]R
M:W-H965TG[
M?'ND+>$>.]%._MFSOB5"#ON#ST\])3M-:AL_# +LMZ3NW"+7$7N3_R=G5+.UZSSNGI?N4^H.4&A0JB
M$;]J>N%6WU'B7QA[58,?NY4;* VTH5NA3!#9O-$U;1IE27K^,QB]^51$NW^U
MOM'A2ODOA-,U:W[7.W&4:@/7V=$].3?BF5V^TR&&1!GG-_OC1-0V1$LL%W/KR/QR5_W2*Z@01?Y6Q&&<^V_*
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MF A]-+6(&@IVNI=58WQ7_ %!+ P04
M    "  @@9M(7__X4H@!   W P  &0   'AL+W=OX+M-NS?KR]I
MMD6(E\R,?MA?V[!87CAB[H:>%-[GL?
M%UA=L9G72@W&233$0K>A=XOUMHR(!'B7,+JSG$3O.\2/6#RW&UI$"Z"@\5%!
MA'"$>U J"H7&GY/F_Y:1>)Z?U!_3:8/[G7!PC^J/;'T?S!:4M-")@_)O.#[!
M=(3K*-B@\L[J=:#\3^$3@,X%GX[E1LOD@O*@K
MBR.Q>;2#B#>X6/,PB(8$;X[&K73ZB*BK8[TL><6.4>@"L\T8/F'*&<."_MR$
M_]*$)X$R"2QNEC\+E+\(E$E@.3E87KHTV67&K#+F6PMV-I1![.%%V+TTCNS0
MA_FF"76('H).<75-21]>\5PHZ'Q,5R&W^6)SX7$X/=/Y7ZG_ 5!+ P04    
M"  @@9M(^"0T-_O+X2!UJ4;
M?/O_X^^<(UQ,C+^*#F,)WB@9Q,GKI!R/$(JZPQ0)GXUX4"17*$:.
M46-,E, H"#)(43]X96'VGGE9L)LD_8"?.1 W2A'_=<:$323V(U!YK]PMBK7GQM3EZ@$3#!M=01
MD!KNN,*$Z$#JXI]SS/'F-5N1JH9(2GCTRYM*(L[F42IP6\ZT ;S=EJ
M(J.)7(IJK:';I)DAR39D!R<)%:3&4W@Y+"*)Z/(_Y@I!N,)R=&NKKD0^BG
M3I*-*/#_T=QL!R5;HR3.?,_9?RN2;2IR<&/D.QCY!B-T8N2K]@>^LVK56A.F
M?_4&KOZ_$5WQ-\2O_2# A4GU*YN?L65,8A4J\%5Q._7"+@N"6ZFGN9IS^^C8
MA63CXPE=WO'R-U!+ P04    "  @@9M(4QVC(=\!  #D!   &0   'AL+W=O
M1JIZ
MF#D[\%A4&S.V"9U_/UX((17-)5[XMN<\.QV$_% U@$:?G+5J']1:=SN,55X#
MIVHE.FC-EU)(3K59R@JK3@(M'(DS'(7A$^:T:8,L=7MO,DM%KUG3PIM$JN><
MRG\'8&+8!^O@NO'>5+6V&SA+\<0K&@ZM:D2+))3[X'F].R46X0"_&QC4;(YL
M]K,0'W;Q6NR#T$8 !KFV"M0,%S@"8U;(&/\=-6^6ECB?7]5_NFI-^C-50+ ?M2W$&MDF>6"3
MW-F$2S9'C]DXS"+BE,R";%;;+S'PK$DXR,K=-H5RT;?:=\.T.UWHY\@UV0V>
MI1VMX!>55=,J=!;:M*IKME((#29$N#(I:O/D3 L&I;;3C9E+?PO]0HON^J9,
M#UOV'U!+ P04    "  @@9M(5R1.\M "  "V"@  &0   'AL+W=O[*K;-[520CM?59EK9;^2>OS(@C4[B0J
MKI[D6=3FRT$V%==FVAP#=6X$W[=&51F$"$5!Q8O:S[-V[:7),WG195&+E\93
MEZKBS=^5*.5UZ6/_MO!:'$_:+@1Y%@QV^Z(2M2ID[37BL/2?\6*+B86TB%^%
MN*K1V+/!OTGY;B<_]DL?V1A$*7;:4G#S^A!K49:6R7C^TY/>?5K#\?C&_JV5
M:\)_XTJL9?F[V.N3B1;YWEX<^*74K_+Z7?0:F"7@'[5 ^L-V(.'H-/>9F[#
M-<^S1EZ]IBOWF=M=A1?,U&;GF70IWWYJ"V(1>?:14QIEP8*$Q:"L!QA+8&$N+$TQ+,V%,3)5
ML61&7.*("V&"=(8@'?_EC, $]@Z:/E21$P.H==6#.K$8HPC,KXM*(G"?;QQ4
MBL%_;^N [,DRH6SVNL".LHF]AV?.^F<2EUETJAM6AY7H.[:7^L+["BS4&UC>V
M16N;@#M]GIWY4?SDS;&HE?&ULC9??;ILP%,9?!?$ @#$F(2)(3<*T
M74RJ>K%=NXF3H +.L--T;S__(=1DQN6F@/F=XW,^HR^G^8UV;^Q,"/<^FKIE
M:__,^645AFQ_)@UF ;V05KPYTJ[!7#QVIY!=.H(/*JBIPSB*TK#!5>L7N5I[
M[HJ<7GE=M>2Y\]BU:7#W=T-J>EO[P+\OO%2G,Y<+89&'0]RA:DC+*MIZ'3FN
M_2>P*D$F$47\JLB-&?>>+/Z5TC?Y\..P]B-9 ZG)GLL46%S>R9;4MP!L ^ GP&),R#I Y*Y
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M#:#,V]-KR[4,P^HPY#[%+L1]IP=9_<#IY3Z7#_\<%/\ 4$L#
M!!0    ( ""!FTA%9@\1"@,  - ,   9    >&PO=V]R:W-H965TFO)'Q@YXQ9MY7WPUTXY\9N[R$(=V?<=_0@%SPP.\<
MR=@WC%^.IY!>1MP<9%#?A3"*LK!OVL&O2KGV-E8EN;*N'?#;Z-%KWS?CORWN
MR&WC _^^\-Z>SDPLA%49SG&'ML<#;XZT0F7OGOE/114P0NS^_9O\MV.?U=0W%-
MNC_M@9TYV\CW#OC87#OV3FX_\-2#9+@G'96_WOY*&>GO(;[7-U_JV [R>%-W
M\F@*,P? *0#. 0 Y ^(I('X$)+)3Q4SV]:UA356.Y.:-ZF%<&O',P4O,)[?W
M>#/4%[?DN 2B*C^K)(O*\%,DTC!;A8$2 V9$R+//):"]Q!8NPJ&I0*TA$G.%
MV-%$+..3J0D+Q<21()$)8I4@1>8$J2-!JC%8=3FH.2A,MAKC E$K1*$0 333
MR!PT,HU&;*2A,""2H+@($F3DHL%@%B06.LA!!VET$B,=M.@Y"RRCSQU%(ZT.,@M2!UFZ 4[=@V6*
M-+6D<.CZ%.Q4* RP) HLVT,%-)5N(Q:ZS6
M<5P]L6W +E,!FJN@R$QI:1JQ]9USN0;0; ,91[P%NB$406I[[5R. - 3,II 
M2D<%LID"<+D"R)_1D09"%H<#+EL FB\@R_BA2_(P>D9'T*5F:%/SSQ>)(;:.KMR75@:C,VK\Z;]%?%?-'A
M(Q.GB)^/:L.M+ABYW+\?YH^8ZC]02P,$%     @ ((&;2%*2."IH @  O@@ 
M !D   !X;"]W;W)K&ULC5;+DJ(P%/T5B@^ \!*T
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M?J"2%<5F@7!&()0"X9!MSYAM'6/.AHXQ;\D3.OD]',11K C>O
M7*L,*4PL,<"$V#Y$[!XB@HX 0+HR,=
MYCM+HUJNP99.%(')[_8L=">GD
M:A>51K/HK!TP 8W!U';"].WK"V&@N]PST[
MV WGPQX 5C:H@\PA ^K%3DUH![E8T@M@ T6P4J(. ]]U8]#!MK?S3%U[IGE&
MKARW/7JF%KMV':1_GA FX\'V[/N%E_;2<'D!Y!F8=57;H9ZUI+66<='>)
M;77P78]MK\91[Z3N)#,+_$G@SP(OW!0$DR#XK""?M(]*:TQ'$Q6VZIAD@BSVYYN LR<).!5LR39OR)"4U,
ML61\$W'\+W%:$1\V0)0QU^)OU.(K?:#T7A*; P0; 0(5()P*C=9)]OHP-!/K
M)"-7_\Q6X895N+**35:%9G::<0*S2;1A$JU,$J.)9E)]:&'JI&:;>,,F7MFD
M1AO->*Z" E'-@_8D&S[)PL<+C.TIDF4Y0>3L3-1Q27UYB)TTEBCL08_3C7S3
MU;D8+8ITF:__(-V'D$X%+![Y 5[03T@O;<^L,^'B[:&>_YH0CD0HUQ'];L1G
M8UY@5',Y3<2I7G RW+\+\\&UL?93+CILP%(9?Q>(!
M,)? D(@@-52C=E%I-(MV[003T-B8L9TP??OZ0JB9NK# M_\_YSNV[')B_$UT
M&$OP0:.:TR(#J02O\\Q
M_Z;41K?_B/YLJE7T9R1PS0Z8 71H3Y@\M-
M2$8?E@!0]&';?C#M9%>*:+;Y#Y5%40GO.M!*<[*:Q&@2GZ)V%7FZ2* "
M6"B2#8K$^%/CCXO('R#=")": +NYC'@-.=@RK*8PFGT19GOW\SGJ3X[_%+;;
MX-JMN!(OE]7LK29SLK@H*U$1/OE1L@V4;(7BS7+*G"QQ&H=>X'JE2O(P]L/D
M&S"Y Y,77I;U^@-02P,$%     @ ((&;2)6"
M$WU; @  ( @  !D   !X;"]W;W)K&UL?9;+CILP
M%(9?!;$OV-R)"%)#5;6+2J-9M&LG<0(:P-1VANG;UQ>2VJEA$U_X_W,^V_)Q
MJIG0-]9BS+V/H1_9WF\YGW9AR$XM'A +R(1'\>5"Z("X&-)KR":*T5F9ACZ,
M ,C" 76C7U=J[H76%;GQOAOQ"_78;1@0_7/ /9GW/O3O$Z_=M>5R(JRK\.$[
M=P,>64=&C^++WO\,=PU4$J7XV>&9&7U/PA\)>9.#[^>]#R0#[O&)RQ!(-.^X
MP7TO(XG,OY>@_W)*H]F_1_^JEBOPCXCAAO2_NC-O!2WPO3.^H%O/7\G\#2]K
M2&7 $^F9^O5.-\;)<+?XWH ^=-N-JIWUEP(L-KJL519&I1NF&0#)K%@,B>,UI0Z#2R#V ECJ4 :Y&Z8= ,FM6!R)TQJI(%%
MM+(SSRKHALDV8#(+QIGFD!EITM+(8K(\B2(W2KZ!DELHI1,E-[/ ('&BK(HL
ME&(#I3!1('"B%-;FK^R*)BUVYDWI%P\2RHPGXAA&,1# 3B>K;BN7X,>GSALIN+/M4/
MF!YP,MW?X\>?@OHO4$L#!!0    ( ""!FTATT9LG=0(  !4)   9    >&PO
M=V]R:W-H965T,#C.)_&VLRUFYV+S:9
MS,7N-;6TFE%Q@-;9MU] ZTB#VEY4P'/.=SX$/N(.DP]:(,2,K[IJZ,XL&&NW
MED7S M60ON 6-?S-&9,:,MXE%XNV!,&3)-65Y=AV8-6P;,PDEF-O)(GQE55E
M@]Z(0:]U#"B0$KB:V1=RIKU- 2-P9!YYWY"K8'("$2
M\:=$'9VT#6'^B/&'Z/PZ[4Q;>$ 5RIF0@/QQ0WM454*)1_X<1+]C"N*T?5?_
M(=/E]H^0HCVN_I8G5G"WMFF*_:.NY]HR,$7@CFNJ/PW\BMEN+Y33*.&
M7_VS;.2SZ]^$FX&F)S@#P1D);K!(< >".Q(T#G,Z2AFW84I@%O
M0<"3 MX@$*HNFSZ3'A-(C*)
M.-H0:;AJ4X]03$0+)J+UM9E&VK4Y-:%'*"8V"R8VRDS,G">B"LP?:_8SFQ0L
MGHS@B3TT@,*%E;4.R=8AAQE(GXXU.?-K1"ZRVE(CQ]>&]9,PCHX5_=41->-A
M/ 7;/=",9^(&(&O,MWP2M_""?D-R*1MJ'#'CE4K6FC/&#''/]@O?X@6_HXR=
M"IV9:(:\3?JJW7<8;N^7D/$FE/P'4$L#!!0    ( ""!FTARB?8-?P4  /H=
M   9    >&PO=V]R:W-H965T4A#-O]L:CR-J@OQ;G_YJ5NJKSK/S:O87MIBOPP
M!E5E*!C3896?SLOU:KSVO5FOZK>N/)V+[\VB?:NJO/EO4Y3U]7')EQ\7?IQ>
MC]UP(5ROPEO\M6RX.Q4O^5G8_ZNNWPM80#0GW==F._Q?[M[:KJX^0Y:+*?T^OI_/X
M>IV^29@-PP.$#1"W@%L[>("T ?(S0'D#E U0TB)0&MJ=S<08VXX..%H:H)@)$K0TEQ):X+FV@.*2*DQ["M.@,(T6-C%Z
MZC)'!SG5;EE"!VBFS*6$,(%!RP*42IQ32>
M7AO0:X,G&&R4EGDV1Y>XURGX#&6RD+U%3.%JD@),&$U,"H!I'A$K&&*,.7( 
MR_-8T!,7,]3)0K8\10@OH$2,]SH#E(YP#=L"JA=QZL[Y/(G+&?IDH:FA1.+=
M20%E>&"8\T?4Z89P'1,& [&$.78%*_69)X?NB4N6A:P4$[=0N;WA>)\S0 E%
M*#&D=""(PGS6R:%WXL)E(6WUD:-RG,VB=MRU1<6BB%Q4/F/DP!DE(U+X3(C'
MLY3+)_H*")H#I$I9K(;OL\;(X&"ZB*@@1$U;XK%9 J\7%3+C&
ME_02C._QYV&[.\PM#O;;YZ,"^*BDSKD^@Q)JCIH)GQ4(: 6XF@E7O@V;X=,I
M"(E-P(S[AP\^.(/E;0$6Q$I<^1))^C8-*G_Q+J/ZY@$ARBB&%)(:6(00:4B@B9@I2FIKST_OP'
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MJ_'YV$M==T7?<1;T"_!8Y(?;A[)XZ8:WG79O=AD\D\[#Y32ULS*@[0=O;?
M+Z"UQ2#UI0*><[@[*FNV=,^<-PO/8_D95XB]D0;7XLV1
MT IQ,:4GCS44HX,B5:47^'[L5:BHW2Q5:^\T2\F%ET6-WZG#+E6%Z+\U+LEM
MZ0+WOO!1G,Y<+GA9ZO6\0U'AFA6D=B@^+MT56.Q +"$*\:? -_8T=F3P>T(^
MY>378>GZ,@95[S!92F5Q,Y?G>AC3TE\'M_5?ZCCBO#WB.$-*?\6
M!WX6T?JN<\!'="GY![G]Q-T9H!3,2(Z%?INGT6MGK?V33+K
M:&9"T!&"GM#O8R:$'2%\$"(K(>H(T=0=8$> @QV\]NS*N2WB*$LIN3FTO>X&
MR:P""RCN)G>$786@?D41V4%'2\)_FM/-0R,C$5A,P"9O]H!"!IM
M'8!&,A58"QW0)$9R%5BJU H$D[RU51 03O VU"(U)^P 9,Y8'03-*3L C>0L
ML)4UH!42.)*UP%9) )SDK:V6@'B"M[$6Z4C>ZJ"1O-5!(WFK@X9YZSW]5U>8
MGE27Q)R<7&K>>M&O]IW8*I#_]8/U-5AL@&%]*SLWU1L\Y+.T02?\&]%343-G
M3[CH,%2/<"2$8Q&U_R;NXBQZRWY2XB.7PT2,:=MMM1-.FGOSV'>PV7]02P,$
M%     @ ((&;2(KO>%CP 0  :P4  !D   !X;"]W;W)K&ULC53;A,)@_M,Y96EPD(!9"5_GT!
MR;+E(6Y?!"SGG+VPVG3@XEW6  I],MK*K5C[*\Q(TWI9:FVO(DMYKVC3PJM LF>,B#\[H'S8>H%W-KPU
M5:V, 63K '2HV0=OPQ:5Y<&N+U_JS^8K/5T1^)A#VGOYM"U3I8WT,%E*2G
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MY]$VS]?L+U!+ P04    "  @@9M(F,71C-,"  !M#   &0   'AL+W=OT1.2,)_;E0.814?8X'^/E/&.T%T7C$,,D*>(1]5/8-N+=\]PVY$*'?L+/
M<[!WQ;E/N#B7PEYXP\_]MLPX1KP@'>44R!VN>(.#P-G8B/_D:3_Q^2%ZOV=
M_9N8+I/_BA;%WOZTS;7-B[2)KYQ(PSRM&"@PT(3H5(1"$C,!#Q70
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MY;&UL?93;CILP$(9?Q>(!8C !
MDH@@;;:JVHM*J[UHKQT8 EH;4]L)V[>O#X22+
M.>O4,6BT[@\8J[(!3M5&]-"9E5I(3K49R@M6O01:N2#., G#%'/:=D&1N[D7
M6>3BJEG;P8M$ZLHYE7].P,1P#*+@/O':7AIM)W"1XRFN:CETJA4=DE ?@Z?H
M<,JLP@E^MC"H61_9W,]"O-G!]^H8A#8%8%!JZT!-F7X5PS<82TBL82F8VI_8$HP,Q&U$B
MDYL*[)*KWBJ*_%8D&0YR&)-FDP<9_@I 5"'$&L3.(=OME@WC%
M('8&VS'+^#'+SF?I-;L1DFW29,MGK9^,\9*PRA;!'G5WHGB--U$RZ!D
M!91\ .T60I-"V0/NG1OVA-BZ!\GL
M2@^@_$VKC63.;TU'[&" -9$D!:%9=DX@B>#["@E,W^/
M(/1TP&L\'SSSKG?A@%0E67@-EZ LUPH9: _X?KT_Y@$1 ;\Y3/9JC8+WD]8O
M8?.S.> L6  !M0L*S$]G>  A@I /_'K1? \9B-?K6?TQ9NO=GYB%!RW^\,;U
MWFR&40,M&X5[UM,/N*10!,%:"QM'5(_6:3E3,)+L+F\7A*F8?$%5YKHIM7I)S$/J 
M.28,C1BZ62#$RR\QZ/]C'.DUO]C>%MA\87(3!3918+W[=EL@_T(@CP+Y)E4OU6TZ7!WI/8UO>X54YL Y^,=-Q
M9=%).]_1+8J,.K]%UHV EH7EEN_-NE5I8W3P_Q'EH]:_0-02P,$
M%     @ ((&;2."T$3 - @  W@4  !D   !X;"]W;W)K&UL?51=CZ(P%/TK#>\K" AJD&1T,ME]V&0R#[O/%:]"IJ5,6V7VWV\_
M$(NIOM#V]IQSSVWI+7K&/T4-(-$W):W8!+64W3H,154#Q6+&.FC5SI%QBJ5:
M\E,H.@[X8$B4A'$492'%31N4A8F]\[)@9TF:%MXY$F=*,?^W!<+Z33 /KH&/
MYE1+'0C+(AQYAX9"*QK6(@['3? R7^]RC3" /PWTPIDC[7W/V*=>_#IL@DA;
M  *5U I8#1?8 2%:2"7^&C1O*371G5_5WTRUROT>"]@Q\K"#$(V',XR)BXMG*
M;R1[8B1SC2PCKY',2?(C>>#D#K3P6\F?6,DG5N9>*[ES\*L'EY-/+O#^+PF=
M=T.!GTP_$:ABYU;:?W.,CBWK)=;O[BZ^5:W,=IZ;3%ET^ 2_,3\UK4![)M6K
M-N_RR)@$92Z:J1NK5;,=%P2.4D]S->>V_]B%9-VUFXXMO?P/4$L#!!0    (
M ""!FTC>0? !Z $  "8%   9    >&PO=V]R:W-H965T9 V@T#NCK3QYM5+=$6.9U\"(W/ .6KU3Q%IPGM%FQ9>!)(]8T3\.P/EP\G;>K? :U/5R@1P
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MHT<\^_\8B,K>2XERWK?*G?$4G:[^<*M#5_HSM8ZT=K6E HE9G&>B[E_4$L#!!0 
M   ( ""!FTA_*4("KP0  ,4:   9    >&PO=V]R:W-H965TUG]JB^<-\:?/"OJU\6E:6Y+RZH/%YZGM5G>>-'^
M,2SK%-J6_X]BGZWV06*QP_U
M;9]NV_V/M.91F?UW/3:7MK?VPCCR4_J9-3_+^XZ/.;B=X*',ZOZ_0,< ^@QXMH,'L#& ?0W
M!6\,\'0#_#' UPT(QH! -R < \))@#7,7S_[<=JDZU55WHUJ6+*WM*L,L@S;
M]74PVBFO%]U/_:+JB/7J:^T&[LKZZH0 LQD8VC.484@L(N1)6&T'GKV@\EYL
MJ-@"UD $" ?MPZQ(,B^R%1''09-]%QD/178BPGRT-WO ,!\?-::8.]8+L''N
M/%S 40@XO8 S"$PZ60PS,R!!C[P0$X4B (6FBT$Q@%S3P: $-A<(4B I5Y&4
M*R;%T*0&)!Q:L4T/30I @?$D183+@&RZG8[<]FPAGQ"OH9%Y#%LH67H33'(YB?74$CVU[8B-
M%TKJXHOY'6+$P=?';H+A7=L#BLHJ@RAW&P341B"14&P5W@C5<3VB\DW"YGUO
M9-37\@A2,N>#E,SZ)BU*O8^H')TX&G4Z0BIWF$?B>221(# =E9<35Z-,@:%2
M8J+>'$TPAL]HK*>6Z*EM(=9>Q"5E"C$7OW;N)AC#L3W$'%.RLR2J+081]QC4
MDU69RMJ)KU6H*BVT
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MFT@]K!U)%UH  *J) 0 4    >&PO+=?E/SRYJZK-
MTQ]_+.=WZ2HI._DF7<,W-WFQ2BKX9W'[8[DITF11WJ5IM5K^V.]VQS^NDFS]
M)-JNLS]OT_-\NZ[^X]^6_WN>3[?KM)U%27K1?1B76750W2Q
MYC:S?!V=1N5=4J3E;W^L?O?;'_$=?F\^/ZEV<;_+(?_E*/YRP\GG\YNRZK(IE7_ZOQS0\/F[3^9:][^GMO'/#T@MYX
MN4QNZ]_>),O2:T;W<9D668X#7$3/D\I[3LW_?_S=W[5.\F56SI-E],]I4D0O
MX4-OF>M/2K_!9W_?KW\BZ_<^OW5Q'EV\/6]HX!Q&
M4$#O%[#7GZ-_2A_JSYUOBZ(^GZ:U.3WMSD[[PX:N7F;+M(C.X;W;O/#Z>9T4
MMVET-I^G\!0\L^#GFX:=KU9 ,E=5/O\YCJZ(CJ-WVZJL@-BSM;?EY_FZS)?9
M@AJ^JN 7+GT9Y3?1NPWV!P18PHGX>/4\.CXZD9,19>OHPUV^+:'1,HZ.\-]O
MLN42'Z[W,-CCU$SI8(SJ7[Y//Z7K;5H^K7]Q6>2+[;RJ?WR5%I^R>4KG.J_N
M_$52#?JK4/*SU9Y465_X0,)#V9K6-#;['H)O95E6GE-OBKRLHQ@H#>9
M-TY9V?5ME'X&AE8&^GN?ED!0\SN:RP)&ML4:1D?2A:K;$U'H\H^>80*W58%K.RV4(TNX*D22&M;I-'\#FG1FZH_G?H3
M%^MYODJCFR)?1;DF*_^I*@7BJF!Q\?'&KZ47CV^DU_@=#F2;E7?$0I:P"=YP
MD3*DC^A8&CN)HW7JK:Z,^SH%9IRJ5ZKDLS]#V.A/68G$ 8^V/ODV;9J@^2:"
M-8KF?)3IQ'GT\2PIL[FW MER6_EG[(]I=GN'YSOY!$L/S&2]75U#!T#&$R05N?DFR9P+$_A2Y/RP3.?YE"KUF5!4XQDUK+,L5P4E4XA-PE/#74:\SI/'"'WU:%1@W_%^DS/7+
M['.TXNLFQ>LF>D-,5(EE_&JW,SO@5;F;OMW>PN?/0<3Y1 QYCSV=.UV&.)P[
MJ#"S^<)C?@=$ E+/WL=\C\6RUB#Z_1:.XLT#W4%E]!-2!RQ,8$6<63Q+
M@$[A^K]"7:#Q*($O+XCO=Y8U+R#3W'/](_;V$&2US&X+V:S7&4
M^*@G7IQ?CEYMTCDNV],3&
MBS5(,E5>9/X-]#R]26%:"^N::A!B+HMTDV2+'3N&AK_D%<@
MD[0_ ]^+;;IHE+KT/HM4
MV[X!UM ]%<09IN;)\]&9%6AY%)2>KF%_1Z0.V#;P"+GYX.#I^
MF\/M,3ZIO846A:?E)IFG__!D(\?JR>\B7R !S0DE@+0H?_WEWXC:JH> !J)F
M5[*J!;=*MP<[5/OHZ[6H\IRZPMLHL2U
MM#P9=>-NMQMJNS\=QMU9CQ:F/^W'P]G([:V=;YPM%AGN)E &'NO3;'T*%W$&
ME!(@O^UJNR36NP Y8>XK.A] IBJWQ8.:2E+!7L']CE,8QH-!3T^@JMW4;9WE
M>UZ#3-]E<$/#SUHTQS+!7N^V74)?>%\Z8O'+; U-9F@*R)6H6V0G
M%1LJ.X;1+?+E,BE*TD9HH^IGRF_ 4"*UP-N[^S6FS+97W#-QZ#C=M_<;I/O.
M[A%J8G>,+X?(72A$O%SF]WO++N\N7[P_^W#Q]E5T=O[AX@\7'RY>7/D'6LF<
M)0KE0!8Y$!-_V@='44PY!=A.^UYRF<0R#/T!U@
MFTT\=3='U@(]9CL4>UK/T^ND1.D)3CT\P^)TP_,O/L]1=,+[YEHTF")EU@$3
MY3,<)?=)L=A'-/*W\!7HA4H>1N$]*S?J7,(N6@+(65!6$!G#VA9D-6N]&D 1
M/M48I%=06N2/ $0Z0X<+R3EWTL%YHN;??[DMCGE#W]@\OKG;0^>46
M[@^@$=R#C8B-KKP8L.[@D44-R3P4;4'Y0]$5SOT*_MB6:#%);D%-7(4D>Y!0
MYVFZ*%FA4SKZF6\F,&I[T\A+-BP"#Z$;!*4:9/'^Y0#-T;.K;06*4G0#0_8;
M31[TF3^;P^R*=#=IVBO2MOUZ([7C/VG[;"-[8@ZBZ,'#@4+@DST.=.+O[.EOSPI\#B_"E';?I'0]K
M:^9[M'6<)YOH3-,8_ E_W^(7<#)7V7857895 -R(C3-&O*>(?%! MVZP"!8(
MOZF(!ZXVR_PA3=57:-]I6%^BLVR=K6 0R%'OL^I.#&1D$,-[@R[$" BE6IK;
MK)7/>@1TPS).*P&]N+D!J97:_CPGABB&(F&.,)KYO@HY#F"1&FK?^\5&E3^&
MR^8V6Z]Q#LB"R&MUP-LI5*RTYI%FR#(XA^G!'G,K(-#>ZU=*1;G[*E_EM-H_1[M.)CG_]Y=_EDU]_
M^;^16./@0[01)>L'^/ DVG!':)*%LP*[=)=\0FM\NL:O0 :$;VRRQB:*K3!'
M_(?AN>SK561#"F1)QD\V6@IV0^
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MGMA(HD1 =X349P8?WP-'!SK,[]>HDFVO8(<]*,C>#
MOF:-M[1.9[K,X,Z@L3$1&D[$P^?CJU>M80+X)AXHO$>(7.C#LR#[.QU>
MH.-@*Y@KTB+O_XA/MXKFP
M#7-'JB.G& I,C1_%+NTC1729XWH!=<+@:$!RQB(*SBD8>37JTSV=7?P-.?X?90_"R)COK=;J<+DC,9;@P#-CJX]AM+4 EL
MRVV1K)C1E>DGBMA A;"-/_.M(1MFI@A*)(9L,$&AWQ$(91GU1S*)XQ)F2U;R
MX8E>ZY0.%6XN' 6^#9N6G*:1%]9%?\BB)\Q:UXLO6/Z.IU3B)?P'L@2^(?-;
M6$NW'GMNR63-PFY#NZ(W__C:XNSR_8(F\%XM#!P-JPTD ?Q.Y L6I6VV *JK
M*-'Z\MMLKY?9?/EP"B-]HV1!.#VN]".6**C8LO?D+T]0W6-PY]JGGJUH:CN
M^>$8VI;1.':XA98/9 .Y1F)&XB%U%JA@@Z2 ]_M=!FV#W #B +,-/#?HR@ *
MRS""BVV$\*$L07Z-=F\Z;=EZLZW"J]&7U6#1A,0Z&EI=7/I-^>7S-OWR!2.\
MU5SOMEAV3YFRE0UYV]M\_6=R
M]V>P&MK^>F[;>3'^A+2@Y^=:"8+SH\0KN/PMC@0'SVRAH0CF4@O4['#G=>B)
M8IYW#YMA=V1>BQ0%3-H\4.72!*C9FIIB:C ",3[#!9CAW8I-
MZ&Y5>]8R93[]JB.,3SNS57$EHD?!^.5@=X1#>?+GRN92#8M%7,IH0=?$I415
MXG-/<@7<1?D]G=FZURYZ:C,]^/J]%D@Q+#;Z6#+W8V&&+X):"[]G'G9),T=V
M=$:.2GP,5P17]X($$=PGF>NQ3/X$5MJ(_FQG?V=8P 6Q /5TWWWZXSIO>G)P
M(AT]C5ZP45_R\^+^J&*3FW..NA,Z#'U^^5N#H(13_BH
M^LTNRZ-H!$VH_H>=F?1OW5!/S;%RW"1Q%@TEG;'Z9B>PQ,@RHPD?5;S6R
MP;0S,DUV]=ADV_:^.(%%%"UW)][-"5_HE59#$(:
M B'J#SQ6@(\$3$1N]($M#MC&H[P6#"(3SWVS4HOS7=G*G,V CHSA;9X 33'-
MX5I)S!5=P; "Z>D")&[6$FA IZ#QK&% *V!J: ?*8!A90=>=A$9#ESD<<[ZH
MTP Y5O41Q<[-OR5?&EJKE /)D>K-U5W30Y A0FVF"S6!F$>#PHNYN24!T;%%]
M9 U$]$S<%Z,BSXT#=)X5\^U*^C5**.F4B6/\21:@1>'0Q7&P#F^(-5@VOR@[
M$AUZHPB+7':=XL8CY\,[J&,I%&14MWB7;6*_L$3I#W=-1D);X,8LIN6#NG^)
MT31[#P(*9BQ2A*-LXDZULX4X&(:[CV0?<%W&).1HT<4:I\2T27[#M2TPBER)
MAY-#0%V649[+M "
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M.1+^-JC%;M?<+9K"5VA$3\US:$,G(0.Z6;,,NPFF3,+I) I
MTY'C)8N5('*=HJT=1$*\$[3+AVS$RAM$ IDRO;N\@-U26W;!8 I3*1.TO&9J
MI9 CEJ3_H]O$< I^+R"KHKV'^&4%PM):DW#AKCU[-6PY?Y&6\R*[QOLD!7J3
MTZN-"GQE+K(2E*&'4@G6$7FE-1S_LZ'^3*P6VDN&J:E 
M_)CN2M^S;KT?@=M]RCH^C?Z8%S_#9.?(VW2K2N'OX6$_BL;TL]L9X$=C^/52
M$:V2=.>4,8LOX?]]>+X+2GX?_G_IK+L]3+65M[%H+GKXQ@:B?^+G=3M/T]GW_&]&&2\TJ5-,E&=<&%Z!K
M->9!IX=+2(:<+OV-]J;=JX!S5>2!_^._K\BKA=WJ0+GC/E#7"?X:XJ\>_\*.
MX->XTX=?/&O]AFH0'L)OK3];[8I'9&K#.4P<6Q3.9Q#?&K\Z>!PD-XH %
MO6,N4URD4V[IHK*:P0F4G!7/5QD-!Z/>
M*M5DF=X:(&(:H65_FGD)/U
M>;*^WA8/%-RVQMMVOF65'39[>9T7^?;VKF&5,^^B+!I2[..HI !;\D>J@:FE
M]5/H,?Q6*,8;_74.4[7&QIR:)\$+3J[_3-G_=9 "QRR@- @KSYH7FWG8X(C*
M[@*N/:17ML?(>I@P+V@-K8FQ,65*S"?HK&A$W62M(8HA[ T+-V.^3N[.H^&_6[T
MXG-&9BV.QH=6B3F^L]2<8WGTI!.]T)-A15CT6TJ/6%F+M3#!-3 <:Z\L.4,-
M"ENZ3CFP111;(! 09AXB((="M GI2>A*VNG4S-GR^E&W;G%%MJ4^P/.N^2G%
M8:GE5B.29=_?NUZWS3IBDQ"4.U83(T(]<<)5^Z@4@7EJXD1/K6/SWG:J<37?
MVV2-LCE'(;.^6&*^RX*&3DS9F(O9'1J6Y$5N5Q8&4LK7ZGO#'C3BADB^DSZI]H]9,R[:.:RSLDS*!P'XG
MPE%2VUI4/WR37C]VW+6GY*[1( *(*<"CM#$%Y#C"RR=\]-4Y9G<_W3X\(K+':1#K(>(]?(,;U;[14QK';B62PS
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M[M)U=-D!XIMC5FU"-FG,:*&[-L;9I#<@3:JVWQ%+*,12M(!;;5[E1SCW_(]FA1T,68&/
M<:"6UG*7N_?"=6JD_.OT(1?R5;EN(,&@[*5E_=@(L,Y8/1G?F.953+E8%,D^
MG%J;I_EDC=\&M#EKK9K8Y-CBBFU@I[/QM\YQFP46?)E
M]T_#NNYQ>W:&==%RUG _2>"BDJN3TE+QW7NW8UM!2Y4)=< 9-@T34Y:\9*2 
M-^\OHFLVQLSS;%DJ>TZTQ) 5-SR0<#7PE"V46HTS'EG"M"OF)LLR-]G=BDU8
MBK/6CF!?R"(BH>DU4:/R;%&T@VH6@FWTH"Q$U]N'M%!QEI2/9W0O)!@BE(6=
M*;._10_A$C@NB4)-Z CH$'RF1\IDEAEH^AR45%O1(S1CJ]63*U(K(,V#
MPJE24!(>$J9^!D3!2RJ,=EX79@W*X5T4>)L&(^H);=$*
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M&S;?6==A7>X8]"S!XW Z:5U76JE)7"'\
MJ]\2J'X# DJG/P*.[CR!$:[TWC$.^-=?_MUKA" Q5A+RNH[^<0L;V:,44GB0
ME:&D,&="HD@+27"7/A&2#2-T8AUW6Z:K[#192U02-@QR/LX(%A);E7[T*>&W
M$N!S'H>T7U3T?-^OFR#@)5^AGI!P;1&P!G4&:Q#5PTN;8.QTQ)
MDO-B8L[U\T<4I:O:.XDH-[=!+]5 .XRGX&\K4D$FGFR2;:H]+!;CB%%RMG2!
MN+).+.Q#ST<%!7#E2!Q2QGS8C23$)XK;1CL%&<%;-DDW0,>=!
MD?&+LB7-8&K!"CB)!4.,)!ROI(Z6 EC3H$;UU?/7'=8BQ@D9_A#K:A4J[$4E:]9UQ,1!F/+D+C?BEIQ_"''
M*>L_-H@A:)G=NL;EB=S-UAMX/6P JR6*CQ 
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M)X9KP];F:KI^C4J/!M/69Q5]<-;G%RVJ^CPOLEL,3[42X=5ZWR=6@K=V9
_82QCI+&&B7M;BI/9\)1VHFO'\C 8]>KC*ZRS^X'1I4T
MQI[09_6*D:[1%]..$+!G1B[5'OJ.X=<$/O/?DU4S$-E\G>"-BS8B3+S#Q(!+
MHP)H$Q]&; ZABRFTCU;.QIH+F(S7CWK V*(^6B/[8TKGZW9_T*F0^I5C;.$$
M>26T/8TPW&5&^6$P#4GBP]E $_@O4%-ZD:Y!\-Z@,ERY^(>7@G_XK@Y7V*)4
M?0W.(MF]GX0'\>3DT6$8.]%'38CDXM'95<$1N).VFW?&;;PNR3M<8MUG=47080_ 8=E_O(<-PTCF5 Z-,M9U1%0U,
M1^R/-7_6ZXMG[]ZS2Z-FJEXEQ2V?1= #6294)DQMW6>3JWUG!DJMU9#2?V/C
M *0+%_>7SMZRANCM,3J=+6<'Y>PQ.+RD[:-WP,!J!A$5"!XF98/]B_!4(E"A
M'9)C]N0#S,(3'% Z?(06CL1WBWD8&HH*^VU =A.J:F=C;/^4QH7$\[+NR(@U
MXK3Q;%E63KS9@]#J@HR-"T?W@+LG[@M>2)Y=#Y-*VOD5I^Q'6HK$&]1!&X0*
M!XB5-9%@+% -.Z3O XBIT3.0$']N:;0T(I9R
MKX'*_C/Z%[)2VP,IK +OAFM4^,BNY^;4H>4D7V5SRT/ATB)G!G":%?6)\T(;
M,19WLI/[=' 7#D-QR6TIX:8^9),-9Z&7-XCCY0YHD:>,?T91R]8B4L@VT*H*
MZ11ZE6CVQ.Z&3/&9 T3*QUFKP%1/-[9!T\(:B]6H0H02R.>,9*G6DGNJ@O83
MK&(+$I.Q#RHODHTD7%IZ-P*HW %=4);7D/T>% OEBLS:FM2^73!MC&#I6RJR61!^';.+ED&4
M0\/\Z_CMYI8/0;8+O!S*34AXCOH2 (\FRP(S)_$\9B"5!50?.^2;9"U))K3"
MOW?1@Z H4*LREQ 9"&@KAY(KB;R-RD2(*8S))C!1E4\DZ41W0$#  %KY7)BQ
MU>X(P]=9DK/OB:2L\WD'1$Q9H.0C>U7U!(R#;\VA1PJ=+;^Q_(CBTD"+R"EA
M+*D\**8W15;FPDH,;7E78NM#Y@;
MNF?J-L,VAE1#@Z#T6;HVQ&3,]R&/S N0&%N>Y<"0=PU3'W<04JO[=(F)H+2J
M=:X;1N#U"0%YZZ"^\&,[6O#+0([95:*=X41D)-KN73J=OK!KDQ^&A%S'(T3\
M\']OJ'"!U=CX.D,&H$C!AD8U]3,Z&AS\I:"6GBO4TG,-->H0R+KBS$?!'MK=A$Q&;F8H&V:-?8%WF !.?;M"98>+K1F@?#
MW)J67L)UI>@&1-W$5,'B/DDUI9U$,&EJAC!5N8:QCHPKN]W[>+/
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M02-/HB1IFTUKE LSN!-SK#7'I_O47SED)CT:4:!"S+<8F%1-JMP_XZ
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MB%<4TTT5^O:+L#7.V;U6@ '2&E9@&G?'O7B *_ ,[3&ZSS(J,?R  ,]6"0?R22'U
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MAX/EG+;:#)RQFL'%%NEV;*=7PYKIJW +'T
M2F,8I 4''F.<8-89QG_^QCG%=.Q8A%%'"Q]:6K>FZ,#\"E)?)W3ZJ#@K[;OE
M5=(CRXWN*QOZ0?M5SN@M8)"P(WQ6Y.KK=T5]==--G%/!3Z=520Z!$0>TC
MX^5)*CG:EED5^S*ZO RH9(<,=/]!J![NX>K@M8 A,37$G>&4HB#YQ#DB_S
MVP=)?Q7O^MD&=PN7\CJ/^D+C]-%/EW_@=VES?MR;=NDT
ML>@_CNW=_492EKL9N[? O_269-/(.L-
MNDJ H&U,5FR4QHDNI80C!E7A_ W!YCI)%LAT@0);'"$R;7;Y_MVS%W%T>7;^
M@OJ'K^?+%%1')K-'G 2-EFX(==\(PX6U4HNGN++0(UK>C>&"RM*K 2'YR168
M4-EF&) X5Q2,S$3L(A0966Q=SB]@NI5;$ -IL]RN5D@I?]HNJ&:)OJA5>.M=
MBA>-]E PO@BG4?ZWOB0T'Q$1=N0PDL3)F/F/92O60+1/*L!60EQ%:F=B+;0D
MEN =.1&72?$I__&G,\6".6$B3VX5@. _CWFQBE"'4TDLXP;WA6&=6
MYC6=%QV%M^ 8!8OR!TH:_0FO;5@LH?V:@F5'-QK@=L7N)D:^K(R8^M^<>7QP
M!Y5(SK)4)T7_ME3CIMA[08'2<*[J7I"X;;SU=7:@%RU@QW(W%GI%7??S'"Y5
MX38YX=FS/=#4#N08E8%VI\BOJ,?]Y=89(<,8-XZQ0Y8:*D<[JCHE:<*^N4'E_E]),*5>X
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M$M31=TZ!^2Z8@[N05&-+T9? ^N%J3BQ,%>_E9#%7V[5/!GU+7"8(X4!K,"
ML!)4*RL"IC_MQ\/)$'YWX\%@2O^>]$<@WL_B47<4_;&I*<;9 X[T"4L$5A(/
M"5QHNR(W?%K,,[Z*!39K8Y*I^!.L/)J L_A],A?#*8C4"#X$TX:%4F\70TH=\CT$S[
MTUD\Z^$JC>(!#.Z/=9!K1.,_I=U&+5A:-";[I]$[JW5W07IQKSN&G]/Q*)KU
M9C#]:7\(2I%9HAY."![ISJ+9P)%E4).VQ^TMCHGA-.'V*I"&H\X<5#*UE)0$
MG J^64:(,Y5W'?$$8LPN026<9J9ATVPRB3EH5XY]+7V=A8K:4^JMW--50>'*#[)C*Q"&/E],Q.'U&
M8SJW"G]Y2:(F/D 2)]23VM&/(@^LHR#TKSXXX08&QH%RHO
M>LN\TZHO2SH;@AHWZPPG AH][@S[(?1#6 CR.ML@XFK<]M$/E(?@P- =(V'!
M==B!"] #:T;M'1AYOF(OYB)=$OBRMA)HI<;!E776EMOTQD BA,QBB_F>?V$V
MR@T)YW5%"LR+76. C14D6PL^>]PC]#XK?SZ]P?;<.$",??LAP@*S/SA_OU#&
M92N'=8!"[ _18$K/N?_2SR_1^W8,4\)D!9!DDJ"&N?
M"_S?D]YJFH LH#H6<'YZN-M'B-$S& O.#H,'C49[GJ2AA0C%IMO4E?B.WU]]
MA*G\+4X6C9*Q/,W,]0$;#_0!&XP(/QX'6#]HS6'EZOS9\(9;LB? %'"2SBEL
M.G/!,?+1@U6?ZG&UH*>HS; A_W!F=O( -$.&0PJAMG?C\AOL!J:VD,ZN(71+
MQD&WZB=6*6(/.>C2!ZP-;-^DK[?/6J;Z]KU@.05DPTSB67#"Y/%99K>9MHIR
M(K:":OM+6N0BCQD \0KUS\HJMVC$W?J5[FA)*NMT+3B1R#?H/)OZ9?7W5+8A2*L<\8?0VFT0*\H:9;S.[1I+CP3JXK_92RO@#BR;^%PUYFJ#+UJ
MZMZ2<-8$RN@X:B#=&SDP9/9U\WOV:RRA\"JQ(\)W) R@J\8^"-2CJ5:&-FX*
M,VX5Q62")FA&CTZ/+./L-#+/-W$"S.GL3^K%GV<3^W*^H7AF'#>JH9^M\2\X>T2]+B21"
MIZ,48H5UV(+^5[ \2"%*-#:\3^ZUDPBUM]F4M!WX-8C^F!<_(THE^:;*
M,AJAE#B: A-ZB0H7(KS?YI@$VQN@TM/KLR&]/QW);RST=UF@"PFQJ[ ,/+M$
M\%I@[>^%_HLX4GY3H4\>M:[)A) F!V/<)O,8.WC,8Y( J
M^3W;9AR?1Y$97!F=G^I-,W8N[W2DHP;,IBNVO<>5^_>5?'6"B!0+JSC.30>!4
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M(QZ"(#YR.=,,'*3&JZ(^&CJ!I?>!C2,,\9A,I>/9@(RE
M8^KB"$OC3JQRCY$GY4)R/ F-:1F0&^@J3!2,]W9[H2H<9C4$$:)
M B9+0LYT>NA%QZMG@$;7'NH=];E@CB9>HD.RV])H!WS_][HSZKH_[K,JA4]+R)H,41(9UAC CV/.H%
M=L5%I";+;V\H -=CMOWV9S00K" \UDHSG=H%ESJO3X#LSF0"(S(;\NN85^T.
M'Y&K\5' A]'E 4[;(]Z2<
M,_QJE!)]/N)17#SK<;O#N#L:>4=GBB9 ^(FS<^DK'A-X./P>H=SD'11<[SZ2
MKIG3K(^;U(M[/3XFD[@_'1/%3^+Q!-?!Y8Z8>*L%15'\M3R HJOM6.JQ9<8!
MB_T&3- >H0#'EKZ1>97\">ZN6R-6);BJR"JQ=(>V2G/< ]Z3!)5$@T7[5H)\
ME:4/KGREA&559::LS)+3
MRP3CQN>[.CL'V2^)#>X%]?:/"33*'?SZR[^?J2N6T*84U #'X$B]S/-DG2R@
MF=EL.5WM.;"7=:5
M,O5PFNIEZF-.1Y']Z(/0(,^"^.$_JT8 N\:U A86*H@V1!-"*"X70S'3"[*(
M+05A8TOG=*:-D\",8.O60*35+>A*#^8I P.W8'Q1A;5O4"%@GV\RSLN5]N1E
MZ1L8=&JG#9"X:("^87VW*G=XG=YD GI:]P.8$D:4R$PGMA9&@]<$Y38%(A)QL05#DHZ+1)'*NC^D0UB
M'6C-0?M7> >5H$MJW*,UE5G6_]1U*5GP.D 3MWVE/\WC.]
M7QA[#4-PU1]XI6Q=V)OW]+XB0?VUB[J92$,VZUI^6K9'Q!_,!>&RP,%P /XP
M$*G.L?3G*L:9H^//+*NR4X/IL*>?3J=L-('/^FS#B/NS&;1ZL4?1RYH;4,'NJ'0YE#66" .UY7PDLAP2
MZS@:.B72 Z7(X/5%8(?X+%K%^+3+*F0 #CNPB'>AG*=(E8*.MW/)1K(%-R_:
M_#WUM^"5>&G5T$9# TKYYC,R-XS10&0^(__.:.0\1[6W@-)FYK,^&A@&@WYG
M5C^+EWSO17\$*L>H:5_@?P4[A?$LK7XTOYE(?73/'SVH>_7!*[ZF+B/@M\_2
MVVQ-RX^1(2SL7YJBN%?ZZBQ_C,XLT[G5Q N.ZY"7ZWK<4S_W9436G0D1\/% 
M9(\E>JGCH),V*5.&
M/!ZE$#%@\\&6MUOAP0*=<88(@56W1Q:,
M3Z)=0\"V0LAWI22>9G])K0@3D@UL#Z/"5H7#
MX>!<<.T/Z*1?:M=T(-'M$@<'WUXNL?C73UPLQ:O34XIQ_YMW8,ZS.J&87S93
MX(1=@U+(F6+Z_!WW1_H[/&$G@J/I/JN>8!?ON\ FJ92N)=&5%.(TF/ES@3PZ
M[A&"XG&7T!+Q=A5,Q6,\@^A&9F\R/T;?,\+B\92Z/EOIHEQ&$J20(0D?9\\8
MC<6-EI[0_]3B1#>.89S'8_KG"]9-K>7K]P3_3R?JF249JC_Z,P4)>$!(X9HSD@53/M78.
MVK/HW^/3[BQVJ (M$:BW!P-'TK*#'E#D*311L0E68^_93*FK8=+)*/F>K
M[2J2B( HW^C2=O@D9M3HKQ4N4E5DM[TDOL5.;CCKF  >+$4HX?$+R!RD53QK(5+BQ%EJ3$0
MM-%9U_@@DE*-P;_%3H6G3-<:LUUK!JX!-BO3GO1FN 8#&[G'R>['' M7JN,[
M'?9/:G2M#4QZ;]WCE7 ]LM/\YG1;VF%&2;2DFJN&<'#+/F4%JL,<&:,B2I<\
M""YVI0IO63['OBZ8(T#&G,2P,N5@Q)KD6O8TFC][LE3FV(Y0L B6K*A:-NY,=>:#RWL
M>[I68=F"]ZJV1
M<0VKX512S,J,)JF^
M832:P%%8URH;,017LN:UU? W/Z_S^[4+,8LQ)M?H[!' _,RB$LZI(:0@.5^U
M),LZ>7$A='E;L3G#R6QWB!VS:_@:QG_S
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MA>1NO)'.1+:%M3]7A9Y)IWV5"ZH3O+_6,3'8A;GH[93Z7. ^)7F+\Q8([3DUTN!
M#D5^L>I8:0^FJB>B**NJ0.YBZO[6AG#9.B%JFZH?-#?M^@_A_<*IMA(K&1ZR
M0'4#HYO%=6GMD\J&H7A5%K"7B=9T#3=>V(@@H-WI0,7K!WT_".Q/35_3'%6"
MIU@=S6ZI2([;@7M"G=O C80V
M>\8F]]!2US-GZ;!3X;*@_$]:@G:0$"/I>
M99ZHL*3]MLON4];Q*8'04 E!6!7=JCI5O2X%-(WI9Y<"7'L8Y_I28TJ(XLRV
M-A7T@SG+7<(='3N=.D@5>BMKG4VELQFG4\^NOC6;?W
M9-=:\/0-GU$_\7.[G:;IM;R_]\E1-;/W.4'1Y]7R:0GR1/H/3S:2C_3D=W\+
M,G0/3GC,[IT:K!C R\/I$ QWR\"Q(X)&VK7@N-QV"!K^^PH]A-2M#F\Z[E.D
MW'%?!6\..<83XR$EO))GK=]0#1YW3: G_]DJ)ZA*[UWY.=,S''4&'@107A3$
M^*0L,KI;JNC,"EQHYKK:BF :"?%6^Z:Y-MVU)=4T81B@VO,T^@#B?O0Z!PWL"!.=)_QKC-IROD1\M=X$<8KYIW\+CI W](88?"M8
M90W]XYIW)X+!@ &MK_/U[2D:=+]@J+UX,$9:A-\S1-[H=_M]6 ?"R.1QS:;8
MUVR*8"?^J"=#C-V=CC%XD8>];!P-Y?]T9\P#!S$"8G3EI>"CPR[+5(-X/("Q
M!9*I6+1[(2DJK/CNE%;T>ZGSGEC?:_.K9VP\9L*\DT15WR0Z08QXRV@B5&&D
MA\!F_GLB5HJV1';,D@1"&YQDAM*\ !GAE4\^38+-QLC>*;2/^#1O%5!45E\F
M2M#O$:X(1FD3O EW:\#;(A#(M6]XUDO^Z5S'?(L/Z%
MAA6UY'4@\V)QD*$Y-)![+;;"E:A_4]K:C-&6,WN.F Z)>8O45E;4@];R0*)F
MF-D_K67/OA9,$"^[P[_WE.9F+90]1@6(P;:2A'$:;W =[C!H_6E C[-P^RZ+
ME$ 6=92>B2'16;"\*^J*PNNJMR9226I
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MJG(>W?1B&OV#NJ;-%>U6\7MH)\3O)?K^]B7Z#JC:5O]9:UK5
M]TT3\YD0\YE50^FC54-)6#]1YKM-(PU\K_/T_W.=IT-+%C2QJ5WO69D,/@I,
M@[_A/T-YA"^8IRFH<*E!QW5]A "TS??J"_^)JB\TW\,"C[Y'I8;O".K?$=2_
M(ZA_1U!_? 1U7Q\V&-6*GWFFC^] UM\,R+J.--EX>5@FVYT@F-_A*O_;PU6V
MT8<)$7165-3]]K# [_B2C4>P]JC')?\_ I3\,J3&?1V)>[# OX%/\CL*XW<4
MQN\HC*''OZ,P?D=A_"^"PLB^7S*I63@-9U(6G6"=+,/-\#EWS"R
ML2==O\&"&XK[?KQZ'AT?^7?5]KI,_[PE"QPG0S='J EJ8XFN^33CG!J)[6?B
M_$O05M24-W4:?56&E%J%$VA()M>^'!(SUI!99>/([$B>:HP E;/GA"CQS-SX
MO7H#=L!5RW=?,T8OQ:EQ$L',)F]/A6V]4%FI*C\Z^INX/#*.)K>SN9_M/;3!P[;ST-8/W[Y#>_BJ[6K- _WB%P_=IEV-??D6[6KY
MZ[9G5^L';TVS2- N\>Q]UYL.XNC=S^Y# U?6^GT@3GK'WCC.^E
M0S+WWX']\W;-KK3N1:A!V)0&R-*VU7_1E!1GF]+#K&^
MJ5)8BR:F$THJ]2DWE$^[UQ0:AMR0-+MK9A0HZDSO*OO,TWN>H['8FUZ]A5"6
MJ7KWT*4[L.W''+Q)AWVT,=M-/N90AX\_U.&C#G57\O!7#GMW\U\[A2]@AZWY
MVC9;=!_8DTV&UFL'KY2!?J0K^\5GN)#?%2@M,%@KVMW:&] \%I.\5<:!7^J+
M_2 &/D>$E(;G,$JNX8D@2?PUN)Z';6U#PX%S>O";PP/?W$&YK:WH:3;)NE[&
M>S@6KNG;ULX>?R,"/1RZ(ZU-[+NL7QM\)HMU.>].$'LF/5QIKQ4QE'J:1#IX@8K8>_'V%FP8X:*BQZ;
M"%S\YZY;85=GYGSL*1J1(LL%Z6&UON3Z5S@CWE H7Z4E1T GA/(*^U+PSL';
M!T$18=,4WFXIT 143,214ZEL=H*%P7\Y%WDU.(@]L"Q.K10PZ_%#CP%C4&M=
MJ5W=/0BSPE>6ZPKC9?* -@0-AK'S#8\#[<"$"#^_\RF-7]&TSX=B8@0"TQBT
MHZD# LK@16IZ9"\2V1?%XLO(AILI=UM)&C;>\[VT05;L?CB,4^&'NW@P%=[J
MM^%.[)Y=?=&#S3>'W(__JA2P%JW>@YWX3!\%_*7#1?E/VZ7
MG0C+T82NV&8HD*05N83CX?;;:VLI-%R/JD(1\%ZV.RYKG#)V A!AF']0L*3D
M]PO"-GH)+$Z^#3 /:X/M-#^#(;/+8MCO]*8>;?4[XW[@P^XX\.'$)TVQ,JZQ
M>*R;( 2B'87'U=\8=?HCKYEQZ,,W4NRMBL$EK%C!^S<=R
M3BHNO5EZE WG!@W--XQ7(\?3+W#A387!>.'9#W<9R)R7"98>#\I$=4D%&,C<
MVO(7&M/6<< '*+SG+;X=H8@6",,V+A$O!1--.2\@5AX>E+WRM824V)07(AR]
M'A\0%P,1KJD$NT#.8N1KK=&O. 5OI#SB5QT,+<=2<# CNSX$3.+1(O#Q(8.M
MG?XO&NQ@CV&T- _3T:"?N:TOL.=I?")=C&KMYB,AP3Z@J[3M&8]>>QKPL8[L7Q6+C!7
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MC]&*KF0H
M+?_B.A!!RR.Z@X&SO!-G&=M:<8,.!M3ZL@80(X?_#"#!P863D3.O94T;P;-.
MHT?#U3K8:4"D*PA;3L^6!1NM6O9S2I@Y8R%N5S"F!8ZUVT=JQ:\=L'Y?:E_'
MQ']@.[[!/=ZQ:M99(JP<_[YP@8]VDIP^J53OJG6;[!#>V#G6^W"0AAYML*:6
M5O">U*)W")%M9[=2Q(3+[9EJ&#:$4!E_N=T.CX
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M\OHH>[[0H#'WO VPX?8\2Z*%N.1H:FP$+](3PT* '07$]M,2#T.Q4'0^,BSG\
M!C&N!5/0NDH^![64_BA$#?U>: G[01I!O-!@W&8-"O$T:@4]/#QY.4,J/WT-
MLUL$FFL[-B'H0F_#&Y ,?>[H QOZB[$3O[#EBFR$+_3%>XU8V,C#%%#AH?O5
M#D*XI_>M"1UP]V"^#N+G OJ\87)9-I!+DZ(5 !0\C>K0@0?3[AL1A?&9*U7:
MGD3^SU5*"%OU+F(NJ"$Z+O]ULB-UKAV7,#!3@2GTY8\P:F%+?PZ(X1YK^GBA
M ;6=T6@W[3;RGR[>GH4YP&.A(!X*PW08(F++W':_+6$!]0B&,@Y%"K1!L?D&
M/\9@VS\8QX]&^;$LJ]_]/U!+ 0(4 Q0    ( ""!FTB8,EJF)0(  ,\I   3
M              "  0    !;0V]N=&5N=%]4>7!E&UL4$L! A0#%   
M  @ ((&;2$AU!>[%    *P(   L              ( !5@(  %]R96QS+RYR
M96QS4$L! A0#%     @ ((&;2+ $-*=+ @  +RH  !H              ( !
M1 ,  'AL+U]R96QS+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4
M Q0    ( ""!FTBWB7<(; (  ((,   -              "  5H1  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ ((&;2!<:Y:MK!0  :18   \         
M     ( !\1,  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;
M2-C&GI\& P  +@P  !@              ( !DR$  'AL+W=OR=%^]0$  &@%   8        
M      "  <\D  !X;"]W;W)K&PO=V]R:W-H
M965T&UL4$L! A0#%     @ ((&;2$3!UC0Q @  F0<  !@ 
M             ( !=2L  'AL+W=O&PO=V]R:W-H965T&UL
M4$L! A0#%     @ ((&;2+/D)D"@ 0  L0,  !@              ( !&S4 
M 'AL+W=O&UL4$L! A0#%     @ ((&;2$C6V%NA 0  L0,  !D             
M ( !RC@  'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#
M%     @ ((&;2$*&"MZB 0  L0,  !D              ( !5CX  'AL+W=O
M&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;2),Y
M:0.D 0  L0,  !D              ( !X4,  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;2"^\"GNB 0  L0,  !D 
M             ( !;4D  'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#%     @ ((&;2+UX-R*D 0  L0,  !D              ( !
M^$X  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%   
M  @ ((&;2([O6PZQ 0  %@0  !D              ( !E%0  'AL+W=O&UL4$L! A0#%     @ ((&;2-D?&0RE
M 0  L0,  !D              ( !5EH  'AL+W=O&PO=V]R:W-H965T  !X;"]W;W)K&UL4$L! A0#%     @ ((&;2)Z>T52P 0  %@0  !D     
M         ( !]5\  'AL+W=O&PO=V]R
M:W-H965T&UL
M4$L! A0#%     @ ((&;2"68D2"D 0  L0,  !D              ( !JF4 
M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ 
M((&;2"-/1],S!   TQH  !D              ( !'6L  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;2/O8C-WL P  
MY14  !D              ( !S7,  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;2*>=%(.) @  P D  !D         
M     ( !L'\  'AL+W=O&PO=V]R:W-H
M965T&UL4$L!
M A0#%     @ ((&;2$_?-)@X @  +0@  !D              ( !KXL  'AL
M+W=OC@  >&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;
M2%.VD4NX @  ZPD  !D              ( !=I(  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;2%,=HR'? 0  Y 0 
M !D              ( !4ID  'AL+W=O&PO=V]R:W-H965T  !X;"]W;W)K&UL4$L! A0#%     @ ((&;2$5F#Q$* P  T P  !D             
M ( !B*$  'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#
M%     @ ((&;2,-'CX'K 0  8@4  !D              ( !N*D  'AL+W=O
M&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;2'*)
M]@U_!0  ^AT  !D              ( !&+$  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ((&;2)C%T8S3 @  ;0P  !D 
M             ( !P[L  'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#%     @ ((&;2."T$3 - @  W@4  !D              ( !
MP,(  'AL+W=O@!   F!0  &0              @ $$Q0  >&PO=V]R:W-H965T&UL4$L! A0#%   
M  @ ((&;2#VL'4D76@  JHD! !0              ( !"
&UL4$L%!@    !/ $\ FQ4  %(F 0    $!
 
end
IDEA: XBRL DOCUMENT 
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){	
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}
		
	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};
	
Show.toggleNext = function( link ){
	var ref = link;
	
	do{
		ref = ref.nextSibling;	
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';
			
		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
IDEA: XBRL DOCUMENT 
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em; 
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
IDEA: XBRL DOCUMENT 


  3.4.0.3
  
  html
  267
  278
  1
  false
  74
  0
  false
  6
  
    
      false
      false
      R1.htm
      0001000 - Document - Document and Entity Information
      Sheet
      http://www.hologic.com/role/DocumentAndEntityInformation
      Document and Entity Information
      Cover
      1
    
    
      false
      false
      R2.htm
      1001000 - Statement - Consolidated Statements of Operations
      Sheet
      http://www.hologic.com/role/ConsolidatedStatementsOfOperations
      Consolidated Statements of Operations
      Statements
      2
    
    
      false
      false
      R3.htm
      1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss)
      Sheet
      http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss
      Consolidated Statements of Comprehensive Income (Loss)
      Statements
      3
    
    
      false
      false
      R4.htm
      1002501 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)
      Sheet
      http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical
      Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)
      Statements
      4
    
    
      false
      false
      R5.htm
      1003000 - Statement - Consolidated Balance Sheets
      Sheet
      http://www.hologic.com/role/ConsolidatedBalanceSheets
      Consolidated Balance Sheets
      Statements
      5
    
    
      false
      false
      R6.htm
      1003501 - Statement - Consolidated Balance Sheets (Parenthetical)
      Sheet
      http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical
      Consolidated Balance Sheets (Parenthetical)
      Statements
      6
    
    
      false
      false
      R7.htm
      1004000 - Statement - Consolidated Statements of Cash Flows
      Sheet
      http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows
      Consolidated Statements of Cash Flows
      Statements
      7
    
    
      false
      false
      R8.htm
      2101100 - Disclosure - Basis of Presentation
      Sheet
      http://www.hologic.com/role/BasisOfPresentation
      Basis of Presentation
      Notes
      8
    
    
      false
      false
      R9.htm
      2102100 - Disclosure - Fair Value Measurements
      Sheet
      http://www.hologic.com/role/FairValueMeasurements
      Fair Value Measurements
      Notes
      9
    
    
      false
      false
      R10.htm
      2103100 - Disclosure - Restructuring and Divestiture Charges
      Sheet
      http://www.hologic.com/role/RestructuringAndDivestitureCharges
      Restructuring and Divestiture Charges
      Notes
      10
    
    
      false
      false
      R11.htm
      2104100 - Disclosure - Borrowings and Credit Arrangements
      Sheet
      http://www.hologic.com/role/BorrowingsAndCreditArrangements
      Borrowings and Credit Arrangements
      Notes
      11
    
    
      false
      false
      R12.htm
      2105100 - Disclosure - Derivatives (Notes)
      Notes
      http://www.hologic.com/role/DerivativesNotes
      Derivatives (Notes)
      Notes
      12
    
    
      false
      false
      R13.htm
      2107100 - Disclosure - Commitments and Contingencies
      Sheet
      http://www.hologic.com/role/CommitmentsAndContingencies
      Commitments and Contingencies
      Notes
      13
    
    
      false
      false
      R14.htm
      2108100 - Disclosure - Marketable Securities
      Sheet
      http://www.hologic.com/role/MarketableSecurities
      Marketable Securities
      Notes
      14
    
    
      false
      false
      R15.htm
      2109100 - Disclosure - Net Income (Loss) Per Share
      Sheet
      http://www.hologic.com/role/NetIncomeLossPerShare
      Net Income (Loss) Per Share
      Notes
      15
    
    
      false
      false
      R16.htm
      2110100 - Disclosure - Stock-Based Compensation
      Sheet
      http://www.hologic.com/role/StockBasedCompensation
      Stock-Based Compensation
      Notes
      16
    
    
      false
      false
      R17.htm
      2111100 - Disclosure - Share Repurchase (Notes)
      Notes
      http://www.hologic.com/role/ShareRepurchaseNotes
      Share Repurchase (Notes)
      Notes
      17
    
    
      false
      false
      R18.htm
      2112100 - Disclosure - Other Balance Sheet Information
      Sheet
      http://www.hologic.com/role/OtherBalanceSheetInformation
      Other Balance Sheet Information
      Notes
      18
    
    
      false
      false
      R19.htm
      2113100 - Disclosure - Business Segments and Geographic Information
      Sheet
      http://www.hologic.com/role/BusinessSegmentsAndGeographicInformation
      Business Segments and Geographic Information
      Notes
      19
    
    
      false
      false
      R20.htm
      2114100 - Disclosure - Income Taxes
      Sheet
      http://www.hologic.com/role/IncomeTaxes
      Income Taxes
      Notes
      20
    
    
      false
      false
      R21.htm
      2116100 - Disclosure - Intangible Assets
      Sheet
      http://www.hologic.com/role/IntangibleAssets
      Intangible Assets
      Notes
      21
    
    
      false
      false
      R22.htm
      2117100 - Disclosure - Product Warranties
      Sheet
      http://www.hologic.com/role/ProductWarranties
      Product Warranties
      Notes
      22
    
    
      false
      false
      R23.htm
      2118100 - Disclosure - Accumuated Other Comprehensive Income (Notes)
      Notes
      http://www.hologic.com/role/AccumuatedOtherComprehensiveIncomeNotes
      Accumuated Other Comprehensive Income (Notes)
      Notes
      23
    
    
      false
      false
      R24.htm
      2119100 - Disclosure - New Accounting Pronouncements
      Sheet
      http://www.hologic.com/role/NewAccountingPronouncements
      New Accounting Pronouncements
      Notes
      24
    
    
      false
      false
      R25.htm
      2302301 - Disclosure - Fair Value Measurements (Tables)
      Sheet
      http://www.hologic.com/role/FairValueMeasurementsTables
      Fair Value Measurements (Tables)
      Tables
      http://www.hologic.com/role/FairValueMeasurements
      25
    
    
      false
      false
      R26.htm
      2303301 - Disclosure - Restructuring and Divestiture Charges (Tables)
      Sheet
      http://www.hologic.com/role/RestructuringAndDivestitureChargesTables
      Restructuring and Divestiture Charges (Tables)
      Tables
      http://www.hologic.com/role/RestructuringAndDivestitureCharges
      26
    
    
      false
      false
      R27.htm
      2304301 - Disclosure - Borrowings and Credit Arrangements (Tables)
      Sheet
      http://www.hologic.com/role/BorrowingsAndCreditArrangementsTables
      Borrowings and Credit Arrangements (Tables)
      Tables
      http://www.hologic.com/role/BorrowingsAndCreditArrangements
      27
    
    
      false
      false
      R28.htm
      2305301 - Disclosure - Derivatives Schedule of Derivative Assets at Fair Value (Tables)
      Sheet
      http://www.hologic.com/role/DerivativesScheduleOfDerivativeAssetsAtFairValueTables
      Derivatives Schedule of Derivative Assets at Fair Value (Tables)
      Tables
      28
    
    
      false
      false
      R29.htm
      2308301 - Disclosure - Marketable Securities (Tables)
      Sheet
      http://www.hologic.com/role/MarketableSecuritiesTables
      Marketable Securities (Tables)
      Tables
      http://www.hologic.com/role/MarketableSecurities
      29
    
    
      false
      false
      R30.htm
      2309301 - Disclosure - Net Income (Loss) Per Share (Tables)
      Sheet
      http://www.hologic.com/role/NetIncomeLossPerShareTables
      Net Income (Loss) Per Share (Tables)
      Tables
      http://www.hologic.com/role/NetIncomeLossPerShare
      30
    
    
      false
      false
      R31.htm
      2310301 - Disclosure - Stock-Based Compensation (Tables)
      Sheet
      http://www.hologic.com/role/StockBasedCompensationTables
      Stock-Based Compensation (Tables)
      Tables
      http://www.hologic.com/role/StockBasedCompensation
      31
    
    
      false
      false
      R32.htm
      2312301 - Disclosure - Other Balance Sheet Information (Tables)
      Sheet
      http://www.hologic.com/role/OtherBalanceSheetInformationTables
      Other Balance Sheet Information (Tables)
      Tables
      http://www.hologic.com/role/OtherBalanceSheetInformation
      32
    
    
      false
      false
      R33.htm
      2313301 - Disclosure - Business Segments and Geographic Information (Tables)
      Sheet
      http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationTables
      Business Segments and Geographic Information (Tables)
      Tables
      http://www.hologic.com/role/BusinessSegmentsAndGeographicInformation
      33
    
    
      false
      false
      R34.htm
      2316301 - Disclosure - Intangible Assets (Tables)
      Sheet
      http://www.hologic.com/role/IntangibleAssetsTables
      Intangible Assets (Tables)
      Tables
      http://www.hologic.com/role/IntangibleAssets
      34
    
    
      false
      false
      R35.htm
      2317301 - Disclosure - Product Warranties (Tables)
      Sheet
      http://www.hologic.com/role/ProductWarrantiesTables
      Product Warranties (Tables)
      Tables
      http://www.hologic.com/role/ProductWarranties
      35
    
    
      false
      false
      R36.htm
      2318301 - Disclosure - Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)
      Sheet
      http://www.hologic.com/role/AccumuatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables
      Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)
      Tables
      36
    
    
      false
      false
      R37.htm
      2401401 - Disclosure - Basis of Presentation Additional Information (Details)
      Sheet
      http://www.hologic.com/role/BasisOfPresentationAdditionalInformationDetails
      Basis of Presentation Additional Information (Details)
      Details
      37
    
    
      false
      false
      R38.htm
      2402402 - Disclosure - Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)
      Sheet
      http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail
      Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)
      Details
      38
    
    
      false
      false
      R39.htm
      2402403 - Disclosure - Fair Value Measurements - Additional Information (Detail)
      Sheet
      http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail
      Fair Value Measurements - Additional Information (Detail)
      Details
      39
    
    
      false
      false
      R40.htm
      2402404 - Disclosure - Fair Value Measurements - Estimated Fair Values of Convertible Notes (Detail)
      Notes
      http://www.hologic.com/role/FairValueMeasurementsEstimatedFairValuesOfConvertibleNotesDetail
      Fair Value Measurements - Estimated Fair Values of Convertible Notes (Detail)
      Details
      40
    
    
      false
      false
      R41.htm
      2403402 - Disclosure - Restructuring and Divestiture Charges - Charges Taken Related to Restructuring Actions (Detail)
      Sheet
      http://www.hologic.com/role/RestructuringAndDivestitureChargesChargesTakenRelatedToRestructuringActionsDetail
      Restructuring and Divestiture Charges - Charges Taken Related to Restructuring Actions (Detail)
      Details
      41
    
    
      false
      false
      R42.htm
      2403403 - Disclosure - Restructuring and Divestiture Charges - Charges Taken Related to Accrued Restructuring Actions (Detail)
      Sheet
      http://www.hologic.com/role/RestructuringAndDivestitureChargesChargesTakenRelatedToAccruedRestructuringActionsDetail
      Restructuring and Divestiture Charges - Charges Taken Related to Accrued Restructuring Actions (Detail)
      Details
      42
    
    
      false
      false
      R43.htm
      2403404 - Disclosure - Restructuring and Divestiture Charges - Additional Information (Detail)
      Sheet
      http://www.hologic.com/role/RestructuringAndDivestitureChargesAdditionalInformationDetail
      Restructuring and Divestiture Charges - Additional Information (Detail)
      Details
      43
    
    
      false
      false
      R44.htm
      2404402 - Disclosure - Borrowings and Credit Arrangements - Company's Borrowings (Detail)
      Sheet
      http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail
      Borrowings and Credit Arrangements - Company's Borrowings (Detail)
      Details
      44
    
    
      false
      false
      R45.htm
      2404403 - Disclosure - Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Detail)
      Notes
      http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseUnderConvertibleNotesDetail
      Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Detail)
      Details
      45
    
    
      false
      false
      R46.htm
      2404404 - Disclosure - Borrowings and Credit Arrangements - Additional Information (Detail)
      Sheet
      http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail
      Borrowings and Credit Arrangements - Additional Information (Detail)
      Details
      46
    
    
      false
      false
      R47.htm
      2405402 - Disclosure - Derivatives Fair Value of Derivative Financial Instruments (Details)
      Sheet
      http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails
      Derivatives Fair Value of Derivative Financial Instruments (Details)
      Details
      47
    
    
      false
      false
      R48.htm
      2405403 - Disclosure - Derivatives Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details)
      Sheet
      http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails
      Derivatives Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details)
      Details
      48
    
    
      false
      false
      R49.htm
      2405404 - Disclosure - Derivatives Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details)
      Sheet
      http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails
      Derivatives Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details)
      Details
      49
    
    
      false
      false
      R50.htm
      2405405 - Disclosure - Derivatives Additional Information (Details)
      Sheet
      http://www.hologic.com/role/DerivativesAdditionalInformationDetails
      Derivatives Additional Information (Details)
      Details
      50
    
    
      false
      false
      R51.htm
      2407401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
      Sheet
      http://www.hologic.com/role/CommitmentsAndContingenciesAdditionalInformationDetail
      Commitments and Contingencies - Additional Information (Detail)
      Details
      51
    
    
      false
      false
      R52.htm
      2408402 - Disclosure - Marketable Securities - Reconciles Cost Basis to Fair Market Value of Company's Equity Security (Detail)
      Sheet
      http://www.hologic.com/role/MarketableSecuritiesReconcilesCostBasisToFairMarketValueOfCompanysEquitySecurityDetail
      Marketable Securities - Reconciles Cost Basis to Fair Market Value of Company's Equity Security (Detail)
      Details
      52
    
    
      false
      false
      R53.htm
      2408403 - Disclosure - Marketable Securities Additional Information (Details)
      Sheet
      http://www.hologic.com/role/MarketableSecuritiesAdditionalInformationDetails
      Marketable Securities Additional Information (Details)
      Details
      53
    
    
      false
      false
      R54.htm
      2409402 - Disclosure - Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail)
      Sheet
      http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail
      Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail)
      Details
      http://www.hologic.com/role/NetIncomeLossPerShareTables
      54
    
    
      false
      false
      R55.htm
      2410402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail)
      Sheet
      http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail
      Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail)
      Details
      55
    
    
      false
      false
      R56.htm
      2410403 - Disclosure - Stock-Based Compensation - Additional Information (Detail)
      Sheet
      http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail
      Stock-Based Compensation - Additional Information (Detail)
      Details
      56
    
    
      false
      false
      R57.htm
      2410404 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail)
      Sheet
      http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail
      Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail)
      Details
      57
    
    
      false
      false
      R58.htm
      2411401 - Disclosure - Share Repurchase (Details)
      Sheet
      http://www.hologic.com/role/ShareRepurchaseDetails
      Share Repurchase (Details)
      Details
      http://www.hologic.com/role/ShareRepurchaseNotes
      58
    
    
      false
      false
      R59.htm
      2412402 - Disclosure - Other Balance Sheet Information - Other Balance Sheet Information of Inventories (Detail)
      Sheet
      http://www.hologic.com/role/OtherBalanceSheetInformationOtherBalanceSheetInformationOfInventoriesDetail
      Other Balance Sheet Information - Other Balance Sheet Information of Inventories (Detail)
      Details
      59
    
    
      false
      false
      R60.htm
      2412403 - Disclosure - Other Balance Sheet Information - Other Balance Sheet Information of Property, Plant and Equipment (Detail)
      Sheet
      http://www.hologic.com/role/OtherBalanceSheetInformationOtherBalanceSheetInformationOfPropertyPlantAndEquipmentDetail
      Other Balance Sheet Information - Other Balance Sheet Information of Property, Plant and Equipment (Detail)
      Details
      60
    
    
      false
      false
      R61.htm
      2413402 - Disclosure - Business Segments and Geographic Information - Additional Information (Detail)
      Sheet
      http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail
      Business Segments and Geographic Information - Additional Information (Detail)
      Details
      61
    
    
      false
      false
      R62.htm
      2413403 - Disclosure - Business Segments and Geographic Information - Segment Information (Detail)
      Sheet
      http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail
      Business Segments and Geographic Information - Segment Information (Detail)
      Details
      62
    
    
      false
      false
      R63.htm
      2413404 - Disclosure - Business Segments and Geographic Information - Revenues by Geography (Detail)
      Sheet
      http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail
      Business Segments and Geographic Information - Revenues by Geography (Detail)
      Details
      63
    
    
      false
      false
      R64.htm
      2414401 - Disclosure - Income Taxes - Additional Information (Detail)
      Sheet
      http://www.hologic.com/role/IncomeTaxesAdditionalInformationDetail
      Income Taxes - Additional Information (Detail)
      Details
      64
    
    
      false
      false
      R65.htm
      2416402 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)
      Sheet
      http://www.hologic.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetail
      Intangible Assets - Schedule of Intangible Assets (Detail)
      Details
      65
    
    
      false
      false
      R66.htm
      2416403 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense (Detail)
      Sheet
      http://www.hologic.com/role/IntangibleAssetsScheduleOfEstimatedAmortizationExpenseDetail
      Intangible Assets - Schedule of Estimated Amortization Expense (Detail)
      Details
      66
    
    
      false
      false
      R67.htm
      2416404 - Disclosure - Intangible Assets Additional Information (Details)
      Sheet
      http://www.hologic.com/role/IntangibleAssetsAdditionalInformationDetails
      Intangible Assets Additional Information (Details)
      Details
      67
    
    
      false
      false
      R68.htm
      2417402 - Disclosure - Product Warranties - Product Warranty (Detail)
      Sheet
      http://www.hologic.com/role/ProductWarrantiesProductWarrantyDetail
      Product Warranties - Product Warranty (Detail)
      Details
      68
    
    
      false
      false
      R69.htm
      2417403 - Disclosure - Product Warranties Additional Information (Details)
      Sheet
      http://www.hologic.com/role/ProductWarrantiesAdditionalInformationDetails
      Product Warranties Additional Information (Details)
      Details
      69
    
    
      false
      false
      R70.htm
      2418402 - Disclosure - Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Detail)
      Sheet
      http://www.hologic.com/role/AccumuatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeDetail
      Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Detail)
      Details
      http://www.hologic.com/role/AccumuatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables
      70
    
    
      false
      false
      All Reports
      Book
      All Reports
    
  
  
    holx-20160326.xml
    holx-20160326.xsd
    holx-20160326_cal.xml
    holx-20160326_def.xml
    holx-20160326_lab.xml
    holx-20160326_pre.xml
  
  
  
  true
  true
IDEA: XBRL DOCUMENT 
begin 644 0000859737-16-000052-xbrl.zip
M4$L#!!0    ( ""!FTCP5?#MFE\! /E^&P 1    :&]L>"TR,#$V,#,R-BYX
M;6SLO=EV&\>2*/I\SU?XZOG*SGGPVNVSGM^:3>_?NS?_^Z7_]X_]]^_;_VH^_?.='W?O;8CCYSI5%
M9U+TOON[/[GY[C]ZQ?A?WUV5H]OO_F-4_JO_I?/V[>Q#=S]*SCE&B"A>% PS
MKGN]+E?=#B9*=NA?O?_OZX\=S1&A"O[J]ECWJMOI=#M4*T)$[R]6:#7]LJ]_
ME8/^C^G?WP'4P_&/W=']<%)^^[^GY<=+^_'GWYH7KS!X(P
M?8OP6XK?U!^[+TM #KPP?^_OOO[^&%T76_^WUW=)L>%X@243_<'WXIQI/F[Y^]UX!Z?SQB!,N%
M'YE^P^.(_E ]47]@T!_^:\W3Z>V_.N.B?GS8Z7?'S3!-WTH@X460AJ/A
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M2Z]=]8ORNRD_\K-
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MG^D#9/:5+\:A!UM<7*03'Q>DOD<(H!;
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MOXTFYW;>GN/TR- ,J8ME8[I,_9^N+'K]B;DNBR*]=
M8;??&31Q\_/?H\\WH_MQ9]@SP][GOXO!E^(,]7,%CA5S-R#Y^MA\TR\G13&\
M=$;G:+X^5E\^ER^0P>^&W=%M\6D"X6J"])=1MY.E!1^+1)KNY+[L#Z_=3:>\
MSNK;BX^,QA,@%[Q6E%^*1WE9>,ATT^_,$3B.[J'0*PFO.Y8BZPOE7*5G6.I#H7+:&/TZE:
M(6V%] E">DJ#Q%Y*JE?%0[$_[G8&"8:90QW[T6VG/VQ5X[1"GQ5L:M7SPM6S
M35?.5V=??;IR4HI<38P[8R<;^U>MPEZ\DUW@\HLD:L\^I?"T?>8\?5N7>5H:
MN /K6H]YR1[S_>2F*-\#P/ 3LZ<^%KW[F57>2W5;YWE@U=W,L=:/GI5.3[E&I1ZS]?;;7H CSI2RAEJSI'.S>\$ D]T9ZHMF!R=-%O
M"R:;5?(L.Z+:W.M2-/&5YEXOL.3IPGQB&PZ^5I_8AJDG<(K>.L+7<(I^ =[O
M?!M#_RPZ9=;C;LDC5O'Z5=2[Y^M]667U^S2QJEMG/IRQW:[KYS6E]3G
M_3SUGM;QOL*:3^N#C^V#V_;NL]#6DTA,6]_Z0@?PK2]LG<\E.9_6;UQZ>\EK
MM-DO5-9HG<%K+FVT3NK8&5)[G>?<-/@D2ANM#S[AHX7V-L$)J^^KOTUPKO+RK3TTU%P^FW=@:M/#^O/#<0
M]\7",TR.'YZ]L"RW]OG"[7.2Z=<:<_!6I@\KT_P5QQPO*].VZ%V-REXKR<\K
MR0MD?25EH.7;D)X8?>R8>)9"D)K?DXUS7EQ]]FF[!>:LI_"B\6N5?_+5/]3J-@MN+1?1L-K
M\/"W:3'[YV]WQ8(PN]'P2U%.^G\-9NNZ/W2^=>#/YR6431@^2N-:%%^15U@R
M=:U8G()8'-]:B%8L3DTL3C#';\7B%,3B^)7G^=&8C3(QZ[J'5W\9=#SZ%>SSQ!$R%3,+X:!RRB=+POGSWY6L_!C\64T (MU,0Q<
M1.@\SWZVU\"6?6>M?:T!/6$-W(Z%;0AS!NQ+:+X;IEI@ G3[G.3AJ4\WHW+R
MN5D 'F\;?2Z&[\O^=7_8&9RA4N=$>H:T9H??;Z1Q?D>SFW@S_>B20+^01AC@U]_%X$MQ1OHP%;B,
ML)4@KJ3L,RG!F2AA$U]?EPIN$UB>:P%J95CQO'8Q[(_*"S%)#SYK&:DVT5DV3>=91U]I
M85ZJBGYR@0>XH;V+&JTGNG1/M%/1C2V*\XN:H[;H=IG&:5-6U(8AQ]?["ZJW
MGF-UJ2WTG(M)RT8\=(;7BQW7OW:^]F_O;\]+\![0>)2W!3PN^:Q_-R/4P/#^
M\)%0[>'0"YJK)JF=9\:K.H,Z?F?%EG%^6P"_"%=8#:#[U,;VIQ_;R[<(O_1A
MUY/=ZGS\T;K5([O5;8/!UJT>--UH<^B3UYZ3S*%?:&S>NO:CV"_'D[;[:"_9
M7MM]M(JP;?/1ZPC$G]])K#X+_&WT9?IHZ%_?I"T_;!
M%^/)1_AMU[F[1-%H1/$\G<4RBVUGT!EVBT\W1=$\N_A#6=QU^KWP]0YH5XS-
ML/=^3Y5G&ER\VJZCV*#+;D^W9ZF&O4)+GDY>-DCQE0"NP
M*P0VH\XKDD)R.Q._K]-7=K4
MY4QBA).0ZPL/'DY4H"\H0VN\NG[I@G>27#[%:^VM6)R66)SKH7\K%A=]S-\X
MAJT5BV.+Q2F,:(,H^<_SV .]H[_5SZE!*9\@O[-/Q=UD*@EL0NP?_OL>(/Q4=._+:8EFP98LOWE>QF1+
M;!_M2C.ZYYF#+%FF4Q;V6_,7+(C8
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M$^*3"%K;5H%3L!0G)PHFS1/-E@^&V[O!Z%M13-N"W]\E IZ7%"R@-3
MKT@ EJ^,M +P^C*,S0)P&9/=QJ]&OQZ]MI=!O5798FMQ;ZHK4ZR0'['?\V
M^H+16XQ/<:SM KDH  G_;$NNI<>?QPC.S\%]* +9^W%_6(S'GV8B,7XL=/E^
MYWHX&D_ZW3/S@FMQJPI=&7(O8@X//N-V"[;:LNB,)_\L.H/)S>7Q-]V!I?'UPRY\V7K]F:X?LJ-RKM1"4]>%%_KQY:P.U]#O*-_
M;?7U/-BZHQG^]*]B4$PZ@TOUL$WXG:\QWIZYK3&^4,:VRCNW/UL,M8S17CY]!ZL3KM
M\:\D;LW^J6J;P6"VCG=T/YR49[=Z9XT83#5[!7JO2QS^W,D:F'&_\Z'3!0YU
M+T86'HYXEG%['>TLHT9+CJYW%T@6D=QR<*PO:-H+P!?MJO8
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MH7R^(O D;]^*P N+P$GZ_#95/)U4\9"[N* B!O=WHV&V>ET')5%_WKH[LNR
M&':__=SI#W\9C<\L^EN+ZJ-VK\7U1;2:+M5LR]N[LKA);W\IW@V[H]MS;5EH%H.IO=@=^Y<*">QO$UN)*'Z9[3-S\5W?NR
M/SG?L<_KN=R,Y'DZAOW8W(:)%\!TW.KV2>DV6[PK>RPVM[I]UDS?.=)OU?LU
MQ>U@#UZ,I2>B$?N%.&VZK,H@G'\K&/W<8
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M\,<;Y)[$_[G8&?Q:=,LRBKBU^G!AG(S$H!!0)
M5P9+[ZL?]\0$]>:GMU/=9K.?7_5+-21^!&;IX8$/4Z6/\-IX"U"HY#,),($'JC$7E6_;I0D_LU/&+W]??%WTU?7/Q>FCL,5:5/0X-VP5WS]
M/\6W+7X7&(XX541:'D/$+CA::P'U*M)%][OREY; &-W>CH:?)J/NOZ;^9/S^
M?I)<4Z\_7-3,JK*2/?3FNU[1[=^"_L$SO\5Y.ED;X3/! :R:&\>X=!6\@@NG
MWWR7;,+TRVM[1:121$LE%N!? ^(B,K$_ #\/G+T>E=M0U!CL*/AF3SRGD:D 
M@CR#4(:@*'KSTR^=\KKX#D*)8I!\7]'[;OH;\^ M_.@B/!^+Z_X8:#^@J*/E_YE.0U\$M6+]/*??
M\GEUM ',H\/(.(4\(8Q;06D4(AHFF YSC)YZ$(YF?_WCARB\-%ISS $Z)&H&QD-I:SP0Q\HG$N@60*V%[?^6+JP)<>R\"<,,N".D*PBW=
MU_QE-+R>+*.]%>E68DW!X5%FC-"68CH%_CPL
M!2+SR E/ B'(:LXP)G%* 0@$J,=TF0+ZA2D@#BX#B$OX1\KD8:/@3 J%*QF 
MZ(R[90K0EZ? @64 44.>N[ .V=YU!9_J1
M1J=_>@Y@,90C,IH-[AD'D "/>FQ/Q^D9Q[D.N1X%\Z
M_4%".([*3YW'**48_UR.QN,_AF71&?3_I^BELO/[89'3>;[ -]TNE,@S3G+Y
MUP2"A^5ZYC85W96R!^F;(\*!]TBA!4Y_J+0&G",QR_22BRYS1U2?D4;SLGA@
M&BFF.*4*5-,I'0VWF- 9C;C5D"0LT^CEJ),.+8HQJ,M194@A9[Q%2H,/-A!_
M,.PJ^Q40A*T;?,_.N#XKF5Y0C)QF/F)#N&,,*:.%KU1-!LXMLZ\E?J%:7#XV!4KIADGC K$
MB4W553FK8Y4E<%0:53,:*#(WC1P
MG?'-IP* A."V /!2 +Y '!6'TXPF.YTE[H?W8*/;/Z2#X/.L#%V_-3_.BF*
MX<:\@5AEI*0FH!!,L,:'BO+IA2QW?$L6_%9KIF<-=I]_;[>1#"!J?:3"'8N<&,M9T$Q2-RG-%4D0)SI
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M6FRIV ;Q.2K-3K\^=[X6XX]%I_O?]_WQM"-C=+74:'LJ KA36 %"9I%CC@2<'1;=)_B )$D@8G(65F/!%6FY-GG,FZ8YQA80 (C+O,81L2GC/X*]$5(&,
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MWD9!>""US79$D+7=1N=-\<,5K[Q54
M?TK->CNR2Z.PI-) *HRH9Y8[5=6L=8S89%Z3H/,3^442/1AOMO#1E12RD8IH
M@K<:,><))JCJ@U'$8:O$Y5%H9R'BB-&@D'>:*J6D#(;548*G6F0M'V1[NPG8
MEE,\.X,J5)A6)C U]6]:#%B!QY\]/D!E*ZM]^*3OD =^./94T)S#7^\AE<_
M -[]^]LJ/=M*[Q8"($=U.@ %V&6*A3 E$@NI2'36HKR1\*U8:)[8%;YG18RM
M0PQA'6TT#K0I"D\%9]4]3AFI%_FQ."!^(H@UZ,I"9&"$X: IE!/%'7*K)<)UC?/;RZ?&T((F2;ZB U
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MU9@ 2(>T$TT'V#6AGH#> XU J:?7XQL.K#>*/F,FV1Q!/.9>.FT(<!EID?PA=(4;IO>%X
M-.BGGJY>67PIALM78QJ,S:*E5)"6&DY,5,$[RY6PMKJ5+I0@9K[![7&HUB)V
M.X/X@.+T9&B12Z?8C/Z2=UV,50''R% T)"K(2DGMY2'"H3B['5VS8C4ISXW:
M1[KN(C&%OQ%VG(%.XV"C8%6HK"#NRB+.RR/\L:^\!&=H5 AB6Q:)I-P;65=K
M-;?Y4*)7QX'#WWKA D^+^DE,"'##7>1$ 7ZHDTE;2JC9AO"8K
M2\5;85V)0 0$.E]3M0A>32'WQUG,^'GT[R P16]J/09%RMFG$M3OPHO3O/0/
M^.WM#@H7&ARQ=3908E('O3(>85)?\!8VN+ST21:J7<\#]<&)L.$,P"/EF8M!
M*!>%TH)06H< D1"6,19S<7@BC#^/'HM9Q1Z]EEMP'TGG0(X-=2#*"N),9&V%
MN"&!9_VB6,L&Q/> ]"#(;N!R&N  &5PD%N**Z")5P56B;B0+&;)D\3;Y\GY$9"9':0,!M5X\BKKS?W%/'I&<&V< (."HM!8ZG2F.#M50E(YV8@>
M.)8CH/=0A1WW.Q\ZW?Y5O[L!-T8\$T&EZ:?:ZV0\ZXENWK'05),&W)0^(F[A
MOAS=-HDKN?@VL2#@RM_XRJO/90?W&JD$:()$B#ICLK/^$X!,(M5R%"XB.)5*0>?:S5
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MHC$$9*NR0RJLZ(SX"W7)R^+ L6^P*AV5X!$CZZ6+:3/CB21#&,).PXQTQ#'#5)"D
M.LG7!A+M[/8[%H>V)N?9P)4VX.5] ;//K[X]0(3 B >3IDUR(Z32566,8,I]
MUDMT<'D]^W:NO=C@N4QMTX1R;(Q(W:ZRNOR;+C.[S(A?)@.>V97NQ0GC$$T5
M/6XYIAI28N8K3ACBHLK:15XE)W;VHWNQ@FG'-.:",T(I)9S&:J6#,C*U/UP6
M*YZ!8 Z"<8TU8)0)6P4>0(KM#M9C<6>0
MD#FIP/ E,U,$&1 +)"#.721(B:!CO4(OQKC&F&]-V[/GQY'R5D,DT0HCIQF1
M,FU?9O6< 2%$WCRF%Q7D]?#GV%DM&#(1!9.<,)'*TU;%JL"@G;8NNUR09;4M
MJUXLYP5S)Z>;WZ(D1(%&*>KJ.3S&TLQ/JXMGU5.%GP3&IGO0I9+&T72!MHY!
M/8EYBZLZKITZSWQY]WLWGJ1.'VJ#=\(987U] 4T:IG1^W?6X7-DK\+6.
M160AQI5&.$R=BM5)D\(0 >OLSN/KYFWM99RQ24K[R*N=K8L^Q[QQB+)'UD1HNA=;4
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M]#,&3Q_Z/)K.WAV.^[UBT\3PJJC]H^E.N\#K>5?NOBQ7S2U871Z27E*+B(LV6(J\L+$._#RE^8;1
M%-!7T*\'8Q] UXUM2]-YF*')8CG-G$6"5X<@\"=$LDP"8\7W!O1CT2WZ7])#
ML1S=UI,+_J=!0#:!;82GX+5$8,P2$66@*N%@/$USP5C6JE(WVC: O0ZH9T'B
MT1*NGRNW.D!-?7R"2!N"U(!F:FFE-,;4\VT4SK*(@R#[6S'92Q.LE&PZWPY4
M60IA+/?U6%;'J,C*"P!='E?]'[I=_Y*0]7ZQ7@O,J,8B>*21T>=![/#<7VW@0:M\ED(1)(&
M,C=#LB>X:\T.8\09L.W2:^0M-;2> L \]B@[%B>"ZCW!O;^]GPZR\,5="<#,
M%H86=X-BZO2&/7,[*FL5^)!N6Y23;RE,J>>OW*V<6K.Z605AHR'K)Q@[FR9A
M4EZ/&_?@ +++#IRP!J/Z+("_##'6L3HZ\,LL.&P02\O\6(QUN1=;PS-6<\[8
MRQ*CNA]U"]]\ ]'0=,EG"GU_&8W3RKOW5Y\[7W..9]),F=2A
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MPIX8B'2%P0(43M?#3S5CD64;AM]B>DKF=G>A1
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M,:->F309+D#D5M>4%(V6Y,:#Z%-*"ARE$)IH3=2T/E,'FI6]\ 5!B$U1I W!6N55]1:70]^)LH)E"?/)U6 V9T\^YE=1@PH'K7$ %4(
M]R!* 0B!/?58B-@0\^"&1I(S(M-N9A=)CHS!Q&DCM)0Z4ER%A)2 FN6G3>PY
M=:S7Z\_6I'[H]'OOA@!N?](9[%9*$$%0B#D@'G/PES6&!EPM$B'1J\R\L,+@E>RU()SFM-[&UC_ZWX\J;;@S'>2
M[+R2ABL-6F,PLXA;'R")KL4#TXAR[2%(YK1= $&_8*Z-!NZV-%KALO*7!
M.U95EH+P,6]UPTIGR>UN$(\_CU;P9$E/WU_-K:!-(UHW3M-^\C;;[;;4FF'O
M\]_%X$NQS5YZZKSE$-!8KU/ 1M."<&R%\R%:S_*1=C1OVW@&TETJ*U8M#%Z5
MF$(@A(@Q3%H7J83LWH7$#.G3-1B5=Z,VF+YG9L9@,/H[=?:#[OC1_5^3J_M!
MWCNZ5T]HZ@75AH*O\D)'DU8AUI<"HN8A'Z:8>_)=@'M&K-;Y!.Z%X-.+E8BG
M K(L
MTUOIQ>JHWVE"+ H4"RZHE2)40^ID9)BY;!*%SOH4-F'U=!+\>5@20!S/.7,4
M K(D&(')6-53!(0.*+]M(;,@X< T$ <7@[2)R(@ "F"CX)#E"%2/O3"J8=X;
M/P()#BP&3K@8J(Q>ARAP4-'4^Z]D( 1GAV289'6#_6D0P04-N_5],8@0ZD]N
MWOZU__3YQ06!1%BA./,4!X:=!0M09291HOR(D&1AW);XO!0-'@*!8M@?E=MX
M]Q#3V.OH(%?U@5,7<;UAB&%E;68',L=P3 H#Y%9'&6;*SG3\^#797<\8XI@'PXLG<4YOJ5$""H(5%6N970T^*
M H=P_2Q2;Z4)44;.58R6U;M5 E=Y4S=(R5$ILCE3G&TN(HB0K3)L#\KOO8*<
MSHL8/7).UV:?AH8\9WT$?"+H[V86HF=&1&NL=1#_I7$.H
M,6EP *6(0L$O07:?;(4(RD,T5,7#)$J9+^-!QW46F\ITVJJHB0,>:\,$-=C5
MX3T-T68VC^2W:(^ SO/I>$#&"1*\>M85(&XQ@E+B7]W#"+K/>9CNNC43WTRBC#0B;9
M@-=:))8!>B+H:W?2.X>=1,JF_G\=%?SML+5(DN -S962\_7YQ7."OF&\""3+
MS!C)?+14.>JIJI><?W _Z7\I'@_:P]?9L)PT0R)5N>\GU5>%3CD$]1E_*,KIE)G9
M'KN-J>\3?\5^:_Z"?%+1XTR;/X!$XX^?_FBP,/.[%:F5-' >*><$G*]VQ)BZ
M%\4P/M]E,YY.Y@%RBT5:/P<%+Y,E4T:XN1%$Z<+^!H88X 2-46FO*5A_05@]
M TX!BVQL8 AX WZN+/GS++2$2<,AYT38QY@F'E!;3?.0GFL(O!N8HFG+DL-I
M"<9!LJ0FWC 'F0"A#T/CI54++J)F"%&$G25+Q+GX$FL5AHC)"N-D!*U0AE>^
M1$+\'D23Z>*HY7+ F,OR*"WA2#K(@B0.B%0-V09B
M,(R;W#L^-$<:'Q7C\J;B^7>P#MV71&4_^670&DYM-1T#468JHX%0+I1"QU%2SWK" 
MI###0^$\ SP4&K[?N1Z.QI-^=U-%+X(GE#A"8@UN4%@J@2^55"D<>(8%0SP_
MRSH4&C]_&WZZ+Z_[WCQ7"\FY4PI.;E$-+
M;V1@41EAD0'=KK% ,3B3=>!BC'G6Y[\U'FL;U;A-RYJ"54@QZG6D]0;&=.' 
M9'=K99IQ]A1(#F5NM)(,$R(P%=(CJ7T]6A(Y2,(S/!3.[Y4<"HWMS0V.ADB(
M] (R!#.N>"2^7L2H&,NJ9E17 HWMS8U UEF4NE4]$A"C@J&LSH&094KE
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M# 5WCN!,=$@FS\]*KU=.?HR
M]1SCG\O1>,?D$\) RZ0UP4#&X S58)ZK)BU"37Y6#?G#LM:OA>8)8*^SV]@B
M"(0\$XYYA*.4HNJIEE$(DF^P2I=I]P7;=<8W\$SZ3Y*&+\"6Y)8GKE.6W^ +
M_KTSN"]V&\2,+7CGZ-.YM!*:1Q>JPW49 G'Y]'E),UN[%53/@,:ZH7N!HR"<
MQ=$J93%#Q,3Z6B&V(?<80J+EG.;ET%C-#0X)OG&:,W)HP:2P2X]Q$[!BR7H!^(.QS^5DB[VYD.BJ1IS?V9U^Z#W5WFS5@
MO:4>(H9T5]6BZ-.6&R!KNNB&TEZ2S.HO1WAG1MP/97'7Z?>JC5PI7)@-2)@E
M?/M3?2^95LH00MB,KBN-,V)P<@$.<@C@J,;C"*I;5P6E:M  (KJ[)[
M!-D.B2=2:'1[VY^-=$F9'B /&7@Q[*XJ\8QN_2,04G^/\!R/-\/U9#26JCZ+:-C4+T0X]8%0Y@WGOAY(*J+3R[.]
MGA^-V>I?Q,(2QA[$6$@O=V/#_C&"_&X_OMZ#T0KL;K(9Z!LA>TR\7,>6@E"\*G6^(V"B2)"HS40Z("
M!40:H65(XR= NT?I6#.OG':".BPB=U0X$NIQM]B9_*I?%C8N_?QNH*U=%HLC
M!\H::)X"]+H:;N#(6LD5DD$K8T/DHKK8SBQS-&MXX;2!O,\.](;;
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M/JY#,IF56O8"??Z1_1H(%0H&*?"V&")#200+IAXT@H+*(,;MU=9G@I> ^O<&XBWG6M!$T.H#PVS'"KR?;\G <>37PM(P7KOX"/5/-T=I]LRRT-:7PQ:3VB(:;@_-@+\
M?DC%^DQ062ZF#3#L >1:.^"BT9&"5$J=%IDXB+#J5D]K\G9KLG!2C9IS0%7D)6!>F*KRV5H 0WS A4(O>5"R#L"MW:"2/I]"4:
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MG)'&-V//#X7][$P=/M&%-SK7&WHUGVBRCS9N @1'$>&40ADI+<1^M5FA%:W=FSA*S0D6[,1T)2![0KN.
MLHIC*ZF2:CI$16$B>;W[(PK(:7-HERL .T$+(CUK&?RMF.PELBAJA@,.6G*#
MTG@Y91X< *!.I<
M5_^^\AMTFCD='$E#1BUUG/E:(JR#M_)!/S+K9]D$T=.@7SL<2&)(D23'J44,
M0Z 0337'A4HA7:Y]2&;#RW>#_JX$2/8K=4;"2=0$;!6!G(YYQ6Q]/Y2F$\Y\
M5%?N,!Y_?GNP-C@R1V,:( 9 I5T/SD11E[2\AG?R98[9BH=MP)HO%4)JG*ZE
M%.G/(..[SWI/@8[AQ"&=E K4RE>;6@(CFC1L*&O(EK<"[1FQ.=!8J6"X#)YQ
MI"!0YMQ"!"@K[B%#
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M#W\9C<94N!W/+4>2Z)(-:@TQ?]8;[YW4@6<>[950^L$LSB89IV\=
M#1_,XGZD1CHB+2D-DA'G8XS.0OB$#%><*DVSPMD%DWJ=U11>$$6),2QX[:B7
M(C+DB+ DQ1HQNV5SV60ZJ.YKI8@PW'%/>/#6(D1!]X.'#!ZQO-WSE5#Z$+IO
MF!2:*R:-MXY@%D&F0?==FK&*A,EJ1Y=*ZDT76AB6V*69-HB08"5RU3!F2#D5
MW^J:IHD>'G$ZP*L[""PKJ$K9 W,,(\AP9N&/F0KU!D$=NEQM.MY78"IA]
MX5TGM6 Y!"1HV$=-E4J]R/4U,ZL](FLDX4#PKI=<+$BZ&0=DM2"XPDY3X1W#7T5,C(ZH'SA"._/(ZX07II;O!.S7'[Z_J6<_)
MC[P?-B\FV;EV0K$#QXX8A)F11:HBJ6XJR>A-0-E9W=ML5-TNX#T?6AM"0Y*&
M0LHH!58>44>4>T +:YF/OGJ;;1IZ&EH/OO1SY^O4[T_'^=X#I]_?%>6T^K[5
M>('Y49V<$LPA(7 J>HAN-?"L$CB(&=C"6/K'^U,$LV6B7$#<8).9-Q K@*95W<6""# K6?^\7.X8
M/&]*SVY&QU%9O92>PQM3UYWE_-$@0%Z!(L4\(*\1Y1 'N7IB6 C4O/GI _V3
M_OH"Y&W$_.QHOD'J'YTE R_I1=#@6*PA'-M8613@1T :Z$[^Y*=!]Z_=8CP&
M0U]="$Z-!LT_7\T]'5Z;Y"$:]LIN$\*2Z91E!C$#%T* HT6B'K*'AS_\F'8IIYD=T\%1[_\:]*^;0L^-5[ZMYT@X#Y&T
M1 +24X-U/?E=0YZ0-<2JY2:Y/<$\%*:/7A:>2\,SWDV*V_?ES^7H_@Z,Z<-/
MS?SN@H^HK_K.\^B1>DL""T9H7Q58F$F=$OE R.54
M_W42]'%(=_V%]MO#'__9!TTINS???BF^%(/%%5WU,^^&=_>3\?0!O/$R*((8
MBHIT]4\$F3I$R>-\1IG5+5H>/3^/R*;.#,728$+)%(N!<()E/:X04F+NLILL
M+7.>D3ETTWY!)W%@4GO* $4I^<,8<&J1,5EP<)',65H.F$HM)1#GY<,#Q:A. ZA@GF0-)N=B!5Y 6],2
M!TL0$AHYZ2$.Y+;NRPN6YAMIGIEJ??AR^/R7U+LS ;N5;%ZUV?3Q%L_J2>L;
M]^TP#0&3\]AS@=.85LOKB7 &0>[==&TSTZN=83P AO-;E59]G_WV:^>_1J5+
M%Z+F+G965]I^Z7>G&X,W38M.!3>/TM$E=Q[,=T 5Q5*7MLZR-;)\7>O,R>7N
MQY/1;5%^+ 8S<;WIWXUK9[IQ71D*7'DAD
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M(I2/R;THTFWM[93Q 1'.0!?33L%@2;V^04H;4;[)+5]C]HGQ_%?OC;F?P)PC&;NY/>J$B)R[-( [I9BG@7#4J&FQQ/J!:Y364I\.\
M/PG2IR,\N^/8Y:C!RS-&6=36&(MZ
M?(P.1IF\38!G'>Q[POE$5/\>[3B@/4TXP5IP0(IH#,FS\ ^(:III+)BH79SA
M2BBW1//G=84K)=@K+XQ([9O"&E=W;G(:D<]N%'-*R XA^!2B)T/_8N&U
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MCLMR#8N.X?^':R5..I!=,&3 R$[51X'Q7&!IN8)ILHD85?6>%A#\P7
M*'=?PO?#BV 78O]K^M,^V:G6E@<:"60;WNI(7+2BWO+HD,H,*),Y$C+D,PA#DB6"564.8(9-7,%66$6P#;3U&YOT0:'\W&D_O?KV_6E;_
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MQQ1D_3+MZ><^PZN_C#I#NRG]Q](1:1R/*D56&)PDKZ>E2<[R*\[+2P,MB&BP-I@4"26MGWX&&C0
M*+X-+2M+O0 5UWIB$HT4"J(2AP$5BY#G,U.0:M,-,\6>49-2 '=?
MCHLS9K]R'H&R4,N<%EJG+>."Z! E-4;8W)+2)A??2) %JA7#HNP,TO*7WFU_
MV G3*6BDIBTU;9_.24X,QR'1#Z#9[+.@T9D:9I\&J@5IA07^7E$IF\
M_4]DJ[,.#/S:H32>(0JQF5#IPJ66+C!=QPW<^X;^Z6S'TR[0CT:]O_N#P6X5
M+J><%1:GN0+3\F_*S*O=9#X-MLS*%0JIY0IG_L TCJ 00!0M0\&V!9PKP'5!L#348L
M"NE.B@$CSY0(5;&<>\66)P\_SFMY.E3K:&6,BPSD!$@5.6.!!%OM(O1I]7P^
M)$FPK.[4#-5LFF'R1VF.3M,X0UM<0<;],/40/&1_."K[DV_U1'!0[<5OF;4-;/?E2J
MPM=544XUJFQG"T@]M=P]Y5NNR,5D"R+[#KV*4HQ#<0
M)J9I^&G*&R?2U,$BE7GAGV2CW9X3V T*2PE6!@5M/0G16.$E(Y5'U=_??=T'2[:6EF
MG5[O?AP:A),IP@R>*&T04_5F[$B0CPV+_V0#W.N!>B(&&PBOO+41HF4B!*/2
M06KFJO-H>,7F;?G9]K)G@O]CT2WZ7_9B@HE:84O_?_;>O+F-),D3_?N]3P&K
M?;/;;2:IXSZJ=L8LSNY:ZRII2NH9Z[^>06!2Q#0(<'!(I?[TZY'(Y!4@+B9(
M@(RIZ2H2!!+N'NZ_$RZD42[&=K]/T^_RD:)9QF(;LA[/QB83L%1[
MRC%UV&J-9+1-01CX,D;F]IK=.^R$B^FB.KO5^F+WQ<",$\]%T()YY01'O*EE
M)2R&O*;W+=9;K<8]NA[/QZ:\0(2UB%&YU'214P#'X-K9Z.E,/!_M=3\<>3P;
M;>^VWZJOU7BQNV&@B#UX9PX BF%N")9&-SR@L*)S0U88LY&D1]*_J4R#:) Y
MT\RA&(R(/!K4S@J6AF0NY]M\*/LC.4C.SW@.SM(>EA #"MS+=!Y!F7<&>^2;
M_=?PB/)97,T5MK74WR+H$91OD'L@0D7@CRL"SIA"5#07.:07PJVX0+Y9;[:F
MNYYU]>MD/*@/O^=[EBD1'!6R6DB$@P+7@@;6SK!W2OC,G=B\J:VDJQ-6-IUF
M>*9ME,ZQ:!S%'DP8M^.!J+2;RW$ZX>7#M+KJ#\]:XVE\+ @PSYG
M&:TGRQ/OC<3MW58.3.:S%S8OTS9T'H+3#8L8#?>4&DI>J[;]5\VS5=G9CZ?#C\OYLDG^S3)
M&K*:Z325HVV?5+P]"<8PJ@"Q(12!71-9G$HAEF:ED(MWNN[-:F)2TQ1-<@8?
M1?83".'^&M\60N2,I.;,-F@,J)\:5#1-V#V1W.B50JB#LU,2PHH4P)TI1S0J
MAGRZCDQ2_QS)7)->5DR%.Y'1M1 HPJ4+#/C
MT4ISD(@?5 AGU7E])V.TN@W%?R^&T^T&\]T+A".2X&22J#F)'CQD"ANK N)L./ZRWVDG$PYA$EQ*C)(@C$"NR0AB
M#&N7WPI%A-X_[=R&JL=SL;9O1^0 .:FV'SD2+$):MO$CA)8K?&A%L[9Y>W!1
MYW/WK:$0UH%#J5AT!O[%$ !HF^(76,5L2T^#Q3.*;U.P*W'K$U6:<$.UXU+"
M_Y!RK U*J%0K;I>C%0<0^U.WP?0"YUIJBP@GA,8T>9FUAZK8>I(%>S2[Z/U(
MXM;F9 B#A:4$UQUS"+6:V#:YBCS)"C2DREVU;8E;5W:Z7WGNPRD:"(OQ5DUPP$X6UD=O56]VIH$E0KP/RT\XTK;-/AU8%8VUTYN;6>:B0M
MPY$Y'CS1&CB#/8TR24G>U)L<2#G_?ECE!"RAFD5I/< FD2H!37,R&>B*L5TT
M:^/3!9^;2T9KY30$$;+-ZA%,N'/40F!$.6R< A:M 4W.*4DO**8IG/6#J"8"J4JEH@!4QSL>\%$U#:8
M@D _OQ&.L]YH'?&Y#6INK9B:A^=>\!6#L$8CH(&1Q$U2+U*V"I
MK5N+F(H%D3ED1#Q^":\#HH<[5#Z1+V/!Z;?&&!Q0NG9@;%,%+:/W.B\%6!%\
M;\=<9P(YL#8PP430'!1/D=0OCCO:.+'(&RPS;D>M;YVE8;%[&O04*'%8@A]80K0$"!256L=2UE"K6'&TI"SB2>5A\"[C8
M6B#U;//^["*.)M_JR]=UCL7+KS9M@-1SK"!P!5PDCJ?,:SOLC8$/FI?G/Z3Y.PIG
M>>;\/?6_F5U49REGEI)H[\]31Z+IU_M'1QL'KP0C0+Z]*2VF&C14C),U@!CXU4#2CSB*+,BHPPS7KE[,L"O&/'
MQBY*@^?D$'+<8B=\:AK;X*4D(B^@("KK*G[[R[QR)=*\L=")77!^Q%_W].IO^X
M;E[VB 4 E77$@JD%!JH2$6:Z;8A*F,@3E%SEN+>1I$=SL'8)N*;I#%&Z^@8:
M4U:WB:R
M7T7W*D+V)G;]V8:/CIK(&$4$8"X@V2;HO?0ARURL4I/NB-UPU(' K]?(L8#3
MI)4ZOF^[MKI@?;:9K]H_.B5V[0QZ8Y4/V,5(C&/&I[LJ;<6^!.\CB\H>1>QL
MVUYO#WM*/FI"(S,F6,$E;,JB.:P&U]CEC>_YPZJPBIA'DOT(AW%YI>1CFI_7
MS-3;$#PB%A3E@AH=M J*M2UQF0_*9'M_'DR?DAB>N7021
M-_T] =FNS*H])2+HJ+'6J;\(T=%;$E4[VX0:@W*M+3+=C 0LA-112P=K-03^
M6MO8-J>&0"^L&()^(DAP<,EN0@ 7O!+&44\Y<3A@D'!LM=4[_/S:^@06R[F!
M2-8H0;5U&G,K1*M=*M"0'9L_CSO_!&9FHB5I'JR#M9THR>UE\-?^^&RW;*@QUI T%(99
M[ 5!W+BV=3BWRF=D<7P_&9.^!L(8 IHP2X!F3#/F04+THVR&95S?=Q@?
MIF1?>M=V 2.4*F\%8 S&Q#!N:$MOL"B_'\VS@NJ
MZ6P9F^XF92 0$-+67=-P4-);UA9I2*QE1K5,-TCOT[V!HL=1OW:RH',0#G-C
M8U"1\,"0;KO%I#8?62PLBQ)_;(7]8X'>$"H=M8P,':%G*91A+9D'XP>
M975/NBG07DUN0\*N!*X=,PIX@#W2*!BF+!;@I35!&A).YD:G6-:U>Q.!X^K]
M^;):#+ZQGHIQVVWRB^EP_.5#-1U.5ESWZ:IJGMWV\'TPB&(24CD:A/Q"I&:O
MG$DLP)#U[83X>%$_Z-_0.X E1P@Q(C6R
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M>5 $."+M_#C -9;7DV.9]5QX.IX>QJ:[#B"2QDH(2B*BGBD3C+A6(HBL,H+EVR1RS3
M3:N9W6")>(^BU,@KQ 3G5CI$VM&'U.;9:$J:HOH'R+RA8Q]*UZ)[\#%*B\%_
M)$:F/EL6M=W"-'8YI4CO0>FOU3P5OWZ :'EX5IW9[W^;I4OZ<3CNCP>IY'DP
M'W[=KVT;[$L1--NQU#X_%4A!B-RV"J-TQ MD_0^8';*U#*]]KB5 B/ 6G$;!96IVR0Q35,T18P"
MS%K!.!ANO$16P(W#5-FL!K_-TTZ%X]ZE6SH(32PT/$@L'@7UH^UH091G-\F8L:])Z
MY_MW(VQM S1E VP;,4TOK>^^8]XVW"#8Y#=69=;STZ1B28$;:)#E*PB][?J:C*M6Q"MI???U]$+L::V2H0T,XLA;$,:O5W3:U*H;[>D-R?E
M$02O%S! JM<0R'D"4,0@LG>^O6JJ&26=$'PM_N9^V>[(@RR$G]8':DR4V&H*
MM+57&*S,AY@3(NX?ZV1$[$[AVF$)'@A#$ CPU/0GM0QO)Q9R+$C>S8&);)MZ
M+(4;L$C08",3@1#0T#2SUTG?UOD(L:)'/LO J ,*UY;O(\N$4D9@B,^-(2RT
M':N()B[F]SQ0UA)C.PH?L0="E*=1C S3="-%>G]=YR'8,:&N&-P&M30T6YW^I^J/YQ::@EEG8ZA'\@U/G8\MIC.T(
M11)-?KK'[WLGS\.B'_:_C"?@I@XVE<5;CA3UV-O4 LL*HK2DC5-)2,B[=Q!Y
M__3R>3C\\_?QQ\7TRW#0'VTJXW"8>14-HA"!4N--O%E#JGUF2UD@\#P,?OQ'
M-:KF_=%6>BH$N%=81$XY8IZ&X$33.A7<+"_S&S0'LL2UKKYT:6Y$M-:E_B),
M0##3SAS#)+^R2W#65;\[*@^$%R1@R:7'VL:H@A01A^:2B7*(D+R!&,UNH#\/
MC]L#!O4&>T,\"PU-L89/1(* _[KVQ3
M;PHQZ6V^L64)Y^?A<"?$"! SV#0;3%J9+I+:=&BU7$;D7=X$/ N[N^!Q@Y^F
MJ([8I!ZD- HG&0?/HKUQF8IK>4AP",W3G<'C!HP-9(
MY0+S.#I00A;:N0RPO'E?&HP/X6+LSN%.@($(K!_SVAJ 0=P>,4S=G<%!=*D5IDRJV$:6A@:93W$0_!#N
M[.X<[N!BN "K9;4S# E,0AHPVRPB$3Z?49,RS;-HJ
M*O8@
MT:?V[=59,_ONPZ@_GIFS_UHL2_KKIAN?^K]_2(VQ)N.[S>L_]'-&MT@KQ21W
M2W :^44-\XB'=@J(B-%G2W*?R0/P\&QR6CMR! 41I+$N@N,A6437B6"(QV3>
M^RW;Z%Z@L'(H6Y:@)Q(FX[M0]B$1-!D/TPRUQ>5B!!\X>XC>35&_H%[1-*TF
M]>Q"3B%GP%*=D(PI*U:TB7W)2[$AJ$OC[X2"^(U%&I$1-M4&M@,NK8",(LU_3*JPM^/%@T920H(PF/@WH9N+XK/YM5#<3/:Q#Q;24%N1DG.7<>*+8=2$>IC&_H?8V:YO[I/P=G6"W
MU/GV7?=H^W-_.$Z!RZ8;MB%XYSBE/)6I]:=&2,IV\(G#+#OK?XM5D>P>/O7CU!\QCP4S+H7@5!#M4^$(!W0/
M3B*:W[ IJ[2MNTTD23?2I2&"XZ 4BJB=QBZ-,ROFR:],<+Q:P3Z)^DL($H/D
M1@47&7CDD?NV1R/#3*\:2UT6:1OW741##!**AT@A0->!!(0<82P(JM0*],_K
M=UZU8)]$^TDJFE86VQ"YY;Z^6M<438!7%'(']?@7*7%MOO:'H_1!H.)C/]6#
MMCT/\Z_;V:D/,O5\DM$'0U%T$,K'=N"P<3(OOGN;=>+NBO2G%,>.ZKACAU@B
MG=!"I7MKC'HNA%%HZ8,'91%_B3)=ZSES)2 8,ODC7
MWD40DBE-M#"8<2IT\%XG##/@8NSB=;[47H@7M?>C$MW&R.LL$DKC:@$A$Z;%;A)J9(O3QWD
M4]./A]<-.Y%,+7Z1C1QXYIBE4K'),K*Z]6Z2!2UC&$((%
MEC&%_X#]6NRT]F[%><#6J;9N6/75=/@5/O6UFOW[HC\:GG]/EWAG]7"NO6R6
M,A/K>A++#,5<,-Z6.AO$A,Q.G+/"Q4<0>U"FUUX$CH9(XBUQ$,XX)M*I6>-:
M,2ET/NKH))C>=+'/0^06@S+8X.@"N)/]+HR5U&:WV#>!:6[XOH0)YL(HVB-39WP,6;"AG0EL;F[)B7*?=W=
M-N,.F7;22&<-$+FI\4X:[;T
M1-S?=P1NG/@XG5R:]^[GQL]_?W[CZ>^=%<56FIA&CCAJ=;I=(MO:40\[/]NG
M=O313#R?I-9JD' 2O!\$;]7$6:XB!9>0<"-!8"1O'OB");6I<8G7/OE1!C2*
M* 2@R]OFCUBHO%G RY;4.IT*U#KL(U/42L11G6!).L44-I;GE=MOY2[[T9$(
M[/WXED>T-U"9X!U"*A@(1CR.@4315*5@)V+>#:& _P
MS1!A(4A! BB2B,8PJOTACFP\C
M)9BL/)_8CN#TI_[L8KET31N9"<1Q*^-M%FA18A!-=.MJ7,@F-Y/^H?]].;UH,JU'C5=GLX3S?QV>PYXP6TS[XT'U
M83(:#O9IZ2D8HQ9S%QQ3*MTB W-M]G*)0G[$(N[GKW:AKCNN-IVZ*FV5B@B\
M-2F#10+QAJNHB?=97BZ[4]L!5[]55XOIX*(_2[,")I>7DW$]F6;WYK@$D"DZ
M" &]H)(H&AW' A@!D^;4>"HL
MQ&@9-*WH1O0D/*QM>BL%%EHKEQJ%IL:71+LD?P$OEN1,
MB1+,1.]:@ 4&\M8LZGZXM)&F3A@X4+,0B':X@@63"@(?JC7E1K>]=S1A&0+0
MC#Q<;]]BQ'LF94$"\N8
MCA %1X/;>0RI*5T>&QX_\SMU'XE.>JZME#JF>;DAFNMNZ6DH6\;__8#BJ-AO
MW^4FTZL).*R;+LP*PH3&R L9J'$IDR;;GEL$&9D?A-]W[9^ ^_6[OO-,X."2
MQV5S8E,;(F23&M(VXN>+YJ7[>X/KXN-\>MH-,9:HL&")LT%RK
MV/224Q!4L9@5*V5]&8^/^9U@6W,P=VRP3S/4O&,"')BFJ[0 %R[O1WS,[.\*
MV\89;YUF7D18:FL-)>WB!Q=BMF?1IU[\#0$G;+-$8XP4YI)[;9#UN!TG"PYW
MWN(WZUK^- P<"+9!=[F$+9=$ &W,(U>HF0[DO1 QW[6>9_D.U.83I:*[5&_&
M"9.::FJNF;Y]U!CYG]76&;4Z&\CSXE=QR5E%';AAJI\#1;
M_*SIZ!-POWX(4W00*".4M-AB6#K1;CM2F9@W:L1/[6T?M*.J14S[H*D FQ4\
M>(I"]B.J?NY#:#X8+U4T2!Y.\/$4X6S'5L\=9Q\X!:MEFL3L,,0;"L?&/B>
MHITSDUJN9Z>N3^UM[\3^KK =86]6TBJN%(UI E@@K=T[QE? 7N=V?U5-Y]]3
M[[&Y&9^E:WA7ERO+@3>U @T0, ?IL&)I?)6Q%K.V%:AC^4WMQNO>P,EJXKIB
M:=,E)2, DS#X45Q':GWJ:-KX$URP%5/9LLK^/5F:5N?5=%J=U<="'_K3]]-:
MZ<[^HS]:5!^JZ<>+_O3>@?6**IV[H\4,$ZESH(>W.6!+N= .PQ8!XJ-[S1;;
M+ZDGG^-;#&U%6A?,W*O@N[J#'\S3\-,_>>96E/NIU#^Z'6+A/T&-(
M7RM_HHDG3@J"C73(,D"Q5IE\B 8?GO2?9[/%%A)_2^^4=#*!I8/0D/A4T>E(
M.S!3>*7O-.)IJ=Y [Y**?6F]7Z1VFU:F@N"(03 GM1$&!8Y:6AU38I6$'TEK
MK?2[E?X)I3AQ@5LI@_#@PD3;'FYY"+BR5-&#%-;?O3-IZXK\C&'<.^.P]EB#
M7^'2K=*FX:0W>57B3J1=]8=G397.@W/-U\I-"@'T$.HC2?$-Y^T8BVBI%)F_
M2[-IGRN)V(/*=2(DG$ID*:(Q77!+HZ5U>[O)(I0I[ MY GZ/%R\]=W;T[1.8-)KX8VG ($\.I;:28DV
M\Q@"RO,/*G-E'Z3II@ IV7&J/7I_OK3KOXW/JNG/\,*X]OG&9_7+MC^KSE+Q
M,$B^KA"NN\O"VT:+LS1Y-:GV^ZOZ6O3.KEX05E(7>4B#D[$1Q#&U]2I8:B(U
MC 7P$["0BD0G*G!.QXD5Y/
MZ) A>.FS'%(V,FY;RKKA9E/9%W>IW8<,*@H4%,%M[0B #@1@6?25%W ^DIOE
M/:Z'>\'L?M]1!6="P$2 M2/F)6^K03R++&3'B@_PLHFN[OC9..D*@1\3M(B 
M_^!D<6]]V]X!XK LY*3<0^9/(U3@6FJ5Z3>X^1$8%''%LR.;,T
M;\N:3=WIDLR'I4F9Q%Z#"_MY9G=/8DLP6@W>\A:DVCP#&M-W6XO#<;(\1_@9_C8=UVYK?_1+?_J/:EYGV0>3Q7@^_?[_NU\?MG22)HI#
M].]Y#(I%#NYGXSX8!M'LQL%O>W&\.KG[YVDV^FX3GH8($,7K.U$0>4L(O66[
M8,B*O,&=5OC^)<7UY#R&\+5!,-(::6$\;*H0X3#8OIK:*=B.[V8UVT/XK+=7
M!Y3_6NTZA4](SE/62%NP>0Y.C&EL7?*TN67ZPK,A].N(V9_HM<(6$#D"A2EI
MI!"B0K5'9P"Q.I\URCC;E^C?JOXH)6;;?MKOQTM[3+[:C9/F)K/Y+]7\8G+V
M\_AKM;R1/(.GUE?=;KVTRNSQ[>*(7_K_!:[Z]ZL40OGJZ-\\O:O)K'ZKI<'*V
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M%.J>@ZH1)E(7JH*'C@4DNDXF%//G//FT:V_>&N8S
M?7TQN+NVKB.5SU@'82*55!-0,B:;MR!">1(VY
MLLYR)&'7;Y"3Z!!C=A[PNJ2]YW:D'$?(0%!/0Z3$:^Q*2M>R-,X1HR12*3IH=B7. 8\Y&>M//X]E\ND@/N'?5[OI1OT[FU>Q#_WLZ@UNNZ8U>7$RF
M\T_5]#(]*1TLWNP:G[Y-/EU,%K/^^"R-Y/U6C;XNG[0I:(Z:&]@8)*;1Q!9+>V@%M@EKI718F\TM8BRE,C2(VT0A:VJKP/ '1F5"J3M9+JUZ!V3CJ6R9BDX0S1O5/L K0_6,^] Z2;Q(L65(2!/
M*P!R183H%2B5!#2%@ZX\T,;X(>EN1_%D_*55[MTQTX K(P5SRO#4$PL)W)01
M*(N4R38&FH;>K2'X%BW[T;M)P%R1&*0):6H3CM$PTPQDTMRAM)I#91CZ!\/AT.
MP'US_5EZ>_I/UOSEW_>DT3:K;XV:EEY)[&XF'?07KTTMU=CZ9GFWLS86QE4K4NT:$#3GZ
MMOJ'HA,=CLD709SUX'I
M7R?-S);;KOBJ!]_SP]>HWRT_/ [/YU4UWI2[9I8'S@)# B):CS5RMAW:(HG)
MNT5E-;K=2&K3W#/#!>+<.VTQ5B@89=M\$:QI?DC/Q**U+&]3TZ^K]Y* JEY"EQISZ^V^4+PYG@_XHB=XFZR$A-TRM=O5=WF!^1]0)S@QD!4H[DS0G%K-&$JME,TD,^OE*[P T]8Z'>WVUK8#TGP
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M#0KG)[_Z_DWCG4F\R]\TM-9A"0.Q]Q)'@V**;][EWH
MN7V&/9N,AF>UIOT,N+"BT&.V[- ;1L/+X;*;0&[4=QM<6HBO L&,88U)U$32
M]A:[2HFS]6GJ1W#3;5-QPFP@&D4I+#<4Z';-. 3%7#IDS>.7;M>FTR;AC!-N
M6/"!QF E$M'39HH>N B&94!+M,C]@<,RL\-@-"X\YX&XM&TH,![@X'KFJD"9
M2RE7G+ =EI>=6G@C&6UJ!84]<@PGV#)M)RCBT8J!.2Q'JQW963OK$M1;,LL,
MJ 7RH/.HJ].4.>@=.^.C@C:* Q*0SCU@05BL44!C)EZ
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M:&9,E7JTKAS<44K5@@R@7QL25>K#[8AO'"6"^=-7_X\V1R-LNZVVU3_.O2W5H/D3]*=>#>FS:91T(0,I]!
M &'%/=I6T;$7G6LKST!@WBDKB480X5 +,--L4SSXO$@9(YV-GNR&T U>J !_
M1A*FE72:1;K0CX>LPV(J\/1N787"1A1<E?)13G@O]^AUY&A=>*>.I\BCREMEBUH5JZ3O;,](K[\G440C >4LV[
MH6DX,R7BII^F8,]/[UWY*@DZFUJ !N*) 5\@M@7ZPCH=NY'O:+2L7U]V3(6?
M][T@[3R$=CE*'I: ]$
M#/M'N[.Y_&@)YZ>3W=.\ 869,:D$FQIA@E>!"=[FKB @%/F42ISG.0]"\]JJ
M;(L91-M"112DXEQ'J=K+ %'FZ3\ XFSGV)+FK]4T#>))A1PS_) ./V$1PW5)
M&KOST37WO2!01K!EP>9)@PG8\\:*& HN+_3(;AO=$\&)2(=O)QWM#/&"2J65
MC5;+Y(4TRH^YR*M [V>1'RFD@P#4*W$"(;7 D
M6#,9\F%/IRR2792%&VN]2*.P(/A72'AE+ A&"&$D%?FLDRP7OTXR*X=.[I[X
MI3J=X0  @NL58R"AO?DIN8FK3J;NYZ17$[(_J5NM9;T422COSYL C:V4_#1YLH
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M-3=M98G!EHJ\-O)P/GVGVR$5A&O44=#P=C/EANJ\]6U7:2*3AIQ_6=88?[]YRX=EZU_SK3]MIC'?
M-!:?U5?\/UWTQ^^OZH8L?TYSTF<_CY?=ZS=&!_5#K[N+MZ_"A\\GT\N4:J[)
MV*@BJ6)44!?7C?#+X
MQ]] A+/?/OYMTZ4J\/R]0900GFKVA-5-]RP%^Y.Y,UBR78N\L.15+88XA$D8
M3Q5VWJ?25(Q3$8MH2^0LES&L6(;M8.15K\)^)J&TT#%J1+@(*MWECI*VS3*L
M%7&526RW:[^,Q?C/:OCE F1JTO'BEZK^HX>M-?:'TQ7-IKO<1LCM?=F8/8=5T^_4ANE]I*65G0?1>TJ_WL]E(&1AEB&NR0&9;ZPJ'8CH/@
M--R_07NSE%2_DZ0LY4&7WS>O2A<$.(>I#N@% .?QD;UP81<#=7Q5A/5V(=4\L3[P6
M.]I5Q\MTVZ@$C9:[(%(_J11Y<C'XB#V9[F76RAM=/,[/9XG))
MPF_#V3_BM*INSP+?)M^6GP%1
M14%#9)Q11)21M&UV"5ZN%@_(3[PJ^:W1/T6-9S)P'M( M" (:8OLM7)&XI$\5[_:"BASB9>=$X,Z!,T"$46W'$H]QGJ[NPB/8
M@[&C$NC:[CR*2&,9"2X&K:5!$:.V":DG=ET?F].2M5Z0$82H[,2L"W7# GN[^!N,YU>#UL"A%:%++&GN77SIYX?+\CTGJ=ST"
MQWD;AR*Z+J4%O16MZ.2*)K-G?MC=<6Y"HM
M=8)Z'75S&*B8N=L)O$AT*W?32:H\UJD-+4U]:(/CC;L$_P>;_VJ)RBXBRE.6
MZ!H=Y5RD0=($!2X=+J]&D^]552=&E@_>=.6(
M.<&]I]1)0ZRRX%6U]0'*!N16'22!"==3Y52[#6R9?6V?A0I@X#
M#'2Q4SUCDKO;<\,'S_[ "P"O2D6'P ^(TDB%6R_ N?OW?FX$K-_Q+H[^7H!\
M(\#YL@\J,'ZG#@8 )R?@-0H8O--=^ G/+^#WB_ELWA^?#<=?]C_NVGU?HZF]E50,
MHC(IA*+Z^A!%"&+NW.)H][5LY$CGK!](KED(74T'PUGU83H<['5JM96T[YQ8
M!2\(5P&E)M]4,G.Q[YC'9PH8VV,W!O$: 3H
M;\]S0Z1L79$$V^6P[( +\GFS47[>)D1MLWN?JNGE@^WD;NLRP A#AF(JE"-2
M<==VZV8<@=ORP[]]X'^GOU!_3TP'H?<9I7*WS2
MPD]I%L5B^KU^EQG WZ?74)ZN'[:[R*X!(8G$\:!2=X54Q6$82FU8A6-,.14D
M>G"O8GI+_F;K99KV^GDZUP2B$?
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MH0V39Y7_N[
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M$>*"H? /0=3*-$JFO5W,F2.K;K0219C<2C&?@KFUN)G:M;&'=R
MD"[=P)C.AY]'U:^3>36#6+P//]_K./P1 I5Y"K_3DZ[SF'6+FD_?)I\N)HL9
M4&_&9Y^^5:.ORR=M:B"$*2?1@R,=/482_#T)=$L3 U(^N(WS%#:+Y32%^*D:
MOY\.OPS'_=%68K0H0D2'&+C^:;JQDA"?"JF809Q9EQ6SWO?-MA-C(O)'7\W[
MP]'L_;D#7L&1L_W1\KIF5S3R!!.P('?8ND$K+(:Q^LUA0"*@XA
M09MHTT0ZH7[XM_\YFO]T-OS:F\V_CZI__>$<'OGVO'\Y''W_\=/P$N+.7ZMO
MO=\FE_WQ3_7?9N!C_HC1U?RG'_[GE_E/]SX^&HZKMQ>U&?Z("?J7!S^37E_U
MG_Z4/ME^
MZ9^ TAV))GL2?>=SGZ>]P:CJ3__UA_%D7/WPIVMZ]B$NK?A;0J/?CWFP?/
MD^7U!M5HU+SG7W^ O37]/KOJ#]K?=]>HR_X4C'))9'\QG[0O3&NRZE>^#<_F
M%S]J_8ZD_N3_\M/GR?2LFKX=3$:C_M6L^K']X;:8TO-N$3^]_BDE*A+)XW_]
M0?W0FTZ^+7_&U^_]T_SLYL?IRB7/]TQ0P(F==O&;O^^?/^=EY9&D%[92.8M
MPY\ (>>CR;G _^R4UJ+N1*A%O>@]M'VFSWT'J12N+
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MX/O[F][5J _/ZX_/>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MU.L/!HO+Q:@_K\YZ9]75M!H,E\.44]#6OYR 3/ZY>NB7\L@5T)[#HP.,(Z]"^+P97 KW1H>0)E+!U:=A(7 [>B=&@I
M878!L]NKT7Q;W5+F:-.PIX%TAQ#E(6!0'@,,GH3>=9@M>;B+U:J?__>?=A\Q
M?3V8^N/@HCI;C*KWYS^G>8/5;!Y^OZK&L^IOZ1[B_>'K=$V:MEV?O6G_7@_\\G(]AN9C]F>K(# 63''6:=Q,H+_"W
MBUDOP/:[2P'[D2G9T47B1P@MJAL4=F"LD5E7ZG*=H2RIU[(<^=59_GO;/AK#Z8>$Y,./K#]]);]QB#\4>7H ]=';N6>RAV,,+
ML(?.YN.]%'LHA\QV^PY".Q;E*DG)
M$]CA7I-I=G?P6$RSF&8QS<[DJ#H\JBNF64RSF&9GL-[+3U*^@8^AU$9I5;RF26?>6,0M!QX%8,H!G'].8*[2V,4@R@&
M!QA$E!@XI6_(.H7^IC[L6U=E-%/*'%)3LTLJ_Y I6B%:67$%)
MXYW.9O=Z3)-U6*->3+.89C'-#B_>EPQ[,-,\D9M?1V>6
M.VA51V-*CD7CGF[@R$E=-R6'\A=6".985*%DB O.%)QY6IPY6%%>P9F",P5G
M"LY=H9@*N]>-4'RT
M*GRZJ)J1B/"5O2M8"_B:&3P%A/7V3%H?C9LSB):CP]R44*X+E
M3[,T>K%.8O;G\.&/<_C/9?W,R7GOYS$\K,IG+Y9AB658XNE,C3NRCY\V]87Y
M4V%^MZ.:2W#X1]5150D>Z;#$1E(O?HI=&9;X%,?TKU[-GF988H&W>WKWX$RD
M ^K=!DD^MR:625W/CH9%*\O(PZ*5)ZB5!2N+5AZ?5C[+X,)6_,=3I'S(LPDW
MF=>^I'7WW[^#.];97K%,[R2(=UV<>^\@_!T,$%4';,
M@C.O'F5
MH?FMFE4I+];KC\]Z9]77:C2Y2A5^^^0<'[Q4_@C)/7.SH])V;$<^RP[\HNVA
M="XN]E#LX::M3^G36NRAV,--[-'9]:N78@_E=/AAV7ZL1J-T42F%'I?]Z3^J
M.?QV"$-Z.=VJNFR_^M*C^Y)%?((]ZB695DF<%=,JIG60.*F[-D/%M(II%=,J
MQSWEN&0J[^V>5P/)S-I_WY\&NWL_E.-8'189^J8UGQDM [
MGFVGV$.QAV(/)VP/F'>7?RL&40SB] V"EB/03L*,(PKK#UQN-I\N!O/%M#WX
M@2^&UX;PRD%"D-:E&3<4R3CBHD6$RTF6DRTF&@QT6*B
MQ40WR!$=JLG[*S3-,K'O +$H_35.IA_[H^IC-5@ L\-JMLML/NX"9\@8I"B64D>,C%S.YF.*
M:8^>=#8?%E?KA_.1QZ[ZW>%\TPH$-!B.@(DT>F^0&B5_[L^&\.ND?N6\/YPV
MMV)[7_NC197Z*#\TI:_Z[\5P_KTWNUX'>&=_WH/%!2WKSV;#\V%UUNO/>OUV
MY=Z>3Z9O9[!V^?R^'9@C.VX&VZQ&"U/LZN'AB+>>8]D=0)]/^
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M_7G:MHFISOSRE_WM9%[0C@%$,&B#!)[
M"B4OODX:P^)';I W&X:X2:7E\-YJBB?F?&9 Q)!7ZKQ -[O
MA[/!:#);3&_:36S1/\+;2 /SW&E/HHB6<83J_A'2.2.#/GC_B([6L_YUQ:W!
M:W'5MXD3HA=,E3_?8?AW,P@<$#7/X5].5+?1.U9O*W
M:M2?UT7*\WDU/7XV]S?%==3?QXW;U!/=,?7OQ[W_LQA7-]NDKI/OZ$WO(^C?
MQ:WM,_V4_@=6-?[PP_U^WKW__S#'WOGPQ&LY6PQG/?Z7])=
MOSE\!-9UU!]4O5^JLX2NUT^Y_LL/?WS3^W8Q'%S<[G;2ZP_^>S&L-Q_:&_C8=)BS[.09EF/9]F7 X'>S=[U/=4>6RZL1$ VTCT;5%WAA??9_#29#:87 T'O?EP-EM4O6EU.?G:'_7.JJ]#>.]P?)Z&WL"#_O;NX[O>
M%= &#Y=O"!%O&-?O>K 2OX(GE(Y ;E@CI.5MPW*LDO9M 1Y>-/"6MD?-5G*9
MI3]>/B 7]08)_(8FN=@)J-?U=\YZL\D"3*5W54T!N--[A^/_6HP':8@I/'LT
MK,YK+%F,9U?58-GYYJQ_V?]2S6H97Y\SW
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MVO>N)K/YVZ71M:HP \2JGY2H!G@"3%Y)=(-GE_W4'U&I;7W8?:^TYO6ETR_,#NQE/YLU'DNJ^ZZUV
M*FH:ESJRE"^P=XO*I>G7VTBS^)]JX23"3/TIV$Q@E9;6M_0BP.:65^&V_&RO
M#QHTO6R6=RFYEH3>!3BV[3HVH@+!+5&CV8#OR:P!IB3Z,6R*0Z#-)%&G1G 0
MHKQ)3>&68'+=NBUM-:F/62V[VV +G[F1ZIO;J $D@/'5'ZX5HS^;I-^^-]M-
M_=;%"+X0J.E-%G/8;9N]'#XXZ*>-?0I7X?G5>\CA&/C
M06*W\6/3GU;[OK?6XW^!H2X^SX9G0WCFF]Z?J_';#]/)Y^1:#B;3= 4[6OK9\W/"&HP>>MS0!^/J+[Y^G())_+C4;'C.OECM(4]@\X =@+G7
MLE\NX37Z#.?UAZ^FPVI>]P< M()=KC>XJ"X3];?6Q%73K_#24OQ_^6V9O;C]
M&A9_PFJ/%;DKD+33S;J, BAJ';!Z??O@SJ2ZM,3Y"&A/PNX/!HLDD!L5GS2"
MK'J@V&?)=7_3^R5YV1]^>V_#F]X'XT)-"/QY,*J&OS<*V2$W-;7UQMANM??V
M&1!>*\UV4VH4=@;T3.KV#X-:A8;5-6%)/QMOH)\,X1] V-*SJ4/P!6P>2X>5
M)S\S376]N_&]J0D>IH?TJM^O6O\)E'>VN+Q,*O1?B[,OMUZPV*.AOVE\ER;\X?^].OD3W\Q[4Y3J_U@TO\"C[V#I;ND?.VN_H@4)Z#]"YJXA^_@SS(S:H'
M@(R^I)[2O0_.T%N?3!;=[-#70-K$J#=RO?[+NFVB=\.^?(,$>X.UO ZM>REK
MMM3(VE8OZZ1RG0-HXM$K0/B6@9MX-,GD08QJ-+7.$]3&/ZW.(=@#%Q#H_SSY
M6MTX#CW:1A9_25X+"*^QB3N!]6-S,7FFO3;+6E_?-M%G)_F>%$\.(03+8S\L
M;^*8^4U85-!Z+5K?[G.]]KR"=(S8G^Y*LU^'Y=^3.+_VI\/)8M:X!( 6P"[8
MX:"J$G4-M#4>Q!0B7EBKY#@V&C%)JY>,)CD/RUQP\IT^+^"-L#1W4QF?DU/S
MM6U47OT^ '^L@?@)?'9IJQ!K5+/!=/BY-:[T/=.J21@T9-XF<#)MZ6M-N]UM
MAO.[JG'7W)?G#=\FBQ%$(7WXGGZBH%HF ,Z6:93J_+Q:IB835RE#,AZDOZ\H(GNIDD3)OTSM_NE;D^CW#VGW_7!M.6L9;EK-4
M]/2'NAELSWQT/<8!NPX$3>M/,O=*1??^6NMJZJ(_J[6C6HXP.%LF5NHTXMEZ
MD\W/MW<[L+YWU'TUK2Z  O#?4TA_6?T*Z[++X;;!1G")@C-,,2(E$4PLAR-@
M*P/QIWVX_0N(S0+A(VU,Y,_]8B?.Z/^BF75:/7=51XLR UD+1N^!*R9C<''NO;
M19_V6CW0!.]!:[I3(G:T0RE ([X,QTLB^XOYI'UA6<17OW* N16LF[D5S]Q!
M7YQT _[">^&]\%YX+[P7W@OOA??GY/U$NF *F#'L^6)
M= '#HH)/H(*_U+.+Z]3ES7 5-SS6RHSK+<#Q.E;EV66W[G.;[G&-^'BO(HQB[
M\A0#HAXKJ#]@_00S6?9JG7H":E9FWSW!OEN K0#;'L#V%+.F"JX57"NX5G#M
M21VV[CK:%UPKN%9PK>#:4> :[6Z83\&U@FL%UPJN'06N$5X"T0)L!=@*L+TP
M8,/\G2S 5H"M %L!MI<$;.()_+4GT)?GGR)7H*M 5X&N\ -NA@>U$>B@=3E+O5_3K'M:=YWM_2'V[_]C[
M7)U/IFGPP6#4G\V&YR"/>CK!#LIYS1S9<#]F'\GN<-OE $$5Z7HGV,D4CT.'
M.G,CBK?PN\FV(QE6(J+]!4KB=DD<["C-=R;E"LXL5:Q1](\;7*!E),
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MA!=%!5^^"I;PHNA>"2^*SKT6G2OA1=&_DPDORDSWARIL;?5E.!X/N^^OO%XJY#>IW:E7QF/:X9#!3CO#GX":E3%)3[#O%F KP+:[H##K<%;-
M,RI,&513L*M@U^O"KDY[YA2?K.!:P;6":T> :X>8[UEI01>$FJ*X
M9,4E*[A6<.TEX5HY!2BN68&P F$G#&'D"3RS5P%=)]+=Z' F]WX.?X)OO[R:
M5A?IXMC7JC<:^;(
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MNNMQM*V,NA?)41<];BV7EUP5>7P0='3^00&@ D#MQWB'PP6EN#X%8@K$
M%(AYGIF:Q<4I^%/PI^#/;OC37<_8@C\%?PK^%/S9*<>#"@ 5 "H 5 "H))F/
M6GD* !4 *@!4DLPER5P@ID#,24%,23(7%Z?@3\&?DF0^;MTI^%/PI^!/23(?
M/P#=*G#^T[P/W*]\_XJ?__>?%K.W7_K]JQ_=[>&"/]?]!G^=S*M/P)P=30;_
M^+?_]__YW^U[??5Y[H>SP6@R6TQOW@)R&B=A_%:=_^L/T1.$Q;^3OW_R/_2&
M9_!"?S!_&Q1"FBK&G?B_['UI0R'SR0"*S?]J[
MOAAT^JVSZT&K/>R<=J[.6V]^62)ND5)?Y50H]KMX8%^"*=\,:H7;/>F+DXG0
M2]_NM'ZP!83ZXX-Y[BCP7/.@BR $M@%64HS[+KL,A2LC=AZ&W+_3M1P?;\?X
MV+B+/#L$!M5,)WW ]NA]%SFV,,#.2Q'^ZT0PY ?NS[/C"*E+MRSH%=:2V3%S\6'^D$XY=["2K3Q
MFNS!6O*8(SPON>;G-ZTW^C.@AY-^?CYC/T@WFL"?,*<$[0"0/#Y3XGWZQX=E
M$,H'53SPD '9<.T)E^V/3)@AG?9^>!HIUV)Y,J47WMXZ[.L/>_M^7U^3(S25
MLWNSX79?>+ZM!%H^;LLX@($B+%!BN!L!AQO5Y6\\="8Y53N#!ML4B49;@KPQ
MXLH]<.6MF$5B.A+AUIRY=3"W)B!:YE;391R&6-3"!2-XB>E3WF"^T*7.
M]0\N.!=8%GW5EK3 TW8(FDB&M@)7Q.(IAJX<(%2, RM''V*N78EWO)T?7D[-
MKR*"/4IKBH_=/IR:ISV+":H5'WI-QE=>^.(5ZSR"&A>
M/=#8VZ2I^M*_%&C(L_OP1=P''DQT%ZNZ8NWA7DZ,]FF_V;(E/559X;*U,2E=
MDHC7)1'D'#\2*0Q\/7_<4\5,A,?WSH^\JN#+R=D?VA._5U]0L$8B6E\5]WID
ML]WKE'7H\14*)_EB'[X&$?>8LV&O[9#V>E4H9"W64Z>03K=U:B]X7)65)*^T
M?J'@JO#.ZT2!LW9S2"A GOBVM/TUP)'C7O4!LW;V2>O:8W*%&+-RA"..VX5P
MY%3ME*USQ/'\1G?0;;;)CB!O@O:XWVUL55B&_JD(:
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M[CL"7"<5F18OW'%"L7AQX2!;KMY1MAD%YL24Z-\
M;+(GXY;UDSW^[%M6Z\OT!-38C.\E8].6,#7&T+(^
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MM%D8G  "PG&@D(L:!:-*!MTDP+2DVJ3 BT",SX7+.+Y8#[_@+L
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MQT80O_? Y!X@OE7=J+KMS*^O5_>\<^X[>W4#RU[=51RBOL(E4H#W
MP%YKO?V!"6XX7J#P\EDH'9$JW]PI1".H6,AO/VL"ZE@8&1 6&
MBA$.6!1R;16Y?)Z%O[,P]SG86H@=L18<>1D<]AE,/KO>TLS.++L'[W!;A&^J18]I.WI=Q#W^NHI#
M"%M2G^E)]EJBU)QZC!L8F*RVDDGD%&V >8+!NE2&% 'O" )_P*
MT!?,M&8K<**<3H4K00=ZE>/:T=639#5S7OT
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MVK:T=;+!/+6S[] @^[$$_4(OM66[Y*PJAXR,9"9S6J5&;UXJUX%>@>I^\I
M>*O)S>\T/L.+,6BK!4&GXN-KX*-)Y$9W !Z0OC9!QX37M6V.#I8)2Z9NBU2I
M\Z-OQ>P9'B*(LAEN%^_FA.!#ET%Z*P&E%ZK+;!RHX3LA?\O]F75*O-.)\Q@'S@+S\K6#A\Y>C-C8TQ
MM\)3%HJ>M9;(C)^+K_&#<,J]Q6 ?7I,].#(I(<+SDFM^?M-ZHS^K&7?2SVM(
M\U5.@;"_BP?V)9CRE5)R4QZ"K)M!\C@*TB],W3K]S8-THPE<#81(ZG0YL#Y\
MIL3[](^5XVGYN(O%/?.Z78.U1?>WKP]JQM3K__!T9;"U97^O;
MZSUZFGQ=)E_[2L'#W53H\)D*;$-'E=-J=U19T:P\-]W2PK3S
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M+2F/<(9PAG"&<";;OR-[AG"&<(9PIE2);H;#[BY>^QHZ)TS)/.3>M7Q;X(1\A[W7CO5C@Q/"&M
M_?,Y#.Y"/K4RY>$>9ZSO^^2S\UDH/=;I-[!SZ*"QT/Y95QHW^14!XY;Z979:
M]IMYILL4YLND%I=I9I:)O<7YO5F_AF_>F8;!2@!@< _+.F'#[H=)X'ES%CSX
M0 H5CY1T)0]ETA;6 6SATD_K/B6M4F44XY-5D[$_LB:70,RI2CNKKA_"(OV+
MSU\8S,F:P3P 16'H\!]XA R+3R;E%^F75?AL%P3P78?S@*Y2B&YR\T
M3L89;1H(9W5%8(QV$P-8VCS3Q-XUKS3<#U @%],Z5W+KP"RPSHXH> *F]/KGPRQD T\.96Z*[%-PO6MT\T%IDG:FB- 
MI/C 4R8")O2B21#? 2?%P"PIF8!7EN<*TAG[3C"%OR/A-ME%^CN@3ASIYN5X
M<=YV=ST(&<$=@5+/,^MXQ'[]>/'I"YMYL6D^SF%Y" .>8>?XY(LI@"T"KAFK$C..OX%$WL$3]9.D%FA\,5=*1$9-
M%DF;^Y]#2Y0=9GW& ,MM%02[?HX;B!
MO@E)IW7UXJHLWO!X>^WT[Y]^C-7)'>>S]U?PTBNI'"]0@'=?P7Z[\ +GVR]_
M_HY4I?/@BQC^_N;E"J^V?
MG7]]O7K#I M?<"?/+
MDE5:%*@GND2OZY)MTQO2'U?:U>3$?+S:9A6M\%6_8_T& 9(-L\?O2RBG/7]Q7Q"=27^(Y0X*(,IX9O*-4WP!#X!R%4(P&X
M[!-M.XYB^%(HE4"4%EX4;P$R$DRE@[)BM*5:-!J!L?D=@FF4O!,D#%^JP!)-
M#=-,]VD(PF&DIDML<&CQ H?/5!&\W(PMEWR#1-P7!^0&,!J$)'QV?JM"+-9(
M&7OF60E:(L3>P$^\^)YHPK41X H%JV<@6^L3Y!2,Z[$)6 C5&E+C\=%'X\31X6CQAN#THA2DVAII-E,8.T%7J,GY())
M$TGM^*1?R$A,&=?,E*J:#PK\_:2JF=$O.4K_+57U!P=]&\(]F(%RK
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M:R)B":W,/M&PTS[]H(S/>3+B:!.,=VSG2X_;2FBOM<68OUK&F/N[8-[FX0
M'BU(#\*!#EQH.]F8@5KP'8WE&^P_T)@ZT("* *PY$+\045P'1SSO:5-Z$R2N
MJHJ-5M[E@GEM;+XUD2(TMVO*45=Y$-2>/.LU4O*['9&>PI<3A;(,ZU,#WK>#
MX*WFJ>6].M\2];1RL6OQY5MF7B+P(*0>^ %R++&U"\8>4,A2IV^=Q?*DLV9<
M1V,*/64@+\8(T"]$=Q:](0G3X:%Q*LT(YQB1#X/OF.G]>$&Q>M_M7C])CC&>36\9%>T
M/R3A#O0F4F@NR*2;[?7>IUR
M?Z#R_ 0);W3,UG(A>KSQ78CR&)R^Q?W]_''PO]@K9#T4$F<68TN%W0_MVICM
M!]P!,=$"F;U4;[]J@8,+C:S]T;QM,C?PP)QHH',]Y2%05?]T'8>!<:+^^'_L
M,QYKS5-DSF,%]/$D/,7SI2[F?X'
M;PGF$\XQK!N:'9AL_R?=JL8=E.)N"=P*) !J&DMJ<00H\<91U]8&^%$,(P#P
M(N;!0YNLX)6,90CJ^,^8AS!JO#J/6B\ES8U K?LX(?$=QA&)S;R6CP8Y*G0-
MA&6\MKPW-?9B#,4:PL =&-8)8E5<6GZ'J5"1OA5 &/D%&Q$F+VPLK_?2%A1 
M-M)/>(#PB3>510GS3N6>SF3=??0O*28P+
MQI0C?)QA8@0G/+3)S5;%Q96JN-?B2O@0PL*D<;Q:DO3#@.VXQ$PH&W"W5QTWL+<#\;Z"@
M3_!?H#^*.D)(,6EL"Q3#Z#E.?K,@;;VC:0C+2J/JH*H>4+E!#6-+X,Z#M]V:
M[L?#MF[VU3) />'N'"%*1ZV*YMF2D9G;C*F]N-E<-'MM' =NS&@^Q7':$_)!O]FW*DKUBS9M
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MB/OL<]]SMHJI/\4. 2C)L>P3KB8.
M;IE:,S_)O1 7?>(XJS4M2Z)+]+$%;:\1P8A_B'_VK@$K9.$OJ\:%$?0ZEG,<
M'CL(?H3N4YEVQ]8)ZT=(UVI!0!DJI/)->>R5^GV*K>I0XK=EL9)XU5<>[Z,*
MX@0G!"Z*POA2JGR:RU]MR%E@=N
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MDZ;K4MC;(3N\%!]<X^$/\0_U#>".6-O!YQ)L+5W$.H%T"2@B7&
MJH[FI;R1VHAIJ=T8'">,19XW4E\J54LF:8.5-E@M%FK;X\G .O 0WD?I(81>
MA%XU0"]*#RD_/>1'W89WW?5[&UB!:"_H4TS#?=%P2^TX\_5GZ;/S3Y-U4>"D,$DPG85B(GQEVIK#9]%@OM!W1?S[
M\PZ'4'(VH2 E]Q/_$/]4DS[$/\0_=+BH!$MK+]WNJ?7%X3+!CK_UQ=O./@N@
M/47.7,2/)6OQG37B5@=2JZ6@"$ )0 \)H.VFM8@H 2@!* %H#9B2 -0J@%:@
M^QH!* $H 2@!:#T!E"S0*@!H?4Z%%9<&CRE5ZQP3=_\=JPBCJ'A.:>;B/X1P=F<8O[H][Q
MUF>=W*Q 5+$*E/[I82*=2?*H*?#>G+G GEA%2GC"B73U*!BMX^!^.\SEY>>B
MUJS'ZST3U6_V6Z?#MM4S46TK9Z*Z_5J?+>G5>O2O>?+=UE&>Z]FLO:UGE2W7
M W0\KI0[A
MJ5D+KL/[RBS[30A9?\*5R7^?=-D"4ZB O4U:9KS3)0MV\"4W9^>L^_NG'V-U
M?@QWR \]]W_-MN&YP[\I%MK7DGE>(&*0_$5B'+A!SK,4DL]AX,.?CDE5^3V(_B6B880H+^G7PM"]B_/.;
MFRL,P_RS\Z^O5V^8=.$+MZYO^Q=G5S77_O-N"__0NSZX'K?:P<]8;
M]-MO?EE:LF?D;:Q;\94\%DM+OCXFA4/+*<462?4H%^QAR.7D:>TU+^NCGT;Y
M@+4:.N_IYOSV@DFEL$_-^>T?[/>@J7\]:9TUV,JL=EEE??E[&<$D'3,,S+4"
MZ3;;42?L-@+A80M?OOT:S*3#3MO#50M]EXDW&::DW<72Y)3M.\=&*8 U",FV1X>3R7#2&%03(DH\H2[-$ONJ0#^ XH.YN:GXPS-6&8Q\ ',A4T#
M> "^/KM"_%V9R6*N'GPM(^; /U'@\KDI'@X#QRR\"0@NRBD\:Q8HN'PT9[,P
MN)?Z6YU?5[B*1WKXA9=,^7@P@NL%)EIR32O-9W")8XH"Z;S,Y&'P&=$@00*&
MCP3C?
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M1ULE7/P?[F\-B^W28/$F6_J"+PGV[B?P\Q%SWM[&H\A 9J=_TFZ]>U]$%@!GI!CJQU\@0(D8N<2GAT"K&:Q+C3NA-5!8#RYG>-\FC
MIP*L2O<)PST=#MRGQ,)H8"R%LRNI@8O8#IC/P<]:;JR3R'ZJLE*"(NCESX%/
M6*?1> !-=@[J!, 'X=)H+_'=$09_TM'R>RX]C:8XRR?(-N'W.#_NPNJ +D(U
M!QRD;\[&H%XN%'I)@5,$#@*MI+BV
MU9-9H"LR$CDHP4Q4@..?LV]^\*!->HG((L>@-^"YP4B)\#XY@R0+;*P?]Q#$
MGIOBN^Z*E!&A!!9OLB61TBH\'5"JPG,MG5(J83?D+!TF*[BEB_=L&=O[DW[6!5W*>Y-F6H[]K3.[J_J[(R=#82?
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M-Z&OY\@91LBT.EMY138E;2MHW0]^$5P?XF/3\6WY[M>$Z[.I*N$K#51%B.H;@X
M()D.R, )"K6.SJ"Y)'0H!_,DM[W=Z)(_FK=-;3KA$#[>?+E%AO==#+(O.T O
MM:7ZS[6E3JV8084I-(X#/DJ5R((J?_RO6LQF*4S\),24%R:^7/#2TVBQCGN<
MYT'-3!R*%Y_[W)LK64Y88QPX,09GT<(O>.QF8W#^7VF'[=,/:BG0D J9V4=*
M76F!6W6F!T/BSWGB#N0@"V^HB?8Y1V)!8BJ.-0V,1WBQV$[N-^WM+65QA]P_KES-^4^-YLP.K/ R O(
M!TB!CB)^'!,5WJ2+S9\@EN',J
M'J'U$Z&,8'ICE--)I'3B.9VM$C,&J;(B3"A$ZG"121I'5FS H5@S0KX1JD6C/3Q=@\@$-"^E9Y^BSE@<(VH:55-IZT
MPETG%V@>SD\PWH6I"=F*&TQ+?>,ELSC4FRM TIFG35=CN*4VM*%HON^54E/G
MM,DH6QV%?#:5F .VNL:XKAD[&,N3FR(K1G^)L:?W1'"YTHVDS#C/"[VE0S+H
MJY(HJF9++TO4$Z98'&Y9Z;V9A(\"T) K VLRP =7JSX5- KYA'K2OC /C=-4
MNW_'[EV6*#+EWY*OT[!KDG-G0A/9WDX:HM!KH/*'H,4P3RQSD6U[)=; & O 
MZ522$=A]9J.F$M)(7YQ&+'E6M^:>@R8RH=LE8F;O\W/9,GMT2:Q8[\!Z
MGJXXDCQW]2(T<-"F46+&=8K?^B$W&?N4; V<-98]V/L@,G5+QOP^"$V4^X6<_8E[L!>8 ?TY2@+/T_RVR]\\&YQ?G
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M[#P14CNZS=;) \D#R0/F>]A
MK=/;L<@#[0YOINUM4IS/G"(-OPD\Z%:&(%FEYX$M,(HB4A2Q0CKJF$2+ F2!Y('D@>XK]VW%W\C@2"!J+] =&D+U(J;42&WON1TLRB,
MG2@.TXT?>#&6[\1^U:5X^D^<2$!6MJ]C+]:T*_&JPFX4C*N!TB,1)1$E
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MNP\\CNE*T;P,Z:N=D'5/[67YOPYAJI[38\'>2I_-!0_5.ZNB=H1=FZB-)P7T*J3%CD>T^M00
MC42+1(NT%HD6B59M1(NTUO:B11M-'Z[DO011==E<"N\YY\Z.-ZQ10N'^JJQV
MV;J(5 [)!G6H$-QNKZNN1[$1"CONIS8Y(=IB(Q:P=E;=JA=Q3Y-]]!DJ6]R^T&M2CB9LV>[C94TF
M6[;9!D@[QJXDOB,65>%G4H6O715& 9N*Z4B$*NL2)'P9A S8!0!D"N8MBP2?
M@M*<2&?")H L!P :T)VG=KJ"V=6=MM%O67=>_XM\ RK.#CSQG&[/1H0O%G+$-TT$1XCQWB0 QD
MX+(15_ EW(EX!".14\259%%6%BN:P#(\@,)D.&JP'\:))2>Q39HSX?Z=2/N2
M;?OGGKP_F:!^"W[.
M1Y>-#$8]Y:YHKK+3KSDZM
M=ZL<@\9*95ZX&T1>>+HM("BII:Z!_E)8!F\/I9;[L?%O\!)MH:ZQ64:"%5ZM
M 66-49)(FRUH[JXY,K03Z32Z6U2+S9[%<2V9((^'7TGE
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MB2NKQY74_K+TE.P+'4U]6#X>J8+20HKS+<(;/Y.\-.HW>ZNKU"
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M=,]HBZE4?^VXW+*KY!#U 5( %Q)21Y)'E\BCV>-L[8])Y'D
MD>21Y/$E\MAO=.UM]Y$\[NQ\5BC:(+?F'EVL0IS-C
M6'<;\U.A(<["*9E#.M25,>&W&/^X[0O^!#''V3PMZ%
M25D#-N5S;$B*C2[56 JWD?:%7M=MV6Q)-=@(>R:K6.]594VGB]7@&LSA:L("
M[&P*WX^DGW5,3&[ (>$U"YV8_ZZ8$X"JSB<)WMP4Q%- MT!%GY4
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MV!72&X&IV&Z?L4_O#.V0P4.!>@G#:2@H+J):SWJ)N
MUX/PYLBQYE>TVL!2 CEAD_DL@&NT2[(@R6;D>#N, IM9NT+!*FJF SM0&P6%
MJ6J6@:MA!"/AB[&,FNQ6HLF!C\A>FSZO0#:Y*G&?R, JTLOT
M'->0&*T299AI\G69?.T+TARV*W+WB1,")5"J^M2I&.]4
M;OK]"[_ .]_1TV'0C([ /9*VP.>Y'NK.C@CO:,
MV$:'B-"06- ^"_Y31VESLG[6P9+\L_2W#87L==CG>O,G'^9O.M23?QX'827'
M_1'# \AX^5!-#*>2HWVKXV'Y4-OO")4(E?; >+?P&CD&4@ AJR@8GW OHYHC
MRS:9*CD\LW^>R\LRPG0(80AA"&&B#W_X0;TEN;NU)%/1L*XV01AD,'PH]KDHI-%0"
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MR2I]0+?H?1\_+V,8-D<\Z1SI42DV&^"JQB/K7#?95^$@QP$'R)V
MPV7(_I=[L6"!SSC[/?!#;%<=PJ#9!5?R\52(;:<^+''F)G8X$>PRF ([SUDH
MIF:ZBD7P]1BG>&^F.&8.B!27,%5#&*1'X?0.BV= !KPK<)*LD(6[Q#V,7C79
M;>Q,LD>$0I\&"J4"FN+%@8I.IB*:!"X3I@6X].^%BJ9XLWEE@&I!WN,BZ*CQ=&W+^3*/"%2=P%@?L@/:]9O_6:
M!)ZK,A(_03VX L3R9 : )QUOSJ*0(ROG/=89O[L+Q1V/D)0KQ-A)XW6;?097
M>3+PK3Q0+YB=H?6:'.I/#?P
MC\+68)Y0"")S]@#S$"=N\. K3(XS SN))MR'@4UG0S#C [ :4,6-.7]%D
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M6B[>!RNFT:[PY=7EY\R(FQ?&.>-S/3"#RP6D$,7?A? FAJ$H21T0$^CQ+63,$S6S4S
M]'5#W+ 8ZXB-XWR:X!J5PH*_D(][+0%S3%E9II5'1?IVH*G2KP67UCRX@9@8
M(J'181G-V1_-VR;[Q_GYYTQ_YN0L@JN9%#XVU1,+C('8^]A44FTT$IX$Z%7)
M %<91,(_3]GXA04OO,<*A+0'96/(>3K7.$)%HQ5FK!=HHST"2R4C=@Z6M]":
M!,ADQ\!M-P<=-K)JX2;^@0!'"^P&.0-,Y,K:B,LU?$-4S*-_HT('S+CGH=32
M'FI10-Y,13VS?8Q01PDVF"N-I,"D4]9A-JD(Y )V4&3(.&
M)ZXU^Q48P&-MEH114*#-:JX:CQN<$QVX1,8TZPO(6QS XNLSI9N[2F@C"Q/7
MR(:F-@WL"Y9D06G =[&>=EPV03=^CT(3Q$K'; )?/*'UT6ZH"V[C$N6>1;Y8
MCTYP=;5J$0)XT#X3NJF>%SP\4;SPL24J/+VSXP+D]VVWQ[3E@(STNN^?E-ZXW^K&;<23^O(<17.05F^5T\
ML"_!E*]LUCU(-YJ\/SMK]MJ]UJ#3_R'=MW!@Q< $%>_3/SXL;S7D8ROFR&;;
M%;VUV<_;9]F:D0V[/SR]'[)V5\;FW&$@"EEH$^6SMTM/'[
M(K:JP[[N6:O9*IT@55EZB_NUK_7,.8!,Y]D@L_49H]J=(>KUS^SE>%5EC0\B
M)J]'27?+DY^GSI]9)?+!!:^D7G7/(%M5N.J5*#;*JZP,Q^TO?;).UG2[T6J=
M[?'\2E6XP2+^;$Z$7/?W3S_&ZN2.\]E[W/G6&]^_Y4'5C_XLCE2^0_X52'#A
M!CDYG)PT>KTVU=7@]/.>??L\ORZ?78]:+6'9Q>]Z[/.FU^6UN$9L:=UR[AU
MI.V9ZZ@_/ICGC@+/-0\RQ&% G2<,EFKDSPWO*6X%
M)%LBX]CSV!C$%6Z8 ^3H.<5*F#PB?1.,8A8&]T 2?5<^%*%,AG"ZGXCW V>>
M8 X:CDCBKJ+[[UBE+W3A/:&(],TZQISD,^EWZ?1:YL:A2<822RM3ORS6A3V5
M-8N1+H$5OHXFH3"I)DI^MR,I4_AR B/W,3O"RB/+W?[ARLXH._UFZP<[8[*6
ME0ICZML9TW+^*>YY\@1L[ RUW>Q5CGR#YJ <\F5;RT&(/P0F-<9 5IHTBIO:
M
MF::V@1()A=99::89J)BQ5EY1^KSDYN3=+B@=T%X.7NC&CL[FQ933>Y/B#QB5
M?#D2OH G)0DM2:)LNA*X^6TR@3EN$FM#9BF%6''/9)NLR9V;&U5EDE/N,/$7
MUW\4!-_8+ YG@<*TX)M7C^M#J_GR&SC/E? = M>Z79AHR3C1(GP
M'CD%\Z>YAUP:A7(4&^: 1V.JTGT0ZH\%6XW'F .G1!1Y)C5E/X9_R[[A_WMP
MKT]%Z(4U:Y*G1)^;[%9$OEO,#N0A8-]%@(FD;V_.;R_>@56K8EBJM1?^,=,&
M(QCF?[R#]S3U*T[:IZ4Y%0NG(]BEQY72&?)ZW4'RLXY.]MP.L/!O_T@G!J(\
MG7F8T:\2]:#3F;+WN^G[%TSMT9P)3TZ!Z%%J(2>.@DZO1"!*CR8@1RH!:EW+
MR>K3%LZWF;P_?;P$+.X@TTOXO1_XV<5
M6/79V[4XK#]AIX_+):M@SC\4WKO^?<7L7.X&,XW?$_"=5,)6*-^YGDZ?,I:A
MBC*G"4B=>#YHA1J%851UJK]U2A&>S@"O9>%YJ5OSN$"OAE8>BY L1E+2$WWF
MN.9N 97SBV&_=WK>OAZT3GM7%Y<7%X.6":CTKOO7-Z=U#ZADIQX-D>KA(7Y<
M.:R9G+4P1T4UF^H,-A@1Y;!5,X>MW6K92UYK#ZQDK_7VFSZV
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M1H0U1X\U[<:PUVVV"6L(:PAK"&O*MFM.SPAK"&L(:PAK2K=K!FS,'"PW#]FH>MD#U,<6X=U=.'Z'0*C1U>=J&NO1$I5EKYL
M34T*^8CEX;_L-S$CN2"YJ+U2!Y(#U1EO=1H?!'F;2]C!4,4H3F<#XV
ME9C(F3DYFK6/*4.^CJ>J8[O1;E%!8HH[5DI]'8]X]5NG)%PD7"1<9>FN-NV9
MD7B1>)52\'MP2IM$Y;IIQ^6-?<6.ZLSG4VI5H>_K= ?-+H4S*,Q'8;[48@.)
ML%8<@"2")*+V$H$ZHD<201)!$I'IB+8]M^-8)((V@3;3]@)[*&!FFB<=;'E 
M?;Y>II$L.OVOO?AJVMI6#VK*39O?:WR"D.<5($^GT1L.
M+1;8(N0AY"'D(>39SN;I$/(0\A#R$/+LV>;IG)W92TQ[-B&WV'V&O+U:UDTP)!
MV'GWVK+3Z')Y2S\/Z;!66J>B_:.ARC1*ZR970(5V,RN^%4='(
MA;3A7W_]9RRC
M^:UP8IBQ% I^O#0[=%CL"'ANXSMT 5KX\$6,?WYSCDIG]Q>=VZ/!UV
M92RMO/ZXTD$W)R++Z?FVBG>VO)]FY6W?KT@V)"LQ1N#B2P_I=S(.PA/%/;&Z ?>,R>5$V>Z  NWGV=O/Z[2L;.AU][NC=N -
MO8K=7N_1T^1I\C68?.UC4\/=3(_A.C-*O\7%9"J=:?0^QAU\5)'F#9_A&8'+
MKN%;]_'4G U'@+LO/ )< MT?I[4#=H((2Z*V?LXEV':'=.Z/[%@KL=IF5OM'
M&"B54_4//Q3PZO\(=UNK?+^C!9?W.86U2#)(,EZ'9/P*@WU6S3D2#1*-79GM
M4P37LJ\3[K.O8CH#RS"RG, X0WA#>'-8?#FK<76$$\2))>9&J7ROB,8.B882H(+.OEE);)0
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MH'0X^[Z?Q0_B,)JL7_W^XNICS0XOQO73]37P)U)(?L*U!
M@(0]@8?Y)U%V]F+$%;PA,*/SA'\7F<+Z$HB?](# 9\S_KA8+A. #%:"-' -N
M^9$'3Q*@5?40'!Z&2IY:X0CS/<3]IWG 9^'I;7'^ QWT&?("7ZX^?QC?2Y[XCN7<+WP@]JMT*_0Q[
MG<'Y^4WKO-?N7M^@">E3(!3^V_L9"*=!OOH.TWV-LWK
MZ+0^)+]DW[0_L"#46%"X:*DP$%STCLT,M>"E,#X!A]P)@0?CXTXQC>YA9
M'*H8\"*M/!3&6)4HJ39TNZB_KK\#//AW&A&G4BEL5E(LW3KYIWZL&S _B%#!(+JF^A7?+_TQUNS175'TE9FP8$^8
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M_D=/BT>*!#C51(35$CTU9="T>9@$*/+!@P]/4_$(%DCR$!"KR@D
M]T0A]Q5W53 -]4M6B]BNU[1G65\3U2%4!W  BY8)81-@ +>'!E/AF
ML7")'8U[J#4 DH+$MP:4DM.$J5+K#C@&)+#8/@UI@RM:FFG0LTB@&L"E^8B7
MOY<1]Z234 9$"N /P>;Z7H/&9:+Y[3@>6\<\RM ,A6B&GA((G)DC"O*1]JY,D=*\PZ\))+C.2!K%.$$]$BG?)XJK>(39<
MT/L8&M%JG^>^A?8&0A-;P8A.[&/8!)3??Q)CH_BTS*)/R!#[/(9A8 O.)RT>
M@F:KT+RT$@G+_QTF\!W,^M0HXK:"KJU6LV4WZII9OWCV.@$7WKIKG78J97ZX4N;M@952YKW^:RIK
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M3SNNY5H]1VOQ]'!HI@/5%/>HRM,P5IV%@PI:>]@A
M)Y*GN-G"%RADBV*J3'CDQ=W<2A+R-L-*Z;
M3,KO^'[P!'&JPB[D2U5(:QV=0%FLM/=:!*KN)79J+'Y'
M8S2V&ZW6< ^'L(]%YDB\2+R>0:>S8;MIK8+XT0L7.66X0:44,^(U[+3;'QAW
MG'@:F\.VKIB%PI&ZW;QVVO@T )J8WO1D9VY3<:3?[UD,DVQ)GM==>H14WZL6
MN$[/HGU) D>.W[Y[+"WP7!=XS@UBK(CP$IFLO"UG[X#.4^0[BA,\/3 K2HH(
M/X=D5>$>QE)H=:4Y-JBR-9%^^*JW>I>#OK]
MR]9PV+H8#KNFR%9W>'W>NRR]R):E1=4?5^KH+!!-QVRNY#U\9S;>+R<\O'MB
MS_VQH1>! T-?"_7M$#9L,NS70MDZ<<^]&%9?,1DIAERD8U"*C8,0/LZ",(I]
MS118(2[)M2T<*WYDWF/0=+];'C<;YA(9\(X\(@KE!/*D7!A7P.9#$/^!AV[""QBY#6-<-@[P
MZL":C,-@:F=:MV(6B>E(A+F%F/0KM31;F*65!^E6)RN#M,- [W>&S8):=T!0
M1;B-WEBPC"M;5'$*XB]],T@>1T'ZA7%N]#>F1MYPT&QW.\-VQV+EQ4[;2NG%
M;K_6Q0M;M1X]39XF3Y.O]N1K4K"T7J$QHL_VQ3;+V*9\@I:/1V=6S+CA;@0<
M;G3D;_(*[NS<1Y>^6\/G$><=[>.:_@OK?:/6)!8L$]LN"G"*YEGTS<
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M?!%\512^JL)TCB0U;*+D%%Y:2VJB%0(74)O$/\0_Q#_$/\0_Q
M3T7I0_QCS3FA'=A7L /;&3;[>R-,55CA(#YLA6).^W%N!]1JJXJ& 06*B>.(
MXXCCB..(XXCCB..(XRI%N*IP7.$ XE.>W&OPWA:)6OOZL-26JUY1R*KPS:NL
MODU=. @#" ->-P:44,*F*NM)6$!80%A 6$!80%A 6$!80%A 6$!80'$"&QA 
MF3+;9):2DX&7]$+*PA_9CQ($NZZ[?V\ *1/.D+TXF0F-IN]/ZX4.!BH[P(Q%N
M?&WA*0LPU +^UT^1/B"L^5Q\C1^$4^XM2%$;K\D>K G$'.%YR34_OVF]T9]A
M]9WT\QI"?953H=COXH%]":9\!=RG/+R3OADDCZ,@_<)H$OW-@W2CR?OAH-GN
M=H;M3O^'E#V!]3P^4^)]^L>'97;+AU_<),TK,;;7GK?9?I_5#*T+0WI2*-;*
MK;F_?=C;6[4>/4V>)D^3K_;D:U*;M%Y^"-'G&6=ZGZ@.O)_#Y(^9<L2"QX!Y9\%,$U[)/
M,Q'R"%..+P,5L2]Y+8B
M.?H0_Q#_$/^\&OXI1042]Q#W$/<0]]2(>^CD]&9>N^ >]QW!N$('Y5;,(C$=
MB9!U!@T=SK4EH14B9^5$U[JX5K[SI;WLP11[G.A#>$
M-_O'FVZS33A#.$,X0SA3;D,\B_WPJK[RA#.$,X0SA\&9%MDSA#.$,X0S)>-,
MOWE*.+,E 6J?)52CHJ0$S87SG27L?CUCKZO2A\.K(AAEVS D#TV+HKO2/)(\LJ1O!Y)'DD>2=[>):]-DD>21Y)W ,G;
M1^X021Y)'DG>LN0-FAV2/"N21[DV20TNVZ$I0J8C#H#3QA#)!*-"T<;]E>_ZC8?.)"W=-:# ;?DX
M]3CAJ&UH>0=*J6UHU^)Q5&H;2@A)"%D%7B6$M$?+%B$D(20A)"$D(>1&A#P[
M/#5KP76$D(20=>%50LA*[V,04A)2$E)6@E<)*>W1LF_QX"8AY)8[8C]&'.BR
M[OJ]#:Q -.Q\>3(Q_3';G=8/B\S= U;69)4^@&7TOHN\;8FNYB->_EY&L&R.
M>5*Q!M\V7:$?FTN)+8ULDWUYJ$6J]X96J+XP^(5![L)X5Z8P8C01\#\9NNS/
MF(>1"'%7-=EU1F@.= [%G[$,#4>$8EI8
M2.#9%*" 5 4^FL%; E?3,R48/FDD\&)#4K@9F!>T])RANZ#IGKTIX?GD.6;U
MTT7);K^(I@#1WKR1@9+6*0DX+O*V
M4!' 8@0+H54^]JE_:L52L.0ST(G?]=T@4G88L-T\MWG9ZGI<
M7Q1UQ4C<<5"@J"U1@^,#.*P=:$57+[0VQP"LT?."-=*+"5>#_03&"^"62-=DM^NY&CQ7K0M .GAB
M2PBM@A+,7U:[I^U.HRR]BW00OM)4//D]\$,@=J@7EWTPFKS]>I,.WIXAA
M8N^,09):%ZZ T6A+)##$=F3HQ%,5(175!AVY%CPR[(!%L0,4W6:WJDJTWVQ;
M5Z*D(@^G(N%+0!: O5AC-/AZ2@EE7-4@! R6_\F@,NDM(!* A._@[?I*?*Y*
M/"GCC"UHVJ+1FCE$L/ +$'8$T9_^BZ,_AU#, CSKK2(A":,8?IKR;[B8 OQU
M=)G!Y^1W!LUAM7U<;:,$\0V)C!>]2O1Y4[67/L1P4*X%T?ED#T'HN0^@/-F(
M*[GL\6\,P+')[8:,E(4SVS;-2Q!X[NJI)W/OBV#L=MAR.PY'I6+;GV
M8 _,N]F,ZRTRQY2[CUMN19W+9[- FOC+;21F$^&SSTWV&W=^ RSB/AX)_ P,
MI8,;#606,6;7V;,_:AD@$UTN"-"?5@?(3Y\71DIH%V
MEK&Y$MD!^.'&6MR'@9E&8H(XC+8C;W&_\/E&Z*$MRB:[T6"# RUL$$V"1?-Z
M)/)-BY&8!PDZX"[:-)["8"(,=F5;%XT\OKHPUI4MBS1BZZ9['@FK\/'8Z)=L
M3)9@IGS13"S )9MVS?Y>84E+-7(&MBWVQTP'])(L6D&=,L:>[=JC?&)\PXQZ
M.7ABUL:$3S;/;&22>YQ >BK-#V(XQ<2'2(23 U0H
M;4FY:3[%_,
M%7(QLBU!@#6= '0.H+\:JXI64J\T *9$]N^!"8)PGB9$C>*Y")N,W4J-4X&&Y@:."R]T#PRRDS%(S#:)0\-GH^$\/5W8 6"?>V!!O/D
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MU+%_XCWBO3WPWF??^6[AW8 -^Q/<(%;$OF#!TR6?$
M?\1_>W&"\?@_\1KQ&KD7Q(+'SX+D7A#OD7M!//=:>([<"^*_VK@7Q]ML\@5T
MU;==B#OI^YB9FS2=/*3X'K+^\TL)::_F>,5+BK^44&_;9Q;;TSQ%K&2*C\S?6\ZG;$]
M,Y6/, E)/$V1&I*RV_/K+T!*EFQ+U@ND ')5I3J2+%+@QEH+P,;&WM U%73-
MZF A"F&#L$'8:B9L9J?5A;!!V"!L$+8Z"9M3P7RM$264(5V0+D@7-@@:WMM#L"'!EV#KD'7ZJ5K9KOUMC P6IUU*6%19LD>"K:BH!H:D
M32,P6Z@O58R6]&R*H JH4D.J%,9P+=.2MLQHRKX!6%%;5OQH8:Z% 014V80J
M[98!JH JH,IZJG1:;5 %5 %5X.P"54 5K."Q@@I,%5?>
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M'^C/-OK3AOY ?Z _T)]#>8=Z9?G!(4 0(%4$2 ,/HU+J!,@:= TN
M<2U1!UF#K$'6%),UQ3U=&J .L@99@ZPI)6O*._ U0!UD#;(&65-*UM3?%]  
M=KL$R7_,*#?-TN\OO%YH?AA$[&3(:]Q"\;V6)2Q9.7/
M+MSEA2H9O._SNP01%]SB_>+/1'$RHN$+!)GB.\\WS@U,/!:&T^_\\Y
M2+S9^R6&N@M&+"5_L$=R$X_H&ZT?T6001$4CZ22+9Q\4J,X_>0S\;,B_S0TQ
MA2^'9DC'*3N=O?CT&H[S=B\>GWB&=-M8>HIF\Q,8TS:9']:39BGGI]?O=[ES
MT%_'L^/9\>QX=CP[GAW/CF?7^=DU.6^KG-]DWMS>GD?D]XZ0?'^-^F;9M,*K+)]\H8DW))9[3"S#E%Z/ [ #[+)/
MM\%W&:"# .Z)1/L 0%QCRT-#\SI.^$<1N9@D"8N\)W*7T"@-:1;$$<00$*P 
M@EP,O['"=7G+O F_+& IL ?L58"]/UF4E&;FA&2,7= S\ 7^5+(+CC(; &K"&Y04@6'\(8GD![&%Y QTCXPW;8E%!J5FAM< 
M9BB35,&X"V&#L&UO*+,ML5;- 0�C70+FA7L[1+:LXF"=.DF77RIZ6!*ABD9= VZ5B==PRX IF:0,$B8QA)F53 S:X1T:9+=J#S*
M?'L]:<7-G%LEN<0Y&^0NK)BY/::2&D!H90;T+>?*"V5'%;-J@"JH JAUB?
MUF6Z!E8TEA4RO=$80$"56E.EUVJ#*^ *N+(!5URLX<$5<&43KMCR8L]!%5"E
MQE0Q6B;6[F #V("U.P8.4&4+JEB89&W%%23S6V7"LQ%_P"Q=V+EG/LEB?A>:
ML1'C]XO[T[W^,HBW+@NEU#ZHUW;-SJ9KREQ1(?[J.S*"H" H" J"@J @* @*
M@H*@("@("H*"H" H" J"@J @* @*@H*@("@("H*"H" H" J"@J @* @Z>]GP
M_"%7D6B6['*A+W%EI)
MD'+S P@0!&AV64=B\8%U5JG+U <2 XF!Q!RFIB:F.- ?Z _T9SO]D9B=^YXX_^WD8>]]^_>%O/[^]U05-
MDB=NVG_1<,+2L\B_2K-@).Y\38.D^/1K_Y+=9Y^C-$LF(M_AJQMSXT?"PC>L
M_\O1]:5EF,X_K+_N+H](X/,/J)>=N-W+RVZ[XUP;9Q?FE65R
MUSZ_.C_Z]56/+9K_+ABQE/S!'LE-/**KE7+A\C"(V,F0Y7@R+>/#"T"9#H=/
M#HD@XLJ;G=H"3S+U]V[(")O9D?2Y(<\2_3C+R!UR[-^4(3;S@?$RSGF(A.DG)O\L@21FA*^G'(1[/T]%U"
MO-=%"W>W=NP :\L!<,/FK$+9BS'/> 4J\7[QIE&"P,
MI]_YY<@XRM]S9?-F[[?GQV/@9\/37J_5-MN&8W4^S 29:V9(QRD[G;WX]%HG
MYVU;/)/QK+7MI8=P-C_54;3,M3^L%_.EPTUQO;GGY9U*?[Z^:7;WETTN2D8A
M?8>5/CX(39HS2-OE\4>7,^1RB%?2/C;.CZLZL,'IJPSBZNCVW=\JYK%A
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MZ'>VQL>[(XJK0:ER+%<,>\K9!_@!?H ?X ?X4= ^B%5<;&U]YJK3[77<\[/+L^ZEW>Y=6:9A%F>N7,NT
MV]<7E:;:$D>LWLNTM6NBIQ=GKI8ET^+ 3?+34:DP61JDXE#5-/G6\\FIMWOH
M6S0!N:96YIHR#4/>,2E7RBFI;ONPQT4,K0^[['EYM3^O2821.,C>Y9LC$R$::Y.5PO)DG"NY#X?!9.XGO^(S0+
M^%SR.0XS_X,?I)X(YU0X'G/S19P.@J 8 I6S#\"%2"KY8GC'DA'Y/:;1(9FJ
M?!8S9&9=O*[;EIC@3O6N7S7IJ@P1#1[R(#2-%QIY&RRJ=_V^0H.5W:<;]A"'
M_$%WF577+@&TV>W(2Z"N2@^7/1ICT 4CFL4(+([?\12^KMQ4!HV:DQF]XTJL
MZ-'TQ.@:453?(:XYW#3;I9U':R YL1;[=!=G-"3>BKVV0\[75;&0-%^/3BX=
MV^C*KG"E8%.\U4@9[9YRU<93WG,E>K!J[PG7B&/ZCE)U(I<#WVJ@(5
MK*L4&K'JQBC7,5O2JD(UA5%8E:V+GPA7[GM4A34E38Z"1[X[.*!G:4IR]*S[)H&R;]H
M.&%;9Y,^:U^VKSKMLXYC.&=GU[W.U=5%GDVZ>W75-0SS,-FD%WI[,0UR6WQ!
MZI1MR$B1*OF><7DFXX2EHG9@D4::&Y4\"*O.$DM/$U'_GY3/\F9=0/I!1",O
MX%._($JS9)(7'R0T)8\L#,7_^96!@!A-TZ#/N2*FA83_)^YX3T-^,2/ID+%,
M?)G_TAOL[?)D2Q*:+DU+9!\6,(?^D2'?Z9QWO?ZPUYN:]UZK1Y>$V>!
MSK/V2O(C;SYQ*S]7\OET)+W-1]+?XV*:>*!OHK0MR)-
M?.GIX!7:GRS31U LLK3$H^F0R(ZC@Q%G45IHRRH"_O(DK8F*ACP _Q4/@(J-,-_
M/32^:$';DKP/^5FX"%B:D82/C'Q,'!,Z2!C+A\P:+I_*G'?\F; Q#7S"OH]9
ME#(^QXA\$HM"S<])*&F^H*^A7=62 !1N*156.H05&:U>Z?90I>?%=8A:A)Q 
M3DJ4$^2$J+D+2O]Y]N%M*--B7_.9L]P9,T:R!B=(L,J*,J]O>@3P"7Q::2X'
M"7R:EFY$.?;!<#"<2H8KX_SBRMZ8_EI^T$19R:SNU.,^CH8R3%G"62ZBG<]A,K>+TH7*'!?Q"HNIM/>V_5[P&]#\(@"YB\';+#
ML_C@S(5])"E;$W4"\-U OA(7I4R]ZP
M"O;R(MI7-(DX.M,_67([I D[IVG@G47^91!.,N9O74C;L&WS_/+R^LKL&4[O
MHGMEG5_FA;3=GFM>&_9A"FE/BR3;EN1-Q#.2,&X3+PB#:3WK/KD7%LS#N/W"
MAB05AB5TQ)>]64J"O"IV/P[YJ+'&7_C>00=ZT2T"\_7[0H:NCKUI)HFIZ?=)B:X9*]UU4;EQ)':@$*J&50&6M
M42E)*Q&!N1K#N3^:%#TAHBZY,>B \0:-1G%4>%93$D^R-*.1> 192B#5O,IL
MZ5BN==SNMDLWDBKH6<5.)5%2LX&DD?0RCFU;7F$GT OT.KSA%**7==RUI"U!
M02_02P'#J4.O;N^X8X!>I2[;ZK4Z^_>J=5DFHH78?R;! PW%N3C23^*1R&0X
M&>5!ZRSQ@I2)<)GBJ_%8A,\4V0^+3R91<-C8?W5X>6P;IBQ+J(*N+HP CM-JVW[.?(2)I)XT'"V
MKY0O6B[B*+>+B'7_(\[XQV/^O6 R@C?AW?*PQX8K+SEVW7T)&G%0KS&LGN1J
M'W<[!LBE(D9 +OW)U781(J$D1D NWA#]$"& NB3+
M*"/2HGOL=KJ56;(1:1_4XZUF V*S^=AQY:WXP$?P$7S?"KE[J@A\/)FM1FF4!2=YPJ_@@U4![;*&0YX!!Y5,ASP"#RJ9#C@4<72&):K^QSSZWQ+@[PX
M)7/(!;4R2S[SV#2DY7U1I<8TFXO'A;#KTX%1/:K6E+?/!+#!+ <,I
MPRS3D%>?$M0"M0YO.&6HU;/!K.T78/N70]RJGN'RDHC/]1.G!14C__> W@=A
MD 4L_<)H.DF8_S6Z8:)6.?\M\1/IUH42V[9EGEV>7W><"\7S$5!N;_$\%5<9]D0S8MJ"B^P*]^ [U=FKRD!L'26@.[W/MM
M/-@6=[$V$..%GG^AH\H6?2QJT/4Z+=NT.A*K.CI2JCK:;I-*^REVN:UUZ_'P
MNCR\]J=M#UORS5X3_E2"I=2WCF+846YI.&^NV?1*E6+=0?*%AYC"WK!QS,W 
MY[.7-&/DGVFP^K[>RE=&9.6""&H(",J'X#\F
M,5_NS\WZ9Q)X+)V_#Z)W#7VH9I]YXD38O)F<.]]8-G_?CQ,EV_U9N <$\.9-
M+7PX2K;VQ]_9 UMHJOD35 FJ5$EY\4$4]+DIN"%5),;7C']7S9;=IRQYR/W]
M*C;O9 O#RVN%L: P4!@H3/;IGU&L-Y/MC9F,C CK-OAVRG.PEO056E '
MM53&6/4=9H X( Z( ^* N&8@3OL=D_V-=O6?29 ]D50$6N7!68=-%@IGP8=S\$@'5; ##8 &0 .@ 8W3@ ("KF5:TC"@2G]""Z %T )H
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MET\X#@5>@5<8I\ G\$EE/F&60WWI#YDY!][5_3(/D7#2?L+$U9EIY%_L*AV"^,II.$^5^C&U'%
M.>$P.Z=ID-Z)7[WC)CH/8^_;KS_\[>
MGL<=\#U>K].]-FS3;O?.
M>U>.8;K6N=NSG:-?7W7?8E?AN;V$A;C5,^:3N$^R(2/]..0#!6_1^\>6
MWWNDA5^V=FRQM>7HLF%S5O7*BP'%>-4+XOWB3:,X&='P1<>9XCO/-\Z90SP6
MAM/O_')D'.7ON2QXL_?;X^DQ\+,A?\F?:2I57&E".D[9Z>S%I]?J,F_4HEM\
MKE#.TAV/S3WK19O:G0_K-7"I$D^?:<_+][U>Z\OU;CT>7I>'7Z4$SW=8MV$K
M:]VSZ_S*W6TP$I?E[QX+_;^/0[_069]Y<9*?5#WEST^<&Z:F]]>TS4RBS)LOE]SE(Q'_E"$V](+.>8B*F;K&D^EM\ VBN@W;)Q
MQD;W+)F!;>/=RU6BN'$BA#(LO'VBA$IM_EL2I^]'@A^J91MYD- EIQGPEN7 VBGE/_9=N.<$")4 )C%H8M4#16E*TCJ,6
MDH:]ES3L@87QF/?V,Y,RY@TC_LB#IT-JCO(;A3CN_B+$[[CGVA++^^(Z
M1+XH&/D"K:F]UIC';MMNF= :: VT!EI3]KRFVX/60&N@-=":TNW]?K4&ZL$^?HY-Q$GLL34G"4I8'>]#()W[AUADQ;L0='*-EA"$=-"^$+:\(
MLBI=7_9(C0&YQGPHX>@'> %>:,\+C!/@ _B <:*LU8="[H\R;7LQ27DC6<(7
M)6&^59\.@W&:KTS*S6,LT[P')9YY;!I&RX O 'Y'=8:O^M"K8W1!+I +Y"IK
M[#*Q9P9Z@5YET*OM=+%)5.XRK5ZKL;N$^HQ$=+15">#Z.C4LVVG9<&? S0BM)S%Q[HCNO59]EMEU0/9PFBJ0*MTCUN5J&KJ"-@DZLISAH.ZV@RNH*8.
MU,2H"FJ"FDI2$Z-FPW;!E*/E%JB25&1%%<155TM%IR.:G6/;DKAYN-8VJJ"A
M?I[C: \4)[-YCP6E ?* ^6!\E0\Y[%Z
MO0I+AZN"!HG>'@DU*#G3G7T_*2/:-S>=TIO;SD>_FM5][EA1@I6PYQ1)-!$!6-I),LGGU0#"_Y
M)T6=,TY#RW2['7EE$UTI51.[=I/*QREVN1JU\Q2;8RGGPGYN+JH=O*DFD%?'
MFUM55"Y;-?:B?!Y061$JGTOI;8S,O6OMZ;)O7]*L>WD_S*:NP6ZAJVN17:%9
M=9 $98Q57RT%XJ3.)UV-)2^_[H8^DA'EPUE PVTT3OKL1A6#2//#Z>1FZ[DX
M_(DI_.'3U:N"G::* '(B5+A:TG[N\.\X^782/.>?WV6^VIRTN_;Z\VUU893NVU?*\:_ZB$OE9UC5A6+6HFBAY7;*TK%M3*8*
M>K#VA9@I!$>(V99B)K.N?./%3&H<^ON!Y,N#S[]F_.$N^?,]T"QX8.D?<7;)
M4FXKFC'_+/T[\P<IOQO^2O\L!W&GD!#?_D.B_NZ8UQ=7AF]=OOZ\KS3=IVVFT>V=Z]=VS;LTB/;
M%ZGISF+4%["T&+/>%E^0":Z[(2/]..0#"&\"*2+4&H2S=[^1!+F"=+YY#'(AD&4W^8BCO+%
MD.AR,N]?$O?)Y\B+1Z(5"?&?04*".1SR/ST. V\XO=6($_&)^'QI%<4982'S
M,L+!-N"M]3S.Y(P_R^F[]-BQ/YI[\J#3ZAA=U[0DGCTP32F'#^R.UN'[;:U;
MW^2'MXU:'IU8/961'F*],"?(E=P+:9H&_4",*6FNZ&)06A@)X/.5[_/MJNWS
M+3_0_VPDI@QB)O(;Y;.5'W^/T_0G.(5]-C_U4,,38G?#A#'RA?]MF)*K2*QX\Z.,1)P3PTE%
MX$P2SFZ#[T 9U/[0]M%]V[_48+8X>:2)+SR5G+T1\7+ON/>4^Y\3ZLE;NBID
M4+7@J=;6X_37NLH% >NQ+EF%*^9N6/QHJ[%F^)?2!#"P=JS]!0"&@JH$2
M BHQ%+?"A.YZHTY.+E@<\_9G$_L3+_DV3A$;9T^\!O0_"('O:/NOFQ;7I='H7O6O7N;)<
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MW-JWLY.=6IL4V!0-YB9-69X+(H[2O,F4*T,8]J=0,%=(:GKM,R
M;4MN 1T+!71$@A&M6X^'Q\/CX=5^>$T"O.OO)*B9?7!.>/7YV^MB52)FK^2L
MF/H#>4!>I\VM#FFJSBJBF_F_^*+^JTYTFM3R<1QYCPJ!:_\&*G*'>Y
M7XK$VEG /V'DHMCT@!A4+P;5D%TY^P _P _P _P /VK:!_@!?H ?E?(+*12\
M6FK=U05G[306:YLTDKJ84"U (E-822,!$ ?$ 7&J& Z( ^* ."T,IXRQ@+@F
M($["5I*K^\KKWW'RK1\G'B,)MHC@9J@)JBYQ$4FK9@PJ EJ@IHR1TU0\Z >
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M2B@EE%(!]$$IH92Z8!5*">>E?@JYL(?V,:/<+DN_O^3USQ\GZ?UUS*W[#D@9T_W3V-
M^=_$]<^741"7S^ ?6RD^YY]\(\=WJV8_3:
MQIGCMKM6[\HQ3->VG-Z%>_3KJPY:-/9=,&(I^8,]DIMX1%?K\,+E81"QDR'+
M9=^TC ^?%CK<8[RUR29W>:&8!J=J?I<@XH-!\7[Q9Z(X&='P!>%-\9WG&^=]
M23P6AM/O_')D'.7O.5"]V?OMGW]$DT$0%8VDDRR>?5 ,>ODGCX&?#4]=IV7:
MEFM:G0\S)G&6A'2I+7\72HQ
MQ?7F82\WM&X]'AX/CX=7^^$U2:.JUY()]MGB^/&:1,;5G'M_;QKG[F9 <5G^
M[K&8Q]W'H?\V8.L,9V:!O ,@KP/D 7F5(V]N5@[!-B ("%8(P:\9_R[Y.F8)
MS41TM/ UD9MYVHJYO3$A!#*K1.9=G"UJXYI7V[M[55[9K?:8RS1S_BL^\V+!
M_3@ZG40<8\++6OS"31R&_3AYI(E/XCX?E[QDPGSRPE,-+:A>"ZKANG+V 7Z 
M'^"G,?@I90@$>H >H ?HT0@]..2]&FOG-*21QPA-Q0+EEHTS-KIG";&I*IZOR13KE!3KN$<>H3*AB&4'=JB- 7(>P;.@-]*9ZO;%;)G0&
M.@.=@.@.=@@,] 9Z$S).M-I=:$S&QI ^R@A
MC?*G0IH7SG>6L/NUQ5Z7TN?852%&V7,8\*'&?$!! _ "O  OP OP KP +\ +
MK"L.Z;-0R&%:IFUO&7_\/%)P3)]&+,I0_44E^9%JQ(/JTH]6RZX,6G.8E.>'
MED[%G\ \,*\2:8!^:!>0=@7A6Q0V >F ?FO6:>T[+ /"G,
M0ZS-- >7;-<4E*G&#G!L#($7X 5X 5Z %QLN%:5-6)LQ+P5=&DP7#"/@!7B!
M8>1 [@V%O(W5I>_Z0A-O.$O=YQ]^_6'O_V\[/('%DW8=1*/KKYG+(EH>#%)
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MQ7AGO.I&\7[QIZ,X&='P9=>+[SS?.&W%3?2Z*
MUM(PB00=[*/==; N[66/+02,R#
M%>=6%5&+J];%,J,9H89 Y1:H=-]%I;3Z5D E4 FM!"JU1J4DK<1YC]48_F<4
M9,PGMQG-Y-6/*2^IS"&WH[H]>1F.ZYE@YH.2 *K9 -)$YG4J*/P*YH%YJAA.
MC_B,KEM!_<*=:*E%T 8X"\Y6S]EVRP5GR^>L]ML;^]OJ:I+$8W9(UY$RK#,-
M>?FX,4^%)['N=#'E#5*@"^A2=[H@ Q3H KIL3!=+GMNB&73!!MIJ(YZE 3WY
MDWI!/_"4]$LHP[LN:A+!(:CVN%9/XKD2" >B+?QB%==SE00#\0[M.&4
M(9ZKZB:7=L3#/M:GLS DL2@')B\^LNQ#88?-(BRO#-^&=JHW!=5CFV9#7+W9
M)F^D ]O -K#M?;;)BT,&V\ VL.T@]2B:RC;=]_%TYN8N&1RU9*UI&!+/R>UM
MPWHS&N0%>4%>D!?D!7E!7I 7Y 5Y0=ZJ\YU+3EB^/"_Z+1N,6)3=L'',NSP:
M?([Z(H%T%L31^=/TCUOE/#_OM%WSZNS:N+@Z[UQ<\GQJ(!+,K4:"5$HREQ\X6S4>'@]?_X?7/C[IL&F$
MNTU/7XTLZ26N\P S9$D_J+S9R+&*S+_*J2%0B2SI0*6&J(16 I7JH1)9TDO?
M6+A[40?S?5?QKD NUY*;9U?401YTP:1RA@,< 4>%# A E !J, 6#^V8G98)%8 *0 6:K *&(2]UCRH]N:\*8 ]J
MM6W/$T;3C/R=T3 ;[N+46EMPNK1S597/L[N="A) J@*,LH=>A?BEW)C<1')U
MJJC&"W*!7 TD5\?N5I"L'^0"N1I(KG:OBY&KW+58O99X5)"4/I&"[C1.=Z2&HT)WH#O0'>C.!MMZQ[;KRLOI .6!\D!Y
MH#R;*8_A8JV%F .)MOT<>?&(D7X2CT@\9DE>($O+1*=ZI4?3"'[*&0Z( ^* 
M."T,IXRQ@+@F($Z3/3TD'=5O):G30M%NRULEJM*1]7,_J26=$(&:B8#5Q0E%
MB !$H-$BX$C,AZ9*1T($( (0@2T>NM/!)T3) +I +Y"J!7'8'N7S+78G5:\&%=*.O&60B
ME(R$"$ &(P#8[X4Y77ER@*CT)%8 *0 6V40'70#("*;X"A5Q62">J1-Q]
M1V( 2-WCZC5BEW(C<@.I);-P*J@%:H%:\QFAA42]X!:X50JWD$JTY%58O19;
M2"7Z.MBUC>U+^"R1*6[AF(F\O!L@! BA/2':/?BS00@08NZ%1O9U.4L+A=;R
MR"6J"?F,LH[F-3#UDD;\U'=X:Q(UD14-U 0UE:2F VJ"FJ"FBM245IBB\=34
M9(-+.5IN@2IDP&E !AS3+"WY>(TSX*@G-,@E"MW12GXL
MC_FP>F65*(/N0'>@.]"=%<&7+N8[B#60:-L+.@Y$J '[/F:1'V23A*5(,'IP
M%YHZX%/.<$ <$ ?$:6$X98P%Q#4!<9KLYB'!J'ZK2)T6B::- TGJNY[4DDZ(
M0-U$P$1J08@ 1*#1(F"UD648(@ 1:+8(."T+(B#!4Z"0PPKI194(Q;>1IPWN
MX"K=P4VBEKQX@T8X/$A/!@P_@@_9\<)![&GP 'YZO:V-\D+*L4&@9KWMBT=JLY0W4CH.;
M3*71"=0"M4 M4&L-M:0%^X!:H!:H!6IA/&>6/OO3["Z\7GBL,(G8R9+E.
MF9;Q8;&!UHX/9FWI[GJO.0MV]UB4L62E!1?N\D)B# [\_"Y!Y/,[Y.\7?R:*
MDQ$-7]#'%-]YOG%N4N*Q,)Q^YY+9!\6@D7_R&/C9\+1KMXRVXW8['V9@YU@-Z3AEI[,7GU[C
M<][Z11_L,\;=I5[US;VX1<,)Z<\_+#_SS37IX32*EE'/>/S=W
M;8K\$K;.UMCR_6'NC=RZNQE07):_>RST]CX._>(^7VCB#>=6M9QCLFHHM Q3
M6D$IH!*H? >5MVRB^(U^KC.M'&#'/5-B4(8J?;FO)TL](5!+/:$#-=.!
M]K'1Z2!;$!9*2'Q? KM<4^;YHKIO(VG$+^5&Y4:2"QFZ2Q[1ZC5P(8WPZ]C5
M8X(JA&W
M.BT;W,*":%,3(O76-M;J60:2,6 MA>0F$M=:IBFS%%A#.*7[6DPY!FZ!*IPG
MDVV^6IPGZQY;KB-Q\MWX(V60,\@9Y.QP<0A]COKB"&D6Q-'YT_2/=]P8YV'L??OU
MA[_]O.060YJP=7-G.M>LX]MF5<6U?G-G7
M9]=7O2O',-V.TS-ZSM&OK_IPL3_6G%Y=!H$WIW=?'*IU7AW$M07G9*+D;LC(
M13SB$'TBDY0WGI+[((I' 0W)*/992+*8^"QCR8@WE&3\ZWT:).2!VYJ1N$^"
M+.6_*6P;%Q9O$7'/XH@0\T\HYQ<=Y,=39GU")ED0\F;XXM[%C?A]4_;R/H1W
M-^&/S;G)[\-?%3\>AWS#Z_!PVN_+[+'@5P)3MRNVD[<\H\OWPT3QL@7_K=A2J[X\.O+
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M%*@%:F'4 K5 +7VHA5%K)OR:I><:)#3*
M#ILI0_GUL;P+@Q'4K3<*4Q6G;YIW!4Z7LH#90&
M2G,@I;%:/93+AM) :: T)=?R:G7DE1U2O>LE^GF/\YRF@T"/@U_!XL2Z\GV21A9R.1+_^_^;U%?&Z4LJTSVI]=&<;E9;MS
M?G5^WCLWSZXONT:1T=X^C7,:,_2+!CE:>,3-J+H&J7WUV2)VQI/K!=[DWZ<4(8]8:BM7D:? X9DDX$:X5I^?N4D[P(V"9!
M*IZKR)2?[IXA_[48MM_IJ(7[O!B*E$UJ7T+&^K:4A/5N%YF[]9DEEIIO+)K4[=;038:5?I>XJ2QJ=&('355>O(@VM"0B8F]9^;V)8\F5&^[R7JS[Z;;3*VQ%YLM;VJ.WW)
MY2",4WZ;K6I"&^9UKVMTW4OKK.N>M1W[W"QVT)R>Z;CE[Z!)ZNW\[9M2(N>3
ME/]>FI*IL5)"(Y_\QN)!0L?#P",+Q;K?A<2F>X!N%5N LZ+60YK*V=_KQY-$
MRHU(DJ,QW]A*IR8_)9V;.$6\89T^!$?:0[WOS=T'Q.V]^^U[LFA/^6]-/
M^)<>6#297C__]2#RXA$CU/_?29H5A<'9=R^<^$7)<:Z6S,M$@[DZG7@T'1)O
M2),!X[9*)[RMO).#9[40M<99MG3#]WC)UWA#!G'L/P9A2 +^E$&2M_3Y!ZCW
MGTF0!OEM$A;FV\H+1R**-L^)(XK##)(7O\IO(LK%)!./"QA_W&/"J2+VJ(6>
MY1?UJ9?G&!9BE-)=-T@D' =?+4=K2@YJ?
MQ6V#?D"?.R#--[=%+RM&TS'O*B\8
)N%OV=$S&(8T*^#$.L/%;KO4G8?A$:,A'J9QDOB"R%[R,8.!,
M"7(;3I)E#'QY1R&&4S$0YWLXX M4!4MZA8J'3/@-^6]//\MOQA'[*/Z18N0H
MEM-7>46F-QKCYVR3AZTLKQ,L>BP-OLMI^"C.Z\$R40]6@S@4\>REM-+-6_DV
MP&V7>[=F,QD.B^>9BZRHF/>JO&D>$S/B@TT0%8VDDRR>?5"LZO-/2@B;,1TI
M<3/M3I/B9A2[7._6X^%U>7CM=T$.6PF]>X ZJDI53;W+)W!?BCG7E9AS'=(I
M7+,#*H#9#&:WP?>=0 9Y0YEHN4A$\?*#JR%0657Q4,!S@"C@H9#G $
M'!4R'. HW:K:.S#W-]I"'-\A5XBJF*.9IU2,=JLMZ\%5ZA E !J, 6#^V8'633@ I !9JM H;1DI8<196>W%<%L >U
MVK8O3@#NXM1J3L%=J]N1QZW:'];6B%_*CGTT+:<9 +Y"JC5+S=19H1
MD OD*H-<[5X7(U>Y:[%Z+;D6LZR402WM&-0SD&L/GDL4U'Z^KMN#*Q^$ "&>
MKS/='K:XP0@P8LX(QY:WZJ@+([#1L]JVKU(YEK*F7W-JKCYK?LMJ6=*6_+M:
M315DP=^FP0#7(&ZVP4UP$]Q4D9OMCKQE'+@);H*;$KGI2-S&:CHW-=GF4HZ7
M6Z#*YJCRXXE(42PMH5\=PI4WMI(6\Y =Z [T)T-MO6.;=>5E],!R@/E@?) >393'L/%6@LQ!Q)M^[FHMMA/
MXM&LMET<:9GH5*_T:!K!3SG# 7% '!"GA>&4,180UP3$:;*GAZ2C^JTD=5HH
MVFUYJT15.K)^[B>UI!,B4#,1L+HXH0@1@ @T6@03F)__!!_ !?)A'N%AP:8,0
M(,1\QM1%]ETI*PN%UO+(-:H+^20N]YN>EDDC?NH[O#6'FI;$>I"@)J@):DKT
M:6#P&Z@PD.A 9",W55.A8F.! :" V$IF2A,5&Q =$$,FU[R<8)
M\X(\>2BAD4_H*.;F^&_^ 9*)'ESCU4&AUR]1NQ2;D1N(+5D%DX%M4 M
M4&L^([20J!?< K=*X192B9:\"JO78@NI1%\'N[:Q?0F?)3+%+1PSD9=W X0 
M(;0G1+L'?S8( 4+,O=#(OBYG::'06AZY1#4AGU'6T;P&IE[2B)_Z#F]-HB:R
MHH&:H*:2U'1 35 3U%21FM(*4S2>FIIL<"E'RRU0A0PX#4Q'U:OK!)ET!WH#G0'NK,B^-+%? >Q
M!A)M>T''@0@U8-_'+/*#;)*P% E&#^Y"4P=\RAD.B /B@#@M#*>,L8"X)B!.
MD]T\)!C5;Q6ITR+1M'$@27W7DUK2"1&HFPB82"T($8 (-%H$K#:R#$,$( +-
M%@&G94$$)'@*%')8(;VH$J'X-O*TP1U6MBM17+1$A=4JO0Q_)7J##3:\4%B(GCP 7S0G@\.-U3RQ:F[6\@=IQ<).I-#J!6J 6J 5JK:&6M& ?4 O4 K5 
M+6SN[&3"BS@9QPG-6"FL6I.Y53MR61*GA&MLHPI X/E3:)2J&Y],>9YR\ E\
M:CR?)'K:P2?PJ?%\DGETHB%\TGUG2SGV;8$J2=DUE5_W5Y=VDN;Z9959PK2!FF#M$':#@;"M@EI@[1!VB!MM9,VNP=I
M*\7C]C&C_-&7?G_A]<)SA4'$3H8LURG3,CXL-M#:\<&L+=U=[S5GP>X>BS*6
MK+3@PEU>2(S!@9_?)8A\?H?\_>+/1'$RHN$+^ICB.\\WSDU*/!:&T^_\\Y7KS9^R6FN0M&+"5_L$=R$X_H&T_BB":#("H:22=9//N@R3QX#/QN>
M=NV6T7;<;N?##.P?F!?[Y)#Z])I)1RSOOGYJY-D5_"UMD:6[X_S+V16W/
MA=[>QZ%?W.<+3;SAW*J67U<&>+\V3=8\MU)$Z^&W^D#'(&.8.<
M'4[.G*[,XA.-E[.-3LA6UK#WSKN^.(;JO#JZ:@N4RK3KW9"1BWC$._6)#*E/
MWC1[EYM&L93;$&^2.$I>+XCT\&":,92\0?(F(:'TC+ALFC!$:<6
M'*Q;>H!NI^:*9R^EE6[>RK?+T5WNW=*0@/&8"6=@2H(HQVL_#OFT1J!W1/\W
M3LB Q8.$CH>!1ZB( 23\OR@6:)]><,_X]XDWI$G6(C<% PCG R5!2NYIRK\Y
M&\M7UNHU&T"]Z
M][T?O1CRCX_)&>_%A(^W-/_5_TOYS8L?FOV"97PZ"T,2BZY-GS\T/_&[I7R4
MSGN>_[873O@'Y()&U.>W_9U_SMO#X<$G$L\/](7/K;G1KVB:Z4*MF]D06B .(4_JM.82H42:-UQ/>]JP#&IY=
MPS0,>7DU3$M*8HWVOLD=+*U36Z#U36F]]KO >Z0?D+!EU5%[RZK\9 UW^7+L
M2[&"NA(K*%E.$S@R ;-Y3I#@^TX@@[QIMR._?8(%Y$QJEAH"E6M1ZLL-$=*>2:2#J8/
M2@*H9@-($YDG,Q0;S /S5&?>=.Z7;PG*.BQ0 BUE%AB32LLR[ ?.@K,UX&R[
M@K1?X*S^VQO[VZJ($SNDZT@9UID2S^=BG@I/8MWI(C$W)>@"NM2=+H:\3'F@
M"^A2=[I8\MP6S: +-M!6&W'Q>(J2?@EE>->M("=R,_BH$?7T&M?J23RW@KR6
M(!Z(IXKAE"%>MR4M<@[$ _% O,U'/$4WN;0C'O:Q%C,%R,)4V8?"#EJ_49XS
M$YN;QO6F]$@+\@+\H*\("_("_*"O" OR ORRBEZL>SUSQ\G
MZR :7 :I%\;I)&%W_ G/P]C[]NL/?_MY]O4[D99^
MDCS=9OP/S]\0.=B%06Y8_Y>CZTN1:ND?UE]WET&:79LJV?8%^Z5W3GZ]96!%XVU)A'TLOYY+U?W/AV4OWV3\>='
MT_B)W Y%6G=NR4GB#6GZ_I'!]YJZ"%5W7'(2]:\1^8,KZ^B>)<0T\P(-]G&>
M$7Y6M8!&$6>8Q_RB2D>0I>0\IHDO,JM?!@GSLCA)"9UDPSCA]R[2R2?/9A!?
MFXQ)%LLI,O _5H$Z0H$/+$:)*V"+F>!3_XSH8DH7<+OVN=LHF%>FN.E3>?FD51J
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M_/Q1W""TR,#$V,#,R-BYX[I0$NT350FO225V/OKCZ2^)8H296>MG@T4J"-RAC.:X7!F.*1^^\=ZZ3O/
MD#)$\&5O^&;0KJ^N^O]X\-/O_VEW__WU>.];!]EW9T;)TOE&Z'?T#/K]$,A1/];,NV#N BZ! SBG:!IP
M>$OH\@;.0.#SRUZ ?P^ CV8(>H($'\HA1?P!*R%7#A96_!^>KB
MY.3EY>7-@OADCMPW+EF>G Z&[P9GI^]ZCN 2LPO1MF[Z[S>DK]-X3.
M1<_!V8ELG@(&X^Z88!PL]0 >IR=\LX(GHE-?]((4N0E(&!]^9@E4#/ 
MI@HB;I&LO.T/AOVS80PDL7H\ !=GCR[\_W3TH_>A]^B-HZ#DG=N10XA<$T)X>A6M;@LH:T9X@A:L-
M028MJB"G#"+_ZL=P??FH/SS=CHIT$MM1$WXN]FE/F4YK!\3)%($M]+$H?OMB!18<9P+@U^FY%318P^:N?HFE'CP>1-2DQC/RQ-0%P[2X:KS8E
M(/6KS0*30X?P,V3<6D$R8-'OK=4# ^2JQ7=H0T@*%?[LIPC:D<&0:TU$#"-_
M;$\ 7U%["F(@]F-^0+2:[(4J!<0,_0,[[ (L&'8PS=U
MN8$<($&_Q/SU\:XR5E>D[W+$F+&8M51S/YR>#W\]'YPZ?><&,=?
MSEJPZ&&L&:^M+Q,P%2'RGZDOT8@F?3D;_GHV&+ZNOH1D'/4E*YHOA.]0%T)L
M)CD/A[\.!X-V+Y[#?
M_\CS%';@WPE/F2[5PW E:CJ/;+$:UUD1>I;MIE9N3CJ(DQDE7D+%C"@%>*ZV4!H+L@:+><*=ZR9<@M$!V'-"G$X6Z5%(\9LPS)G=
MR,\T@'E.GHM_]J*5"Z%QBAYG:/*NI(, \(:EW78I^4KLM6(OA3R-Q!Z-]U>6
M[7X4>E$L=YA#P9_(?R*/>F%XF<9[0O77KF'NU0#B_%J%>.LE6+$%#@1
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MFD!0:I(VW8R9Q"9I3FTFK\IV@,2U@VD
MZ%G0\&P, )I*K"DVR&*WX;@&B_P)^ ,>S].DMPL(S1%((
MC%-UHIFU%JGU"+5B+N7QLV*6PSEJ/#D[TQ8G&=+)C'GHXO\$$)8KSQ@G8OHG
M].:0/4*7S#'Z WIW^".@."V.:*$"K4:I58-2YCZK!G+(>%$5LSRC%>'(3CJT
M(WK&@Q^Z/MC4"9? S-F[MYKL759BAU?VF^%>'N_W A^FP6*HIL([] -/3H_&
MYS5:B&^GH]?.V]+^2E8+8E)R$6X\9V-ZY(RU.SURU*OTX8@QR-F()[;8:@>F
M)7)S3*I9&BMD=]P*JY/N1\;14CH'2:M*]6U11+SU,+72+P4TU=)/QLWTB9*+QY)A
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M=3OQ/1D??P\0WT30=BD[*3&.I";*>W$2YEU"J+2N*+W)
M(R0KQG60)S]ULK5:1 T(S'DRW66">@$?X&+Z!?),.3.D3PM 84.)Z&'-R^E[
MS7(J\!0JG 4R1V$[=$G$!@XTM-8GT("WJ
MR\A5GT= >/Y "18_7:N:#A,&MR&R6AF6_"B-#$L/#S+;6GKC
M5NM5%;1YD?I%LTAI!'2 Z](CE&>)71[(8EF54),?QT/B;WB]D)]B;BJ8!HC,
MZ5?=O;8YI%&J+4'K1'B/TLJ\Y.T+';<;PYQVU=U7VDC&Q\)(*RV(_IN [Q _
M0G7(=$)&KDL#Z.6A74F377[BU8:OU9V2H]14=^)?BB(G(DENCD9$%1!%9!UU
MJ[%P]Z54VVA3R67;6IN.6M18BZR%L'"K+L5TD %OX6W:W'&B!35GD'0?V"N+X> N.WGBQ/U^)7CW
M9.T4Q,QF=ZX"V"R(@4X0$E%?87*RJ Y>$-O'/?9XS>9LH/%7J\1W#&]J!:Q_
M&IWJN,/UMR;N0!EV14.MXI1<4X/B5#;%)UX0;G;_XU'7XE=GY9P:49C3D@.-
M0UHISD/T0;6O]AM$\X4\5/8L-'S?
M9MS:&5]*BQEF?$Q(/Z+$R9#BQ+3(>#0L]U:8G(B>__-)_MO)FGD78+5"8@V5
MCZ('&).0>O5,/H)^>#DNF(H $+C\LB?B0-A3>B<48OW?T>G@]%2YN9_A<@II
MS\%@"2][FN?(]^7)TJ"U65O/:4^ND#"[O8<+JB][&&"<;"\
M\,@2('PG&B03/2?L*&PR(MY$=?0"&KF:)Q;$U]]W-XI@$[ZL0-JP'#X1*$2H
MO7N.=8Y:B<>:3OOB2L/%-/XDH_J49E0E*8^<0/2EP0+
MFT(W1>ZG80&(8!U.$=>]$X09!YC;"=KW(_T4#%%4FIZ5S7N;I5G2B:L2EPM$
MO0= ^4:>U6$9VJO:]R&=9CQE#EG+BQ1GD%+HW8:7%>-YGK]F?;O,JU J>;Q5
M_//N\ U8 K5#FK!7T?R*'+GJ6ZV6DZO T73SLD#N0DP;-'/#"[B@]RR=![AV
M(?28:%D)^^:BE1A6@>1Y;H>@NV_E67A(DK1;0I] ]E27H(NQKYA"H)PL>4OS
M&,/D9=C#=:P"LLD+L7X)6%1*%^6
M9$;?ZPM$F8.#>Q>580K114:.X
M\XDF/<[Q+/H$&.'15ES8^0N#^'B"F$B]D%EZH(;-G@H8L
MRS8@/XZ/F/WX52';IF_:>XXMJB 9SZ[%C!+3/'OZ*":7_G$_9[R8@>T
MA?'A,9J=&]D;L9KY9"64$+H++'<]-GG+:NK0O37C!H$Y%LLT<@L+A*ZA ZM!
MJ6KM"TSG2D5CUTQ@M3 ,'^ H&89F?3NWQQ!_92N^E^)>Q&%RD"3$,77H/#=J
M?[F*D[BQ&1<>OUALI&,13!7_KV+'DP/ 7^4.1^P4?F5R;S;V>%/)-.S1VSVJ:/MA5LA;1)FZ%#"L(12:F/=:#.W=
M\[UN$7.!?SH8GD?N2I&7JN8.L_+6S$JIN<.LO(O/PJAQ2JR4FKO'RJ<-?@KH
M7'Y&/"\/7[A@+H*?*G<=A-"*B%I44$L/>X2B$25_"]HCV'>I\1MC,0Y/W
ML!V.?;\",2N5'=DR=*\WN%_*L#.I'59X/\>1%^&DD8 ![$XC'%,V1
M8$M34MX&L$4W8)/897U3>SG&].R,YAERX;VLM97+!0U/\'-B
MRCZT@FS/,1+K]!S2'3%,9FY<#OTBUD;AA JR*5\ /!S(MO1T& T+'O)W0M;Y;G2RJ7
M0+\B5 R$EBN Z#*S\-7TZ:R;%[W_6T(G8"W=5/%46LCD0I-_"6E!3[ASX@F4
M3HP2'W+5D5*QDG_%*)7OSK!U+OHLOC V(:GC"ZUV?K;"T+D74VG>'L*0&>$&
MY[CRYJX5Y/[-7W97(RK32V6N;]NWOUNHII^4/43)',*5@NYZ?4$Y_K*CN;=.U?/828]5\71K&N':C=R
MG\55VT+1,A&ZGH4W-Y>F%+65T;==V_JIIT3(1\?N!%
MP6#>.^VD['7'(9ZFLL+R;R1S!:J@7(,
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MWDU[,I^?_>7Y\V_?OOUR432S7^KF^#FG-'E^U>O!%N$OU/<9?M?S+1?C@5OMO2=>:::V?=]]>-6W+=0UQ6/;\GQ_>?^Y8)&75
MSDUEX=E?_W1P\&M3S^ 3^(/P\\NG=[?ZG]2S^KBTO]CZ]'GX_OD+BS@O L*'
M\Q-H7M6G9PV<0-66Y_ .E^@4EBUFFYJ\AKDI9TAS(/TO)PUXG+2>72!23-*$
MRX#3GR>8:O[]#'Y[UI:G9S-$]_DCL7]DBAFT4=B_/54$]G^OYV.P=FN8OHK[KE,CP
ME=LI[M%U2O+VT S[C3H"4U5;STH7K/"79A;7448E^C-:X=.%&-O=61DZ])CL_=V459#5P^J*FG^ .X;V$]CZN"K_
M#>Y=]<8TU;4_MPN+^PP_)IN] E /M1^3D!!K=8L97&OP)1ZH-68+%]#H';[<
MA9\IIIT&ENL/7[0M[LLOYE>2T\]:W6_4_9E:'3F@]?8&C;?Y]QUK
M9ZQR[TM3E#.$'=I50W>(?KY=- TJ_"Y$O0?C(\PW#1#]%%6/KGN3=WG><[&=
MG#5-QYQ^C\=YMU%&('INJN/PY"SE:CMYZ]N/3L@^%O20L49GX'H_OM)9+TYK
MU%+_[J9?Q=/["L7^8T_(X-UO]F5J\WBC,])/@VWNM3=1'TSS%=G$,3\'%=ZI
M]6TD;>HS"4'[/)1#QYN$D>"1H>.)"_BJ;N?=7GE4ASUJV7CEJ%X>\KWYUP+M
MTU7OG@8WP@L0?/YQ#2PC:Z-G:8AZ7(]RTYN#WU8
M48N6V>MRM@CAIM &]?*BZJL2QYUE&J;[24F/KB.0]PT=^< XVKL?F[K"7VT_
M%Z]'U[W)ZR(+-\/N.SC'??I.2N#&[W"#/D>HZJ;LZ\M-,-4CLH\"/
M^'T7OT!-?1:$9VHP>DX\*33]GO_^(^Q-+(+B%G;^APGI'7W,I@<[C$_*/@;3
MH,'&9^'V!SVMG]U&&9_H?D*ZI=O>9'V"<*IAYXL0D.EV['/\I,2_X17NA\?;
M*>P_0@1B]XAJC#)X!!97/X[,5Z@^07= <%2CI= LP-WN;;NSP[&XWV_>QP(F
M.B)/ HI^NF77V+:OL=FFWN-352OD\E-??8G:%[;K^A!@0MN
M-E1M+W-\<")6UG^Z"E.^J[;G:.S#]LB33P11/ZW2I^]$!/X!
MY?%)"#2?(R['(0BZ.#WK\/DR+V&H[B)87??#L[W7;80)UT%ASC,EDM%ES,H7+@G@2!ZT0I'H%K=/U8DV^M9IIPHOZ.VVA$[%)9
M%&G2WMM/)'KZE?!<$1-(06)FM;VMS98$=.6KWK1%5VRZ:,FQ,6?/4M7B.&]!2:DF)9L)E_U!;/=8RU5-@@^3'7/+?Z\KNM.K7'7(/&3*7
M%L1QXXE7.B-,9^$WGEF@B4H-&[3P_,==^+W@N5[[7Y_?T:-3ZM:A58-QM.T=
MZK8HW36M\X0FN*B.$:LY$ >0$=!91J0WRDB=.,KA473OS3200[_*KZZ.PWES
MVT4AVN[4J]W ;]\A\LP6X N7$$M1P"&SC@B'.HES"D:#$TZE3UA+[[VN=33<
M(FCPV]0',"X)1DOVM%R<]I:8-7USY\'R@DDBC$B(XE(0L(E#.JA2'%B:)N()
MB\HT2[M1?L9!<;/@W'/$PR?WZ/" FX^[S?0:8>C=-R^$!R8OB+ 2F.Z%"@G%#6:5U;PJ-;>F:"Y,PX:DC%G<"DEK/"2V $>.<$DK(
MU/AMT=')F>X1][W7.&<.4NH*BT.C$2-EJHC/$D\< R7 >>=9]H2]Q'$7[FY$
M< RX_AL)CA8)GE06QH\.3R8/E][KD;FX@4DOR=C6-7>)IK10E$AC@&16"_1\
M$DV$H=)GS*9.\GU]QQ]51B8 +Z*TK"S*G<3D7I]<6),98QGA"96$,2<)!4B(
MHX4M1"H*ROT@^1 _CWR,@5H$P>@R1G95( ]WRI5/K;+>$40)99YK2Y+4%(1+
MZ:32D@D^;'M)?WS1&!6V"++1P^M9(QP;>N5IX@1CJ2F/B\1^9??O[3A:K!5VO>RO.3\UI4*:Z#H/TBNF00&A2*96Y?MFT;ENEX/D%K(B(T+@D%QR3K(4'?@$
MI$ EG().AUD<<:1CJD6[+QM[81;%@SUKP);;SC5O-LLATR[C/B7,I/B/9884
MR D^,UY*#XFR=%C<,TZL*]+B[PE9C!PJ]W^+MC.-PP%]OP/N!_OD+F."*8F&
M%- B'/_B;UXGI+!):KEE6<&?
M7%AHVR-S\1(J\.7\+8*VGO[=7)Z]QLV+3#!?"$\22T-E1&I)45A&,@F4,<.H
M],,V-1DGW2^2H,4&.>+1SM4%IZO4M!6'/0YX'NB99X5(E...R*+PN,D/XW%P&61=F>
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M\!0?MZQ@Q""CQ"2I\,/$K_J6+94P#Y6+(3KLF]D>>VJ_C:BX$4<9XPK3U1%,G<=/7GLE$)=P.M+1_JH#T%$#&R>]:ATYP$MI]\P;7
M#)*GF4$SD]-AR-0ZD,?( O <[/_1O
M+NQ)N$SCDYG#8;4>ODW'_CL,DXLDLZR@FFB/#D>X@(84$E5XIJQA&56&F6&G
M_'$RCZ+)UL2@QBBLN%7<0TXC+
M,I\W9;'HWM9X5"_+GK:=5PX?&>TJ2 "A)L)X=/.RQ*$^5(90:X2R&8A4NJ=L
MJDXD4_%A?2**_Q'K[*[?WO$8N\^CJ>3)PB4K&D,>XK+D=X&F[S7(+\'7S=4K
M)"Z@_5!6=7AM[>4]=&C/W!YE62WZ >8GP:8*/MKI%@LT(A6YIV!8$4Z#M5?$
M"V[QNN> R> +<<2UUD6F_][6W$Q]TC2I48R 4P]RZ#'OVTNAK6N=!K-.4 6%2
M)"0%SE"D)1#\BWF7*6/DM@C>1/F03=BDFWJS/-]HE1M0G.H4&3 J(SQ%9S_5N9O+N! >,%<8K;9_RGC=X+>K1\(A1[V5FT*Y(_'M=N^! ;%C<=M@"W:WD&@>8R"O^&9KSTL(.BWZC
M1RZ$LUHG"=%>4X+[;(:6%LZ9V:1P!HI44_V$W?/1UWT_;*)<;-7.#WTGGI_K
MF=NPY'=:YD(5GLG"$L:")95DAJ32)018*CS*,6YY3]K6'$N9[X]+_&7N>7' 
MAEXY3SPOD",B&14XG0?BN<6)>>$H4U12;O8]V_L!EW]/C**)PJ5BVKKZEPUS
M2=/,BP)!*K(4!Z7!&^,HW!1%W/#4:S;,=HN41#GN@N\!2TR'L/@LQK^TE9!O[Y=(DMJ"I(5Y;BIK+2^(X]6BZB,RGB4.S]2F_@6W/M;OG
MN(T+50S;'F:SD$)2N0^F^0HWH-ADWC_8":U8*:VV'(V:! @%80D7 H&DPE"C
M!  \Y4O3QY6'47&*49T,%;(_0WI?N-.R*MMY ..\1YWIEIYY2)?4B6>XF68)
MX;CQ$4F19VNUT)PC$&Y8"F&<5*]QQ6)\L"+(QNU+BG:X_F!SQUQF'%@"CJ#,
M>U2-2N(>[ U)E):>%3;3V5.^(7U$NP]W[S
M7 ,89[@C!>I$XKTU!"C^F8%V4KE4,#DL%2A.O;
M7K TT=N>;DS^UI1-]^;!<&?#Y:>KG-A 4 "Q.]6-1=#UQ217I/T#W'$(]MGZ
MN"K_'9)VWYBF"B^8BT54]Y[KR6?Y;$_ +69P?;OTDG/TL&8+%_A^8>WB-,P"
M[J%DI%B07!-[_>%2P;Z87ZWUW;3C+1 'A3S;L\A8G?[W?%U@?E:9# JV^[Q+$=W@D_!557'ZYDL+I9O+9JZ XK5"*+
M)NP(+TU;QJ=RRN?A1N;.Y!-$E\2'+.5I9XF_,]^EX%K+7CUV-ZW;J[?"QD/^
MFJ*[W\2D8LH':1EE"!-\#MKB5JG6]#/%E[EU5 1C"RU Q#A$XCME>50'E;9L
MO+(8@_EAJN^K-X:L>F]^9>RTWO4Y3AP8>5LWX8#X_OJM\ZP?[)0;"4J:1!!O
M!"=.2D\,-X*DF4PMA(I663Q*PM==FF\M0!"BI8X(-XRN5F\' +8/EGMGM1(V
M)2"5(C1-DQOJ #BS1&FI$4-NB=%.K-YF'W)+
MGW2FRLAR$@O#245D>>/CT;=Z;R&Y&BF72<"+ ^$\O+M>AU1AFL(5BSQ-]RYA
MGO(L]%'E9!\8ATA*%WB8GY@*(3FK&]-\+]$**)O3]35I6_OD0H'C3DO"P_L=
MN#(%$4Q1(J01:9$P2/VP))=(.0]3K/[(@$T5Q5QG.DYIFM\J7?@(37>5>L2I
M+LWB[RBVJ+-S2I[B8M^A1N;(ZWF 9[CA2;HTNH !!!%4)*11G1!4JO-N'4I1XG;CT<0HD
M'F#D'@?=>NX.R/IQ\LR$FVW!(AR>$V.I(,Z!)E)X+;W#+]7 ^X.B6#^3KGX=
M%]A8=U$%_6QFX=6J=;4D_G8E\/6['SZ:[UWTNFG"A1$]:B;W'#RG0F@AE"-<
MX*(4*2B2:306+#CI*.G0"R_!\V^U9X6KVC8&1
MD4;.G=.%%:X@+/'XP%AA"77AQMW.'$7+E.MASE^<;)48 O=X4$]E$:XUFZ8U
M";^M[KO$1?C8U!7^:J<\FNM,\YNO(9[\W''3C!N_\S=NO'X\>_22B.^;JYUN
M-LO!@-+":FNE=D^Y,'?X(M[;@B> *HH5
MN*+[C[KY&NYVKL,+P'86D(=[YQF3R)^5)-%A>L%H0#5<*B,D]87.=#8L]A['
MCAM?0D;%*J:(O U9JR?@+NM6=Q.1AWOG*0=JT!8AAB:>4%TX4E"#M/!0'8E/
M1F&'E1/$L;S&%Y%1L9K*=!J^S:/LGT$S__X1O^_RH?ZU*+NBBPVW7,T6M@G@I*
M:(82+S7R:E))B57H8DAT+(T;%AF/8PR,MYCUQ+ -\;T_F&KAS2K!^(H"I.9S
M[>??;L2E[[K66SOFPE+.,PVD2$ 2+="=DVC-K-PYQ;-"#7L1YB.O^X#EJ2<&
M;LC*7TW]!?5H\VK1SM'?;;ZTYAA>'#?P8#"O?^>-8>A/(R52X11"1]^$>:I3SG>3CX4XY
MT$*!H1FA*9JVJ4@X<4ISDA2",V$2I\RV]+7'+ J;4#A&!2V&9)AJTZTQX>L\
M]8PE!0IRFKJ$).'2/;U&LX:L.4J"_QL!MW25+>J !X$;E/2[TA3Y$4F#$L5)0DUB"(D
M)M1H,J*55$8*8*G?^Z[P*;.W)G-2'Q'AQXA037G&A]BXA9W_8<()^W3E&/>F
MB5^+<8^$VQ]LKJT8>^XIE_16>7:70=>]WBEHYCO5[['GC5[;MIVDU8\C\Q6J
M3]"IE*-Z]8Z^V[UMF'W22JR!U.Y,YG_";0L]XTWKIN\"(&\NROEA\[ILS^K6
MS,+.\5#4:88JG#-,N
M3ST=>D,6_:T)6>?S[Z]F=2@F#P5D#R[VNK:YHTQ ZB7),AG>6!YN0Y+@KS+$
M,MAZ=_UC!)3C+?)(J U9W/M;Z/I#TH<;Y]1D)G,N(1RT(A+]$X(PF!6AF60@
MGW)2R+@Z>RR(IG*CMIM04UK>JT*6LT5C3TP[[7TQ=^::\!J=S_/:?NVRL4-1
M.JKF"?,QU\\5W6]83\;Z3U?;U;MJ^WNVXI,\J;2OG?%.;O>+%A756U=T=!UWWP[-^P/SZ/'Q3X&1__=/_ U!+ P04    "  @@9M(% ^PTDA$
M  "O/ , %0   &AO;'@M,C Q-C S,C9?9&5F+GAM;.U]6W/C1K+F^_D57N^S
MQW6_3,R*/SY-E^MVWY>SOR^E->COY.9M.
M5IO7WJQ6=W__\<>O7[_^[=OG?/ZW++_^$0& ?RQ''7PB_NN'XK$?XJ]^@.@'
M#/_V;7GY_7>!N<6RQOR[)_\>_WJY*@<\?IC^N/UC^6@<^V3JKWCS+)12_KCY
M:_GH7J3+I:S+^F[(,W;
M=/O$_-@C-EU-9O- A5>FLV_!5 A QBQ".G_[N%5J_N[])_?+V>W
M=_,@B!_/Q/ZGR>=YNAR$_:>O&H#]7[-5%ZP]F:8UV7JRG"TOKM[GZ3*L)IN5
MH(K$(T/Z($==7L[B?R?S=XNK++_=_'*KNY5H-IRN/1M9GF=?P^J]5(O+L$*'
M5ZH\GRRNT[AF5Y-=;WC?9!Z!JB4'-6;NF[GX94T6]\N'QSKAK&K:OMEZMUBE
M0=M7[MM=6#32WQ:7<1%9!-MB-0OKW6;QZ(31TU_4-^OU]HZ3)FE/\GHY6Z3+
MYJOXB\N?TNPZG]S=S*:/=+^2ZA/G&8SP-FM$=Z\8C-T/Z9=TL4Z7^K[X
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MHW;X\A1^^GAM/[ \_%(MEV%?5JM2<^I9J^UF;<_4[G0B6&\N&&^K^Q-PV?E?E7S[!RXO@YT_7>1X6_$V(N@7C';RO'R#J+50UAK8F
MKSCO^59-SIY'NWQ]B\_YM%DZ('HU65S'+V>K5]7D[7^^M7UXYZ@6
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MY=/1T\W985?B6BRWC2?LB97]O]V%*=\MJG,T
MVK#=\JE)G;$\$_I[.KF]BH/E+P.4Z!D'7MW<;?'Y;S>8QN>%3MHE@
M;89?W+666P0EMMEC]>#F[_7'WS(^3^7,V]E]S*VZN
MQ=MQ=,/=HY$=TA-^CND*V>*'R_1JLIZO&E)W<)Y^:,UN)[/GRVT#4I],TR6E
MFXE_N$UO/Z=Y4S+WS=$AC3=AJGRZ_IS^4 +2D-(C,^VC-RC(;+'907X.C^P>
MC"0=7TYZN\28?ENEB\OT-%?ET^^R_#+-__D]+ ;M/JR3]H!X]WHHX6:# 1<8
M#;_8K!)_G\ZSL"'_\_O@Q:0/O\P6J_#9N?G&2@H+Q/:61-\J5]IEVS.QR'&V
MV.0Y?9L=^^".CDNX_HCXY+&+&0
M(2A$&JU
MU0HS;* 68;\L=TD$6!.)H]^)OD_7:!F]6YB'%0K@UG2H1#
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MHS)L!]/A$4!]9CM!IU?9YB+)?+)$)$PZMEH9(2Z 56@1B
M2REI'[R5)CI(7[T.#@+F %KVG$H?(*T!XM9(7[T/7V)V6<,B[?(U"0DF$_'6
MA/]KZCU3GLH"1$M8([>*O7J-/"/$ ^AI31AKJ.*),R72!RBJJA<:2)MO%7KVW]HOB@4/_X\6F6TMD3E_;E9I:)2WTG5NW)G>[HW97%P?M[
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M"+T&!?$.J8$N<-7X;E@ $H:36&0Z@M
MT ?EU0J0$4IN+';,N0767E!^EB]7Y:MM>/7QG>W0\PF%Q@"DE!1848TQ#;27
M>['%C5(".K=3V@.==8]%$[%]C/62+T^0V\$!"=/<(,PXQT &_L/_>)Q>$7TIWPF,5!X2H"RFDJ.PK9. R:%21:&FJ MI21TD+SC-%1&#V=2K$%^X-<3'IL!538
M.R\?3@(8! .A4+#_@C$H"*#E J6D;V3$GGXAXVR&3VM$!A?QKY/;ZF..0T,2
MJSERV!-*M&4"624UD059DK.!DD?.(J=62#01D$( H1K'BL^?2P 3C',*-!+40VPT
M,25IAJ)&YXB]W>?O5D@ML1@BK2-=S++\N%@//IM0)'RP[P&A2@9GRQ)2&/IA
M6=!T7-?<.Q-M5W@,(-[G#;G?3^ZC#5\IZJ/C$D("1YQZ*ITE*BPP'HF"3:QE
MHR/FWFZ6=R[V+K$9(GM^MHB]3#?;NI_$]I6K^\?%Q^RF,<[V&O$1C3AEFD1H
M"XD.7CJA%"(,N7IT5G(>K2#0LTIDK"24B[CE7'EC-(&&5("B0/&([;^VFM#3R@U,=^?LO8^3^\F
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M??C&$R888AC6.06#X@YNCSR?$:P PQEX!
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M&PVI5CJLEHQ)C:4$QF 2FR&K4E4J.WQFDP3-YP;PT>UA,%N1= :*T T<2X @EJABJXW_K">VV!
MUNFM<1HF0]P/Z:B[@C;6!A80\AYHQ(G'SA:,:23'5\BP&S'5:[/0#)PW)/W!
MI=ZDM\; 0F_OKC6[-$T=,10('@-+6CKDK"C(LJQ9,N;0G35J0WOLRO1).#01
MSX?T2S;_DN;'Q?/TJ01Q+@D,1'#$H!4 8X4+L@! C6)D0[?$:"2>5C@,>J/=
M*X"IXUH#0[U (MB-I"!- 350B>4SB*@E$@/M9T49\.J\QSU/)X1S985W7@B%
MM4)**5FP))AOEM8R=/R@J3_3'I!7G.:J73#KH2$"2L44XQ>?Y['K;?/WWV>HF6Z^>DW=HK3YMEH0RYYTVPAOB2'#N# 0E
M6T;"1B&+P5/83A5Y_T -NP@4K#S6VWJKP+Z1"3*Q_'G8%16!#!)CK"I9]5 T
M*IXY>+9;!\M !^ ,O.''7(Z3]OR' 0F0AC$AJ38RK&V 641]"9CBC8X?!T]F
MZV+;;XS)P,*N*>(D&+;(AUW$7M0K G(G&6\YYGY3-^
MB^>>S_>B\YX /:3]UCT!VC,BL<)"3K$4F@AM"7.PL*F#I2UE54VT(=BKJS=U1L+M,X)T&F8O*(S &H%LUA[: 764GL?+(>",8BH?ETG
M0+7%5.\PH!DX;TCZK^($:&"ACR5TUK(>I-6&*F: I2*XA#2LB+)$#6OU*GJU
MUQ;52=4@3T-FB$S>)Q7)(@9%$;+W>7H[6]\>48+*L8EQAG!)O7'!7_& 2 II
MP:ZD9JCF,?5]K2XMP:[A:7AM_ D-VYSSIX7G#AYSU1B;$.&=!"@V(#-><0R=
MAN4"B?&XFL)V)>&^X&DB83U9IL]JR_DLY@;G::0L]HL[>$VLSM@$ .B=ER10
MKZ5AVBB-RR4+RT8F>Z\A\/^86,I!MGS
M"G$B(&AE072X_;J/:\?T_I=EU/KF[F4W?+:ZR
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MQ?;J#DTTA9ASS@"P KAX3Q673'C6;&ON-)#7M3"R7@$::^1NSD_W\4[0FDX,^\QH96AFH-C
M$B^)49;<2N XGMM^0Z ^G-Z<+8XG9C4H&&HE^FT[]=
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M!: LH\ 7V B$&W5H'V$F6VT5.!0RO>SB;7BVRYFDTKG*\7#\9.
M+1@ 1C54@AFV*A'M>]^H:X9ATBT.AB=9Y.EJO_2B?SU
M,L)94$,J 3>0*([*K84W*W_?=["JC8!:0]!$0C_=+SZN\^OH$!X7T(L'$ZJ0
M=]P:!+ "&BO,2:D^#.I&-SWZCCBUD4];!)J(Y^,?Z3QXH_,ZG]"^9Q-!L'5A
M\>;>4,@IMPK:@D2,2*,H1=_!I39"Z@"$03+C\V!9APVX1I&@)T\F7$!B0:"=
M22UHK*;$2,$*1[11-FQO5\';R;,;"$:6\$H8=T!XK00-WE$L8Z!+XDU8/\9H
M=?03<&@(R0#R+'.LWRVFV6WZ<[8\)MH]3R=20+CC<-&N8
M^"JEW!Z=00HUW.7I=+:]E?RHI(1:7):5:GY-C]W)KSE#(GQL=6X%@QX+@I@U
MM/2KD)6-SGKZMIGZ48Q^$!M 6=Y/[K?)89F*_:;S]'V>7:XW#>[5O>52
M.3:1/.R%!/)-+6E(,':Z,%5(M%S&:*_UHR!=8S7("7Z%_'>$@)_/)8II^O$D??4W#O.W])#9IN F[3_#R>W]U&8-=7ER9R?+&S[.O
M_3/\Y*W9;=B&;V+,^$OZTMP])PWG$\7.9@U_[>6U-LUG7R9Q'SOVE?7^;C^9
MY9ORB['P9O';706^2$]12FMYG)Z>#?."L$?TA*7JO]++ZUC^+5H# 81T^7#'
MZN@MGD[F39R.=ZVMI] [9+3TT F@#9+!(J485 4^^X&J%.?RD8P?KVT_1SHV
M![@/#\0E/Y],-S6;]?V.>YLN9]>+A[WN"([]O33QV'HM""?>,.N!I404($,$
MZ$"58"K:7@RB1=E(,1]K/L<^L7R8+?^H2.@.ZD-G4+U1O1A;]LCXU&%P-7A<8M9,[NH5.'K^?((XM 09J+Q4@!* 
MI,2%%4!DL]K_/79WZ$) !ZJWML%E ''[+$_#+NB^36]B!=?PSZ^3_+)2ZL>&
M)Q>A%^A_ ,H /[K*<*J_+0D 1Y1B@B"B@:
MV8G-(DOF"+*-_)O39?_:+C ;^D^(J?&
MFUO<7F0U=* 52&]0&\9F/XY)"88_0<[3N\GLN/D:,MG<@MQVBMT=BE89%
M_4D2Y Q3QGNC'),<D6 *:&"E[4-#.Z$.3SD^2^H!HB%RE26E,E7CR;
M**81QL%4(@![0)&"VI46%%6-#II[,S![D'Q;1(;(&9A.\W5Z^?-L\GDVWT2+
MJR__'QB2& *90 PZX1DF%%+JP^)I&89<>TD:I9WUEEW4@[@[ F:(!.#=:6^T
MA]-]P92MTJI5:7,?RQ$^>;+$<0:#G^8]9EBHX%W!L.46GP$9ZK;KR9[GD.@OC&
MQ[DO)DBD8-3(&#[B+&SMGE!.HWA$V.N5Q(D?L1I:)@12
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MI^$RZ%>_9WM][&L>\J#7GCP_!]^^2(KH<=Z%3:;;C,A%I=NL9JM[A_=8N_EA253
MOZ23F.:Q$>IP;SJ]*,8P5[XOKJX>9U/%C?I1+LR)301:S)H A!F@RH45G4J"
M$822(@T 1@0Z3JO2BOJ!Z>$K.\%)<*,8, 40W+&!
MCGN.ACD&D?/!)@.=8SC>Z,7GU:.:".BKSUN"\,0T87PSA_((_1>#[*W";/ U&G[K.T\V^<;P$]]Z'$^.9IRX0
MR3V&$CFEE2V())8,%&RN[9:UA3KK&) !/M./Z6*6Y9O3VLHXSXMG$^X 19@@
MZ(""B#)D>(F,5;C1%MWC->Z.Y-L5'D/-2G+T]CD/*>>.D1O<_*IS
ME^K B(0$H  &!'O 55! QW7II@0>J^Z.#'NU[AP??S? ]1,RW1O,<\O5[#:F
M1#V4M8BU2,/*E:]FP3/=[&B-@GO[5ZF7[PO^\9YRF\=B=,TF2H1@BF&+.<92
M"A(\;0N@\H;X(%+MJPZA.F;P4*#M]$D29S4-_(3_*ZD0U132DK%@7PY4]F!O
MF*UO464#@3;6N-H>_BJ":P=&)&&-(P)1"+UPA@67U%A9X&&Q'*@$5ZT(6Y_2
M?IZGW0E: ^SQG_+)8GF5YO%&\,*0(['+
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M+R\6']+I.L_#)Z@GRUFSH%JW&7./HZ(_Y=GZ+M!6BK>\+V,F=YN[-,="!*; 'O)D16>^D.P-$&]!Y8?;CI/4OS0._-_<_IEW1>%=^K-4$2
MEDQL=-C&N49 LV"&652@);@;4[BO'RTXK&+=P39$>8ZC^U')0674Y*1Y$H@=
MI0X2#P+W3&"-I"Q@ )B-M[Y/UV(^I$4]HOBG5:K1Q=I>DRZ=3X?>+>[6P4.(
M>,#JLD&'1R7 0ANX$LXQ8S5B6 !=L.B-'-Y!O3WF?Y0_3IKD:SH=IS
M),A[IK W0L#P/PR,E[A@7SO3Z'1OJ.Y#?3A!?2$WY%*R)7(/)_6MU8HI$B&4
M5I)H[YC@!%' #"F8E\+CT7H_/F6'CHMYEWP5&0VP83TOY%C6#3JV0_'17L9Y.V%HW=TL^WDSR5$^6
MZ>7[R?W&TZO4D%.F29RC&BE,O3>2$NS""OG@RG'8R)8@KU9A>H1N /W9IA'L
MR8%0GY<;Q3^B-)5C$X8!Q IYXXAR1'/#,2U.80'1X\II/-N9<]6N!T$R@,JR(K6^V%_5FQ_:G,/W"-KA7\ZBJ_H:%
M>FT9:\^10"JTI)YB*XCTB"%$R@\H&/:-ZC;V9O+VN,P-9(HKWX'%R';:GW.@'9
MTV9,6/B>').2=V$9'ITL\
M<)19:S&CF!&C+7ZP%2G7=%0+6-^*U3^  UX%Z+'.\+8@\Z?)M_[G/[W$;]M7
MKR:+30AH:U<-\I(C3 Y#P$.%T/*>C;J-9;;_O2'%?8NAJW1 V!\(>OZ7,UY6
MB8R%3>=+K%+^E*B?ZUQ(J3$\410K0! 7EL<*YD8H!*5C  H/I-95_0C[8?Q1
M_=C#/)Q0KKEBDL1XXZDF2$$O.-8F%JDK0- (-C*JN[Z TJDP#U=E[A:JT5XU
M.">T-MH10T")&]=^H#M.3:LX=Z85
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M!T7]'!2)-":X2!AY3@'03^_0DTX/G/]U"-M;CGXW1
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M#@:Z")LC K)@GUDWWH:*GI_FF?.MP;RI"^K--9N3%533(IO%FTVR^
M7J67FV>"Q;9>-"R.L7^)=9-\,5M@:U7NV_J.13Z?O\$%:'U'M^:*.20
M=@ "'ZPI(2V%NULT02Y2BC&5K.A"NY[O2*-!=@C#9B^MM6H+5 U-B%,T6 +>
M<.N$0AY#6#(;?#D[VLC\*#2@EE:V1ON-J]C80O9O4K,&UZB/JVSZQ^,N!^_G
MDT5EB/_(J(!=@,LCAQGFRL9]PH."14[EN)(BNQ/8\P2'SA :)"%RN1S(NKS9*YO%BOEJO)XG)7IW=Z1#5.FB>Q%@J+
M8F;
M<,^G[$7K')7GL1%350)U^\D3"Z340H"8PFZ%P,004P 6:TF,8A7J2;4&AZ_)
MJ4 M(C_=Q*9=X0M9;HRY>"1_-&[:7"!7*/.H;WY[SUK1K?A[$8 
M]W,6N_?(LM?#V*]J.HWL!T#>Y]DB_#A]:OYW^KY-2L3CADF/JM0,_L*C?[N*
M]P\7X1.**:7]M6IH3E^0UEV:K^YC *O(@]T4YCP3M3UJ:6#UO&5LM92>$GA?-M(YEDQ0>VP2-GT9;#IM)%5,&^.HW+H%4AH+394A,RS+
M53?^CHY+D DVK/7 &"7YIK:"5@6KP#?+3^NX-E*'\LKZ@Z:'?(5#P8A5FB\F
MVZ]QF[!T('G@V..)D48310(K3EB@N4" %-PQP@=*6C_I$EY'XLHZ1Z=93.G%
MFP\>D!X?D$@3#$)(L"(@\H^I*9+Q(OT>C>[DO1OH*^38"IR12W0L!]UC$F1#
M7WF93O]VG7WY<6/YY_=Q/\;%/Z*0\:.M>/?KQ/RZ1Z0/?TP8<@!I+QR&& II
M@8.B(!7)D51!Z0KNK"7[ T0UGFTG(N,4#I7G6C$L,9E9U@U8_0887CLXSVGMT(%^\ND>O<7/"
M'UZVCOUK-QG>L:#0+/P[-3>3_/ILKSV]"V?_628%P?&.8B ZMOS(OQQ-4S]E
M>*(9 8H(PJ%24FG+K8&0> ,1YHB2JLVAIQRK\M['4%RF#10$9"CCF>WXCQ87J9KK,::.;^-YI9=X'^.(HWR
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M=H"K:T?6F2L!%F ** [ND1?!,E(6RM(ZXK31[0_^*C6F
M;^SZ25^L3K#;_>?3Y(]TL3.2/V6;C,ST\NGHZ6;Y?-NY=TB*X $08(3"-#B.
MP FTE1GBB-L_2^Z=HL(;+C6TSC.,-$78%S  [@U=;G"UR[T[#ZD^4
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M2')EQ<'9%7 8DVZ4HF\#5!/9;_)#+H)M.UGMMJ$/:2SP%%>>
MXQ*O'IE81S0R!%-G+16.42%$>=I ?:.E#WD6WXO6;R=(O4
MF93B1$U(M- NK'"0:^^H9\ 06:ZB7IAQU2_I3$(U)'\B,DWV 3-9WI1WTG;=
MR ZF]N]]."'"Q[LEC@?2!)-*N0";%EDT,@N-J'-&1K.IG19^&SJM.T4%62VP$PM1(@0DA6,D2
M/=FL=L>(,J6;V@_=PO;J$C*\(2 XX0IB1 @$UF)>?@!,BO$U^.I<;K4S,YI!
M]>8T8FPVP_@4830I.MX%TJ#PG&CM.'4<$%2XZQ+@<654=X!WG12=TS!Y!2DZ
M0;D9X=1+&^QCQP1A#A<,>0C'%?/O6,C]X?0J4G0"%XI2Y1%QB#,7V"IZJ0<_
MR9%QE6,;5O1M@!I=B@XP-MBRL?QHO+-IN8'357
M6Z5Q%@7-E<3!X/,Z!XPHV+*V\NQD['DCXT)]@OSG +LJ$4>&:C#
M=U_:&<8WNKPT^!771E+L$)9FCM7.XKNX^CW+_[C*\FFZJ[9\,+WJV)@D&)[!
MZO#QA@Y''%GB!2Q(-EB.JU1,+YD976/4*,K5MDZU5,CA8/=K0 63D!@.RAU%
M&-LH5'G>9.5&8NP FU=P;T%9A['D$%/.I'6605^<_E$EFG7D/6_M^8;?;%^0
M-=&!EXF/OZ;[Z@@??C@A4$('K03< L")(]J6L1FC4*,;!^3G;=I)[
MMPB&WNTVL>9LR>?[6ZBH/)\LKC>Y/_K^X9%=[K^*]PE^KI&:WG[R!!M!A"+!
M%PU;)L8>,[UU:J306O*J7:GOQ/5*#I>'6*R?UM[R'8G64%#%=%BWG,&8:KM;
M%*50#@_5#OUHTON0BG(P)7Y8G,>:,+]E*)!8<5;RY+F$&:X%M4IKP1"/75=T
MR3LTS:J.#984/YC@L^X@',#$; [+ V.+R^@ _3JY32N#[GV\+F'<.R !5<99
M(Z56W/H"5.0='NV934/=>+ZXC0?3OQ2V$W#'=L3TBO5T&BQT8PI[+G0N#!X%!-N7"4"SBO@K!],APKSS&*OTPVQ
MOP6)+3]\_*W>191#XQ( O9**68Z1M)!*K(4KV=1V7*W<1Z4Z7>(Z@/J\3_--
MC&$Q33<05=]@.C BH4@(X(1@GGB$F6=$%2N[1M*,*\5Q5"K3#:)C,)\.@;9=
M0I<_A0=7RW>+P/ L.U;[J-L7)48#(2U3S'AC(:8F %H &>L]OZZ-L,=(QSEA
M'X/^'OSJ]S+X>SJ[O@D+O8I%;*Y3]RW-I[-E^CXL_T?C=L-1D1"M ?&QMCD5
MX6=B@O@+$4A-&SD+Y]O'SZCY9Y/)&#Z+"MXOUJOE:K*XG"VNM]V8>US97[PK
MB!P92P)X4CCKA!&(X0).:YK=G#^?W3'>Q;TM\J]+D?M:V[NA(/$8"*NU(L *
M%^2@J2V5@%7WL!TV%>-M*'V'\ACSI^#^9SU;W;];Q*R"S<:WN=;SZ6:R&,R(
M/Y&$A$.MD8*(,AZL2F^T5[  WRO6Z&/H+4OE-7X,_0KD#7T-S]:(S1_M9)7Z
MR2S_UV2^[F7KZ)K&A'J-D+/(>R )TX+)H%8[\1G*&]V!8']]3Z.1V*O^X'[-
M%C'!+;WLS]4XE88D@(\)1A9[@8B#'BNK"O@ID8VNF_"_/IC!)/(V/HAQ;C[U
MR4NP(C1(2S"L.8NM>6+9EV(5$\TZ!(N_/J,Q"*O)C85?@C1OU[>?8A+S:OM=
M[S*QEN^6RW5Z>;'8'+$].C[9[)C330[<"U5O/6?899WE@5-&F0 \+#%*L()E
M3'&C0U'YAO1S:(0;*=7DVW'R-G@TT:RV$R<&&:V@@)K!\&4!)*2PY9XE0;,:
M4.#-Z=? .#=1L@TYE\? >98E\*]X96-Q?3"DTL&L"?3(*0H45<0IA96FKO01
M"%.-;F_!MW0*.CS(0V:4I?F7V2Z_X 5WY;:_07#Y*5M-YH__'B]3_9JM_E\:
MF)]FUXO9O]-C@;_>WIDH2A"2VBL0=@:H /2VW!\,00^WW$I)0XV,:D&1>&X0TB[I1" ) W*C4&'R+!Y^CEDL_ET+W
M7RS<_]M=&8EW@<7%,IO/+B>;K6U7V'MY<;4KZ7;6#CACOX2(H*'$&1E\%P&H
MP<"3[>UOK:&!KJK%\E^7$-/$6NH9!@%) :QWDC"S/3322FF-!VHXWOI3@K!6BUUFOU8:8S75"LK10G]/0Y
M#= !+,5^.K=H+Z%"\3J3HUA!@QAT!9O>X?$6?>Q$=B>U<&D&U9O5C+'=U!N?
M0K0/Q46[/=:X_9(NUNGQFI!['DTP4QQ)*V'P-0CF,GB\IB!08@T'$F$7/7EJ
M8YUUBLDP5^#2\)J;6/TF4#K/[B+[.[^FSD6XJM$)V"3T01KTWW/ "!5NAYT&
MG(^L@8HP$4XJ=TD>:3>:!87=X&_)>K&-KXDM;5BEKC$^)U
MV(4 DX3KP#(R#H+R.S"@T:[16W9V/ZK1!U!G*IK7IJ\+GR5BJ>5R?;O-U?IM-9O'4XA/V28AZU&IBK_B] <5
M57H4UAA"X^F\5,0 !'97DJ&DM#+(]U>>QQNF;%0N48:D'5%!@D) 06X&**E%0$$<'TK$SQ>)K"_YH
ML<#3(!Q#!OPKJ+UFD!42<&F-,Y0"& OY%*L"&*,+6#-._%+83
M<,=V!/&*]71X_8P6_V,&(\'5<<
M);QJ"_FYQG6&ZA@6MD/ E;=_'KFA'V;+/WR>IN^">9FGR]6'R:J7BV9UWYT(
M%TQUHCG WEMH#$:*%7!#@8=:\@:+O33V5$8FB=>F^,\B,__*YI/5IKG3D%_ 
M42*2L$MRA[Q6$&D+B$=R%Y:+*P_QXSJV?"N?0IJ;^%S-^^_OI8E 0F.!M>:*J6 O,K_+3@@ "]+L%MV8L^);Z?P81/#*U_V"
M=3O[,KM,%[T41&I 1@(A%\&.51PB[ADW"G!16K*6-C*#QEPA;(QK?TNAC/G+
M&$_YHX8E<[ Q/JB*4AHHQ7&LZN[*10JH1K[NF(N&#?Y]#"*78V>___@Q/ACW
MK__\C_\/4$L#!!0    ( ""!FTBOL!*A<<0  ([V"0 5    :&]L>"TR,#$V
M,#,R-E]L86(N>&ULY+UK<]PXEB;\?7\%WM[9F*H(N8L$P0LZ9F8#O*#:$:Z2
MUW9-[T3%&QET)B5Q*I54DTS;FE^_ &^9DC(I  28=,]$3[0[=;%)M_=_NN??OOXAGR,WK[]T__^M__Q
M+__?FS?_-_SP#L3%>G^?[6H0E5E:9QOP-:_OP-\V6?4'N"F+>_"WHOPC_Y*^
M>=/^(]#\8IOO_O@+_Z_/:96!;U7^EVI]E]VG[XIU6C>V[^KZX2\__?3UZ]<_
M?_M<;O]G^6D;8_Q3\[?#CU;YJ1]DG[5_^K^_O/O8^/DFWU5UNEMG?_JW
M_P% 2T=9;+,/V0W@__O;A[=GT>&?^$_\M,MN.=_OLS(O-A_KM*S?I9^S+8/1
M?.VNS&Y.?V);ED^^P!G"G"';XPS]SU<^7#\^9/_ZIRJ_?]@R>GZ:@%\!:6\:+3Y[%O.4_]8[]JOM!_O41^6V,=Z)Z].'L6YWM-MFF$@_K__^6G@QM/F"O6IYI" ^4FK3XW>#J/&2[;_2G;UE7_)V_XG[RQ
M[&Y@_9^O4/.9)/'AJH]F+0F\3:UEA3IQBY$5_^9!]R7;[K!K,A$'L1D$48L>F
M5H!(8@5V;R:.0KJJAW'AU=XB_7&9;E*?&9]&^DJ/YR]G>X8FCL3$Q"@]CSG8D0VE&E;AEZHPR\T-1\YA?B8;K.JL_5S46PJELJNJ.,1"V*"$AA;
M?F 1)R:M*=>S44AD5$+)@&&E>%\6F_VZEM,)-:;$M,(X27)ZT< !'9XKT""Z
M @S3O*IQBI41Y9A$XC+48YH+A<9&I:XB'[/R2[[.&FL1CFPWMJ&'*,(>I,3V
M!FLX""J/"
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M\IPM22(4T)\4!U46%&6!W!=EG?]77F&(BX
M]"@QNT@94O-D7)(FL",G3_UJRBK H>^[$0TAL5$2Q-BSW=X(6QQ"@@GN]@R\*HM^ @-Y!9_Y3YKN$ET 8*:+'(:8$4.6)"8(H7.140
MHL2( ASY/]+]55A:1M]70EY,;R-RO?[Z(2M9LK&[3;X]9+OJZ$R(%0>!ZWHP
M<8B+:.0G%AI4)J(PDI:>$4V93NDR%$:#'X7NQB:[X5IE[&?OR&X39U^R;?' #ZYVQE>1Z\6^Z_B(
MNDSN',_S(>QM>MB6.N$QS9)A%>K!-3.5S0&>[%;M)#)%]V_GXE%V4_>(PB-D
MO4+-O=D[PM+H#K .=I>A3II\>;%7K(\AX1-HV9;][2TS^4M:_I$=Z>,J3@(W
M=BSD$Q1&;N!:S$IOT$5(*DF:8,;X0DJ#K.E;]STVR;-H$S@44Z:9Z).3I6/F
M!EB7T:3S_(R=2IM.ZC+42()&>(4FV['T;,L,DLU]OLMY:E;G7[+>
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M2@,6+;QBIZH<,K1):H[GA6S[?/6E-L3I6QEE6OXL!%H<^F4!$-;8H2#+W!'(3$EIG@*!LQ/,GI
M<8"\@26G)NK,B4G*+*3)ZQN-/,:3
M5=>[Y!O/@O9Y=<<5ZOHFSC[7J\"+$HX1ASCS9O=K
MC(UM=VMC>QE*I=&?YUO>FID27JKA5PY_+7;%TQE=+Z'8#0,G=B"V;V[
M*!J,^KXO=;]BFBG#.M:@ZR9:X(CY$-
MBSP=N+G7>4:9&EORT4/Q,I1+ES//%X)TV;X>UEW#
M[*8HL_;G/J7?LNJ7?%>4>?W8IXADMWGZE>3O>_;7OV3U7;$Y3#FK54)56OND>P,;($=G>HOKWDM8XA;)#,G7[]8&$:%P93R_>.A# Q.I!8]5&T8GB*\+XLO.7]"#K 031[4%"B4&8#,
MLJ9ILDKHN
M\\_[.N5'Z.L"O$_+L6OH1G3D"3LCZJ'&XC(T0Q%[H:,=R>E#DI8[ED15[[/R
MXQUK#8>"$"[Q$HBAY0:$U^!WF3@-N5CWUBX0!!E@EYF,9!#(?S*:X72=795K-@6'@:$-,41I I-7G13])4;;D"
MXYS-HBL-! E1D:-QF8HBZ<,K;56 '!#N!$[O(P_P)1,NE
MO;6 "=D4-1&U8?HD20MCFJ((\Z6F*2:HFJXJKS$WBZYT("2419;,96J+M!>O
MJ(L:*Z+Z\K,&8/F4*/ ?[
M+&7R8T+LV"51&![*>^-(Z@2(=N.&%:G'"](6,-@UB/DYK&9^58'B %IRLJ4_
M$&**=M$8R$G=0'^'%?PZT-_"!4=X!Q6\V 1.EMD1I306I&5(J#GWBID:NQG1
M;1-+.[*H'U'+=5$<(L=*D#\8FTHQ
MJ4$OY2+R?8FEI&^*2JG"X$29[,;U%U!67H2I0X,HL!/LT\"G?C*LY@4PT9&:
M*MM>XEQ9.[^3Y'(6:N=(.!?8E!?-R7%9M&Q.]TY,.#6Q*'TJ*\ZK];:H
M]D>;'B$)W3 FV$J\!"4(1TG Q-IVW"#P?4HCV6-%"B9F.5ITP'6Q*> (1R)'
MC"8PNXQ.I\63-)K,CO 9_;W1P?2'M,Y.'=9<.;$500O%*/80)LCR
M[ , UXJAU+*\/K.&LX^HN'](=X__7(&LQ\S/00(&3_+HDDZJ!5?T+\.RY"+_
M0.N1OG&VU!A+([U/"[G+Z&]Z7"D,-#[%/A4^ABEKE/
M_+SKRL*)1[$/XX"Z/@X"V%[F:$PC!DLFX=!BT'"J<>AM5^#S(^AP@@8HZ)&"
MWQNLYWN>0;XEM6PNJE4U;0K+9O5MA#D1G=-!_,+T3HM+YW1/'U\*^C?\\J\Y
M2V3*]=WC._Z.%OF65RMJ)TX41I[EA] *O0@F,>R-!WXB5=E+4SHM3IW7.GV<2:O=+UG*L\OF
MSNY+&'%QG^:[E>TDKIO8B%K,M!.[
M;"LKMF-F)$@2+XI#Z#F!%?86:82E:D!/L6-8 __/ON";TN_+?)U5(-\!TJX-
MMR\Z-L4(WFY8:/)UNNW>E (_- X ^_S]>OUL2RJB8:+54\$6V!7H* 2_M^@N
M)8,O>1(1O0GL+DSBIGAR3M FLS-%OF!G$2=6;%DTM ([B6,_H DFO47;2B;+
MEZ@=P_+U,;_=Y3=,G'8U:*L#7G^NLO)+Y_[8IS4N5HD"IA9M6ER@2INJ3*69!4.4I2)<6@4!#;[CV-%%#N]_3"1N\*H
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M U@KR;^D?%-3[0%*20K%I,8\>W)*,Q#77 1BB"ZD-"=Y&1&::3PN0VAL^E1+[0"7JK=1L@)H'NTBQ![;B(U
MSYMDR?3DK@4'>G2@A_=Z)S)!J^ $;C9&)6=MZF2:F:2-\30V,]/"[S(42I,O
MS^=@&AD25:PXN\G*,MOP6\;9KFKN,?9U5[/-^_2Q.8;604@2-X3$<2F-L(N<
MA&5JA[T%WY9:J-)JV+">]5AYO?=\JS!IT\NYF+I=C&XYL1N8/L9Y
MU1:$>?.90P4]U@O)GPR1(VIH)![+$$>[<'(#>VH@^4P:;?4+E<9 C/C?L#I
M&Y%78' ##'Z WA'P.W>E?<)0^9Z6J3A*[B L(83J.POFHF?X,I@:ZR)[$:8#
MN@S=G\_=LU?+9N%9='QH+P>W:Z%0ZI#?
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M!%0.[LQ%_;3#/.J0'QDYA0E#A^7_#%P0X.9-)2328-9Z-'*"57#751*J: %V!33OZ. "YM
M$5&,NQ'=TTS^,D1/MU.%T0:KN&M^A**K>+6YWGWHE]+XTU?5]>=M?MN55O>8
MUB8>QK[O0.QB@ETW'-"0@"IMEFO&,)\@FEN/-!8?R4WP"X9&3EV/4"QC9J[&
MH,@^MJ&8+$-TC7MY;M?:**L35TFK'MSCJ44$:B6N%\>QX[F.AZ(P=@X+MJX?
MNAJ62JY)3"ZCDTUUXL5);0V\;3D(^KN^RS7Z;\8=SWQ6[VS?L&_>@Z4('I)7:
MJSU*=(J+CDDFY11'$XG&5.@94Z](D"JOR]$?90].B,\T-H27\5FKX8V&6_S$
M_F5;6"J&Q(JQ;25.0BFV$+7CWI1K$RRU:*]BP/2*U).N<@4X+J7Z=FKL":[/
MFR9.@3,S:^\G>!E;:9]"XS*499H+SU?1I_.AJBU=*:8DLB+?#D@4(QCX
M$#&306\LL>2>)U0T<1%]4:H'I\JAFL88H$^'RERDJMMI;B241I+,96J-K!.O
MJ(T2)Z_IS5VQ_;;ZQ*R\*])=V%V>I9@_+N-C;/F.YP464S2[-V'[KM#! Z4/
M&]86#@=P/""4+$NB1M.XD!AG2$X^YB9G4ZR;#+W9X[@<24]@R)&U;X8'J6 [U&+D\Y=T(D)W%P66FO9%G*9"H>)Y\,.!(W"6"@=,V3:
ML)3V@$&/&##(H,<,&&C0HP8-;!5-,1 0 4F^;"SD1/M[#8.$^%\V'&K#PQ"6
MK ]+S<)2]V&IV1\4?5AV'/G4042:I'/#C#FV%S 0&72NF*7%RJTA?+PKROK3
M\_4*#U'HQMBV(^2S_UB)@_S>EA58HC-1=8KS[ CHSF2?"Y4=62]>$UWE%@16[-\
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M8%A4&UQ@  ;BIK7+SW/5&130UUG(DQ/9R_,FH;>S\*YD
MFA:@O--]*'0V' D-_I@Q_S:GC'FA'T''\WW'PDSUV?_[@^#'L2=TBWNB"=,'
M"!I@&N1D HD".CP/?W)"O 3J)*1X'@K5M%B12C$Q/NOX.36>SM0"Y%B#$X76
MUB-WINL#?XRV6;^([("ZR")QZ&(?8I2X+/7N3VX@7^H4E_A7#.Z:I83.2D5HL/(N:O!^Y&35O(,+>-LE0+N8FK;4.CEG8X08B4>?X#%M]@O
M(YQ$;CQ,KCTD]5"]S'?GZ>E*)S*EZ)'H[0:84>KO%SEI><3 :WU>DJ<%]7I9
MY*?ZO9+WHCW_EWR7W^_O.QL!)4[L^@Y!(?L^2Q^<8#@7'D2.5)UEN2\;[OT=
M&,E9@2))8@I@CA\Y#1"FQH@*/&%A1 ?4V%J&$BAB+W2T%TDU2+\=V4@2&&$4
M1Q1';F2%L>NA88F'>IY4A5^Y+YM6@Q:,JAK(D22H!L;XD50#46K,J,$Q"V-J
MH,360M1 #?MS-9C @%H]S6;ZP5(/Y%@!@<2'D4L"9+G#](-@.J&O"
MLY*/2NL"*J2)281AON1T0I*J&6ICOK)X,(&]9>C&% =&"V,J<*&F(+^F]_T.
M?ASZ,'$HX'M>S#LKH&YENL&0KOJDXW,JR97@$-37(%0)U)%6PQQ.$EA
M1.F;06D.] CKC0*C2U0=%3=&M4>9%Z$-Y:C,-GE-;LLLX\;ZA930B=P@CB)D
M)TG@(R=$7F\HL7PD]OKH! ,R?4;IF=$6%AAP2>R!*E(VKC(S<26G+\])4MDQ
M5F1+8K?8/&MJ.\4=>VD/;.K5G9-^GML8GD;* C:%)SI0:&L@"J5!>PN^G?B1
MXT#7IQ3&!(<(]Q:P[PD5#U+YKN&D[5#[U$
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M,S]-*$'DB%@:B<F+68Y'1/B3 Q>3/-E9R*#31U<*Z:%PKFU:D3
MC(S(T13^EJ$ZDSPH]+4F.0TA]P6;E_Y7LSUR?4/S7;I;,]V*BJJNR&X3Y]6Z
MV._J:N6Z@>MCQW8A22(21C!"@X0Y+),4.WZFW:SQ0VF_%KLWZ[2Z.^1HG?2 
M],@'GC)L^-1ITR%OB@1OLINL9",$N.D=!&ONH9QJZ0N1F)1=)#9R^D:>43^ 
M! W*AOP!Y[RR)\K>B!9J#\ R!%*_6X7AABMQSN+I+/M]F3VD^>8]2P'7^4.Z
M9ZE3O7I(
M'5>]R_ Y;5&NIW9 ",AEJ)4XY3$[Q6HG/QJJ\P/5#V=:\=2#PR)TG#LCHI7*
M!9P;T>M/8:K1R276/Z>L%;TKJBJKKG?)MYH-1/N\NN,XKF^:A-[W;1OCP*$^
MPD&"72LX;%1[%&*YC'JZ/>.I=-.WLB?0P)8AGC=!>Y6HDH36I^C&G2!&;43F"<
MW1SPW1AY% ;G^"AZP$CUE:
M3CFIH4ZVRL&-65B>-&5,'U#3@@!@WD]L\X:-"@EECQT1X(@76U2\9 3B^_
M/_HEUMXN&0;%VZAW&6#0F>A6?'^''WEBG_3;8])7[->V=?3K_JX6W_9AOW6Z
MW]ZGCV#=GKQMOM \ULF3C0)4=RFSWG^:^?Z0[A[_N6(_W@2WXC2 M 9I]X&F
M"3PT38#]F_3AH2R^Y?=,/K>/X)^?(G;!"T?;=!
M^/+G&92';%WG7]CGKD"U__R?['> P4PW_[FOZG8 9]99OE07[?FO+4NX.)3/
M^RK?957%)RH?V3C3G"@&MLMY@;E?F(#? 9O_*()'/_J$S^=T/_V1K#UE5^P.2(_^OC?[4&;KK/G#YSY.71.6[*;GEH=-]?8%K!0;[&'D4Z_/S>P82FP>JGS<AHX_I])/=3U?J$K^<4
M>0HM"U#=2? +3$TT9
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M3&;R$QK"Y)U+K W0OX!,VH17A=E&*Y?.EQK2SZ%P0<_A
MRECUJ2";3<[;<;I]G^:;M[LH?;T$@G+B)C0CQ
ML(-=+[9<&&*3F#6;=ENC]DZRS_PF]<4<;!QVR]+_.^O/?*3F(4$<@708P0$DX$T#/(4I.;/0PK3@S&%NDB5G!A/Y-9/Q
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M9S^)^QEJ-HSS.#+G,!*.9:6H=L7M5;.H@2?TOQK]GFEJ5\A)]J8;E=
M5O''%;=%M2^S3]FW.MSRPJB(T(C&-@J"B(4]L&$(K1Y2$-A"I=QG 6(\[^JQ
M'V4 ;77E#CXXX <'!\#OW 70^" H3O/$330S6TC(5,<&$]$RE+NI,SV:R\T0
MP*7D=G.X^B+7FXU?4;W_N+[+-OMM=GU#T[S\=UY"A515UL!ZQ[+/?-L ^B5+
M.9I-\XS2ON15WYN,]!//3P\8&3Z(*;01<8AMP1@[2=!@Q!BQ_Y)Z9(9'
M!.X":'P K1.-O!RY 7H_N@?(6D]4YN0S1U1L:%AN,.7&BMZ/Y@WR(:97"D%E
MHT#D$).J;EY>V0SH
MJ_9%T:-!]#G& *( 4DP3A*S$ICB";H\1VS%6&X?F0&9X'!H0'ZG7BXI337$(
MU4%GEO#)#CI+BYSZH--[TH>.CSAG@_IL#7I)8XZ&B B-.7-&?FECSJR^GQUS
MYH^ \)B3W7)C'YK'J?C\JU]:S&\[ZFAQ?Y5.VYX;>[FZ*\;[88
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M)5Y$U:>IJ5.U^52RS>_S76/XE^;1\A6;
MYT;$=H, DXBZ,+!=_F9?8Q-:3B)T14J/)<,Z= Q.3G/#0"#LUK=:)&+O-CQ0M2O!$+'@E)U%]6M&!X'6F!\G;ULN&_.
M('0#L^0YDPE,BJ6M\Y HI_8'_@94_7[$S'<&S[(SDJA.9W092:H&/PK=;4WV
MKQ]Q/);961]J_
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M0FIK:>8B);;&ILC+&1NVVIK=AV'):IB=)PER?3O"$%MQ
M8F&'LF%YV#I*$JER8A/,?'^K=BIE5:NIH8=2/=3C/WR^B"NITJ
MC+97U0M1;W#^2"ABK>@)AHU
MG$91X=*MI 'D%.I@+N@ ^
MSN#8BJ/N("Q#(/6[=?:BDE;>1$7R?5D\L'G&SF(S=IB[&$$_=ZPFR2QC#QJ,'=Y8>R=N *-&VVQA]X1.:G40;^82,[,
MO)P\CC)Z<75\G;H17=3(^S(44:=#A;$V*GMW85W<9Y_2;ZG7;,S)*=>!M&64(!VC
M:42EM+"[#'W2X\J+2PO:^!&[LW"7EMF'[(&UNKNTR@XS9*)^(5.!0\ W_:
MYW/[;U,I6L#^VF07"HU-1BZ3^50VY2(?/]9,F0X2%5K$(I@BE#@X]&,2HL2U
M70=BR_9#+X R.8RB"'-2.9RFIF1G&4B
MEZK?)=55;_7UM2X2& ,'1C&2?,L#HD]UZ+M
M3 TZ 72D7IV89LFP\O18E(K;3.10<(%\-OHD\SY!YLRL>8^1,K;0K87,9:B/
M)E^>+VEK9$CRWD%7X2*(0@L'@>V$.,1)9'G$LGH;EN-)59N0^_)L6J-4VD:2
M)4%U,4:0JIISPO3V]W157GZZHK*V$Y
MMF-9GAO:)/ BC_K4"GLCL1T*7:U3_+1A13@")/-NGCQ# BM+9LF14X,C+*^7
MD-%"D,RS@D:)4GQ4\(#ISU.?$GSNWKFU(G4>%K!*- %\H:4M2"ABR.>%]5^S
M=%O?=58HM3WD>RP5<['E1S8B/NRM4!\+Y4BJWS:LB2TBT$*2Z/0J+ G(HF&"
MY'3Q"3+'$;0<8H4.<7PTR+!GAT+'0A4_;5@??_Z/7T&/2*+G
M*U DH(YFV9$31X9E($9%&Q48DI!<RI*2-O2E4':JHPOO#OG"ZJ$[$ 69P 
MOM#2&&2.(?R1;;,ZW3X1WP Y<>):+"V-7-MW_9C8<6_'@4BB5J+*UTTOL'68
MY)-'-:X$!-(X39++;$\94I%)-:IDCFF8IDSQC$9/G9Y$\I279T]E3&%D :HY
M#7^AJVW(%N0O'XHRK;/.BA_8*+;89ST;&'>BL^=*7*"LI^V[!N#G!D
M:^U+,B2V)6&2'#FU') ,'0IE]"^*YT]A0;5:VM%%
MDW=#\=/0=F,,O,\_>J70AEEO61+[8G.
MQ[/25ND4BF>I?7:*MM>W5O6PO@P]T^O2*Y7.-/ E7?04>7YB!30D@1NBQ$EB
M' ["&K$I[.I+5GXNI,N>OO99F;YUC$"XBWTJ>*+_:MW&BY<_%25J&=U!'O:Y
M\J=R?HLVZZ%F<'MAY%U152M,;-\C&%FA%X9V$ 21[0]S"S_RY%JXB@7CC?U0
M #MO[T/]L&6X?IRWU9]@9J0#3.%Q&7UAD@>%OE8EUT-B7O9VG3>##+GGX\Y_
MM;_>;#9U D0].+('8X)PAA+W;K49=/T49XCF,T5
MZ/0(JURNJXUEL73W$@3+9;S'"*_ ,<:&Z0'E%6 XY]4M0?)&M$PW_
M%68;K63AC?2Q.:WZJ2#KO^_S,GM?%IO]NLZ_9*2J,O[:@.]8#K+]P+.8_B+'
M2<)^31+Q)4JINAN3K9E>/TP?LMTFKWE]*,E2&M,)%1.[>;F4D[D>
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MH8YT _X*-/#?-/C!,.&Y5%WI:7R/+>K,$\AEJ,1NF["4T&+R%O,*]S;J446A)347,XW%]%$27@;E38/MB:)(+J:;#HAF99\A
M%O-*^\42O(F4ZU#WB<'\SN1]JK>J^JZ%9?F'"48.X(2/W5\>I:V6@WT+NA$,
MH!S$-7P+M3$/&DCQ/':VT'#DEB'4QKT\^_J!25;EA;D[)D890_/YW$QZ2$^JDK\!:(H.PPL.X#J0T7G%^ 2 WK/#D]J
M@X-O?*NZ\PX<'O$]"G^^!MS#!8TIVH,F-.Y]SUTX0:O[.5!?>S+IHAS$J^>\$WCW'#"]@J%0NF7KC L
M0S$-^'4V-=++G*A>_I+^9U%^8O^DNKXYI]B\'C6F%D$$A780X8C:",(@Z:TC
M+Y":F.NR:5@K&YB@P4HI%(A?HWT
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M(NF_:"34LO]/=WD%.A. 0AA<"M0KQ JSXP
MM@!-Z+($^SK'1LV,SS$ZMI !PWSA.)@8(QHH%;Q3&BI5610:+*]Y*ZSOTAUK]?R)B/(QOW](\Y)WGI4=![:+[## T$L\
M+W#PX2@3].)0K-;S=#LR/5^MXG/3%SD\,. #!X 2LCN-3X&!;C8BY8:TI3 H
M,43-QJ3:8*3*J-AH,.;\.=W70M@"%%Z/'X7NIC1MS^4P?*Q\&P0]C@.N
MRVYC''!(;%>(WC+Z.VS>/KB*8"YV)VD%WP)F,]M
MP\<.6%/'B*7(U5W^$#ZV;[=\9%ES4__R'0]D4S[CU,<^Y-4?[?4;&-DH\"*"
M?9?],L">X_J] P[!4A=@%@3;\(;H:5VZ:C?F?N#N_JAVTW!!%$X96)8?=!WC
MD%R\YQMOC+ O.SQ=M@DL>#2[,#$B@]\28C=EK.0VF^M341"1T$4^=F!DA9@Z
MD1OV)J'O3A[=A U=8CQ2NK\YC4[U(<,(DQI$_B*W,L<(DM1A:5Z7JYSRK@AH
MG2(_\NH4%;MFRL O,757E1R2H B&'K4L.AEF4EF=Q$DTK$XO"1)2IPF\+DV=IKAR5ITF\Z-EG>'=< O&\BW?
MB1PGL"E$21![-**]<9I8EK8U G&32YC?OY.]=*>;=@T3=#.,&YAKMKMK%Y9?DRN\MV5?,/^,PX
MN;G)FL<7W_-K+.T[LG:(L9V$GN?BB 8ABE  #P*.I5Y+NPA PXH;W;'?914_
M!_BE>5JMN %WV>8VV[ _8M_+JAJ4:?[#^C9E.(
M_0(VIPSY*<2:R4#6_'&5?P/W;%"]JT"VV[!/_L+:PAV WA7@1SW:?VK]&4O\
MTZ#YI^Y?-"J_L::E89Q80JO2/ZH3%<
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M1$]G ,1D[4+C/=C>=A@.VE!(KZN?TM<=P&7H]DZ_3"ZTH,RRJ_%%:W=%M
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MWS1@3W1NI8L7.@,@)J47XEY.1S72;D1%Q4DBB6O#9PW
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MSG6IZ4U^]/.OO"1W71- "7CC3X$2A
MM='();MO=^_+8IWQ\C]5QLN3D=VFP\!;56?;"1.+(M<-8RN,&(X 0KNW'5!?
M*L758]&P-+_=O7EH48*R@]ELGVP.0.526$T\BR6N\U,LI^-O=Z #"#X+@I=H=*;^JR9/I[38622=P2RZ9GK'JE$EJ6'8(%4=79N)8_9
M]+0^P3<4RI(]KJ^16XED=G:.U?+:,TUX:+Y3?PE1C
MD\N'/Y7I)N-+'KV9T',3?F/)\6F(/8A)&%K#FH<+I8HO2W_,". Y++
M9N59$DM5M&AJD.O]#4?B3RQG!?Y;N,EY)?
M-_>DARO1. B(%4=.$"<0NZX=#'M1&,-0.%-4_+YAJ>A1@6T'2R)9465,(/6;
M@2PYV1AXZA&I9'>JA$GD2](F\K* M&RJ!X6^5J)M
MW_W=<).'N ZQ$/2#V.?EQ:. '!8"UY)_>ZC'K8G;Z2;(5KG
M[OD%KRN*\*:V22Y/^S(R1;TNB6^'J_*E0?M^+HNJ6B6VE_@>M0/732BBH1/8
MP]9[$D)7D^Z)&3.L>0T($*5E^NIM2F+@FI
M:_7;V38,D=!\V:!YPQ)W! L 6=[*"XINKA4H?*'EGO"CA^R/B9318&?AVI6J?;_\C2%^F:/VO#8UB'!U#MI3X.JWG649\.:PO,=&&^1$PT*_61"WTA
MVRMP*HC7HMR#SBH*N.Z[+5WCM'DM(OAFVS8P!',BGK\7*=3S;L7S'"6!D
MQ= *$P_U6/CRA3G5%T5@?!FUEW;?I+0+\VU"S$U0/8=\<]R  5^R7'?<:A-H
MV5A]CY(L[>,D$59CU*#L\F? 5[YE,:)]SZ4>8IH?^Q#A'HWK4*D7'DQAF$UZ
M ^/2*\:Y,?'53O=\\LNA+UZ .4B]$BP5L>]6A.6\G"[#"JR:$V+*NLLJAA$.
MG!##P+?M) J= ,,>#(D<77?TIT"838:Q:1D68]R4"FLG>S81YLB7KL$FO;K+GTU_V;Q:OO^QG]>JO3+B^6_V5[./M'7T0$\%#CZ M&H?\&&S6^:'P@O"QD(G)LR+B9J<2AL/F+FGC!7)'I'S
M66*X#&V?Q]53;RG/PZ_".RW]\T[7-S=ARCK).OMXEV7UA[SZHWOPP+=  7[SN44,&LB@P3SY
MP18-D1#,IB\5!,E46C/_IE]N>97+L93:1$B6H;EF7#O_?HMN_L0J$I;9)J_)
M;9EE1Z4/(^I1-X%6[%/'QC A(8E[0RA&0B]$3_B\87UL08$!U=3Z;*=\/-%E
M-!"R@%(?$QTHM#4.R3WDL=YU6(9ZN[LIROMF;^7=@HYGN21Q(L_%R(&V
MC=T>4>*[(PO9O\^E!V=;Q,?>3#E)HA)@,GN!^]D)A);DJ;#I>9W6EU
MKL>VJ&>(X#*2EED\?;Y9/1N[PJ^D%Q4;3NJ[8G.T3<%O1_DA0C#!U(&Q$T0N
M&6Q%4.Y&DIH%TXD- P5:5. (EN1#YFK=KD1%*6,3-OC9\B943-II&X
M#)V:Z,/S1\$U,"(T77I?YKMU_I!NR7VQYSL@85&6Q==\=\O+G-AA'+ )&750
MX@?$\@+4FW.HYZR^9.7G0FC:-,6,3&FK
M\RK-O(Y+SZR$RJG/@ JTL%B>!@[ YJ)/HH+G7#2JE?'\D#WPAU/XF9OZ+F/M
MD#7$V[3.0+&OJSK=->=I#HVVN %IXT8%/O=-NFW(_%\_7R286A)TA+IS:P4Z
MV%[ BH$6-PK-K5 NG^3G6][NJKIL6N60[ZX02UTMQT(.M7S"(I[XX; @Q\P*
MO1\
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MKNW'5H2;9X1"&%AV;XH&GB.=O ./3'6!L36+Y<>?KDQ
MZY*1G_T2BV)X1A9=+]D8EK%@>U$&)&["S!,-\9VJWM)A<;KZ.)T
M\),XQE!NZVLAH V/A@<_CW:%^+M(O.!#JXHO1;%5PJ/G0K@HUD4GIE=@\+I1
MQFZ%@?W]YPP0@ AO_2T$K\F]Q.6U'4,;E//$;$GNS2 DG6VCM?JJSNZ+;XV%VJ;8BGD:),YL4(K])((!QB[;@*A%7N=?1HY
MKE1I67U69][X Q]I>:V_K)(&T/CIC,7=M)$$>1X1'?RR6H1P&_'I1CL@,
MGDX PNV%_S2<"/H(6\0//
M"Q/;MZW8BF@O)M1U/:E#9 9A&.[=!^1/4AJ6Q'3X0>_ B^6 *Y:O<"_D5X-,
M1DTL $81WGGKT4=9Q7[
MJ>:EQJ8R2KZ[/?J!E9OXL6^3&+N6%Z$@H@E!/4HGM (9X9\;F^'10%Q6CF?#
M@/D%#H[U-8_XL?^CGY(;(F8/NMBXL>1XRPTF%PFUD1%&M\K$@<$3+(CMK)(%&6Q,X#/77OW#$@11(6DD=A-+:!W&H'G#&OJQ9B#>-%C!,=C^O1)>QCXJ=E6QS3=-QC64 :[X
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M!QMVY&&9T4/NRX9'@+9_W8B4+/(P[U@]!Q>WM>
MD$@=[E>W,L?>,2@:1."!_97DJO8$^L2T>1[F) 6VP_1D-1G\WN*:66G/\C,B
ME],Y78;F:?"CT-W:Y-3G0U;59;ZNLW:9][==7EAXU$.DG^6'$,N]QZYJP[ Z'<%J3P=)*I,R=6*:- =KR%X7>)J9YB>_JCX#.$4Q-JWSSQE%R(WF>$%YF,?!5XJF+ZC*T
M?4Z'99?U='-M?,3HSE7]S'ZPKM[NV#B7%YM5%%H!CCWB132*;5XO'/4KC:&'
M'+DS2O-",SR2=*# +4+J<"ZV=8I?'&K=&FJWTJ*\
MR?)Z/S8)6M8@WA.Q]<)CJO:Z#1$0/S)Q%.HNQO(G07$9)O6;G.
MJ^Q]F:^S%0I#"U$?$^H&[-@_Z.4.\W:!Q?V#BH+Z)&#ER8:U??R0AZ
M"6:T'<\P';VY)GS7AV>E?]TW2YE.!*,8,50X2.(DB +H.3W..(JD*GK-CV[&
M!<3C.]%7W79M=W[DZ+'N>6>&"N&<9W)H-I*7FQ\>^<6FAHUG"QL&90-C<$:H
MW@B^DR'-G/^:YX53(W&!X6ET<*6.%<1A2) 5!PES)73C8375\V.I(XI+P7S9
M*2%?XRJZ11?;M,(3$AJ[G(R>A44B)W<.G1*[8_V) ?P<'
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MDX<6%]?1N@!EML[X$[UUXQO8-Z;US::!Q--D
M9H,X/FXO*WYR@VT?NA9W-]\=7I*K0(L=7.^ZLE_'E7?>-BOEW('%!$KB*;G%
M!$SM1;D^<$\[U5''._0OEO34X&NQWV[ YPSD;43;O*GO:=W9U(>#KU-?H9M"
M[XFD8[Z0+>!-NGG\+.;N##)CE9;]=_;;
M?'?;'36T*4R(:Q&7H(00AX1N,FS:(X]$JR]9^;D0>VC=+!(9H3@&+:P33VK"
M'IV@^]+"Y#(P=EIY_M (#, +BHG"DO3FU+OJQVO2+VID=_!?.UD^?ZQD7EQ?
M3LS4!MP6"!]6Z_P^:R?#]_NJ!MOTH "LM[&_S%@^?/+D*LN4>=>;
M_#C[)#K/C;54U^ 7%86&_6X:M/19UNC_\^
M*JKZUZ+^CXQYL"YN=_PM\A5Q$80XI,1B$WF;6#:-A^E\A*#4HQ"70VE\1[L<
ML#RI6 *R;_S7DMO7%XRFV)[T]Q%(N5']\,I.Z]39!W2/=HK;'>;JZFD6P!UC
M/U.#QXRG ;UO%WJH1W>(1O: +]\LEK&QNP >SCTT=.'(7'P\:T=A6I3='_&?
MLU=N1/D+ MBC801AZ/$ZT;T3ENU8BQCDU* ;'OE>U#=I9Z)-_EP>W\\
M2#;)],D27X]96JJ^"K<,RB\]B)IO* L;6:^Z.773ZHZ<_@<9<4_&\Q+#\+2&
M]0\^-D\D9ZX!6T<,14?QM[N:Z0#?9215E=55G%?K;5'MR^Q3]JT.65C^6/E)
MG#C(AB2,+3(((6H]Q(IX51L>%I;C+EQI07
M/((#/O [1P@:B#._/2- VHAPZZ1\&6JKU:/"7 .5U366LF8?Z[1NUOO><9+Y
M$N"WO%HY24P)0@0G%L(64\^@>[@U)*'M!T(G3738,:YC'!H8L($>'/B=PY-\
MM6L2H:)R-@^7LC*F2*,A]3K+T:AJ36=V*6JEP9,7*J6+G8GJU#UK'U)L$Q@&
M'DQFIEFZG$*U /5HE"BMDU3* */:=.HU,N=4JA:+O%9)
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M%;"?LUU6IEMFEFSN\UU>U25+YK]D3VTC&K*RZ83I$YAR>J:)7C%1FY]9.64[)O4IP@O+FQ!Q(QJGE_AE")UFGPJ3
M355Z2EJ7^W6]+YG&1G?\)F+5&;1M.W9]UT$X]&R/XHCXM#-H>U$D>)-/@R&9
M3JAT4>\)MG8FFC>7]-B?2&K<%#Z%)Z!S$"D][SQBL$-UNTO-5$Z8GC6<.6*O=
M2%*E47#6:)Y!R;GBF0/*2ZCX.#8GG,;C,E1GJA-"=0HE.1%6FW[;]/J&YKMT
MM\[3[?NB:@[9DL\\&5O7*X_:H>\E7IQ$V')8XN6[Q"8)=2([BAPB>E1 BRV#
M76@X*E#<@ $@Z!&"WWN,?=3S]?HIV1;+?%5UXQ
M@Q9E7.P_US?[+5FOB_VNKCXT9:[2S]LLVI?E]5C:)U5CR,R[O%:4-1@G4.JXNR:3AO5R0-G>8;T"#VGW1@'X
M(=^!3;'=IF7%[\&VE=M^E--07;R+B><%*)=3S0/;'UNV&4;6S=N3J)NV#C^_
M_=G>*9U7,,7(&U%*S>PO0R)U.U48;;%31+$MKT?V]5U1-K40D.4X.+ QBOT@
M0(C),H*]48@"J56EB:;F%L%T@-:H8%NS59(:2Q906^1YS>
M(D5R522FV)E5YG3,(2>1*BUJ1OF<(F87GCJ.4"0F7,K$+DZPU#TY+U03V5$6
MJ"X+1*$'B6/YF%J8N+X-/7N0PR3 4LM1RY[
MTJ'61Y';<2NJ*KK'4WSLMFL
M^6NVN;$KK<($CO1=_4%8
M1K\UX-=820N-S&GKKZ?>1;&1CY ?Q@'TD..0D$F)W4-Q T_JN*\1 (8SHY?]
M.3Z4Z>F+SDPHUZ,M#IHDU'0(#*CI(MYS4B%VBLI.B=-W(KB37)35WNE\BK^Z
MLLEN\EU>9UNF))OGCU.1]=_W>9EM5CYVG!A'81C8GLNWNI!%(0ZH'X74\2RI
MIV9UV32^3MO#?-/@!"\?;^NARC[)HHES,96]!-URPJJ#:4/OM0A1-R*=NLE?
MAEIJ]^K%:RXF6)/IEXL5'1%FS'#*GB\17(,$O0HN_T0M4V0"1Q+[4K-0Z_ZYM.BF%7:
M19J'X8F;18HSLT+)\
M:D>!8]D^]%BCZ.W9'O&ESF,I6S&]*7/<;U0>2YW GUB>.P]UDALI$JR9K1OX
MG)2Q(U>3B5Q&EJK!CW-E 2S.US:]V+A@D.?1NA&,8619A&L1T/]M@?
M17(/R:A:F55SE)X_G<"@H.K,0MX4U;G(2Z=G:1G3G290F_"LQFOIE,,V8U]J7[EV^HIHU*
MU">QJJPM?X1!$2")J2#  A!:ZNG''5L$EP!]12![;*I3HB3<Z>IH>M2/(!LA+$<0IB1!(0)J,)OS0$4H*A#YL>/3V6,0"OQ@Q?+'>
M&"=B0[F'<:&W14XYF(GE4E2M(WS+0:\T=!7!B\*;(ON4;8N[8CO8 8@$,/ \
M/XA1Y,4(QL-;)-0.6RP4N@Q<^.N&18 !^FU )'B_MSA1?'I@EB,Q46!8K ',
MA:3A%1TS^B!/W3I$0@'_RUNS%9G@6M4"^_U-^\"VO;-\I)A>+PHQ+X+
MO"1.$F1C;S0%/,!UE%3)@&G1V.^MBN$2.4TE31;'DM02/ D*!Z6H@V1-F-[7
M#XVD":PV+4&>W K3U,^L[8A-];31&6?/+2"IIC4D<>#"PIW6I!":)IFT#_ 8OOW6 8;4ZL/I6N04(YQ#L
M2W M)N#KIUG;A@(S=!O;5,!#NXZ=!1,M<
M=C?:%^^I\<_YM[P\Y-1. $A* HRC"#H)\A!(@JG*[R.N>S7EOVXX3(PX!)1)
MCB0.M3?.CYBT'^$PE5F,* &]-DZ8G#B?$%?=6?4 3#4E?\O9P<]U_%C-W"<-"8H=$*(
M<#):PY[8Q=2R-@S'G;?&EM0N8FD.^5;TEJ!/+&[(,&=D=>\,-3-K?*IDKF.E
M3]F+2F\7$[V2.BN;.SI@0;G[DM??BFU1WI^1/OKAYNT_&C<;NL1GI0X04W"(
M)NLPF60QC*#008=%@5U W1K)#3V>W7[4!V:K-Q1A+=YV5V&."R5(C],'=M-G0@$."9N
M&(?1:,_V$==M.^I6#&LW'9^V\'V[:K1Q5#468TQ,02DL:\1E46 613;>BBN^
M942-18$*Q6)LRA4D&*OMR"K[7TM9U7)C[9SCYZH,6LA:05%!CQ^5[FXD+\[?
M\_VW_-1D&KE>&B>>EP(?(9?0J!!.\<"+X>9;7G^M9!1:V)3((#E%)2+3[CLR
M+34D7GK*.2JD"5K?P)!W969L*/(C,SP>BKK-GX_),'&C%(6NZP'";H<)0SPE
M3$D:MJ1&AE3YS,8PN;K2FY%D$SG.
M:PHX)5V!N_6)NHHS,[*NS)'6A?P/QWU8<0A"#WN1YR5)[,,T/H*(8.IH7\SG
M-[VN!?T/4AM!#32(QI5],VUA='5_-KIS1GV5MN$YGC;;[,!G@T3.R:ADR1!B"(_0FBT'*2>
MT!%>'?86"U]W;(!^8_ :MF5SQYXL+(YM(_IRM0:F^=;&EB99+"Z=OE[&X%V=
M"N$)Q*5?MWZ7LYDU+9V,KV.I2JM'KU[ ULV6^!NV:7>5[X>WKO)]^>Z6BZ+(
MC;P4("?QL9?@ '?;@F-,TL0'V[-.W&MGGD\1+$R\F
MD:><]WA_^W#F$O+U/*'+3>R,CIILIG7HJE$/S[[#:XI-4=VMYI"D!_9D#'BL
M:&CX5S>I&EY'? '1(8Z-,7%2+[+M- P0AND$T8Z%7MQ9%-B"2GU,8D]AC^_(
MRLGV,HTGIN>K:S=30D^SY,Z;-]MS-5% 1W-PA(=%6WU=<6-9U\\$E OPSQMI
MV(3BK:>*@L3&J1NE00#LT T<$B7]?6< @0!X7'>'JMHPK/^PJNOJ.WO/LEO2
M0G6^*UH+U#7]2[E$Q4*:2CX)7X)%,35FB-;Q6-H9;F:D497-=:B5WCXF
M^);V(:-CK0M7-=0@ $-L$]#>L A\##W(_TBS^97/#Y CF8N^T
MON9C9F@HD+>.4:'BP,MGD56Y$*^T?:JKW6';_CUC@:C]^:'(OA;[HOWY(AW 
M+L+(!;$=AH[K)"&DD$88@1UQW2=BS+CAR#V@M$:8LF4U752+UM0NP++\/.LE
MV=8$=S73*%Y&N2IIFAMG'9)HSKVS-30C//+=E+K='AX/W7NLP_V!CT]U_D#G
M5'3^=5UNJ\=\4G. "/(=.X0H\3$.P\0FPY.L,((8OY=P:+=G;DR?H)PN"SW!
M:?5 >5(4PXR+W"9Z(>8E;QC5U@*P:\6(6Y7ACBFZ4^65
M1;;G\RB\+ML;0Q#R(CL(Z:_3($I&L]C!7%>9:C-F.&%\)\
MI0M#//-N4EF08M$=*CK8-;1-99ZUV3TJF@A?1P:HSYU7NU.T\L25X>&\S8I]
MME]THPTK%Y5]6/7=8BD-UI9ILCH[X/7E:;1JM,PPPK0%GM[S:(;5.H%YL,42$QYG\T$ASK"-7
M-./:RT>3S/''O_FAV=;%$S-U<_R+;LZ0H'EVZX;)9EN' AOV\=6V#_.,\JW<
M['8%0\'.]$TSU2D(P #"A'C0#H&''<_Q@0]L"&.8QD$2!>]MI-)@P6#6-.$Z
MG:1+KL:HL2BR_K(8FY(K+M*L5VW>CP[+A
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M<=THB&T4IY[M)VX(')0.]A(2IOQ/S2E9663'  -G3>BL(SS%N?*FREK8
M6L%,68\?E>Y^)+SF^=Z>1C:R^^>WXM2-PCAQ?2\,$AS&GD=2)W ]#Q& $XQ%
M>-;)O:O69F\GYU6?]#;*.C,6,
M:Z]7GTWQQUUW;*EUIM?DGX>B_E10D4S.2N%B/(K)GC"%9FI_<^S,U?JTL+H.[=+D
MR\M:GD:&>-7IA:GA_:HX=-(XB //>'3NC33\ 7$X%CFAH(I1/
M>I;C4DR"7M%X6AY_]PD8,X\MSU$U(TMZ*%Z'/&GRY>7SRQH9XBH-?V+3PJHL
M2HY9XX B)BY.<1J$D1^%R(9QF$Y31L?WN2Z!-V7;L*0-B"TZ 'E/O(N_T62B
M2>8E< VM(2:*?]B&$-B!>.$&D=N6:*!A^-9@Q-DZMS)CD/<5K->8]*Y:IO<:
M6=OYZ\#&T? "^P1ANLE7 NBQHRO:XWG@^QN2/V-HG6QQTQ[
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M>B*O_J95"ZH7;57M\7+^ -O; 7(= 5"T'21BF[&F7G?8,NTE^TG^B0>P/37&RT[32*2)1"#WJ>#P!Q_ FN[6)W4^;W;#Y\JQZ#
MC&/E4J^D5Z]7;BDIV2^]A[]:K+O0I'THYA]/5'VJFK;.VZ+N]FQ9 P=61\*5
M[N1_93U(+<:MH]=HBWGKZBF+1DG5EI2(FHMUGG5'T>5HX(RJ"[>+CBD=S%F1
M[W.^W6=-4]P5VVXBVK"0'SD8)LA/L._@&,9T5$Q58)AZ8O=_&()@>+KV_CK+
MUPZ[]0K\U6P6OV@KJ<_%%FH@S3,OR;99?(9UGEW)^92&YEJW[NMR4F"NI(U3
M_@M%GIM**3LEAV])I;WE/A:+)ZV_YU;,%C&,&"R37NY9M23ZU7VTCBL6 EVY8
M3$,X-YI=#0M8= [2N7.Y\IO.QI@)&1=I\W4$DLNX_NI>D(OQKWEOW(0B22D*
M A."4!P$L9.$R!M1.(CXF[9JL[W6K7'R>U^DV11X)&ZQV*ZY0E5W9W3
M>;DM\N;X#/ET_:L;)B[$<91"&R$7@B@.[/[":>"Z-N9-\_0:-3>R3W!V"?TA B2[ZQ)GC]E]
MWFQB-[8]%P0 1=B/W1!&#AQ-I6X*N(_!R1HP?11@ &3M>CPBM[3+4C:O9M]3F(T4%N78ZU2?-#OC\[FS7ZH4K>" 
ME[(+E<8N(Z"S?\G*PUTVU.;8=0U/K!]1S?]2W;7?LSK?8"\A7N0F*$Y X,8D
M=/U>W!/BN&G@<2NNNBG#VCMAZK*C9D E("<:R.30XF5Y%%/E9]BL(Z$4G?7E
M(H0**/6RQ,II]I]K.HFRLE&YV=2;SK9>O$RYH[,P]B?[JKS_;4_G7[LK:Y?3
MZ=BVZ+9V,,6GZ%9S>;0/OO8Z0A3C3;OMMNYN*.O
MP5<0@30Z4QD9% )1:;+SUY)2A@Y-6SWF]5\;&@7!?9WWCT=M0AL"+R1IF,0 
MDC#R'1>.AD$2!=R128^YQ:+3@:&TM@-,.@HI3BN;@ KHJR:>.8+6\A2+!:XC
MNQU :T1H=1 M<$%V!2+8\BSKB&*M; CK(QC5H)/ \K3/MC0JT9]/ Z23Y>Z%
MV+NJMKX_%-L'JRU:^I6BL7-?C-T%,G A!+T4H21T0
MN2GVIU )0Z'#6FJ6# >K$5R7YQ4GZ,06ZQ39Y"O?+T>D6$B:<'4DGB*[LCIL
MRQ;G9VF:*<;KH7<=Q7=-OE0F.J"83GW(LR9G)R)?&PP#VP]C'V'HH@@%P//L
M9#08@U3H2EX%,X85:D*F($\J)/)ITT+\B0G3D;J+B])Y?F8420.IZY C'8Y4
MVCN!?A8R4C6PCRRS$L[B_W)=N'NBQ:MO9?[M+B!_O5H [(
MCXACARX) VHM<.,XQJ,]'"1\;G^R4Y]L%6*J]?1&
M_-U:)8N9RHC_5#ZY <>%C/8
MP@3]]3X?[BD#C^S@^K^ZGY_%R*X.C5P4$P]!%-FA@_UP@@=QY(T7K_ IW6*P
MN$;O\SM61*LZ36/]K_\1NX[S'U9VD3Y 8;D0^15U7ZRF?
M.3GUX[?,G6Y;D73DC
M_IBWF\B#H>?[J9MZ,$DB!]C '4RZ'G0B+?DPCZ'+9L-E+GB:7(U4Q4Q8-Y]:
M\^"/,U0NFP53)#(YL B[ZU! /:[PYK_B_'!?D%3?9^6@DJ@JFVI?[+)!03_1
M'CEN([JY2XLR*ZG.[J>'2IOIL)&= IPR]03L*EX0$.0X/3;H!C#B'7W+@#$W
M3$_Q7UG//.B&[*D/;"/5Y(5U=.-B!_VTD#\S^)=MW'6HQ,(^O[S5YP*,+Z([
MQ^..M_F/%E+&_[$A$#HI1'0CLD%@=G>N=7UA3=L813
M\()7M"W>7@N$#---=8'H<7IBG#EE=5[]D4+)&XUB*JJHM/]_@P"CY+[.6*/>
M#KQAY\OV(=\=]OG-'<[KXAN%]"T'W/$3*3G"-HJT?-]O0SW%8'G$I.=Q" 1WB6
M:QZ^0'+IEA&+%88:Q4@TD&!V1O!-MM,Z--VHA]5RO5Y6F5'6/*3[ZOM_YKO[
MO+GNS\+NKGF>3V6W&;U Z\/ CQW;C]CK#5Z:)G$"1[0H0DA.O9?%N*#",\<*#18FPCDRPNT0&+JP3,JY.ZSW/ZD GC Q[>J<_&4BYLD9:-(;G
M-3>G<#!?LS/+A/X_3+=*/4[K!M
M_Y[5=5:V/]\J!+N![T!@@RB%V*?_UTZ3XM'FY=T@OD"%9U0UNQD-\[[_WZN]ONTJK_3?\3FE [PP\ A
M3AJYP D<-^S110[VQ$YN+H7)L#*.;K "U.A(OQ%R<,5Z.>BOK-$=ZY?1H5^M
MWYE/UN"4X)QGL>;ED^ UMJR83B_74N8,
MMMOZD.TW";0#N[N#.@B2Q(;8==W1F&^[://4O:9$/:I;J9R9UY"(9KS$)+"Q
MK;^?,&//*M.Y3\EJ$FR?6_=!I(ZJ0LBX-EQ[$SZZCA [+R_HC&N :ERBO]+WK;[OI;\
M;R:Q6T$MP9-&[$(:YDPPVO6,'%GN+1+DB/%:6$:$80\
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MUDO_3HHQ%NMY%G.Q>U6+.4E_T;)+W)HCW!'3
M)W8K)?6C;>OBZZ'MDMCJ4U:SRRA1!"'!V+;MT$L<.XA]!X]P'>(*+9I>#.0%
M(N0OO6N_6JS'7%F?V(^'2W/ZO_ZI:MHZ;XNZWVPV.-]=IDC__M'_4T6DW^E9
ML$YI8&]1]D2L0S%5FU-",!?K0>O6R^5HX)3+A=M%QXR"!Y6=I &,$Q@[4>@&
MMFLG)!A1D93M).&_+MS[3/MVPN_*6&\0=03]J7;0GM:_D<+
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MG:>-1]0TD+XR5=/AT3E9T\:6L*ZE15DT#_GNSU6U>V'91DD#1$A*F5B840]'.J(.[_>\/_H=K_V)"L9A=4
M-)_R^LM#5O?WZF\!2]YB,AK;G
MAIV(GG?X#2G5P,YE!56' Y6VGB*66X&R+7;%_L#N1CUN!B0_^NO=V7Y!MM)P
M&!^B>@D-_GS[ ^!'0>>X+G$AL6GB%^,D3G#@^,&(.$EBH=WKE\1I6.Y/D9WL
M-+9^9^ $#_-=M#GY"837D.[KB.Q7@43U?I&G8[(
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M$D[,E61E.>%-%?^>%_X0WV$X2&,7;;B-B]S=_^\J\&B^(MD[]6GH7
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MWCX(7('_=O%%O;7.56D6[ <=7*-+$
MHI$*,/C:M'6V;3>NFX2.[2",TL!#,$4>FN88@1<+;2,P@V"A@M!OXR!G;Y[]
M-N4$PUBO\_Z)AK;Z=[$*CZ%6X2OJ7+Y!Q/+UJ3@W +9ZQ%.5IK%.0%]9?2'_
M]Q'XPGL9I,C55; 7;JQ5*[(N'U4*^)*,+G1L CQ6A[+=.!%$+DR\R*$9(?9L
MY()Q/P1@_&VMGD
M ]/]UUL=KJS>DS5LLA4DW]QA",'&74.XT>1"U)J/TS\Q!&Z
M=TJK8ZQE@,>W7VP9\$G\Q^L647!_S1K1:A,4923;2
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MN*#=I=M,V^T2B%Q,LW&80!L1/PR2V.O>'B1>BFU/[%)&L4\;
M#@W@RQ=R^T5PPYD@.7S9K$%>Q(2\!W*Q+;O/>9C;C25'V#IR3UGP+_='J7 @
M)@;H4+-'9B=;?NI%<81#E%#%P0 EL6M/M@*;Z[4&-0NFL\8>#KM>@H(3/%(@
MR9F(5)BD2T8QKJR1LWE4061[7)"32/KRI)VJ,<+^53C,<4.[8?\CQ
M2A?0HJRN?]($IULUW@" 7-=+, 1Q"A-$W-1&HVV"?*&'[?187&*RRBZLV;)?
MG%QV(_B(NAYV^01I>6(EYJ:,T^X7)Q"OK*RU1I3O[%,P\XHZ#W,S$J:7^75(
MFF:?7KZQ;H Q7LG[G%-%+;9MON-#@>,H3CS?\^(P\MTTPBA*1Q2.8PN]M:+;
MMF$9/,+MA%!,_+3SS">#EZ183!!/V)W1QB$/6%81!4F_)^._2>_&]'_TW'^Y%RQ/WS*M^P(U?ZG
MX"Q6B77.R>Q2A O.:4>N/Y]P39%=2!7G6)J;X>H@=QUZI\>5E_-=??Q(O7M,
M)]/("Q"T0YC&MH=CVW/5//#+R]4ZQH$<]+D'?L7\
MY^WG.+_+Z3C:W68_^JK2R;-AGB0U;I1$B,;AF$4
MNKX[5;Q=*+3@+?1ATSL^>RPG@L1[:ZH<37SB8XPA,;49R;F=9<7,QLP3!N:V
M8,H0M0Z1D(/^Z\E%R/(A@Z.#8 P2&/HA"XH>3Y! 42>B!
MH(6%A"'O4?5/)E3M0UY;VV?KX%)J(5U^Y,]
M$-J"T[4*+0>/5^A'C$)KG
MAYA!8OG"]N*3YFVX-+8Z\S]OLHHE&VMK7(
MHITO7IF;/@\QC(D#'$ 2-R0QHA:"\?.00*$%1NZ/&I:K$8>80/%3PB="1M@0
M$YIWB3"B(AQ*(W$41S:4>@!$F+H
MNDD\VG(B1V@Q5@9(J&D@2QB< YKD24X.>IBGCF" MJPYOLC(C%6HL
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MA@B0.A0J:,)PEC,=47SJ8ZD.^>YT[;>+8"_W$=TD*@@BY@>.GPP8PWP$X$-H4+F_%
MO,@P8-/&<&&1D26/6V<6X$U8:CK*WII,+:XV;[,S+SB*C*Y&"T[6I@1
M/4'[.?^6EX=)YM(T\%SDQ$X((6&7$P4I'HT%82KTOKBD"<.:,QW[K'M8)-#*+()3"Q
M_2 B:1 FH3-N6Z&2AH76@24^O\B:\'@(Y:0VK%H:?I\WV9*P5LK42\&7KO\*
MU7VYN5N'E*@X\&Z=5Y +F?KNR5X5)_+2.,+TPR@A*$ZCT)OTRD<0"BTRR9DP
MO:K^K)S;;9=G5=Y16X;"KWR95X1,\4JO(1[5BKW'W?%K*OMR[6%3Y'8E^J/H
MQ$S]5YH3B;N&3K3OQ"R.'"_QTL"UL>O[,/1(,IF-DU!H&[RRL:5F3R>W#DDG
M.^K,BDVK%B%5:J/M>XQQ3+V4R5Z',F8M>0R%OY(U5_1,B3*@ 9XDVU!G1I57K%
M#G\E2(+1=>F0@A_S]2!I9H0.&+TM=8X'40@CQPE\W_,P]$-W/*?H@-@1>H=#
MP8QA[>G/T!PWZTCG32I,\NG00B2*"5'/W_,DZ9('D40S(PVDKD.+=#CRUKDD
M'=QP/Q!4/3X6;?>.+KMVOBK;HKS/RRVUO<$!G3J2&$8@P2%@FXG(N-;OD #;
M0L\"*=@QK$8S7 L_^W.>
MH!EUTD'K.N1)BR#+1M77P]M&QKF]56UJ?L
MHJT\4OM*VGT9VEOM7>@B$MI/2*:07!DX4XL!WILI5
M$CA"5US)?-^P,$V0K(9ANK+^I_TGV[&>LMKZQO!9G5HY_V$Y5Z'KC:^G9X?V
MH:J+?^6[_[#L\8=%TQQRSA?KE1CGTS'39(L)V)'G+SW/': KZWJ>-%,7W[YD
M9D:A5'A?#ZREM%-D0F=55Y8B8*HB3PW2#Q$4QF>5)T;<.69*'_\9\3H$'[O,=NUW!-NMD^T]9L;LN4?94
MM-E^ P%!B9?8=A*B$-.,#,7N:,V!:2ATND/2AF%Y.L*RV(7GOQ7E;]L>F> I
M#UD*^?1D"?;$9.6$N$_]HBL7TZI'0 N?.GP^XS-
MR)5&NM>A7#H=>O50LV:N>/7LMLZSYE#_/$G5( SM-$V1'8+4MV,;03PN"+K0
M$WL_3>+SAO5J1#1.[++6VE9-.TWH_"O/\LN@8"<6D389<
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M)YN:NX4E76*D3C6?-"W*LIA0O7T%]+KN?9Y1*&W,KD.O]+DC>+^S($_>\:>O#EIV/+N\IA,]YE\BAJFF;6Q80-\0.8.+[$7 #W_$\F+I!
MQ$[=.JX7,2Q"&Q UVC6](W& RD[C/P/;#<^#3A3L0O1
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M,PYR?8_F;@Y$Q(E[!DEFK$L1QB&#IKD2$\/+T"0@
MC*;IDI-'0=KX1/(-5\])I0HK*Q!,)?B5IMXA()YIT6RS/R%/@"3*1(F7'5C)0.&1;2'Q?8N!]:V!\9YO8<:;1PRN@1C8E)Z2M: 
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MP2YCZW_M;%S'"1W@.C$E' ZQ#[?2[-9.-JV#WA5U[ K.&
MF7A\RLNFJSXPLV7#SI7O#[OAQ/FK_*[9N&[@Q(1$OH>C *0VLN&XYS\F(.%Z
MV]P\"M,9&<-N=>"M4_36 -\:\5O]UIJ^5#JQ5CJ_6WIM3/6HW=\M3\2;$(JL+@N4KI(JVR
M@G+J,GY62_=WD?6P;,M.'O]$^ZHYU/T\9V/#,$%V$J&4V-CW PC81MG>3NQ%
M+O]BF,S73:^$#9BL;0^J'X4BRSE2E/$L@)EF2W#U:R1JP",<9.2($EGT,DV8
M7%#XG#_1/^W>A1IJ8"P,'+IW#=JJZWXH
MD)??&WV]LKX_%!30L\\>GNA?8$\@%OV^*G:JF]EY]1'ZX:SM_FC;_=&!_F]'
M)QNJ4?*MKG)VG5"E6ZT@JJGAKW0-,($H]/' %AYO[NZ*;?Z!4'7/S5WRY\,4:5-^R=AE)?#0%&7>-)LH1L0.$$8^)H 0C,)X7&V. P_:FS*_9VAO
M^==UI&UQCO8'&/30;-HGG>E,;21/#K %%L]4:>5+[5&K-$2@4VBZ=W W-K:]P X\-_;3.'0]@)UD6MZ) BB]_JS%^J(+T0/B
M*^L$J39$K,$5>G&2Y2;$&LOEFP3Q\
MG)OW:N5R!3-=O?Y4IGH=GW;M\F(R>TO_Q8:X:6*G01+[/@F\.':![8^?]V/(
M]:2E\$<-9WG3,&%@^&1'G)=YZ39*B:1"S[(QDS\U^?9/]]6W?Z,^L=3)9[]@
MFN&?9$PO_7U#'*0IN:P&R,.N%+L"_X@&]-L[]OUTG]UO8O9P&_8(B0(OL3T2
MX=@9OQ]"Q'4,5ORKAL?T!,9B:/@'M2 U[X]JGQG8[.8KC$0[D@:?PQW1Q?DL&=ERJ-7THSAJH+N
MNI@.F;AJ"%/'KQLF69-4#G["-&K'"Q[>40]9UM:C'](>O*$@:FR(:TBO6+TM
M+W*)G20D2%T(?&H-V6BTY44IUVVX:A86UI$AKBHIB1"!HEIBBCLU->&B3;N>
MG'#!I2@RW*U-4Z1\.*LJ\HSPZ$I?Y?RLN%FV'[/'?!,3)X11F(8V# F(
M2>03=S03XI2[7"'U<<-J,M3HCZ LAHI?1^0(>U]"C',EIAZ"-&G0C;<(.",9
M2EQ=7BW4X%>:^HRH1B"J2'6VORYW^8__D__OE,K3][YX+,*'29K!"6:> BRQ9MVF"-*
M*NG@Y$A;QO',_=E\0XZHRVN$$OI7N88*"P(SD^KQL2J[]]V[>R":FT/;M%FY
M*\K[C9MZ+@!V:N/8AQ[VH>U/1F/@PBBQ
MRSV?68I8NOE'QAO^^;0F6>/6*=:>;NV>VA^=>4^3; 4' \5S?=VR,O<@?
M[85)S+7O3=V*88WJ1E-U]^)Z0+F7GQ6HY).H95@4$R=) HTHU%E^9K1)G=-U
MJ)(&/RK=O4WFG:D0=/=X-:,I0C_NQ&GD0TBB@$2V[PZF@L3VX.9;7G^MQ%Z:
M$C0A,G9.T7 /H>.+/Z$U0!-4(#4*Y\5G,>[$=.?2I,F\-660/-6WIB82=3TQ
M]=S7-P18"S4K.+.H[,*;3TPI\<&EN,\O*>^LW7ZOQAN/!3Z49 F
MV($A"6,_)-YH/G440Z$L1JS*3[6%*/C1JF'(!
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MX%Q4T,C>"F*!3F\J,WU,0/?/SF12[,((0QCD$.7%F!03YA61**#0BY$II])G2554Z#FWSZFT%JI6H-1Z_*AT=R*A
MFOR0F=_<_;VJ_W%7TRD@0^=R(U<[*?#G7G4'O(2K@L@U*T8
M5NP)T,D,4ZC\JT(@5Y%](>Y$B^H#+.OFSCIR.");C$&A@OE"3"H_;-GDW^CL
MF>I/]]3"^++6U[S,[XIV>O:2O1/)WG)\\?)C_OBTKW[F]"\<2BI^[SQOB8:/
M/7M0,B^Z"DS&'A/*?VN+Q^=&!B"O'J.\+XM_T7]-Y_W9UWUN5=2)#F"=__-0
ML AIR]KJI+^]J>5-]07]@?J2PSGN]+Y)04-
MW6\%04^/'Y7N@2F[$#T,@+^R_D;H.+FI\3!*/M&>M@&8>%X2.5X0A0DF.'32
M=#0/8G:O6M5F>]%U:$6C0B%QPB>Z#%T_?TZ]ARR[,JI*L^AR]((,JZQ&C_+;
MX;084.NFMD:H%L-Z*<9EEZ(79%ZR7L5&Q-N]>P@[K^(E"SI:EZ7G2>):E=;$
M\RHBB@&WSJY):^6-[TDBFN'0S(,]13X8_YBW&]])'.+@Q(ZP;4<^\2&>UKX1
M@K#)O)<*')&L<@<(\86(AX92K,2!01.:Y$GF(R3AGDB\O
MG7 W]+$KUN%4U?I-?\_ILAHY*U!@10^>X1O#%DM)"[CG.4:B[,'NF6XH-W
MX'277*#JD$(VXG]KBN^E\/6L/S$(;IMSL*RBH&5*P^S7D/
MYWI8XKSSX?) S7X'=/=\5^1-P4 L>ELTP_=1/?GN*ZGW*=/U\A;,.!DBVX
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M7[;HA2:1TAUK1<%T==0L.)%4;#_C ?>F1_UG]A!IJ>L
M>P8\7RHLF^H&AB/S"GK XL'Y9HS&O==640Z/Q+\1G[N_TKW)>!+3_R Q6JYM
M381IP[WL#QZI3;.C*U@OTHK<\3J_9\ ^YT]5S6Y=PD6SW5?-HIC''$=.-!ISW!F*/.FL0:L3;=)]L]Y
M12/ATT.QM:[+NZI^[)I;,"KJ()LSDBW,LV#TZ=%9$SSKB,_ZG2&T.HA+;Z1\
MG[0Y6==(^4JD6*='+^53.UO XH= +E)I-&\X?3M!VF<,SO&()@V[.^03L@G2+R=HLT^M(*<2XG%%!
M0XVR#FTTY5RU2,<63#^V#_GNL,]O[DA6EQ1 0V> XTRQV%)@N-@?V+HHNW#F
MB,:Q@6UC%"8(>QZP4Q"-"Z0V] $1FX49PF#Z3$;.^E.Q+Z8[BSJXW=@? /<%
M*PL\5@?:RH+3,U,MPYDWKJ!1!-/* 3%KB1$SJP'VC7#U1NO\WF&W+C?#D^-X
M+CLUW&KK$&CC7K[,;1=AE?/2IV_5_EM>#X?_W"A*?,1&Z.,D8/[*7$/+RQ'OIT:F#
M;^BO"@TKN#A#%GFEW@G$TM4/57G/=NCA_&N+#G5->\;&CR* XY2D<0P\"%P 
MQC?B41B'8@>E9+YO>@+?P[!V%))5?=T7]]FPTLDN)**Y3O<'.SIC8$GFL@G,
M&W3-)"\_>"/5C6TEDG';)M0=.6CU6;-YL@
M)"F!*$Z13WR00N38_H@ )8XK\/:X9LO&CSPPO+^Q"V)5AYKY1N#(62[(OEA.
MPX!VIPDL!M4ZP6H-8*T3M%8']X+4"Z1%%VP"N;2I:XHW1X#U?6B*[4E3E RV
MZ@UE8B2=2[T,4;V"U,R49Y7YCBJZHC.9&?%TYCYE/]FL>N.B%*11:D/@.Z'C
M(X3!9#5UXE1L"4?-EO$U&RF]T\8D[\+,N5E
MEJS9I18]-*\C@];FS:O%%)TLR4Q'CSUK8RG\V:[[<5/3($N=L5(+6=0PG52=FYJ32G,@,GDWJ$3>-L$=3
M"CL.;0A=-QA-0.Q"D>M.A3XL%,K%KSGM!PGWT-! %%_P-L:1^.2O5P\&Y'**
MP:D3W$RM3QWXH<]H@J#_:B_>^K8=8Y=M&[.]U(%):MNIXZ?(<=THC!S.RSK4
M;)@/HF^\.KJ6QT9YR5G!+%G=!Z['1L48$>W^PS-YDZTD2D#JA7$<^AY!T,7>
M:"MV0JZSA&H6#,]RWWX:4^GA8D$&."**_R>MO^>=JOT^KFAWAWOA!B%R,L$,@3B")XA"XH]4D$-N,KVIKT7$W
MX+-^9PBM 2)G#JR-7+Z"VY*\BLTGE"@U_P+3:ZYFBG6Z6%Y'_4Z;-W-/-"FS
MI*)B&QA#$L2Q$\&4!&EH(S^!HZDT1M&F?V3[2YO5K;R O6M&9'2]1,0]T/J[
M-:RO^7U1EMUCX-F>/8^NKE?OTR@O4EJYTZ!,EYWU5 ?A^MMFHT?ITY,"(GHY^,P 8":FPPA/]R4^7W6YCN.J8F<
M :ZAD?1#XQ0+]PB9(%E/ R:! J D:1Q54X-LR6T(HGBL(U>?%N-*H%)JGC.Y
M,NGK+J:ZY?--3\_-6M5H6<'\5-&!2EL7$9#3F_8AKY]I]V3-37T$B&>GD>=A
M["<8P&2TYB4P$=!4!2O&A;7#)B.J*M1Q**MISJ3DM2?K>;8FH;$JU D([4(4
MRJGM",5J*ZO)VY8=9^_8??Y0\O PLJH2GZ?BG!QK(&\%FJS#BTIOE](PEZ:I
M310D(/1LA&!/@@B2P29C0
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MP @5VP2(*/%% !K6ZA.?V!2\'KWJ;H H.K_8S]GOMDQIGDZ4IIKT)9O\^G-'2DT,6BR*]2]8OS*E?V1__4<**B4::"3P7[1/K"$V7
MI:!:T1@5"V\X?Z+JVE^>NO%BZ& GL3$.701#QXE<9S3AH5#H<@>A#QL.)Z=8
MQ"*!&#U\"FZ,&3'EY2+%B#J>6IY1-2F>UJ%&AC5?[6S6&+DO[KO&FM_ =[.6[A
MU31>NN8&G&[&5S+^M+OUAA
MWZ/6W=%J'()8K.ZC9LMX*:B'-ZTB9#]$+_949I.W3+0\%5HLQ+Z9\NMHTH(2=],XJHNP'6H8S:
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MY!_K[0/4BVW=2KB1/'G
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MXC<^6^UA$@?000E;0(Y"[,7Q9!>X?JBV.B)JS?"BR%1Z>NKQZ"KM<9.I6MHMZG=YA=N*(WP)$JYXF2O5:YD_:'NY GQY22B-6'?/?AN(9)
    <@W*(WL*(P)B)(P"GW7
M1P@.=A,JNU!-\D2M&=:[Z6!.W>-1539A,F5ES22/6C1M8O;S.\PN)&@O"!-2
M,UFRURIETOZ\JV-J3.F_R7>#8.3#Q'/=,"4X]J.4P#%W3!!V_$U;M=F>3\TT
MFA62M0DA]YC\R'O-HZGK?-_GG4_X+D2YF )*7-^[UCM[9V310%.L0Q]-."9]
M-Z\@=XJ*R9:@FS.W)]II&/L)M@%*XM -DL2F,^])NE.N1^0-FC><&%Y__!OY
M8N+N@V7U(H3*ZZG.EIIU;JJQ4$^?=7'):_.CL\GW59@
M^\]#4><4$A7Y]B=[9;T%Y8[0GSZQOT*%'MNN%\=IF.#$=1R'))/0NQ&)Q(Z7
M:C0LL3 MN"9-?_[ 9HS5'4M0.YA=H3$?,8HIK4[2^11V:;:EE/7T2;8!IC7B
MO+(ZI%<=[>1=VHVH*3^),RIJH"76H9XF'*N,]V*!MSJ/UO^2E8>[C#VLE4\6
M_UI2?M&A::O'O/YKD]WGX+[.\_YM.I+:?HIP$J @C ,;^ 2-=ZOL*II&371O*^L$]E%C
MK0ZX-2*W.N@66%O["+Q+NI)VDGNW]/8A[RMEU:&]VU??7UX_V;?9TS[;TI]E
M[7%<=?&!6FJLNZJVOC\4VP>K+=B[IT5CE55KT32S;(8:./U82PVQN^RR\N?_
M;J;/*+^$*D_^&T%UJ>9PG7_+MH>Z+4A!30R["41R#E"U ILX1 B:)2"U(JV'#5: 1ZW#]:;;O
MYBP3WM_HT/^M83\]0A:S/Q%@,>Y&8R)YEC)',:(
M:R]G,>;X$ZWZ4'NG:#X4=_EUV1QJ]M3SIVI?;!F$- XPCE(0^"2,3%B>K'*3\.&'2([ZC];V6(EZ&G'M3 W( '\RF>@)G-LZVQ7E_8EX.[X;
M)TD8Q!$@R$Z!3?"TF<3Q(J''UK09-9R!LOC5J>7CH3UD>^ON4(H^A:"/7_'\
M
MJ9$WZ97$5_?BLF7*V/,)362)'R9PX0AMUU:V9GHF_L9BE>$NW!H8E
M5PN-DJN^2'CA^[C?I4MD.5":ZI6HG#Y_WEO\4V1*X8K-\9+/0UU31(-U$N'8
M"0.,0FK1]9(03\YTI.XK_)WHS^Z>9_'2JHW:OWK]#4P)K^O;D;:HPDB0U(Z(1^[./ <[P!
M ( 1<32<9I Q*Y3[*9QF./2[0NG_'S>%:C[)(,4YGS)>B&XQ<938C+O6';A:
M=MYR-\4Z=-*$8]([;06Y4U3+Z1'8-[;ZABAP(S],HC#V2.*[:1B-94O@V%CH
M,A(#Y@W/G-/KC^ C,G"208ER)=%U.,BG
MK_JXY-79S_G34"&XN?M0E?=T!OO8O0M$[> T(B2%3DB @QUJ7B./"-"=XZ<
M&3E3YG,=HJ7N1J6YG\DO"W\HRIQ:176^*]J-'<1IX(=V2&#D Q!ZMGT4O" %
MLNO 8E86W7K806-CJ0'GY,[Z(^XP>SE5;.4K7H4(:
M_)A9EU5A1BH1>F8O)GX2001M%#EAZ+LQB*<)KH?%=$C>BF$=>A'*571(@4F)
M3,@8B4JIT"5UZ"P]O,F0%*7KT"$-?LRE0PK,R.1#UTUS8#OS;NZ^/&2T\W7G
M1Z[I#THZ.V1W '<_AAF=.[(S1WG9=&>5V+G.AOZU_:';PM)6VW_)&;NC!PW-"V V? #., BFTFN2A2PWK(JCQ/SW*+8G"1#>MM]?A8E5;#
M %M/AYK]2=N=)7M\VE<_\WS\(^:??!9W@?87SP37W?0JV>3U28OWO@VG;B?O
MNG/UW1_]]I4Y:)UZV)V];ZZLR4FK\](:W+Q<(,D^;'-F^8V^P'S,K\KVNY0T)O0WJBH;A(709< )\$ABV8TMW[-:="^ZX?;A"U+K:1JQ(#2T"@5N
M#3$9D/DY%7HA:$M8RFTX_'9>\'HNR>#P\=D'@^]&MQJ();$DG00WK"U:3
MM^T^G^H;$J%AT;:=#Q"K:T^5+?T6]:"+%2<^6(,3['::W@V+^F&-CEA'3X8I
M2>?+"MM1_'J:-;6G_%4U3Z_'9T,_?KDEP&TY6CF^*L']YFKVZE_:KH:1['AW\A!+M&MUG-ESF(>OW%]
MSK)LZ]^2N(E3.T"^'2=!8(7;]N;.SJ_?*!=
M-_],!?RF9)BH>K/_L%O1OF7[[NZS,":N!SV;$)B2(/;9PHM_I?=SE<)ZALF:'[17[$+EB1T]H7'8]6:)%0O]WP2>C':
MQ23TK$Y>63U6ZXWSV,MJJ B3,QIJI$'6H:%F7*L6Z- Z-!30?+FN?]+4^&_9
M_I!O[-0!CH^=* I2$GIIB%Q_LNUYZ>:IP_RES>I614)%[8H,XI<0QJR*#]41H(Z!FK,GO?\[#U%>^O](0Y3;)ZDA*L88
M[Q#]LGW(=P=V(W-7C#^P.^]9A:DKTK.R/:J:MKG-?[20$O*/C>>3*+7M,$@!
M(KZ3$"\%"0EM)_$ !&(O3^NV;;C>@QZRFM5U;K-_Y.6T2MM6UC/T7=5V;H?H
M,LW -T.Y9 N(35*>'I&DR!&Z
M"<6$_4NI+-ANZ\.X_\6(VJHUBY+B+M8B8JH[HF6YZ'/>!\!LZ9)![H[+4=!K
MU>$Y?L6U6$MKK5J/]7C(I\D:V>1>W\QJ5@5AI:MNN^S1'J;_SP]1XY5R$7
MH5!PR7' ="2-JMZE].XL07-+B8^->\0"._80(O: A\WW#VL,@64=,0\)P?M3HXXU/
M<4Q3)J8UHFP9T9@W*)E1%Q4"UZ$K2AY4^KJ38+&]L]*RR^$_5FW>?,I^,FM_
MR1^_YO4&0Q2 $-DXB!T?!=1,@D:;'@3QAO[;KQ6OKJC9$ADNI[#XYY!'>%:'
MSQH +EQ)GV-IKH*NA=UUC"5-OKRLF&MD2"Y6?RC*_+K-'YL-I@E!%'A)#/T8
M8C\D#DA&:VF2>/+QFM_&TC&;(;,Z:$J!6X!$F>!MAC_% ,Y#W0)1?.*&.Y*+
ML[D.!5+V8C:BR[+"JSK@L:(Z]Z_N%-K-';.-BV9;' $H]TD0$1$?]2M&5:B4X"LYLAN>K5V T8Q*=+ +)\H+4NJF#R]
MY+.3JQ$>>Y2T [CP;K]W"9O1+'UDKT.]-/I3F>J6 O<#O#1ZE]=UOIL.MG2+
MTR
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M\6EQCN7BT^V+;;>=I3O7>WI5+/MS]EI&
M,P::+L!D]W7>7<-R97U_*+8/[&*5.M\R^=U96?,J**I&(1[RST4AK0VW@BBD
MUY_*5!=7J?X\#WR@W(T3MF83I3Y D0T]Z$38!1[!B3^:1TXL=%I4FU&AF9/$
M2=&J_*T[.?%R6%VR6G&>+NZBA0;&UUB[T.'6; E#&V_\SV3W_8[TW8Z54,B/
MX1[=4V@;2' 8P2!T< #B ">N1Z;2KR<:YIFO8'L1BL5RQQ&B-6"\ZBJW5]:$TSH%NO0+V7STS0BB]A98
MAR#J=^O5(]E&>!-9(K^>BBPC&';3QI>6334_Y36[C3R[SS<0)M#UHBC$=IK$
M3HJ3 $ZU96(+[;/5:-:P*+[>F/)R((LOI^LBG'^%_0)<2RRZ'U%>'5EF0*^L
M'JIUQ+K\2CP?A^\LSFMNB'6(I G'WEC"-\*=0N:X"6& @CA)X\ . TP+3.%DOF]XMG;]8I)VQ>ZOO7AB(I:#<'.XCI&DY,'[F84@&WSWQ]?5
M[K!M_Y[5=58^>T'9#J,T#+P4!1"A*(DB0OI-?4D"H\2/N*X-E_ZZN5@U8+*.
MH'@>'-?*G,A%W8LP*%?CE6.2\Y[JS\_
M%-G78E^T/_M=^"Y*$<&IC1!((CN*7!\.)[X39*=8]#4]!4N&)QTOQL5/:X(G
M=_A&D5:^><9RC"K)M0B9IIZ&.\_33':CA]]UY#F:?'G]M)HVAKARGR[%*KN8
ME^W_DM7_R%OPHV@V*$'0!S[]+HFQ#:/8M?W15.A'_-OA9 T8UJ=GL*P>%XW<
M%)E(_B/-'D?>N 1Q$O7?RW$FD#$NP9U,;G<[FB*D4KR!257:@T
M=ADUS<758U:4FP1Y<>#X'O!M)O->@%QW$GB2NBJJRVGB(KK;8U-4$5X.Y;37
M 'TZU'=1YM04V "#9&:#38)0$((0(D2")1KO804*O=*M;NV"![8/L27D-'*M5
MVLS0JZ_:QL/LHB6W#QQ'ZO61O>[2FX0_G.4W6::XMUS_OY4E9N: AOC<\HN"
M$W-2@U.32R&7LB(. S.R,'!R-'4!-FZ
M"O;1N'P+2@6EALRK%X*MD
M@#D5ZJ-*$K?G4R,>B"L!Z1T%I)6!<-?I OM(NL5 ]RD@'#C@YZT2$79XBD-J
MAOS@*!"IZB/TY>Y4#RU$H8B<:H!%;+8=%TP$2"0E%J?:<0$ 4$L#!!0    (
M ""!FTC$RWVG/W8  +;"!0 5    :&]L>"TR,#$V,#,R-E]P&UL[+U9
M=R,YDB;Z/K\B;\US5F)?^G3/'*S9<6YD*FZ$JFOFR0^#IC]]R>>+23'[C[_ OX*_
M_)3/QL7-9';W'W_YVZ>?U2?S[MU?_O?_^A___O_\_//_T1_?_V2+\>HAGRU_
M,O-\M,QO?OHZ6=[_]/>;?/''3[?SXN&GOQ?S/R9?1C__O>T_HOT\GLC\^C
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M0UXM)K-\L?B4WVV(/[OY-2_NYJ/'^\GX&?=K1WUD/X,-O,T_OI[M\+6OF P4;>_[TVM=?T/)FC#>2.IM]9"A/7D8;(LWQ@FV&68
MNH+#-ZD?<8.F?0ZOQC2-[N"G^SROM]MJ&_8WM ^C
M>8#K/E].QJ,&^![32Z>#_A2L\,U*>W5K1HM[/RV^'H7KP0[Z&^IK/^Q]L4@?
M^.'NAA8CF3RI??=U#Z\':?#[Y$OK\W3S_UDUF8.29Q#(OE?!UB7!PO2FK778KWZV@RBUR]FE6C^<_\
MYBY??,S'Q=UL\L_\YMW,C>:S)W_N&!';=-^EF(T"4/N>[W(@,=9ZLYKF3S/X
M!H\P:TQ7-Q&-QN'+8^3IX[7]P/+T0[58A'59+2OF-+-6V_7:7JCMED.PWEPP
MWI;?CW!UF[1M/H6PC>P?OZ
M :+91-6@:>OAE?L]W^J'L^/1+E_?XG,^KI<.!KT[BE[/A5?WP=C_?^4#:
M6- I?74NP--Z7,U9ZJ$(L]0_UZ_?QM.;DJ)]WST*^/(W;84ZW%_G@C2;P0ZW
M:CVHWT;S/X*8H<]/<0I?3^MU0SK4IIJV\
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M*+M_N@U3OIO5YVBT$;OCE_<$4;-9I4G;G@;X]WQR=Q\#S5\"+G%SC
M\[?E9!J3&ZZ+=01KW?SJL;7>.GCAL5 \/X0F-V#,\KO(C/>CS_E+.7:TF\[G
M/S2+!]]D//@&-Y+NZJV[0?Z>+[L=Y\L.NQOJAWP^*6[[JLN.QEN A.6KT=8K_;'9Z?;WH>'
MMH_&+@_/Y[V=(LV_+?/937ZS/D0;1C@MQC4S??Q)UN!MZG.PGD?C9?F^:03G
M/_X27I =VT7F-:9*,^R<- 9)C;2$D"*,C9-*4?*C3--X^+F8;T'?)=0&Z;5:
M;T>+SVO=KA8_WXU&CX$7D/Z23Y>+\B=1?/HS@-N3S_]S^^,F L3(^7IEWP%"
M2C>9\(@S(1'!C$K+!,;.;X%05EI; \1S_JGY^*=B?I//_^,O\"\_A=_@!*O1BE+1Y&D]D!*NU\/A,,>D$%Q1AZ8*D,+].E6 HP=#$4ZDB[1?>@
M#L 57\R#9SEEHO^0!ULGGE*/*DES>X&&?:"4*NM5IAA [4($W0U+2/ TMB"+ITM
MG:!YF":[788/<74M9I,F)S?V[H$
MX/_O=JL2['\'N^O+J]'GW[$,\4A%\L
ME_/)Y]4ZZ?>ZV)ST/D#D0<>128RX$U@)9['T-B@>LE(-P9-*G%_/T/#OCZ#%
MV]'?"3^C"*[Z,II,X_ #%I]&/QYE>"ETPA=R["LR9;4'R$@:?#1!+4# N57-"7MO\-J!VH_-9^,LRIA;O$*?;E:#M*S, /.>.>XTUQD0I
M!TD%+D V,5+8W"6KVUJ]./H/K+$!/H>G*@G/BH^4\:_G%3OV0>)N;_-Q;+\5
M.Z!PX%/HXW69\M!R @B"%AKHF>!25,Z5]NIB?,O!^'\&:CJQB:/SVV)]Z&PZ
M6BPFMY--+?!%ND&SO\.,0ZNE(=(2:(468;"5EK3',''/D/Z)^3N((@9@Z,M1
M^@!I Q WOLERDTW5P!#O\C49"=8>\=:$_VGJ/5.>RA)$2UBB)\K^Q&P^H7K.
M)W;8@,9']I1)'Z!P6CIC!*4"2F;*#1L-C:M+B=K#5'XT4U\EY+U9IO:K@2(X 5U I%$PTBI60CH'@LR/ 8%U*7$_Y654A
ME&,"W]A#*YV/6<0:^2^>,;\;S;;%RY[.
MXVTVEIZ/[>JVJAC\=%3OP#??:?\9\,KZ.*FKN$FEJ#-PPP:I$=6#!%,=OWDKI3O6O8Q1=P]OCYWS,W7C#?+XV_[Q\F@$;?+R[
M&V0DF'L14J6< 3@&W8W;&']&*0/JO.@AA&MB#NQID5$)K$=!1AKS.RETP;0M
MQ:,*)^;6G_NJWE;7K_8ANP#W9)]GXU(C;^O+]4Z#^'_>0Z2UM%1[CZ60"!+'
MJ*M+M^I/N*?-ZKH3PSN>S@SR#'((E5->QMBW)*X4"XC:*.C;65+;JG7'1]H.
MRP%VF=X7L[N [$,<['5X:=(GH >M4=W=S?(PO)F.!3*6(($1R2()TK!'##F8BC23JTU'$D",^5 W75X
MZ?MB--.'3\N]>"SS$FLD@\T!.&9,@" F+ <&.;V<4[9M%5-T!F**=G\OOJQ?
MY=85M/+9]=?B^KY8+4:SF^M\=C6?W$V":;;>F3FL_Z,[RHA T@0G% )" S;:
ML> T;H3S1MO$>> ,,]*[9$C?, ]15.2^F"^OF]L9.Y_/&/&(AGD4&L+#?V$Z
M);P4"PB@+X8]71H:74!Y"H;4FAI[6F0<4$(40N'#XDY2K(&KR"]]ZAQSAJM0
M2\W6\20)SB1K(W7]J9\(J93"60+A>.U5[1(ZXM21'/
M#W[-IU_RXRBQJUD&$(226F</<8#[L?S!B67H8!>8N%)=QQ)4PY.*]\W<;\VRG0T875T F&K16\=^W?
M]V@6EC86#%NJ,"6*8:HXJB8DI$CB4=MZV.55'2/8XK*/\7+R6Z.T/G>
M!AG3W"#,.,= !OG#_W@ENK4L<1?BC!;N;I7>%9!#'.:*^X(U\8#JF'"&AUJ[C &DPC>4]FN+9SU[*E,*.,:&&J M9:0R6SQC],U;
M ITRH 5T@Y39>+[(U1@!KQ_. A@$ Z%0,(J"A20(H-7$J*1/M I;E0@8*)NL
M*].@-:B#L^3WT4/]YL"^)IG5'#GL"27:,@$Y0WH;_Z* 4G$*YW%PQARGY8.$
M248VQ9W<9A+>S?-U'N%A5W+GPYG2V%!AC2'0.<$)UH25@W2 #Z7^+_G\@8VS9Y*BXP1A1[CVR2FHBRV%)SBYUU[BMCENAF*)L5W].9RJ80^2_AZ%=W6[,73\:3Z;!2G]^
M]X!=7^"]*25V@#S'=),);2'1WC-"*4086&,R\M$8@0P($"U92+?.*AG%9>SQMD47MD!R"+
M>HC%9/_Y8V&&V9TI%LMX_C(>:5N?[#[ H*9=9,$&H%S&8G3*&:4-,J0"$@>,
M!_*U3AP_:4^LG@!/\;M_%.W#/'\<36X^A-EQ/'D<3<- 5SNKN#=NFV&- :/.
M"@>UE$YR_F13,H9/L67_AAC3%\X#3$RQ,O8BEJ?+%UW
M-6M:;=N,!\-32H$])U(X28%X\DF91XDKW-'.VIN?BKI&>FABQ;KKJWFMD;2W
M348)T<@@3)6DUL2ZKLZ7X@DL$@/$9^_"=X4ZPC]VV+\+YQ5,Q=="K7L:YX@658
M@;H=C.WM!,=O86P;9@ $S)!&4G#%$;,>6[CC#O-I^+95D2),R)M8O^OS]Z_UD
M?+^\SR>WXPV%\YLOH^DJSS?+8?C-8QDJ&!T,YR1WF&&(89A?%0PV/P?(BVHG
MB$*L4[?!X-EGV;1S
M<0\9(X0'IX\8Z@PSA$G@J^\ >9JX(0'//LVGY<33&\(#S#1_GT^6P9&[C=')
MC8;6T"P6J]%LG,S\=/B5UV]^CR8V&Q?LT%'F2)8<2.0((XB 0!WOHHO
MQ)O<$LER_*UY;XLL?0,]1/I%==/UXKIX*FW]832Y>3Z9Q<<3SXA_&DSWT8+UZ-O
M^>)C/AJ'(2W68RUN7PQO_YS7N(M,8B\]<09(Y9ER$'-K*B<"FL1$:7CI@>G^
M(!YBGAO@^A;H+#$*4^6(#Z(B(C2K8F8T-0R)_@3!ZQ[@33*^JQGR+7$:=5?)I%5\;"!\T0:PCU"%):B:FH3"X*A"PYH#XGWX+LC-E^,YY/'
M3;KE?XWFDRA"M"?7%X,UWC$YW$T&,/2.&PVI5CK,THQ)C:4$QF#""4^,6*(+
MCH(/ /,3UP:^YB:NY:/9]\738V__CAL-" +4(Z[CP0CC;/C;]H:A>#RLKOS.
M$)]ZRATW'DBK):!4">6UE-@PM!6+<<5.<==D?]]M&[4VN./F."R'.,35P1TW
M/,PP"G(O@-!: :*?;NIBU)SD I,3%9IIK-XF%]X
M:,2)Q\Z6@FDD3U&/=@"^M--QL]MOCD-VN"HCU!%#@> QRA/F3N2L*(=E66KB
M[QFN(&W5)<$A@&P1@",%2Z'!0!*
M#':=H5'?I6I;83AH^1BO *:.:PT,]0()2@0IAZ: NISZ\%VJMR6*;ZK$@V>:
M:14$ HYYPC (UG$IFH2I%]&?X???I;G7#9@#67SE/1GUR=<[GLX(Y\H*[[P0
M"FN%E%+EK;M,,'_!5QJW4O .2EW,O
M7M>LZ137%+/C.6VO/D\G=VLE+/X^6=X7J^7+X>TS2H[K):/,>:>-\(8X$J9E
M T$EEI$P<45ZNU48CF5/_Y@/.Q>5HCS_!)I-1KM:9LC$JV."-:@(9) 88U4E
MJH.(F
M_MLMS-"%190,[\"\:ARL;VC3E%K!+-8>6H&UU-X'(Z<4#")Z
MBCVT4VV:-M9QLTW3XY ]72"M9?UNJPU5S !+17"H:/BR9(4:UBKUY-[9>QYM
MM7Y4,>_C0!YHI^=IPFVZT[.C16:%A9QB*301VA+F8!EOML)+>8K;P=_8@M4-
MLD.<9OBA &MIX<4CA G]JVF7&&<$F]<<&S\X!("FDIKJ3F%'=4
M#DZD!.4?+)+;'N?$&BL_C&&#_H\%>_>F&C1HFQ'AG00H7LIKO.(8.@VKE1[C
M/\6+?(7-7E]$4].S/,XLG@9\]X#QTW:9@! [[PD8?1:&J:-
MTKA:>;%,]*>:;_O(#55F^=WZ>/<;9DP/< ^^9O5;Z)U[H@P'&FO(+5(Q)XB4
MPALH!KL]:?@ ;7\K6&=P#\"U'3TBT\XRKBF#EBI!
MK4385>A2D7KJ\RW_!4O>?5'CXMXTKS5,^UH4XR'9QAA#EG
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M95XC(XPFC! @G9$$(57"8B4_1<+;P-]_8V+L-1[[0GN8-)5%,9W[]GMK
M\N!V-\B@MA8Z8SBRW$D+A#"T% Q[.51BR@ TZE/KK]-4VF-]$A+5)LCM:Y(A
MK 1"P"%.-'",>TA$*9Q@]D+]VK::KB5.$KI#!2T7FX_%32"_O]@1RXIDTS
MRY%FWA&AC-(.$0B"%; 50!J7F(U[[M&.(1:PGE0PP'Q4WJQW]9C/1W'4I<=T
M8"[:VR:3PE@E.<7,4,(L9IJ4N"$,4&I5\C-E6/=:+_H!>@ >?&6>&A$@(YB+B4)0!*VM[3Z2Z,6+TAGV(;;>;"XG:=
M7C6?Y(NOD^7]W3P?!;27]Z,9!/%WI4&8W\PW7\4^>RFQNPPHC"W17F- ,+ :
M4UT9@9*81+__C"XGZXU5 \(^H-VT@6A3/KVQX?2Z4>8]1:6[ S4T^]&E"NY_E[^^OME[$4 %1PH!RRD$L?S'9X2M=GH
M99(3=/1>1%UZP1.ZHVD)^K[-A*9-,TTACGMF %@!7"Q@AG4IA&>I9NNY.C?=
MZ71WND!7. ]AQL94R#C YV.NV3;8VR:S!&H N(=&8  Y8H'#I7B0I58G/5<:
M=:_UET9J1T /YPX]'VCMOL'>-IF3FD-"+++ $^F-A;82+_SH4K,:VJM[MY?3
M&N'&!%KDX[_>%5]^V=C WR-_J*UI".<"TX5;SXK&^D,+SQS+@#% &>Z-MO%A'2>5E
M*01A\!3E1]\4'SH =8CC@XO)Z,-H/+F=C&OI\>K93!E'-<684&$X%D8+[DMQ
M)$R]X/9%[0["G0(;KM\^EUV=?V><;/FF8#6"PB ], Z0;&FH#+-I4X]
MI7ZNBTEO'DN/F*>0Y^EH7XR=[=V]V_ML)JARWE%K.==0&AP61%I]+,1<6'&O
M?K17= ORZ4.8V]]?7#8U<;$PE@F?.-0..,@(V9:&1)B2VA/&EYI-S5 P9PSQ
M.BR5BA"#C-4E+%Z3/UM,M#%+.DBM/@[Z(<.DK^:*AJ'27>TRARS"2%NWOAQ6
M64:!+\44""<>T3M[AO5)B'T1U [P'RZ*VC1RNK7L@Q,&I! PEDV4LT,
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M*>B%XPQ*QK *LS9'LH38&IBX$W'V$:3^&'YJ%?6W,IKBX6&R+!=%4\PB>THC[NL@DI *2C!@)!=:&9"3X1YM;_1HRI.,DF<69WBT\P?B$FDK>!>
M V.05EQL]:040L#6;?DU/5JSOCPN>E;AOYMW,SMZ&-WM3XW?\W@FD C]*JH,
MMR288)I#70[6(Y^XO719WW=CA1:= ][G5_Q4OD:/IJ/9./]TGS^+D SJ[Y8)
M@-5==:/IAV*QGDN:^+X-FF?6,>L4)XY[J1Q1WE*$O'7288\=K7/T^@Q*-1#Q
MQP\,4B4B/%C\TJSF$:G&C'GQ
M?$8\YH);9N)18*N,% A48H5I[3*)DZK;G11I!^D0V4JCQ7U%KI]%P(?U3Y3RB"$I=5*>"V-0QZ84FQG2.+]T6^#2.D!
M](#T(+DG0>[).%@.;:EV9$]9L,*$Q 1CP3A!GEO#?0D%A.!""T9T2[I^,1]B
M)1QO+B_^F(_S,.AX:U>^W*)S:$$\T"RSTBB !2'ADW*(0HV4*X7DT%QH-D*W
MQ.H0X %8]&[V)8RKF'\_G,[R_+$L@&$P-1HP[8,;9P4@L!)"TL$N)W_++&D!
MZ"#Y3QL]7(^^;<1N-+4<:)4!RZBB3'ANL%8QJYU4TZ<1]$+S";KE3'?X#I',
M-,\?1Y,XUH/9N<\?RQS6Z]I,4AB@&>,,DAPK-A>
M.UH_I>Q\/L/:Z "*P,II1A1GP7NMR.Y,8E7.XZ\"OP">M$)VZ'A/TSA/YJDA
M2BLL,,"Q1*"&6#[-AC#Q()HX\[OB.[9C6R ZR$Q2/.;SY?:I91HKP#&!AB(''("4VW$3$"F$@]IO8V_.K68<$.D1W$[UF.9G?Q
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M\_F#S3\WV";8\72&3)B.B31,@O!G6(]E3 3=TB;;UO_V"!:_RP8 I):JIVET"L%2L&,2ZV)?^XK6P^LZ03?88@S
M7P6MO$+@,'=VM\F$P(Q(@IQ7E!M$(?';J":!RM+$C81SC]#T0Y].(!YP;WM[
M?JWYMO:/#3+O*48&"LBT=C$CC7I;"D99JE=V[N&;'KC3";XG,9R/,I@SH3A'
M3DM *'>>,LE@&:D*'T7JE93'AW2&=>/[L'#:8CNP2=PH#+B[008Y]H+;((21
MS@C/&:Z^ F)TXD[F&S)P>O*NND![V$2L9Y@T(E1=T\QRB"7V% $;? +-L).5
ML$*RQ/V'-V3\]$.MCG$?WB(ZBEVOVF18(DLK_8TRB+6))T0A)01CJPE#KG(A!$P\8W/N>V&],ZHSQ(2AIZFW0Y[Z?UH6.7V54FA#Z/)S;N9&3U.EJ-#:89[
M6F1:.2.Q!$ RPVQ R@A4B@:U3RQJ?NY>?P^DZ0;@0367[C1O-9,,86
M:CQ>/:RFL>1-<"HGX\DA:Z>^<4:I]) *RSAC7@87U*@RMQLQ"1,MZ7-W^'M@
M5.=8#T"NZW@AV6K^O=$*]OKA3&L&O/?Q.AQ/@ !&V]+31!JG'OEKY=N_&;ZT
MAG.8_?J2P^MX0UAJ@V;N\]EB\B5_N@+B]WQY=7L]^G9X%_^8GC)*8C%1+7D 
M0$OH'2&EJ8<?NX/>QT/4*_$G<_*/<^\PC E1P'"120(?YEQ!7Y@XC
M%'S7H=SZ83=N>V!2:VS/("^[13YV1H-(84YVS!O#A<"8&%_-SC(U ^#Y/)!NLVN2'-9#W^3+>]_GC:"ZG]"3S4',6\^V-!!A(QVD\MN6Q@<9@
M=9HK&-1T6GR-BO#%W!:KS\O;U?1U!9\&.8;']),Y+RTQ.$R?,3&..HZ-+Z%0
M,C5W[/QC?%VRY*65TJ,"!H\;A_G@:KZ&ZV9MUW_(YY_N \:-0\G[.L@@8=IP
M![A$, :XA*:@$ERA"\TGZI5YO2 _..76@URHU?(^*..?^4UCJKULF!& L110
M$AO66D+"AT90*2@B(G&[_OPCC(-1K"7B)Z+6N\5B=32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M"!#:.8@T=M A37TIGN?H4B^".B>Z=:6<(;CW;'25+NAER=X.,:A/,&ZZUM@XK!H&VMA3,(I*X&I_[MN%9D; 3S0Q .?=MG =<
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M@F%X,1 ;"LA--C^:=Y)!J"#2BO#J7>( TXI5Y7E@FFB<7GN :4!
M-W5ZT\5)R/CZZ,]1-'S=/%/&:4>< \@@%;YBRCW9"BTH$XEU+9MO[9QTENR#
M'+7\:ZV$DS"OO-G]<%SH8+O,"DF#AT:%]%BP8!%[Q4LQB:*)YP.;[^O\^;B6
MCOY)2/:AV>WJAQMFS'HGK04(:24=)(:AIZ])N43#K_F:^N>C60OX3\FS,JRT
MM4;5[.;9%8LI_#O88:8Q!]9198E73D(!414S%5KJQ%!-\WV;/RTONU3+2G(&/WS15?GJ YTE@'/!)$6*",%
M0U1*P.S3U^D3"Y*>>TKMD.>HND-_B$HFH^_;O2$U_L=J,L^#-.$S6G[_,!W-
MEL%!BB7F'A\.%P=KWDGX'BU P=SU3%J)((1.5M\CXF[@*//)9\=.N/*R\DE?
MVCA,QV+Z+9*, 8S8FF+Q)\\&\]MHMKH-36 O\V"^LQJL2P>\OG?%J.[
M7-W-\\W!WAU\:]ECYCP@WEA)#66" D6<*;.#9/C0$Z]R3PT[7Q3YAE7-("6>
MBG&>WRS6V9"C:7YUJ[Z,)M/HOOMB'G_R*1^OYG5FXS'=9-H&49&)5:Z4CXZ9
MAT\@V)<7WP^R!_QF"3F  @9CFP#3T=/BH2XR
M2)"0DE'!E3/ *^!L%4R F"<><3GW(/6)YL<.-7$*U^6(I.K:MED$36#BPCK@
MB)#6DR?3V$IXBKIF;Y]K':-^FC3 ,H=Q>]O[\7O$.WO('+<",FH-"^(B+)FM
M O32.)I8X*:+_/W+FO#ZT<=910X[B1AF05@74%6.048$L11#O 5 :>Y@W\G[
M9Q7&[H.)O>GB=&2L3F%W$<8^T%G&#$6<,,F9P$X2Y!DOC6(%@;W8:_Z&"V-W
MA_X =/R8/VYMBZO;]\7L+BQ?#S6GE_8UR8)4PM[*JS:+.RRIW$&C9&(4(2!TY &
MB8-C50IL#3]%A9LWSZ[.81]X C-%L #FR^@6'3&'O6B562D<-(+'CTAS#A3S
ML!)1I=X\^7:"R7W/6^WP'CA,]WXRR^.8@]8.ED#8VR8#5'A*&&!.
M(*.I!8]:U9IY\W3J"NVA#:R&9-K;)A..2*Z-!H9#Q@@22E3N#+:I9#K#6W%/
M95.U0#MEE__=+$ 9G-:/P6(UH\>G?5UU%_X:[=@/\_QALGK8G[>>U$\FF$4*
M XD6X]5C_$73+:W.WYLQ:1@(."./-(6( 4!+ZT(+
MJB\TG_E$:_&IU7=6]>!V@'W@*VC5;R:1T2CX_=(R Q40QD)7PH0E3]P#:76)
MQV6Q?$CUM$@7C!O0HV]_GRSOXT7'81 ?\_7][-?%?X6U*;\)GV#X2=R]"7\&
M2";CY?:BM[_-)K6I@RU[SR"W 8%X^1+"CFA@<55/5!.;&B!\(_5DAC)$3J*K
ML]HXZ63#)!,>T%BG65(*F!8,6UT6UM'*X,0 (P1O_?+:+HG(3NEFXP)A[#&P#GM'16QYE/E
M,5!@3Q%)>JM;=SWB/@#Y=H_S0QZ4L2I"2L"LAAKZHVO
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M*8P(ZU. MQ31\-2K79NG]%TV ;M#_FRVSS:?QGV^#(O"],&D7 ,X:Q
MM%AP2(0,_Y2. 2B\H%#7I= ,O[8]6YS_O]5H.KF-F[=J\9_YS5V^2#?>ZKK-
M@"":@8"3EE9(8Z7QJ@3*<9-XR]71.W7G9Z4U9M 1"UG'VAA^HME6+W]VR&C(
MZ60#9#6>9G=;[FJ1!609Y8Q;3BUAED@/1="I@9 8#DW=#D5?QU?7=Q,T*4;S
M\M%,"TN-,%IBZ..5IPX(6 IDC4[,X6KU&0]SE40[];XZGMH*U@&LRAC"7FR'
M^6M1W"P.1[1V/9YYS!1 4A&'+. "*&S51BC*(*E=&]\H5])U6W2.Z=8B,]) :B%BQ!/)D%>05:))@Q,O*#SWM(9>Z)(.ZR#5$S82-UAV
M,F2TT,*)8*5H!PG&6LER\(3IQ%27XW?XAW5%.^-$(HZ#1"T6P4#>CJ^!(;+S
M^8QA1164T$/+"4,Q@&Y+L31GB87OSGW*Z-H:Z0+;P2BS7@D_%4_X["5+]63F
M3%@SL29&N^!ET>AG\6H*9*SW(G:GH4E+M>XD22JFP]-#/<0@[C_72FM.E>>M
M,JR TQX31C'AE*"P6HI21*[HA+V!NTF ;6];3)@A:"4(1>@(MYP!TC%
M>.-18H#\W">1KFW9KO =Q ]>Y.$U\52=#9_+M%A?#+8=]T'G^$"[S% 6,,.<
M>!H^$^D.MPP4\R&S\=0(Y6 AC&A+*2VX)["23O&.7$+C&R<_RABF%]^.ZYTA;9(8G2J S%CJ:13WVDJG@*#$@,_Q!Q$NABS)V Y E\W%9-$GW(RRK!5^,$EL=Y/,"DHT
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M2>^\28-W .;\/9_\%=KVP]PWY&'*Q;"8_J)X,&>&X\H)18
M33!PA%=A'(EMJBU^YNSKCRV)M$Q1QNDXN9W'7TEQ/"OW]90Q(SWVP@CH)/>"
M>^ZJ)4<@ES@KGOL*?&I>=J2._HJU/*LJHVYN)K']:/IN=EO,']:=V7PYFDQ/
M4K%E9ZU.-;N)%6]^N'703A;C:;%8-7*(6_0:IA-CM.12*XBI$4(2JR!DQ%LI
M CN.OF3ES.Z:QQ)B!QE"R&G/@S&I,=^*)QEWB5=PGV$YIT$XT.K2^>-4<7CA
MVG,1\7PR&T\>1U/U4*SBKJ8NYO/B:_0N]A'J0)/,>\#C7&89H=@[$[#QY8")
MIXE)=:V6EPOA3G>HI]"D9.[VMF*[FN\[?7WH\0P!22&WP$B' 3 :"0#+@?JP
MYI[@L,"%T*,;Q(?*3WC31:DU(-P:)YB AF &$?>RA%0"D7A^Z@POY1B2Q.>C
ML &^@;KR\S](N99M/%X]K-87P@II1]-YG67S3;N(W-  \V:<8* XH(Q[2"'()A]OOQ,
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M!KUQO!2287Z*BO_]D/,'?WX=S6]J&7.H
M6:8LX,@Y+B%'5BKI#2D-C* =8-*(<]8I#!T2IT-H!^#/KF6]QDC:UR1#G@6;
ME"B@:!2':8LJX4AP@"^&-V=H('6DE!,QKM8TVM\H$YYZACR-)Q/#IZ6#O"5B
M"#EUBIK _;"NO8H;<"8)U %8\V&>/XXF-]4!U]G-)D]B'9U=;BHZUJYZS3O)
MD#-,&>^-+X*.IB,/D^FZ_!<+4?V-@W0Y6.0#U5GMOA.._B_626OUOF#\<&*AOWFSDM
MA%364^@=,EKZ %B).\4@4:D7R5PQG::0/QYN7%57UK9) =[V=)'>4P-[?%?\S'
MQ=TL)C2]FY4E!?ZUZ_ULKU$S @"!DC-*"0+.@4V\73@F +1UH< 3)(]7,_;'
M?+HFS>)^\JB_OZ@*L&O>_W&[H6X7?+A!9-92X)4P1 GBXEV"5%=*8%HEQF,O
M8XX[GJG'))"?4H]O=)?<8\(%,306I*:6:,QI*:0$Q";Z-6^%K":*,]E(AY$HSSK9#"7% 8KQM5'[-K?ART;W0KE%@-+1,"*2Z-
M,))X_H0<4J5>5YV:7\H8]^CF35 .RXP0IQPYJB3
MU$K' %342U!;XO!LPCC7 3X=1O-'MW&@[B*LN-/539QQGA^-WU.$XE_!
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M%H>$O7!GM&ON%$,K9(#5M9.0<9Q]$WC+3ONMO1T5]V@5%^/-*939
MC9LMUY>F5Q<. %M?D*#=IF"B,>;]OV!'EE&674;#:*);6:H[HB/8?F
MN44^_NM=\>67FWP2IS@2_Q)%),]FMO"C:IPQPK5#EI>/9 YY"3R5@A!'<4S@
M Z0<,A'Z%&'C'B]0ZT&512? -E[OFO) A8'S82#
M3'/F6;PG)>8[$8?*X3/K$VV25A?5O%F2= !P3_PP>=R5G[X++MVW_S?_?I @
M+Y[-3+R/03BA@&&"8&R UJ4 0MC$NJBMKHAYXPQIAW#G%-D6&GM:!P\;L/L>
MSQ3W&E@JD>#(*, C[RL+R_O$VB*M+EIYLT3I".2>IA,_F>9S$X9S5\P/3R8_
M/)EI1!BPS"+N*!2" &Y\.7BO5:+YVNH:E3?+D/;X]K76% \/Q>S3LAC_\>KZ
M^L,+SX&&&?(8*04\L()H;(D&I!)-*)1:N C\B;G3(=[]A:RKS=_?\E'<$?CA
M]K A\S2J@3PK&-4@$>-0LPQ)(A@1E@ND@U&HE>!B<^R)!XA)W=9/SX(^0_S=
M[#%PX[CS=T?UD[&PJ@D*0&":9QABJB HH2#.G"*KJ\?/NUMV[+NXI@?@!_[0
MUB
MF(#N9*GNYOG:EMA[A&O_PYGQS%,7!LD]AA(YI94M!TELK7U^$>I/T5G1,;)#
MY"KFLP#LNE!+[6&_5\]FW &*,$'0 041#4LSKY"Q"B9+]L1-[K"8?6TR>S[9F'\K[!J;\6O68174"5PX9123""4-(2(L=I8C#L7!.)!K5PAE/+
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ME;2.,B&88MABCK&4P?[UXDDXKGUB=7,T^YN/5?!X6#3U:3"XLN@F@,8XIRJUBS'DIU-9$M@99[NK\EIX%
MU=^?1^-_G1>KQZ"&NFS8)LVSF'OM)4=6>,JE$ A25@I.8&KEM7.=&;KEPKZM
M_.[P'C+;1']_NNUJDL_#J^^_O\^_Y-.Z,&BC#K(PT6&C@ZG(-0*:!9_!HE)P
MP=V%147[X<1^PG6'_)"4V[D(51+4QC^/ZB>#V%'J(/$@2,\$UDC*$@: +S[?
MOR..-#C[TY4*AF3BYKS2&@]8?R7M_E89L- &J81SS%B-&!;;K;,@HC?R%%
    5&M^_-&(Z*GHU8:[@-0RTTG=S&0$2,B
M5_.UF>J+^5,(Y7&MXL,.0>,^,N0]4]@;(6#X#P/C)2[%UZ[V>MBW/J/UX1/T
M!?Z@YQ[6@]PA27./H*:+3 BEE23:.R8X010P0TKAI? 7ZHWV0(Z]QQDZ5< 0
M,]\_5@'\3S'&N8U[UJRGNQL$P;Q46A+DL8$" <1X92UHSRXUCZ9SO;^P :=7217_##A:)""4"0"OZXHE4(4A.4>!WX&9[OZYTW7> [Q-I7S//)W>BV6IY_;.\*J'WFG4)Y)+/%FL-KFMNZ=$BO_DP^KYV=6K9=4PWF7-4(X6I]T92@EV8F9]\&0X3
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M+^R^M9-;<[UH94B?N$&6]=7GZ>1NS8A&KO!Q/68L?)B.2PF@) #XNN3D?@3=40#Q
MF!-""?>B=_">\(E %,Q.2%2P'@"R$CM100EEXJ'Q??P[ WI;SB_3>["GS]6*HLA=\=O"?S A&!O/2.!(\>>FD0+6&4T,H+
M]S+ZX??PBNEON7PW"W_-KT??3K,\5J\_RL4^T"KCEJ-@%7O))<$.NF"";-4K
M//>R+AMF,#&;S 6'FF7,*RL-0XH$@TM(H 2FI:!$\$1K]]R7KDY4_RI:U1G,
M@WRH9W;Q4/??L%::ZN"\ ,<<<40:)PS4$%,A./?^--<.N=O;?+R
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ML6#&T\WJH*6DHO8L54_A_S7-WN^DV6N5?C@@8[V
MO%F&1V-JO:Y!/K!^AMCI/4JH*,/UUZ(S
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M-M:7+![SF^M\?#^+)M3WP_QC[>O, 8MP+8C//%XF-09RR(&BR-[?!C%FR#"F<-VF=8.^ )I=H";0($ L4 
MXT9LX?FE%C?NF6M]ZB!E:M,V40DR$
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M_2<$@\P"SF18X#PR7,%-YE6P@ @V=>&04V_H'5GU
MH6EO&0E(<,2Q5P9*8K&TU):P>$DN] Z_GJB3O,67JH\!2SH4AX3PJV4$['7&
MP]'<[>(U&7006.N"J\0!\(P:JWT%(A")IT+/?>4;EM0G4%1_B^-OH_D?^3*.
M[>D^E%,LC<]JWL;*&+%JQHM;6AH=&F_:229HH(%  @,@03"?'<=J R)5P#
M!V0%L#0J,0/_W)?7/ABXOSKT*34V[)34X3G7W>'T$EI^S$=K?Z$L"+*/MB_FGT'.SF>70U?600AN552R:%U@@#
M#RG!6PBXYDZ#;[[Y+&NRUH;M%>0#+>1W%OPYOV]:YVC4-'LZ0:]A#1B0G
M"F/-J-4@N _$NDITRM ILI'Z#F9WQH9B",C/@VVU67"-^\B C 79*+#.0@D<
M$DK!4GP+X>4RA.H 6 4:$F8DXIQ4@H&C3W%9LG)
MN'2LKIO=Z7D
M+>_S^;,?'2!HMR_*O/K_V_O2'K=QK0YY%DFL\9(SKQ'QEA);
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M3-WMAQV"W\-J]!R-%ZOTP>4JORDMN8J5JOG+,J*$1H0X$Y1G9YH^_B*S\OUH].R]\O7+,JD]V1*&^29B36TB0"Q
M3B(V42U
MO7'$>I>5[KNG2HL(#Z!CO70)KZ%+/33*PD8M!%$N !4&1[#QLC!%F%>I(3;-
MP]M7V]GME2\\K:/=[T7+<#%W?5^6F*!22(0=AUYRS$1TJ#Y( 0>[')R+M>][
M8M>)$:C1.D,":$6M-$ 'LL6@>U)[PJ>!W-_/?Y=M##;VH
M^/R>KS]^"R@.,>G=;+U<++^6?:@QQ4\UR0@)1B:C&,!X*2XOT,L,XT/MDF"UN1)10A$/8BR+R-><2+(8:]:**AL)=+_/F!;$L ]SQ!"R>(
MQ?Y][[_$8Y=Y3.JVN-T%L^V S=UJMQPR%W:;,UH9R#2FGAC@,/3(('RXN%;2
M @<:!\2_;I"]8,,)9X33#V>08 T,AIH098&1R*NRH]:DYNVYVGE96VZKEI'M
MP_1:;AD)4M K8
M!;@\XF^"*K,8AZUZMCMS\O%=O/A
MX^>S?*ILEW&,M+2(RB:6L1DK,UK4P5K%M8>%Y8]\\?5;3,#W/5_/
MON;O=I&K[[_LN[UYO]MNMK-ES/ZQM^TK%II&[\FLA<(BP+5 6C/!/&&R7%^U
M.)?AHJVM[.D58=\$2V#%JC_0>^#>F^5\G<G,FE'*2.$JDTTK3 +=]
M.+U2*I&&%Y63SAL%]N+WZ\7'[XU6_^6Y]ZDV9P8C:F.3<&TC1'Z.WW;HET,>F*]:X9TEZ7X:09!! 8XVGV&AOL"EW XI%(A?'
M6OIB#)IC(O3CO_PX7$YV=\UQ>'\&N3;!]L<29+J^;I].%>X5KUBA*?*<^R)-EX)+:4IG VULN1<^HR.#NM+Y\L7MQE/
M?1H2$LLW>F,&@0+ &B:-Q5@!K[@R!3Q$#9(O8%"/FKIL.9DJH$OXNUP _E;S
M>5R30M]_7Z^6X A[Z8;]$NC[E\W'J]6IM5H-1\7XFOQJ+0Y#49
MP\YI@(W4&'('!$'Z>%Y.C0L+\R +A\%&19,>.^(Q= Y0;UD1!R6;8H\YHV3
M\I^J:KU/&_[^RS$Q^N/.'7E2Z1;?_"4QUSM!U ?]$Q)!#(->TF)@6+'$>[BQ
MS_2VI;[J"?]A)G;E[[[$2(-E($5,&S&8$VY?ZT!<\H.1&)=Z I!E,A!D+ZZ@
M/5K'A]$9"@G\^##[^[?0\_5B=KL)%M[[+[$0]OI[99#<^<89I\:3L-LQBX2!
MV@OE=#%HPOGU)QCHB@2OU,=H%>I>KE"/??YCM?ZK++#>F%RG6V=J'V8:ECMC
M@/>&(.]P,61&P'0R /?%KM:P[I->L7#5)IC4L6!6]0C_K\"@\EC&$$<2(*P* U$10C&PQ" I3/=/&
M>A79-WN:(SQ&G3S$N:.AFI;P;[/E[DOXW&Z]6'XMT0U(?UQ]V?[]*';WN?5[MF%FPXZ'.9)&
M2$61< P14 P >3J$-CN>^5U;NJL.,4]R32X^^SE,M;79;;:KNWS]>3/[FJNO
MZ_RD-U_]QAD#6F'F/)-":<[^_7J^Z&G^QQ+52ML5;N,"@>YT=@;(SU4''E+RCFB66+:_XL4U>NE5Q>0
M]\"LM_ELDX>IT8A6IQMEC +"!#%6(\,-51@7"5P=%,HG>G8VUV4GQ:G6\.Z#
M4+-EU>U@_'74Z1GS!BJ$.,+<2,UQT>FHFD_+WZTODC1'M@
M^,4_\:>SR\O)-IDAW$' D&,T#"[H=:)('>B@I3)1DV8_-W':@KL'-IVT@L]1
MJKIA1BB&C"$L)'..4(68*Z>-=*D5)O@T3F!2>=4JYGUXWL[GN[O= 88\"&Z^
M.%;6OK_-]Y)=WAQ3,A]BJT\-K]I;J)5/9$)XCHQPV&C# 8.6L!(\;5,OR$1B
M-MO)4'8@^0RY\G0YA#1-3=LM?JV9+B ]S
MCCV<3W=?!]***0N)U,A)QI4 !!ROS)7BTOISP0]=^WN7-Q]FMXZ$3G#PKGY%
MS."-B;6>"4-!0,)S6P(@G!^B(-=X)GYM=IST[VX5_2'WECJD.]\X8RQLGXR:
ML/*98( P21 O!DR=2SPNF,@Q>"K=6L>]N]TF=/5F-]_^,8L1](\CT_O<7/ZU
MF\6OY[4VDI(2Z;^UBW.,L53TC[?#H
MJ]QP!K]^ _ORBZ=G9G6####N&<7>4!UK*W'NW#%(2FHN26-O^RYFY]O%[,_%
M;:#NN5*^E>TR9+QQU@-CE.2 V+5%73\6+4$U+Z!(@
M6\X.,^I05^)$1MNJQS,CC2:*A%XY88'F @%2=)21";E6MR2O5>N8MB3\D[E@
MJQMDTF!!(<&*@#A^3$U1;27V/_6&=D0$:$=49^2>!&9M6VR3S__WU]7W_]K'
M[JQ_Q"T#%_\3V8$?[1;'O\[,NU>X\/#+C,4"Y=H+AR&&(F8)AZ+H*@I+WV3E
MWE14JPNAZ\?B?G5M>UN1'K-VVXR$*:'"&F@D52QLDHY*7@S70C.$V]DU;!%=
M =P_G]1\OM[-;A^4IS>;S:XRZ+O>"S)N@('8$,:+_)I 8T*/502QH@!=JB0L?C
MD #4UWGC?;Y>K&Z"C-;;_DX=>R='K8VIH4@FI.M(QBU$H1-AFD-O/05%GB<.
MN5,3#=X8)PLO%,Y@K#RFCFY@SCUKF%',M*9>(NB1X@H#(6 Y_2!,+&>86O;\
M9^=AHEBN: ?VW!F#K:%0>!8& P'WQ< 8D8FN(8WC/PX[L%O^](QK*) >#<'A
M_,0NM?RB1SR6GE$$G5+: J<.9\B*6(7U.7^4KOV_*D^UFOF!U7M59I&Q!BD!
M&(,(2J8#. 4@%/"))N^[A!DG?;\Z0;R[6;VO#[4[!F+O4Y#&(N#[:!+S;;;^
M.LP$?]ZKH_N4FF\7W^N6N:_]CDQ#+@P,/<$D.N4I6M93PLXB<>Y";2 (FOGZ
MI+PN@X03PK45B!&,E89$P@(8*M@0-XT]+ L=$.>UHFS="F/(%:/";VCZBPDG
MDB% B+&8>4,D)89 X@U$X?_#[C*P;G%B(&:UV6[.N24U>$OF -4R\%5%[S:,
MM4>4'V'@QJ.)>IAW0).3BD;;,N@EMU:L'Q"LJ^W>T'H;I1X%7%W7NZ)5!KB1
MR&!AL57<*RRD <40@YTTT?JSG9#@98VTEE ?CEAGJVU7MLLP1LX[+C@#RG 5
M1LA-,*Z^L?@2;
MI&((SZWAB-14Z%6Z\R4P]\VC&*=S9J=[]?F,822X\Y(Y#P4EF$D-RTEGW1#9
M;B>RQ[6!]Q T.KNOG6B184V"W8@=4-)809UG4!1#\\ G7B:-?2&Z4,SG2).$
M;8H/NOE0IA3SPE@ID7*,Q])EH# S8GJ#(?3CGF3<5"JKEC"\
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MA@9*;!QD,=?@R
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MY='0^+3:![+D-T];S_?+^<_B%"H5A>)=[I41J*O3Z3J'-8+X:IU#KK7,\6!W>
MA[%9R(*B4 S+GOU>?OJUVFUFL_?=EF^?+:M>B4\]G! !A$<+.@C!1M/0 
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M,[N-9Q.UMK?J5V1$"Z\=LH1*%39M+J4KCR*,@-=?+*P;\9[R"/P0^U
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MIA@R[+#0'C@1# -"B@$:!(>HY3UX $)MH=SB$FSU;HNM*EJC6A
MUW8&;(;S@,Z WH6N0>$YT=IQZC@@Z-A1*@&>4K!""]*JXP[8#-$K< <,4X,1
M3KVT03MT3!#F<#$@#V'G=PPC< =,(DAW&%^%.Z"+=?RH\H@XQ)D+PU*@&!)T
M9(B<@(-Z=W7!H4L0'YT[(# VJ' QBW0,++;<0&[+.2!(8EZNL7MLM4R8UG&^
MFD!N:9Q%80I(XO9UPATPHAB6M2!QFQK[>M.[S92(]U4%H5,JXT4,4>>I)\DUE
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M*W-,8&UI$>G?:E !Y1AKS$#!/H]A*16'G.1^T#'N2A
M0P?^NMP/O'A3AHGC'@!&O3(N+'4.>U7 H55O+@2C]06O39FN55&7\>'5%9M.U>.9MP )3H"EP"MM$9: (14/QYCD
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MP*TB581?K1_PB%KQW=UJN1].!:O.-\XH$F'#1HABY+1E7"JKRP%#EKA@"27"+-
M$#"$P6(@SKI$\[=^I=OK8DB'T/9FS;Y;;1N?P'9JRRK N(6.>Q0^ 22@PEM(
MD2>4,$W-N5N"'G;].F=/KS>(QA-0TA/BL-3<*DTV;9=!2[@X9%P9+
MO376!8JC8 %ZP8+JKKT0,8/P\5I#*.;,N4H$7=^&/?#OB6S7Z]GRZSZ7QD;_
M>,%1%=/0U4_A=>$W,JVAH(IIJ+@S&%-MCRX, 4*'X41#8/KBW/)[R\^&!W;QN8QQ[Z*QI(RS1DJMN/4%J,@[/$UJ)Q+K^3HYO$!Z
M8+F[N[]=_==VBY
M4C>L47&P30'U<7>6K_?V[7*>'WP/SC+P1(MXF2. $X)YXA%FGA%5[#4:23/1
M-#2CXEX[HAF#?GD*M+&,AIB8L'@60L4;\3ZK/
MMLC MLC?AOS&,!%.+BJO#O"/?/'UV[9T47+_Y.OY8I/_'I2ORI/;_GJ1$:T!
M\5PJ3T7XF9@@_D($4M/$(XC1;R,CGD*#"7<,\^O,V-_OMIOM;'FS6'Y]MSMC
M!+3^K2!R9"P)X$GAK!-&((8+.*U)+1)P]>;#>+>;2T5X73.BJ]VFG1YD'@-A
MM58$6.&"'#2U)0G8=(LP3V+VM"C8,<\I]]^[P(8WRQC&N-^*]QE4/WV;+7LS
M=!IV(>-0:Z0@HHP'A=D;[14LP/>*)YE6!$:I"48UIP1QG0LI%0LAP(EJJCBUWP<<#ZV+?64P,G?%LO%W>[N
M4\PWMCTL$,=KP[^'S,+)3H6N7O',?T<[#2!EE O"P
M5BG!BB%CBA-=6^0OHK\:G=FCJ)+8.?NGNGM[/%(H>NF+,X.,5E! S6"8H@ )
M*6RYBTJ0FJ0-_"+JZT3M66!).59B=VZJP'GF-/;OF.^QR.Y1&0B<_-8,>N04
M!8HJXI3"2E-7VE&$J407%SC*@H1#D;-7$?7I,)VOOR^./F8O1E>J,7L$-\?D
M- ^_C[$][U;;_^1A\//5U^7B?RH33G7VS4Q1@I#47H&P04$%H+?E-F4(2DUZ
M]NMZ_J3N/!997O-4.:P-^Z0J^[^*S\$AYL^K'@K_N\?N?5&T(N.^X[=?_]EA_Y,TR)DE;W2YN9OL--_SW8(A_.=9QC+6%
M?\5X/XNU%<01X9ACE$,&"2/.'_R+,,RU]>+EQO(U'BB*HCOBM:9=A9KPA1^S*U
M(*S@XA@7IY6&7$PTI?P %%EU)9/A:'J_Y\M=7ET"]I5',\P41])*&!1>@KD,]ILI
M.BBQ/I=$9EI$:"JT5:O@]A/XG(?/?(N%;4)/;U?W??@-Y+>WAX(W88>JYN[Q7(1
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MYM(*7 #)M9YH0L&>B3X*V?6]>SX+J1X+.+HE(I%SP "O@",TE3?R[';UL.K ;V+;LQ<+W,*/#+ /RPV?_EUGK]9
M!F[DF^V'8!!T,17J?CL3+N!+- ?8>PN-P4BQ FXH\!!:Q77G:X]>]5L*D7MX$N?4ZERDYD03'E#GF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M;%!+ 0(4 Q0    ( ""!FT@^2AXK^!,  *OC   1              "  "TR,#$V,#,R-E]D968N>&UL4$L! A0#%     @ ((&;2*^P$J%QQ   CO8)
M !4              ( !C-(! &AO;'@M,C Q-C S,C9?;&%B+GAM;%!+ 0(4
M Q0    ( ""!FTC$RWVG/W8  +;"!0 5              "  3"7 @!H;VQX
G+3(P,38P,S(V7W!R92YX;6Q02P4&      8 !@"* 0  H@T#    
 
end